0001757898-21-000007.txt : 20210209 0001757898-21-000007.hdr.sgml : 20210209 20210209080020 ACCESSION NUMBER: 0001757898-21-000007 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 90 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210209 DATE AS OF CHANGE: 20210209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STERIS plc CENTRAL INDEX KEY: 0001757898 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38848 FILM NUMBER: 21603965 BUSINESS ADDRESS: STREET 1: 70 SIR JOHN ROGERSON'S QUAY CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 35312322000 MAIL ADDRESS: STREET 1: 70 SIR JOHN ROGERSON'S QUAY CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: STERIS Ltd DATE OF NAME CHANGE: 20181101 10-Q 1 ste-20201231.htm 10-Q ste-20201231
STERIS plc000175789810-Q12/31/2020false2021Q33/31Large Accelerated Filer85,352,713falsefalseIreland1 232 2000353falsetrueno11,60512,051500,000500,00085,33784,92485,33784,9240.0010.0011731715205120.400.371.171.0800017578982020-04-012020-12-31xbrli:shares00017578982021-02-05iso4217:USD00017578982020-12-3100017578982020-03-31iso4217:USDxbrli:shares0001757898us-gaap:ProductMember2020-10-012020-12-310001757898us-gaap:ProductMember2019-10-012019-12-310001757898us-gaap:ProductMember2020-04-012020-12-310001757898us-gaap:ProductMember2019-04-012019-12-310001757898us-gaap:ServiceMember2020-10-012020-12-310001757898us-gaap:ServiceMember2019-10-012019-12-310001757898us-gaap:ServiceMember2020-04-012020-12-310001757898us-gaap:ServiceMember2019-04-012019-12-3100017578982020-10-012020-12-3100017578982019-10-012019-12-3100017578982019-04-012019-12-3100017578982019-03-3100017578982019-12-310001757898us-gaap:CommonStockMember2020-09-300001757898us-gaap:RetainedEarningsMember2020-09-300001757898us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001757898us-gaap:NoncontrollingInterestMember2020-09-3000017578982020-09-300001757898us-gaap:RetainedEarningsMember2020-10-012020-12-310001757898us-gaap:NoncontrollingInterestMember2020-10-012020-12-310001757898us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-10-012020-12-310001757898us-gaap:CommonStockMember2020-10-012020-12-310001757898us-gaap:CommonStockMember2020-12-310001757898us-gaap:RetainedEarningsMember2020-12-310001757898us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001757898us-gaap:NoncontrollingInterestMember2020-12-310001757898us-gaap:CommonStockMember2020-03-310001757898us-gaap:RetainedEarningsMember2020-03-310001757898us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001757898us-gaap:NoncontrollingInterestMember2020-03-310001757898us-gaap:RetainedEarningsMember2020-04-012020-12-310001757898us-gaap:NoncontrollingInterestMember2020-04-012020-12-310001757898us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-12-310001757898us-gaap:CommonStockMember2020-04-012020-12-310001757898us-gaap:CommonStockMember2019-09-300001757898us-gaap:RetainedEarningsMember2019-09-300001757898us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300001757898us-gaap:NoncontrollingInterestMember2019-09-3000017578982019-09-300001757898us-gaap:RetainedEarningsMember2019-10-012019-12-310001757898us-gaap:NoncontrollingInterestMember2019-10-012019-12-310001757898us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-10-012019-12-310001757898us-gaap:CommonStockMember2019-10-012019-12-310001757898us-gaap:CommonStockMember2019-12-310001757898us-gaap:RetainedEarningsMember2019-12-310001757898us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001757898us-gaap:NoncontrollingInterestMember2019-12-310001757898us-gaap:CommonStockMember2019-03-310001757898us-gaap:RetainedEarningsMember2019-03-310001757898us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310001757898us-gaap:NoncontrollingInterestMember2019-03-310001757898us-gaap:RetainedEarningsMember2019-04-012019-12-310001757898us-gaap:NoncontrollingInterestMember2019-04-012019-12-310001757898us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-12-310001757898us-gaap:CommonStockMember2019-04-012019-12-3100017578982020-04-012020-06-30xbrli:pure0001757898ste:ExpectedrecognitionwithinthenextyearMember2020-12-310001757898ste:ExpectedrecognitionbeyondthenextyearMemberMember2020-12-310001757898ste:KeySurgicalDomain2020-04-012020-12-310001757898us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2020-04-012020-12-310001757898us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2019-04-012019-12-310001757898ste:HealthcareMemberMember2020-10-012020-12-310001757898ste:HealthcareMemberMember2019-10-012019-12-310001757898ste:HealthcareMemberMember2020-04-012020-12-310001757898ste:HealthcareMemberMember2019-04-012019-12-310001757898ste:AppliedSterilizationTechnologiesMember2020-10-012020-12-310001757898ste:AppliedSterilizationTechnologiesMember2019-10-012019-12-310001757898ste:AppliedSterilizationTechnologiesMember2020-04-012020-12-310001757898ste:AppliedSterilizationTechnologiesMember2019-04-012019-12-310001757898ste:LifeScienceMemberMember2020-10-012020-12-310001757898ste:LifeScienceMemberMember2019-10-012019-12-310001757898ste:LifeScienceMemberMember2020-04-012020-12-310001757898ste:LifeScienceMemberMember2019-04-012019-12-310001757898ste:OperatingsegmentallMember2020-10-012020-12-310001757898ste:OperatingsegmentallMember2019-10-012019-12-310001757898ste:OperatingsegmentallMember2020-04-012020-12-310001757898ste:OperatingsegmentallMember2019-04-012019-12-310001757898us-gaap:CorporateMember2020-10-012020-12-310001757898us-gaap:CorporateMember2019-10-012019-12-310001757898us-gaap:CorporateMember2020-04-012020-12-310001757898us-gaap:CorporateMember2019-04-012019-12-310001757898ste:CapitalequipmentrevenuesMemberste:HealthcareMemberMember2020-10-012020-12-310001757898ste:CapitalequipmentrevenuesMemberste:HealthcareMemberMember2019-10-012019-12-310001757898ste:CapitalequipmentrevenuesMemberste:HealthcareMemberMember2020-04-012020-12-310001757898ste:CapitalequipmentrevenuesMemberste:HealthcareMemberMember2019-04-012019-12-310001757898ste:HealthcareMemberMemberste:ConsumablerevenuesMember2020-10-012020-12-310001757898ste:HealthcareMemberMemberste:ConsumablerevenuesMember2019-10-012019-12-310001757898ste:HealthcareMemberMemberste:ConsumablerevenuesMember2020-04-012020-12-310001757898ste:HealthcareMemberMemberste:ConsumablerevenuesMember2019-04-012019-12-310001757898ste:HealthcareMemberMemberste:ServicerevenuesMember2020-10-012020-12-310001757898ste:HealthcareMemberMemberste:ServicerevenuesMember2019-10-012019-12-310001757898ste:HealthcareMemberMemberste:ServicerevenuesMember2020-04-012020-12-310001757898ste:HealthcareMemberMemberste:ServicerevenuesMember2019-04-012019-12-310001757898ste:CapitalequipmentrevenuesMemberste:LifeScienceMemberMember2020-10-012020-12-310001757898ste:CapitalequipmentrevenuesMemberste:LifeScienceMemberMember2019-10-012019-12-310001757898ste:CapitalequipmentrevenuesMemberste:LifeScienceMemberMember2020-04-012020-12-310001757898ste:CapitalequipmentrevenuesMemberste:LifeScienceMemberMember2019-04-012019-12-310001757898ste:ConsumablerevenuesMemberste:LifeScienceMemberMember2020-10-012020-12-310001757898ste:ConsumablerevenuesMemberste:LifeScienceMemberMember2019-10-012019-12-310001757898ste:ConsumablerevenuesMemberste:LifeScienceMemberMember2020-04-012020-12-310001757898ste:ConsumablerevenuesMemberste:LifeScienceMemberMember2019-04-012019-12-310001757898ste:ServicerevenuesMemberste:LifeScienceMemberMember2020-10-012020-12-310001757898ste:ServicerevenuesMemberste:LifeScienceMemberMember2019-10-012019-12-310001757898ste:ServicerevenuesMemberste:LifeScienceMemberMember2020-04-012020-12-310001757898ste:ServicerevenuesMemberste:LifeScienceMemberMember2019-04-012019-12-310001757898country:IE2020-10-012020-12-310001757898country:IE2019-10-012019-12-310001757898country:IE2020-04-012020-12-310001757898country:IE2019-04-012019-12-310001757898country:US2020-10-012020-12-310001757898country:US2019-10-012019-12-310001757898country:US2020-04-012020-12-310001757898country:US2019-04-012019-12-310001757898ste:OtherforeignlocationsMember2020-10-012020-12-310001757898ste:OtherforeignlocationsMember2019-10-012019-12-310001757898ste:OtherforeignlocationsMember2020-04-012020-12-310001757898ste:OtherforeignlocationsMember2019-04-012019-12-310001757898ste:HealthcareandLifeSciencesMember2020-12-310001757898ste:HealthcareandLifeSciencesMember2020-03-310001757898ste:AppliedSterilizationTechnologiesMember2020-12-310001757898ste:AppliedSterilizationTechnologiesMember2020-03-310001757898us-gaap:EmployeeStockOptionMember2020-10-012020-12-310001757898us-gaap:EmployeeStockOptionMember2019-10-012019-12-310001757898us-gaap:EmployeeStockOptionMember2020-04-012020-12-310001757898us-gaap:EmployeeStockOptionMember2019-04-012019-12-31iso4217:EUR0001757898currency:EUR2020-12-3100017578982019-05-0700017578982019-07-300001757898us-gaap:StockAppreciationRightsSARSMember2020-12-310001757898us-gaap:StockAppreciationRightsSARSMember2019-12-310001757898us-gaap:RestrictedStockMember2020-03-310001757898us-gaap:RestrictedStockUnitsRSUMember2020-03-310001757898us-gaap:RestrictedStockMember2020-04-012020-12-310001757898us-gaap:RestrictedStockUnitsRSUMember2020-04-012020-12-310001757898us-gaap:RestrictedStockMember2020-12-310001757898us-gaap:RestrictedStockUnitsRSUMember2020-12-31iso4217:GBP0001757898currency:GBPus-gaap:ForeignExchangeForwardMember2020-12-31iso4217:MXN0001757898us-gaap:ForeignExchangeForwardMembercurrency:MXN2020-12-31iso4217:CAD0001757898us-gaap:ForeignExchangeForwardMembercurrency:CAD2020-12-310001757898us-gaap:ForeignExchangeForwardMembercurrency:EUR2020-12-31utr:lb0001757898us-gaap:CommodityContractMember2020-04-012020-12-310001757898us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-12-310001757898us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-03-310001757898us-gaap:AccruedLiabilitiesMember2020-12-310001757898us-gaap:AccruedLiabilitiesMember2020-03-310001757898us-gaap:ForeignExchangeForwardMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-10-012020-12-310001757898us-gaap:ForeignExchangeForwardMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-10-012019-12-310001757898us-gaap:ForeignExchangeForwardMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-04-012020-12-310001757898us-gaap:ForeignExchangeForwardMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-04-012019-12-310001757898us-gaap:CostOfSalesMemberus-gaap:CommodityContractMember2020-10-012020-12-310001757898us-gaap:CostOfSalesMemberus-gaap:CommodityContractMember2019-10-012019-12-310001757898us-gaap:CostOfSalesMemberus-gaap:CommodityContractMember2020-04-012020-12-310001757898us-gaap:CostOfSalesMemberus-gaap:CommodityContractMember2019-04-012019-12-310001757898us-gaap:CarryingReportedAmountFairValueDisclosureMember2020-12-310001757898us-gaap:CarryingReportedAmountFairValueDisclosureMember2020-03-310001757898us-gaap:FairValueInputsLevel1Member2020-12-310001757898us-gaap:FairValueInputsLevel1Member2020-03-310001757898us-gaap:FairValueInputsLevel2Member2020-12-310001757898us-gaap:FairValueInputsLevel2Member2020-03-310001757898us-gaap:FairValueInputsLevel3Member2020-12-310001757898us-gaap:FairValueInputsLevel3Member2020-03-310001757898ste:AdditionsMember2020-04-012020-12-310001757898ste:ContingentConsiderationAssumedInAcquisitionOfKeyMember2020-04-012020-12-310001757898ste:ReductionsandPayoutMember2020-04-012020-12-310001757898ste:ReversalOfLiabilityBalanceMember2020-04-012020-12-310001757898us-gaap:ForeignCurrencyGainLossMember2020-04-012020-12-310001757898us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300001757898us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-03-310001757898us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300001757898us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310001757898us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-10-012020-12-310001757898us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-04-012020-12-310001757898us-gaap:AccumulatedTranslationAdjustmentMember2020-10-012020-12-310001757898us-gaap:AccumulatedTranslationAdjustmentMember2020-04-012020-12-310001757898us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310001757898us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001757898us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-09-300001757898us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-03-310001757898us-gaap:AccumulatedTranslationAdjustmentMember2019-09-300001757898us-gaap:AccumulatedTranslationAdjustmentMember2019-03-310001757898us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-10-012019-12-310001757898us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-04-012019-12-310001757898us-gaap:AccumulatedTranslationAdjustmentMember2019-10-012019-12-310001757898us-gaap:AccumulatedTranslationAdjustmentMember2019-04-012019-12-310001757898us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310001757898us-gaap:AccumulatedTranslationAdjustmentMember2019-12-31ste:plan0001757898us-gaap:OperatingIncomeLossMember2020-04-012020-12-310001757898us-gaap:CostOfSalesMember2020-04-012020-12-310001757898ste:HealthcareMember2020-04-012020-12-310001757898ste:LoanRate4MemberDomain2020-12-310001757898us-gaap:FinanceReceivablesMember2020-12-310001757898us-gaap:FinanceReceivablesMember2020-03-3100017578982017-03-310001757898us-gaap:LoansReceivableMember2017-04-012017-06-300001757898ste:Years144IntRateMember2017-03-310001757898ste:Years51512IntRateMember2017-03-310001757898us-gaap:LoansReceivableMember2019-10-310001757898ste:Years144IntRateMember2019-10-310001757898ste:Years568IntRateMemberMember2019-10-310001757898us-gaap:LoansReceivableMember2020-12-310001757898us-gaap:LoansReceivableMember2020-03-310001757898ste:CantelDomainus-gaap:SubsequentEventMember2020-04-012021-03-310001757898ste:CantelDomainus-gaap:SubsequentEventMember2021-03-310001757898us-gaap:SubsequentEventMember2021-03-310001757898us-gaap:SubsequentEventMember2020-04-012021-03-310001757898ste:EquityInvestmentDomainus-gaap:SubsequentEventMember2020-04-012021-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
 
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended December 31, 2020

or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______            
Commission File Number 001-38848
STERIS plc
(Exact name of registrant as specified in its charter)
Ireland 98-1455064
(State or other jurisdiction of
incorporation or organization)
 (IRS Employer
Identification No.)
70 Sir John Rogerson's Quay,Dublin 2,Ireland D02 R296
(Address of principal executive offices) (Zip code)
353 1 232 2000
(Registrant’s telephone number, including area code)
_______________________________________________
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
Title of each classTrading symbol(s)Name of Exchange on Which Registered
Ordinary Shares, $0.001 par valueSTENew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company,” and Rule 12b-2 of the Exchange Act.
Large Accelerated Filer  Accelerated Filer
Non-Accelerated Filer 
  Smaller Reporting Company
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  x
The number of ordinary shares outstanding as of February 5, 2021: 85,352,713
1

STERIS plc and Subsidiaries
Form 10-Q
Index
 

2

PART 1—FINANCIAL INFORMATION
As used in this Quarterly Report on Form 10-Q, STERIS plc and its consolidated subsidiaries together are called “STERIS,” the “Company,” “we,” “us,” or “our,” unless otherwise noted.
ITEM 1.    FINANCIAL STATEMENTS

STERIS PLC AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands)
 December 31,
2020
March 31,
2020
 (Unaudited) 
Assets
Current assets:
Cash and cash equivalents$252,502 $319,581 
Accounts receivable (net of allowances of $11,605 and $12,051 respectively)
556,117 586,481 
Inventories, net294,132 248,259 
Prepaid expenses and other current assets73,324 54,430 
Total current assets1,176,075 1,208,751 
Property, plant, and equipment, net1,226,895 1,111,855 
Lease right-of-use assets, net149,741 131,837 
Goodwill2,926,551 2,356,085 
Intangibles, net1,043,904 565,473 
Other assets57,614 51,581 
Total assets$6,580,780 $5,425,582 
Liabilities and equity
Current liabilities:
Accounts payable$134,471 $149,341 
Accrued income taxes13,068 14,013 
Accrued payroll and other related liabilities152,331 128,261 
Lease obligations due within one year21,364 19,809 
Accrued expenses and other184,633 192,183 
Total current liabilities505,867 503,607 
Long-term indebtedness1,713,199 1,150,521 
Deferred income taxes, net264,041 160,270 
Long-term lease obligations130,217 114,114 
Other liabilities89,264 90,346 
Total liabilities$2,702,588 $2,018,858 
Commitments and contingencies (see Note 8)
Ordinary shares, with $0.001 par value; 500,000 shares authorized; 85,337 and 84,924 ordinary shares issued and outstanding, respectively
1,996,843 1,982,164 
Retained earnings1,872,533 1,647,175 
Accumulated other comprehensive loss(2,386)(235,463)
Total shareholders’ equity3,866,990 3,393,876 
Noncontrolling interests11,202 12,848 
Total equity3,878,192 3,406,724 
Total liabilities and equity$6,580,780 $5,425,582 

See notes to consolidated financial statements.
3

STERIS PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share amounts)
(Unaudited)
 
 Three Months Ended December 31, Nine Months Ended December 31,
 2020201920202019
Revenues:
Product$375,314 $363,795 $1,015,926 $1,009,196 
Service433,610 410,466 1,218,062 1,198,708 
Total revenues808,924 774,261 2,233,988 2,207,904 
Cost of revenues:
Product202,881 195,105 535,234 539,664 
Service260,182 247,803 737,288 712,377 
Total cost of revenues463,063 442,908 1,272,522 1,252,041 
Gross profit345,861 331,353 961,466 955,863 
Operating expenses:
Selling, general, and administrative182,373 172,927 510,250 527,667 
Research and development16,438 16,487 48,812 48,321 
Restructuring expenses20 (448)110 667 
Total operating expenses198,831 188,966 559,172 576,655 
Income from operations147,030 142,387 402,294 379,208 
Non-operating expenses, net:
Interest expense8,899 9,813 27,056 30,702 
Interest (income) and miscellaneous expense(1,299)(1,378)(4,776)(2,163)
Total non-operating expenses, net7,600 8,435 22,280 28,539 
Income before income tax expense139,430 133,952 380,014 350,669 
Income tax expense24,842 29,285 71,294 66,083 
Net income114,588 104,667 308,720 284,586 
Less: Net income (loss) attributable to noncontrolling interests87 (263)171 297 
Net income attributable to shareholders$114,501 $104,930 $308,549 $284,289 
Net income per share attributed to shareholders
Basic$1.34 $1.24 $3.62 $3.35 
Diluted$1.33 $1.23 $3.59 $3.32 
Cash dividends declared per share ordinary outstanding$0.40 $0.37 $1.17 $1.08 

See notes to consolidated financial statements.

4

STERIS PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(in thousands)
(Unaudited)
Three Months Ended December 31, Nine Months Ended December 31,
2020201920202019
Net income$114,588 $104,667 $308,720 $284,586 
  Less: Net income (loss) attributable to noncontrolling
interests
87 (263)171 297 
Net income attributable to shareholders114,501 104,930 308,549 284,289 
Other comprehensive income (loss)
Amortization of pension and postretirement benefit plan costs, (net of taxes of $173, $171, $520 and $512, respectively)
(510)(504)(1,530)(1,515)
Change in cumulative currency translation adjustment128,737 77,299 234,607 12,371 
Total other comprehensive income 128,227 76,795 233,077 10,856 
Comprehensive income $242,728 $181,725 $541,626 $295,145 

See notes to consolidated financial statements.



5


STERIS PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
 
 Nine Months Ended December 31,
 20202019
Operating activities:
Net income$308,720 $284,586 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, depletion, and amortization160,193 146,294 
Deferred income taxes783 (1,139)
Share-based compensation expense19,924 18,862 
Loss (gain) on the disposal of property, plant, equipment, and intangibles, net865 (540)
Loss on sale of businesses, net5 2,553 
Other items4,494 (2,506)
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable, net60,574 29,860 
Inventories, net(7,520)(32,816)
Other current assets(8,906)3,615 
Accounts payable(30,974)(18,610)
Accruals and other, net(6,373)(38,833)
Net cash provided by operating activities501,785 391,326 
Investing activities:
Purchases of property, plant, equipment, and intangibles, net(164,497)(153,649)
Proceeds from the sale of property, plant, equipment and intangibles417 387 
Proceeds from the sale of businesses 439 
Acquisition of businesses, net of cash acquired(869,431)(107,166)
Other(2,392) 
Net cash used in investing activities(1,035,903)(259,989)
Financing activities:
Proceeds from the issuance of long-term obligations550,000  
Payments on long-term obligations
(35,000) 
Proceeds (payments) under credit facilities, net
23,782 (48,467)
Deferred financing fees and debt issuance costs
(3,122)(1,206)
Acquisition related deferred or contingent consideration
(2,968)(452)
Repurchases of ordinary shares
(14,560)(40,322)
Cash dividends paid to ordinary shareholders
(99,696)(91,595)
Contributions from noncontrolling interest2,258 6,050 
Distributions to noncontrolling interest(627)(840)
         Payment for acquisition of subsidiary's interests in noncontrolling interest(3,552) 
Stock option and other equity transactions, net
26,018 22,958 
Net cash provided by (used in) financing activities442,533 (153,874)
Effect of exchange rate changes on cash and cash equivalents24,506 1,134 
(Decrease) in cash and cash equivalents(67,079)(21,403)
Cash and cash equivalents at beginning of period319,581 220,633 
Cash and cash equivalents at end of period$252,502 $199,230 
See notes to consolidated financial statements.
6

STERIS PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended December 31, 2020
Ordinary SharesRetained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Non-controlling
Interest
Total
Equity
  NumberAmount 
Balance at September 30, 202085,251 $1,990,880 $1,786,878 $(130,613)$15,310 $3,662,455 
Comprehensive income:
Net income
  114,501  87 114,588 
Other comprehensive income
   128,227  128,227 
Repurchases of ordinary shares(9)(5,417)5,290   (127)
Equity compensation programs and other95 11,380    11,380 
Cash dividends – $0.40 per ordinary share
  (34,136)  (34,136)
Distributions to noncontrolling interest— — — — (627)(627)
Payment for acquisition of subsidary's interests in noncontrolling interest— — — — (3,552)(3,552)
Other changes in noncontrolling interest    (16)(16)
Balance at December 31, 202085,337 $1,996,843 $1,872,533 $(2,386)$11,202 $3,878,192 

Nine Months Ended December 31, 2020
Ordinary SharesRetained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Non-controlling
Interest
Total
Equity
  NumberAmount 
Balance at March 31, 202084,924 $1,982,164 $1,647,175 $(235,463)$12,848 $3,406,724 
Comprehensive income:
Net income
  308,549  171 308,720 
Other comprehensive income
   233,077  233,077 
Repurchases of ordinary shares(121)(31,065)16,505   (14,560)
Equity compensation programs and other534 45,744    45,744 
Cash dividends – $1.17 per ordinary share
  (99,696)  (99,696)
Contributions from noncontrolling interest     2,258 2,258 
Distributions to noncontrolling interest — — — — (627)(627)
Payment for acquisition of subsidary's interests in noncontrolling interest— — — — (3,552)(3,552)
Other changes in noncontrolling interest    104 104 
Balance at December 31, 202085,337 $1,996,843 $1,872,533 $(2,386)$11,202 $3,878,192 












7



STERIS PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Continued)
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended December 31, 2019
Ordinary SharesRetained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Non-controlling
Interest
Total
Equity
  NumberAmount 
Balance at September 30, 201984,797 $1,981,660 $1,472,725 $(225,717)$8,977 $3,237,645 
Comprehensive income:
Net income
— — 104,930 — (263)104,667 
Other comprehensive income
— — — 76,795 — 76,795 
Repurchases of ordinary shares(25)(669)(1,785)— — (2,454)
Equity compensation programs and other19 6,116 — — — 6,116 
Cash dividends $0.37 per ordinary share
— — (31,375)— — (31,375)
Distributions to noncontrolling interest— — — — (840)(840)
Contributions from noncontrolling interest— — — — 6,050 6,050 
Other changes in noncontrolling interest— — — — (538)(538)
Balance at December 31, 201984,791 $1,987,107 $1,544,495 $(148,922)$13,386 $3,396,066 
Nine Months Ended December 31, 2019
Ordinary SharesRetained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Non-controlling
Interest
Total
Equity
  NumberAmount 
Balance at March 31, 201984,517 $1,998,564 $1,339,024 $(159,778)$7,988 $3,185,798 
Comprehensive income:
Net income
— — 284,289 — 297 284,586 
Other comprehensive income
— — — 10,856 — 10,856 
Repurchases of ordinary shares(304)(53,099)12,777 — — (40,322)
Equity compensation programs and other578 41,642 — — — 41,642 
Cash dividends – $1.08 per ordinary share
— — (91,595)— — (91,595)
Distributions to noncontrolling interest— — — — (840)(840)
Contributions from noncontrolling interest— — — — 6,050 6,050 
Other changes in noncontrolling interest— — — — (109)(109)
Balance at December 31, 201984,791 $1,987,107 $1,544,495 $(148,922)$13,386 $3,396,066 








8


STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)
1. Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
STERIS plc is a leading provider of infection prevention and other procedural products and services. Our MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal ("GI") endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory testing services, on-site and off-site reprocessing, and capital equipment products, such as sterilizers and surgical tables, and connectivity solutions such as operating room (“OR”) integration.
Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below:
Interim Financial Statements
We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented.
These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. The Consolidated Balance Sheet at March 31, 2020 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.
Principles of Consolidation
We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.
Use of Estimates
We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2020 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2021.
Revenue Recognition and Associated Liabilities
We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018. At the time of adoption, certain of our capital equipment contracts were comprised of a single integrated performance obligation, which resulted in the deferral of the corresponding capital equipment revenue and cost of revenues until installation was complete. Since the adoption of the standard, there have been changes made in our selling philosophy, product architecture, and manufacturing processes with respect to this product line, that impact whether the promises to transfer the individual goods or services to the Customer are separately identifiable from other promises in the contract. After review of these changes, we have concluded that these contracts consist of multiple performance obligations that are capable of being distinct and meet the criteria for revenue to be recognized when the Customer obtains control of the asset, which is upon delivery of each performance obligation. Revenues and costs of revenues related to these
9

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


contracts totaling $14,609 and $7,560, respectively, that had previously been deferred were recognized in our fiscal 2021 first quarter.
Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers.
We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets.
In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately.
Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.
We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.
Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2020, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements.
Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue.
Product Revenue
Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation.
Service Revenue
Within our Healthcare and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair.
10

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure.
Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service.
Contract Liabilities
Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2021, $38,181 of the March 31, 2020 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2020, $46,744 of the March 31, 2019 deferred revenue balance was recorded as revenue.
Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances.
Service Liabilities
Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract.
Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances.
Remaining Performance Obligations
Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31 2020, the transaction price allocated to remaining performance obligations was approximately $1,014,800. We expect to recognize approximately 50% of the transaction price within one year and approximately 42% beyond one year. The remainder has yet to be scheduled for delivery.
Recently Issued Accounting Standards Impacting the Company

Recently Issued Accounting Standards Impacting the Company are presented in the following table:
StandardDate of IssuanceDescriptionDate of AdoptionEffect on the financial statements or other significant matters
Standards that have been adopted in fiscal 2021
ASU 2016-13, "Measurement of Credit Losses on Financial Instruments"June 2016The standard required a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard was effective for annual periods beginning after December 15, 2019. First Quarter Fiscal 2021
We adopted this standard effective April 1, 2020 with no material impact to our consolidated financial statements.
11

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement”
August 2018The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy.  The standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.
First Quarter Fiscal 2021We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.
ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans"August 2018The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans.  The standard also clarified disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation.  The standard was effective for fiscal years ending after December 15, 2019.
First Quarter Fiscal 2021
We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.
ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract"August 2018The standard aligned the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or
obtain internal-use software. The standard was effective for fiscal years beginning after December 15, 2019.
First Quarter Fiscal 2021We adopted this standard on April 1, 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.
12

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


Standards that have not yet been adopted
ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)"August 2020
This standard simplifies the accounting for convertible instruments and its application of the derivatives scope exception for contracts in an entity’s own equity. The standard reduces the number of accounting models that require separating embedded conversion features from convertible instruments. As a result, only conversion features accounted for under the substantial premium model and those that require bifurcation will be accounted for separately. For contracts in an entity’s own equity, the new standard eliminates some of the current requirements for equity classification. The standard also addresses how convertible instruments are accounted for in the diluted earnings per share calculation and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity’s own equity. The standard is effective for annual periods beginning after December 15, 2021 and interim periods within that year. Early adoption is permitted for annual periods beginning after December 15, 2020 and interim periods within that year.
N/AWe are in the process of evaluating the impact that the standard will have on our consolidated financial statements.
ASU 2019-12 "Income Taxes (Topic 740)"December 2019The standard provides final guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance simplifies accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted.N/AWe are in the process of evaluating the impact that the standard will have on our consolidated financial statements.
13

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2020.
2. Business Acquisitions and Divestitures
Fiscal 2021
On November 18, 2020, we acquired all of the outstanding units and equity of Key Surgical, LLC ("Key Surgical"). Key Surgical is a global provider of sterile processing, operating room and endoscopy consumable products serving hospitals and surgical facilities. Key Surgical is being integrated into our Healthcare segment. The total purchase price of the acquisition was $849,717, net of cash acquired and remains subject to customary working capital adjustments. Acquisition related costs of $10,842 are reported in the selling, general, and administrative expense line of the Consolidated Statements of Income. The purchase price for the acquisition was financed with a combination of cash on hand, credit facility borrowings and proceeds from the issuance of new long-term obligations. Please refer to note 5 titled, "Debt" for more information.
The table below summarizes the preliminary allocation of the purchase price to the net assets acquired for the Key Surgical acquisition based on fair values at the acquisition date.
(dollars in thousands)
Key Surgical (1)
Cash$12,615 
Accounts receivable13,967 
Inventory22,167 
Property, plant and equipment6,032 
Other assets6,680 
Intangible assets (2)
491,009 
Goodwill423,239 
Total Assets$975,709 
Current liabilities(17,683)
Non-current liabilities(95,694)
Total Liabilities(113,377)
Net Assets$862,332 
(1) Purchase price allocation is still preliminary as of December 31, 2020, as valuation has not been finalized.
(2) Intangible assets resulting from the Key Surgical acquisition may consists of patents, trade names, Customer Relationships, non-compete agreements, and technologies, pending the outcome of the final valuation.

In addition to Key Surgical, we also completed two tuck-in acquisitions during the third quarter fiscal 2021, which continued to expand our product and service offerings in the Healthcare segment. The aggregate purchase price associated with these transactions was approximately $20,908, net of cash acquired and including deferred consideration of $1,194. Acquisition related costs are reported in the selling, general, and administrative expense line of the Consolidated Statements of Income and amounts are not material.
Purchase price allocations will be finalized within a measurement period not to exceed one year from closing.
Fiscal 2020
During the first nine months of fiscal 2020, we completed several tuck-in acquisitions which continued to expand our product and service offerings in the Healthcare and Applied Sterilization Technologies segments. The aggregate purchase price associated with these transactions was approximately $117,259, net of cash acquired and including deferred consideration of $894. Acquisition related costs are reported in the selling, general, and administrative expense line of the Consolidated Statements of Income and amounts are not material. The purchase price for the acquisitions was financed with both cash on hand and with credit facility borrowings.
14

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


Purchase price allocations were finalized within a measurement period not to exceed one year from closing. Any final adjustments recorded were not material.
During the first quarter of fiscal 2020, we sold the operations of our hospital sterilization services business that was located in China. We recorded proceeds of $439, net of cash divested, and recognized a pre-tax loss on the sale of $2,330 in the selling, general and administrative expense line of the Consolidated Statements of Income. The business generated annual revenues of approximately $5,000.
3. Inventories, Net
We use the last-in, first-out (“LIFO”) and first-in, first-out (“FIFO”) cost methods to value inventory. Inventory valued using the LIFO cost method is stated at the lower of cost or market. Inventory valued using the FIFO cost method is stated at the lower of cost or net realizable value. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:
 December 31,
2020
March 31,
2020
Raw materials$102,212 $94,321 
Work in process42,109 35,643 
Finished goods185,762 151,381 
LIFO reserve(18,753)(16,937)
Reserve for excess and obsolete inventory(17,198)(16,149)
Inventories, net$294,132 $248,259 

4. Property, Plant and Equipment
Information related to the major categories of our depreciable assets is as follows:
 December 31,
2020
March 31,
2020
Land and land improvements (1)
$69,591 $65,994 
Buildings and leasehold improvements567,113 531,267 
Machinery and equipment753,851 682,488 
Information systems186,421 181,112 
Radioisotope567,353 508,593 
Construction in progress (1)
211,183 159,731 
Total property, plant, and equipment2,355,512 2,129,185 
Less: accumulated depreciation and depletion(1,128,617)(1,017,330)
Property, plant, and equipment, net$1,226,895 $1,111,855 
(1)Land is not depreciated. Construction in progress is not depreciated until placed in service.

15

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


5. Debt
Indebtedness was as follows:
 December 31,
2020
March 31,
2020
Credit Agreement$304,618 $275,449 
Term Loan550,000  
Private Placement 864,425 878,409 
Deferred financing costs(5,844)(3,337)
Total long term debt$1,713,199 $1,150,521 
On November 18, 2020, we entered into a Term Loan Agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Credit Agreement”) providing for a $550,000 Term Loan (the “Term Loan”) in connection with our acquisition of Key Surgical. The proceeds of the Term Loan were used to fund a portion of the purchase price, to prepay and terminate existing indebtedness of Key Surgical and to pay fees and expenses incurred in connection with the Key Surgical acquisition and entry into the Credit Agreement. For more information on the Key Surgical acquisition refer to Note 2 titled, "Business Acquisitions and Divestitures".
The Term Loan matures on November 20, 2023. No principal payments are due on the Term Loan for the period ending December 31, 2021. For the period beginning January 1, 2022 through December 31, 2022, quarterly principal payments, each in the amount of 1.25% of the original principal amount of the Term Loan, are due on the last business day of each fiscal quarter. For the period beginning January 1, 2023 through September 30, 2023, quarterly principal payments, each in the amount of 1.875% of the original principal amount of the Term Loan, are due on the last business day of each fiscal quarter. The remaining unpaid principal balance of the Term Loan, together with accrued and unpaid interest thereon, is due and payable on November 20, 2023.
The Term Loan bears interest from time to time at either the Base Rate or the Eurocurrency Rate, plus the Applicable Margin, as calculated and defined in the Credit Agreement. The Applicable Margin is determined based on the ratio of Consolidated Total Debt to Consolidated EBITDA, each as defined in the Credit Agreement. Interest on borrowings made at the Base Rate (“Base Rate Advances”) is payable quarterly in arrears and interest on borrowings made at the Eurocurrency Rate (“Eurocurrency Rate Advances”) is payable at the end of the relevant interest period therefor, but in no event less frequently than every three months. There is no premium or penalty for prepayment of Base Rate Advances, but prepayments of Eurocurrency Rate Advances are subject to a breakage fee.
All of the lenders under the Credit Agreement are also lenders under our revolving credit agreement dated as of March 23, 2018.
Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.
16

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


6. Additional Consolidated Balance Sheet Information
Additional information related to our Consolidated Balance Sheets is as follows:
 December 31,
2020
March 31,
2020
Accrued payroll and other related liabilities:
Compensation and related items$67,883 $42,205 
Accrued vacation/paid time off14,663 9,917 
Accrued bonuses51,100 53,041 
Accrued employee commissions14,591 19,298 
Other postretirement benefit obligations-current portion1,488 1,488 
Other employee benefit plans obligations-current portion2,606 2,312 
Total accrued payroll and other related liabilities$152,331 $128,261 
Accrued expenses and other:
Deferred revenues$44,308 $53,299 
Service liabilities38,948 47,505 
Self-insured risk reserves-current portion9,711 7,342 
Accrued dealer commissions25,174 15,827 
Accrued warranty6,796 7,381 
Asset retirement obligation-current portion1,202 2,671 
Other58,494 58,158 
Total accrued expenses and other$184,633 $192,183 
Other liabilities:
Self-insured risk reserves-long-term portion$17,452 $17,452 
Other postretirement benefit obligations-long-term portion8,587 9,880 
Defined benefit pension plans obligations-long-term portion10,152 10,987 
Other employee benefit plans obligations-long-term portion2,341 2,333 
Accrued long-term income taxes10,841 11,959 
Asset retirement obligation-long-term portion12,379 9,843 
Other27,512 27,892 
Total other liabilities$89,264 $90,346 
7. Income Tax Expense
The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The TCJA reduced the U.S. federal corporate income tax rate to 21.0%, required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and created new taxes on certain foreign sourced earnings. The Company applied the guidance in Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cut and Jobs Act when accounting for the enactment-date effects of the TCJA.
We consider the tax expense recorded for the TCJA to be complete at this time. However, it is possible that additional legislation, regulations and/or guidance may be issued in the future that may result in additional adjustments to the tax expense recorded related to the TCJA. We will continue to monitor and assess the impact of any new developments.
The effective income tax rates for the three month periods ended December 31, 2020 and 2019 were 17.8% and 21.9%, respectively. The effective income tax rates for the nine month periods ended December 31, 2020 and 2019 were 18.8% and 18.8%, respectively. The fiscal 2021 effective tax rate for the current quarter decreased when compared to fiscal 2020, primarily due to an increase in favorable discrete items.
Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various
17

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.
We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2016 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2015. We remain subject to tax authority audits in various jurisdictions wherever we do business.
In May 2019, we received two notices of proposed tax adjustment from the U.S. Internal Revenue Service (the “IRS”) regarding the deductibility of interest paid on certain intercompany debt. The notices relate to fiscal years 2016 and 2017. In September 2019, we received another notice of proposed adjustment for the same issue, for the 2018 fiscal year. The IRS adjustments would result in a cumulative tax liability of approximately $40,000. Notices have not been received for subsequent periods. We are contesting the IRS’s assertions. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but could be material to our consolidated results of operations and cash flows for any one period.
8. Commitments and Contingencies
We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief.
We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us.
Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations.
For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020: Item 1 titled “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factors” in Item 1A titled "Product related regulations and claims".
From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized.
We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q.
9. Business Segment Information
18

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies and Life Sciences. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income.
Prior to April 1, 2020, we operated and reported our financial information in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products and Healthcare Specialty Services segments were combined and are now reported as one segment, simply called Healthcare, consistent with the way management now operates and views the business. Prior periods have been recast in the financial tables below for comparability.
Our Healthcare segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. The segment also provides a range of specialty services for healthcare providers including hospital sterilization services and instrument and scope repairs.
Our Applied Sterilization Technologies ("AST") segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers.
Our Life Sciences segment designs, manufactures and sells consumable products, equipment maintenance, specialty services and capital equipment primarily to pharmaceutical manufacturers around the world.
We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company.
For the three and nine months ended December 31, 2020, revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
19

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


Financial information for each of our segments is presented in the following table:
 Three Months Ended December 31, Nine Months Ended December 31,
 2020201920202019
Revenues:
Healthcare $521,662 $509,222 $1,392,247 $1,440,237 
Applied Sterilization Technologies176,462 156,266 498,371 463,459 
Life Sciences110,800 108,773 343,370 304,208 
Total revenues$808,924 $774,261 $2,233,988 $2,207,904 
Operating income (loss):
Healthcare$115,412 $105,227 $302,565 $298,777 
Applied Sterilization Technologies81,626 65,468 222,416 198,889 
Life Sciences41,541 37,731 136,435 103,085 
Corporate(47,941)(45,260)(158,463)(151,613)
Total operating income before adjustments$190,638 $163,166 $502,953 $449,138 
Less: Adjustments
Amortization of acquired intangible assets (1)
$23,194 $17,508 $62,649 $53,407 
Acquisition and integration related charges (2)
11,563 1,721 13,984 5,585 
Redomiciliation and tax restructuring costs (3)
296 487 850 3,274 
(Gain) on fair value adjustment of acquisition related contingent consideration(500) (500) 
Net loss on divestiture of businesses (1)
 76 5 2,553 
Amortization of inventory and property "step up" to fair value (1)
1,784 602 3,101 1,783 
COVID-19 incremental costs (4)
7,251  20,460  
Restructuring charges (5)
20 385 110 3,328 
Total operating income$147,030 $142,387 $402,294 $379,208 
(1) For more information regarding our recent acquisitions and divestitures refer to Note 2 titled" Business Acquisitions and Divestitures" and our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.
(3) Costs incurred in connection with the Redomiciliation and tax restructuring.
(4) COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.
(5) For more information regarding our restructuring efforts refer to Note 17 titled, "Restructuring".

Additional information regarding our fiscal 2021 and fiscal 2020 revenue is disclosed in the following tables:
20

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


 Three Months Ended December 31, Nine Months Ended December 31,
 2020201920202019
Healthcare:
Capital equipment$147,855 $155,408 $407,610 428,894
Consumables148,839 130,255 355,390 362,370
Service224,968 223,559 629,247 648,973 
Total Healthcare Revenues $521,662 $509,222 $1,392,247 $1,440,237 
Applied Sterilization Technologies Service Revenues$176,462 $156,266 $498,371 $463,459 
Life Sciences:
Capital equipment
$28,993 $31,762 $88,664 $84,993 
Consumables49,627 46,370 164,262 132,939 
Service32,180 30,641 90,444 86,276 
Total Life Sciences Revenues$110,800 $108,773 $343,370 $304,208 
Total Revenues$808,924 $774,261 $2,233,988 $2,207,904 
Three Months Ended December 31, Nine Months Ended December 31,
2020201920202019
Revenues:
Ireland$20,316 $16,126 $51,779 $46,405 
United States572,397 562,502 1,613,554 1,611,755 
Other locations216,211 195,633 568,655 549,744 
Total Revenues
$808,924 $774,261 $2,233,988 $2,207,904 
Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments.
Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.
December 31, 2020March 31, 2020
Assets:
Healthcare and Life Sciences$3,595,753 $2,705,377 
Applied Sterilization Technologies2,985,027 2,720,205 
Total assets
$6,580,780 $5,425,582 

The fiscal 2021 increase in Healthcare and Life Sciences was primarily due to the acquisition of Key Surgical.

10. Shares and Preferred Shares
Ordinary shares
We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method.
The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share:
21

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


 Three Months Ended December 31, Nine Months Ended December 31,
Denominator (shares in thousands):2020201920202019
Weighted average shares outstanding—basic85,330 84,788 85,153 84,740 
Dilutive effect of share equivalents702 840 698 890 
Weighted average shares outstanding and share equivalents—diluted86,032 85,628 85,851 85,630 
Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:
 Three Months Ended December 31, Nine Months Ended December 31,
(shares in thousands)2020201920202019
Number of share options278 347 370 270 
Additional Authorized Shares
 The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.
11. Repurchases of Ordinary Shares
On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $78,979 (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). As of December 31, 2020, there was approximately $333,932 (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program. The share repurchase program has no specified expiration date.
Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020.
From the start of fiscal 2021 through April 9, 2020, we repurchased 35,000 of our ordinary shares for the aggregate amount of $5,047 (net of fees and commissions) pursuant to the authorizations. During the first nine months of fiscal 2020, we repurchased 205,059 of our ordinary shares for the aggregate amount of $30,000 (net of fees and commissions) pursuant to the authorizations.
During the first nine months of fiscal 2021 we obtained 85,574 of our ordinary shares in the aggregate amount of $9,512 in connection with share based compensation award programs. During the first nine months of fiscal 2020, we obtained 100,124 of our ordinary shares in the aggregate amount of $10,318 in connection with share based compensation award programs.

22

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


12. Share-Based Compensation
We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Board of Directors or the Compensation and Organizational Development Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares.
Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of December 31, 2020, 3,592,261 ordinary shares remained available for grant under the long-term incentive plan.
The fair value of stock option awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits.
The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2021 and 2020:
 Fiscal 2021Fiscal 2020
Risk-free interest rate0.46 %2.26 %
Expected life of options6.0 years6.2 years
Expected dividend yield of stock0.96 %1.22 %
Expected volatility of stock23.04 %20.27 %
The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.78% and 2.77% was applied in fiscal 2021 and 2020, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually.
A summary of share option activity is as follows:
 Number of
Options
Weighted
Average
Exercise
Price Per Share
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at March 31, 20201,796,126 $91.29 
Granted288,936 181.33 
Exercised(385,090)68.75 
Forfeited(47,955)121.18 
Outstanding at December 31, 20201,652,017 $111.43 6.9 years$129,044 
Exercisable at December 31, 2020897,953 $83.41 5.6 years$95,303 
We estimate that 736,801 of the non-vested stock options outstanding at December 31, 2020 will ultimately vest.
23

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


The aggregate intrinsic value in the table above represents the total pre-tax difference between the $189.54 closing price of our ordinary shares on December 31, 2020 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares.
The total intrinsic value of stock options exercised during the first nine months of fiscal 2021 and fiscal 2020 was $36,850 and $36,939, respectively. Net cash proceeds from the exercise of stock options were $26,018 and $22,958 for the first nine months of fiscal 2021 and fiscal 2020, respectively.
The weighted average grant date fair value of stock option grants was $27.66 and $23.52 for the first nine months of fiscal 2021 and fiscal 2020, respectively.
Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of December 31, 2020 and 2019 was $491 and $629, respectively.
A summary of the non-vested restricted share and share unit activity is presented below:
 Number of
Restricted
Shares
Number of Restricted Share UnitsWeighted-Average
Grant Date
Fair Value
Non-vested at March 31, 2020575,830 30,894 $98.07 
Granted139,229 14,208 164.58 
Vested(158,250)(16,238)84.61 
Forfeited(23,997)(228)103.36 
Non-vested at December 31, 2020532,812 28,636 $120.26 
Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during the first nine months of fiscal 2021 at the time of grant was $14,764.
As of December 31, 2020, there was a total of $51,583 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plan. We expect to recognize the cost over a weighted average period of 2.1 years.
13. Financial and Other Guarantees
We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.
Changes in our warranty liability during the first nine months of fiscal 2021 were as follows:
Warranties
Balance, March 31, 2020$7,381 
Warranties issued during the period7,411 
Settlements made during the period(7,996)
Balance, December 31, 2020$6,796 
14. Derivatives and Hedging
From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. During the third quarter of
24

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


fiscal 2021, we also held forward foreign currency contracts to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature during fiscal 2021. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes.
None of these contracts are designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At December 31, 2020, we held foreign currency forward contracts to buy 30.5 million British pounds, 35.0 million Mexican pesos and 2.2 million Canadian dollars; and to sell 4.0 million euros. At December 31, 2020 we held commodity swap contracts to buy 946.8 thousand pounds of nickel.
 Asset DerivativesLiability Derivatives
Fair Value atFair Value atFair Value atFair Value at
Balance sheet locationDecember 31, 2020March 31, 2020December 31, 2020March 31, 2020
Prepaid & Other$1,377 $124 $ $ 
Accrued expenses and other$ $ $659 $912 
The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:
 Location of gain (loss)
recognized in income
Amount of gain (loss) recognized in income
Three Months Ended December 31, Nine Months Ended December 31,
2020201920202019
Foreign currency forward contractsSelling, general and administrative$741 $79 $661 $784 
Commodity swap contractsCost of revenues$153 $(398)$904 $271 
Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $51,323 at December 31, 2020. These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.
25

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


15. Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions.
The following table shows the fair value of our financial assets and liabilities at December 31, 2020 and March 31, 2020:
  Fair Value Measurements
 Carrying ValueQuoted Prices
in Active Markets
for Identical Assets
Significant Other
Observable Inputs
Significant
Unobservable
Inputs
Level 1Level 2Level 3
December 31,March 31,December 31,March 31,December 31,March 31,December 31,March 31,
Assets:
Cash and cash equivalents$252,502 $319,581 $252,502 $319,581 $ $ $ $ 
Forward and swap contracts (1)
1,377 124   1,377 124   
Equity investments(2)
10,484 9,624 10,484 9,624     
Other investments 2,785 2,507 2,785 2,507     
Liabilities:
Forward and swap contracts (1)
$659 $912 $ $ $659 $912 $ $ 
Deferred compensation plans (2)
1,822 1,475 1,822 1,475     
Long term debt (3)
1,713,199 1,150,521   1,781,304 1,143,978   
Contingent consideration obligations (4)
17,931 15,988     17,931 15,988 
(1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
(2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the third quarter and first nine months of fiscal 2021, we recorded gains of $210 and $138, respectively, related to these investments. During the third quarter and first nine months of fiscal 2020, we recorded gains (losses) of $636 and $(1,843), respectively, related to these investments.
(3) We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
(4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.


26

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2020 are summarized as follows:
Contingent Consideration
Balance at March 31, 2020$15,988 
Additions334 
Assumed in acquisition of Key Surgical2,940 
Payments(917)
Reversal (500)
Currency translation adjustments86 
Balance at December 31, 2020$17,931 
27

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


16. Reclassifications Out of Accumulated Other Comprehensive Income (Loss)
Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended December 31, 2020 and 2019 were as follows:
Defined Benefit Plans (1)
Currency Translation (2)
Total Accumulated Other Comprehensive Income (Loss)
Three MonthsNine MonthsThree MonthsNine MonthsThree MonthsNine Months
Beginning Balance$(7,833)$(6,813)$(122,780)$(228,650)$(130,613)$(235,463)
Other Comprehensive Income before reclassifications323 972 128,737 234,607 129,060 235,579 
Amounts reclassified from Accumulated Other Comprehensive (Loss) (833)(2,502)  (833)(2,502)
Net current-period Other Comprehensive (Loss) Income(510)(1,530)128,737 234,607 128,227 233,077 
Balance at December 31, 2020$(8,343)$(8,343)$5,957 $5,957 $(2,386)$(2,386)
(1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.
(2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
Defined Benefit Plans (1)
Currency Translation (2)
Total Accumulated Other Comprehensive Income (Loss)
Three MonthsNine MonthsThree MonthsNine MonthsThree MonthsNine Months
Beginning Balance$(5,215)$(4,204)$(220,502)$(155,574)$(225,717)$(159,778)
Other Comprehensive Income (Loss) before reclassifications195 576 77,299 12,371 77,494 12,947 
Amounts reclassified from Accumulated Other Comprehensive (Loss)(699)(2,091)  (699)(2,091)
Net current-period Other Comprehensive (Loss)(504)(1,515)77,299 12,371 76,795 10,856 
Balance at December 31, 2019$(5,719)$(5,719)$(143,203)$(143,203)$(148,922)$(148,922)
(1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.
(2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.


28

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


17. Restructuring
Fiscal 2019 Restructuring Plan. During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions were eliminated. The Company relocated the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions were designed to enhance profitability and improve efficiency.
Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $43,961 related to these restructuring actions, of which $31,660 was recorded as restructuring expenses and $12,301 was recorded in cost of revenues, with a total of $34,062, $7,568 and $668 related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1,663. Additional restructuring expenses related to this plan are not expected to be material to our results of operations.
Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The remaining liability balances at December 31, 2020 and March 31, 2020 are not material.
For more information relating to our restructuring efforts, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.
18. Loans Receivable
In connection with an equity investment of $4,955, we agreed to provide a credit facility of up to approximately $11,606 for a term of up to seven years ending in 2025. The loan carries an interest rate of 4% compounded daily and payable annually. Outstanding principal borrowings under the agreement totaled $10,326 at December 31, 2020 and $7,084 at March 31, 2020. On January 4, 2021, we purchased the remaining outstanding shares of this equity investment. The acquisition agreement included the capitalization of the outstanding principal and interest borrowings of this credit facility in the amount of $10,536. For more information refer to Note 20, titled, "Subsequent Events".

In connection with the fiscal 2017 divestiture of Synergy Health Netherlands Linen Management Services, we entered into a loan agreement to provide financing of up to €15,000 for a term of up to 15 years. The loan carried an interest rate of 4% for the first four years and 12% thereafter. The loan was renegotiated during the third quarter of fiscal 2020. According to the new terms of the loan agreement, the outstanding balance at October 31, 2019, of €7,300, will be repaid in six equal annual installments beginning on October 18, 2022. The loan carries an interest rate of 4% for the first four years and 8% thereafter. Outstanding principal borrowings under the agreement totaled $8,966 (or €7,300) at December 31, 2020 and $8,072 (or €7,300) at March 31, 2020.
Amounts for loan receivables as noted above are recorded in the "Other assets" line of our Consolidated balance sheets. Interest income is not material.
19. COVID-19 Pandemic
The COVID-19 pandemic began to impact our business late in fiscal 2020. The pandemic and related public health recommendations and mandated precautions to mitigate the spread of COVID-19, including deferral of medical procedures and treatments and shelter-in-place orders or similar measures, have negatively affected and are expected to continue to negatively affect some of our operations, which may impact our financial position and cash flows. We have experienced and expect to continue to experience unpredictable fluctuations in demand for certain of our products and services, including some products and services that are experiencing increased demand. To date, we do not believe that the COVID-19 pandemic has had a significant impact on our operations, as we have been able to continue to operate our manufacturing facilities and meet the demand for essential products and services of our Customers. In response to the pandemic, we have implemented several measures that we believe will help us to protect the health and safety of our employees, preserve liquidity and enhance our financial flexibility. For our employees, we allowed employees to work remotely when possible and have implemented additional safety measures in compliance with applicable regulations to allow personnel to continue to work in our facilities. We suspended all non-essential travel and enacted a temporary hiring freeze on certain positions. To manage liquidity, we have suspended our stock repurchase program and deferred certain planned capital expenditures; however, we have continued to invest in expansion projects as planned. We do not believe that these actions will negatively impact our long-term ability to generate revenues or meet existing and future financial obligations.
29

STERIS PLC AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
For the Three and Nine Months Ended December 31, 2020 and 2019
(dollars in thousands, except as noted)


While we have been impacted and expect this situation to continue to have an impact on our business, the full impact to our results of operations and financial position cannot be reasonably estimated at this time. For additional information and our risk factors related to the COVID-19 pandemic, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.
20. Subsequent Events
On January 12, 2021, we announced the signing of a definitive agreement to acquire Cantel Medical Corp. (NYSE: CMD "Cantel"), through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and dental Customers. Under the terms of the agreement, we will acquire Cantel in a cash and stock transaction valued at $84.66 per Cantel common share, based on STERIS’s closing share price of $200.46 on January 11, 2021. This represents a total equity value of approximately $3.6 billion and a total enterprise value of approximately $4.6 billion. The agreement has been unanimously approved by the Boards of Directors of both companies. The acquisition is subject to certain closing conditions, including Cantel shareholder vote and regulatory approvals.
We expect to fund the cash portion of the transaction consideration and repay or otherwise satisfy a significant amount of Cantel’s existing debt obligations with approximately $2.0 billion of new debt. We have fully committed bridge financing and are working with our lenders and advisors on a long-term plan.
On January 4, 2021, we purchased the remaining outstanding shares of an equity investment that we made in fiscal 2019, for approximately $44,255, subject to any working capital adjustments. In addition to the purchase price, the acquisition agreement included the capitalization of the outstanding principal and accumulated interest under a credit facility in the amount of $10,536. For more information refer to Note 18 titled, "Loans Receivable". We plan to integrate the business into our Applied Sterilization Technologies business segment and to fund the transaction through a combination of cash on hand and credit facility borrowings.


30


Report of Independent Registered Public Accounting Firm


To the Shareholders and Board of Directors of STERIS plc
Results of Review of Interim Financial Statements

We have reviewed the accompanying consolidated balance sheet of STERIS plc and subsidiaries (the Company) as of December 31, 2020, the related consolidated statements of income, comprehensive income and shareholders’ equity for the three- and nine- month periods ended December 31, 2020 and 2019 and the consolidated statement of cash flows for the nine- month periods ended December 31, 2020 and 2019, and the related notes (collectively referred to as the “consolidated interim financial statements”). Based on our reviews, we are not aware of any material modifications that should be made to the consolidated interim financial statements for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company
Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company as of March 31, 2020, the related consolidated statements of income, comprehensive income, shareholders' equity and cash flows for the year then ended, and the related notes and schedule (not presented herein); and in our report dated May 29, 2020, we expressed an unqualified audit opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of March 31, 2020, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

Basis for Review Results

These financial statements are the responsibility of the Company's management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the SEC and the PCAOB. We conducted our review in accordance with the standards of the PCAOB. A review of interim financial statements consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.


/s/ Ernst & Young LLP

Cleveland, Ohio
February 9, 2021





31


ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Introduction
In Management’s Discussion and Analysis of Financial Condition and Results of Operations (the “MD&A”), we explain the general financial condition and the results of operations for STERIS including:
what factors affect our business;
what our earnings and costs were in each period presented; 
why those earnings and costs were different from prior periods;
where our earnings came from;
how this affects our overall financial condition;
what our expenditures for capital projects were; and
where cash will come from to fund future debt principal repayments, growth outside of core operations, repurchases of shares, cash dividends and future working capital needs.
As you read the MD&A, it may be helpful to refer to information in our consolidated financial statements, which present the results of our operations for the third quarter and first nine months of fiscal 2021 and fiscal 2020. It may also be helpful to read the MD&A in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. In the MD&A, we analyze and explain the period-over-period changes in the specific line items in the Consolidated Statements of Income. Our analysis may be important to you in making decisions about your investments in STERIS.
Financial Measures
In the following sections of the MD&A, we may, at times, refer to financial measures that are not required to be presented in the consolidated financial statements under U.S. GAAP. We sometimes use the following financial measures in the context of this report: backlog; debt-to-total capital; and days sales outstanding. We define these financial measures as follows:
Backlog – We define backlog as the amount of unfilled capital equipment purchase orders at a point in time. We use this figure as a measure to assist in the projection of short-term financial results and inventory requirements.
Debt-to-total capital – We define debt-to-total capital as total debt divided by the sum of total debt and shareholders’ equity. We use this figure as a financial liquidity measure to gauge our ability to borrow and fund growth.
Days sales outstanding (“DSO”) – We define DSO as the average collection period for accounts receivable. It is calculated as net accounts receivable divided by the trailing four quarters’ revenues, multiplied by 365 days. We use this figure to help gauge the quality of accounts receivable and expected time to collect.
We, at times, may also refer to financial measures which are considered to be “non-GAAP financial measures” under SEC rules. We have presented these financial measures because we believe that meaningful analysis of our financial performance is enhanced by an understanding of certain additional factors underlying that performance. These financial measures should not be considered an alternative to measures required by accounting principles generally accepted in the United States. Our calculations of these measures may differ from calculations of similar measures used by other companies and you should be careful when comparing these financial measures to those of other companies. Additional information regarding these financial measures, including reconciliations of each non- GAAP financial measure, is available in the subsection of MD&A titled, "Non-GAAP Financial Measures."
Revenues – Defined
As required by Regulation S-X, we separately present revenues generated as either product revenues or service revenues on our Consolidated Statements of Income for each period presented. When we discuss revenues, we may, at times, refer to revenues summarized differently than the Regulation S-X requirements. The terminology, definitions, and applications of terms that we use to describe revenues may be different from terms used by other companies. We use the following terms to describe revenues:
Revenues – Our revenues are presented net of sales returns and allowances.
Product Revenues – We define product revenues as revenues generated from sales of consumable and capital equipment products.
Service Revenues – We define service revenues as revenues generated from parts and labor associated with the maintenance, repair, and installation of our capital equipment. Service revenues also include hospital sterilization services, instrument and scope repairs, as well as revenues generated from contract sterilization and laboratory services offered through our Applied Sterilization Technologies segment.
32

Capital Equipment Revenues – We define capital equipment revenues as revenues generated from sales of capital equipment, which includes: steam and gas sterilizers, low temperature liquid chemical sterilant processing systems, pure steam/water systems, surgical lights and tables, and integrated OR.
Consumable Revenues – We define consumable revenues as revenues generated from sales of the consumable family of products, which includes dedicated consumables including V-PRO, SYSTEM 1 and 1E consumables, gastrointestinal endoscopy accessories, sterility assurance products, barrier protection solutions, cleaning consumables, and surgical instruments.
Recurring Revenues – We define recurring revenues as revenues generated from sales of consumable products and service revenues.
General Company Overview and Executive Summary
STERIS plc is a leading provider of infection prevention and other procedural products and services. Our MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal ("GI") endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory testing services, on-site and off-site reprocessing, and capital equipment products, such as sterilizers and surgical tables, and connectivity solutions such as operating room (“OR”) integration.
We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies and Life Sciences. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. We describe our business segments in Note 9 to our consolidated financial statements, titled "Business Segment Information."
The bulk of our revenues are derived from the healthcare and pharmaceutical industries. Much of the growth in these industries is driven by the aging of the population throughout the world, as an increasing number of individuals are entering their prime healthcare consumption years, and is dependent upon advancement in healthcare delivery, acceptance of new technologies, government policies, and general economic conditions. The pharmaceutical industry has been impacted by increased regulatory scrutiny of cleaning and validation processes, mandating that manufacturers improve their processes. Within healthcare, there is increased concern regarding the level of hospital acquired infections around the world; increased demand for medical procedures, including preventive screenings such as endoscopies and colonoscopies; and a desire by our Customers to operate more efficiently, all of which are driving increased demand for many of our products and services. During the first nine months of fiscal 2021, we experienced reduced demand for certain products and services resulting from the reduction of deferrable surgical procedures and increased demand for other products from our pharma Customers focused on vaccines and biologics, as a result of the COVID-19 pandemic. For more information on the COVID-19 pandemic please refer to the subsection below, titled "COVID-19 Pandemic".
Acquisitions and Divestitures. On November 18, 2020, we acquired all of the outstanding units and equity of Key Surgical, LLC ("Key Surgical"). Key Surgical is a global provider of sterile processing, operating room and endoscopy consumable products serving hospitals and surgical facilities. Key Surgical is being integrated into our Healthcare segment. The total purchase price of the acquisition was $849.7 million, net of cash acquired and remains subject to customary working capital adjustments. In addition to Key Surgical we also completed two tuck-in acquisitions during the third fiscal quarter of 2021, which continued to expand our product and service offerings in the Healthcare segment. The aggregate purchase price associated with these transactions was approximately $20.9 million, net of cash acquired and including deferred consideration of $1.2 million.
On January 12, 2021, we announced the signing of a definitive agreement to acquire Cantel Medical Corp. (NYSE: CMD "Cantel"), through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and dental Customers. Under the terms of the agreement, we will acquire Cantel in a cash and stock transaction valued at $84.66 per Cantel common share, based on STERIS’s closing share price of $200.46 on January 11, 2021. This represents a total equity value of approximately $3.6 billion and a total enterprise value of approximately $4.6 billion. The agreement has been unanimously approved by the Boards of Directors of both companies. The acquisition is subject to certain closing conditions, including Cantel shareholder vote and regulatory approvals. We expect to fund the cash portion of the transaction consideration and repay or otherwise satisfy a significant amount of Cantel’s existing debt obligations with approximately $2.0 billion of new debt. We have fully committed bridge financing and are working with our lenders and advisors on a long-term plan.
During the first nine months of fiscal 2020, we completed several tuck-in acquisitions which continued to expand our product and service offerings in the Healthcare and Applied Sterilization Technologies segments. The aggregate purchase price associated with these transactions was approximately $117.3 million, net of cash acquired and including deferred consideration of $0.9 million.
33

COVID-19 Pandemic. The COVID-19 pandemic began to impact our business late in fiscal 2020. The pandemic and related public health recommendations and mandated precautions to mitigate the spread of COVID-19, including deferral of medical procedures and treatments and shelter-in-place orders or similar measures, have negatively affected and are expected to continue to negatively affect some of our operations, which may impact our financial position and cash flows. We have experienced and expect to continue to experience unpredictable fluctuations in demand for certain of our products and services, including some products and services that are experiencing increased demand. To date, we do not believe that the COVID-19 pandemic has had a significant impact on our operations, as we have been able to continue to operate our manufacturing facilities and meet the demand for essential products and services of our Customers. In response to the pandemic, we have implemented several measures that we believe will help us to protect the health and safety of our employees, preserve liquidity and enhance our financial flexibility. For our employees, we allowed employees to work remotely when possible and have implemented additional safety measures in compliance with applicable regulations to allow personnel to continue to work in our facilities. We suspended all non-essential travel and enacted a temporary hiring freeze on certain positions. To manage liquidity, we have suspended our stock repurchase program and deferred certain planned capital expenditures; however, we have continued to invest in expansion projects as planned. We do not believe that these actions will negatively impact our long-term ability to generate revenues or meet existing and future financial obligations.
While we have been impacted and expect this situation to continue to have an impact on our business, the full impact to our results of operations and financial position cannot be reasonably estimated at this time. For additional information and our risk factors related to the COVID-19 pandemic, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.
Highlights. Revenues increased 4.5%, to $808.9 million for the three months ended December 31, 2020, as compared to $774.3 million for the same period in the prior year. This increase reflects growth in all business segments and favorable fluctuations in currencies. Growth in the Healthcare segment was primarily attributable to the impact of our recent acquisitions. Growth in the Applied Sterilization Technologies segment was primarily due to volume. Growth in the Life Sciences segment was due to increased demand for our products and services from our pharma Customers focused on vaccines and biologics. Revenues increased 1.2%, to $2,234.0 million for the nine months ended December 31, 2020, as compared to $2,207.9 million for the same period in the prior year. The increase reflects organic growth in the Applied Sterilization Technologies and Life Sciences segments and favorable fluctuations in currencies, which were partially offset by a decline in the Healthcare segment. Growth in the Applied Sterilization Technologies segment was primarily due to volume. Growth in the Life Sciences segment was due to increased demand for our products and services from our pharma Customers focused on vaccines and biologics. The decline in the Healthcare segment was primarily due to reduced demand for our products and services resulting from the reduction of deferrable surgical procedures as a result of the COVID-19 pandemic and reduced capital spending by Customers in response to the uncertainty surrounding the COVID-19 pandemic. The Healthcare decline was partially offset by the impact of our recent acquisitions and the recognition of $14.6 million of capital equipment revenues that were previously deferred, recorded in the first quarter of fiscal 2021 (for more information regarding this change refer to Note 1 of the consolidated statements, titled "Nature of Operations and Summary of Significant Accounting Policies").
Gross profit percentage for the third quarter of fiscal 2021 remained flat at 42.8% compared to the gross profit percentage for the third quarter of fiscal 2020. The favorable impact of improved productivity, favorable pricing, and recent acquisitions, were offset by the unfavorable impact of incremental costs associated with COVID-19 and mix and other. Gross profit percentage for the first nine months of fiscal 2021 was 43.0% compared to the gross profit percentage for the first nine months of fiscal 2020 of 43.3%. The unfavorable impact of incremental costs associated with COVID-19 and mix and other, exceeded the benefits of favorable pricing and improved productivity.
Operating income for the third quarter of fiscal 2021 was $147.0 million, compared to $142.4 million for third quarter of fiscal 2020. This increase was primarily attributable to increased revenues. Additional expenses from our recent acquisitions were partially offset by reduced selling, general, and administrative (“SG&A”) expenses during the third quarter of fiscal 2021, as certain expenses were suspended or decreased as a result of the COVID-19 pandemic. Operating income during the first nine months of fiscal 2021 was $402.3 million, compared to $379.2 million for the first nine months of fiscal 2020. This increase was primarily attributable to increased revenues and reduced SG&A expenses during the first nine months of fiscal 2021, as certain expenses were suspended or reduced as a result of the COVID-19 pandemic.
Cash flows from operations were $501.8 million and free cash flow was $337.7 million in the first nine months of fiscal 2021 compared to cash flows from operations of $391.3 million and free cash flow of $238.1 million for first nine months of fiscal 2020 (see the subsection below titled "Non-GAAP Financial Measures" for additional information and related reconciliation of cash flows from operations to free cash flow). The fiscal 2021 increases in cash flows from operations and free cash flow were primarily due to higher net income, working capital improvements and deferred tax payments under government COVID-19 relief programs.
34

Our debt-to-total capital ratio was 30.7% at December 31, 2020 and 25.3% at March 31, 2020. During the first nine months of fiscal 2021, we declared and paid quarterly cash dividends of $1.17 per ordinary share.
Additional information regarding our financial performance during the third quarter and first nine months of fiscal 2021 is included in the subsection below titled “Results of Operations.”
NON-GAAP FINANCIAL MEASURES
We, at times, refer to financial measures which are considered to be “non-GAAP financial measures” under SEC rules. We, at times, also refer to our results of operations excluding certain transactions or amounts that are non-recurring or are not indicative of future results, in order to provide meaningful comparisons between the periods presented.
These non-GAAP financial measures are not intended to be, and should not be, considered separately from or as an alternative to the most directly comparable GAAP financial measures.
These non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision-making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.
We believe that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures and the reconciliation to the corresponding GAAP financial measures, provide the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.
We define free cash flow as net cash provided by operating activities as presented in the Consolidated Statements of Cash Flows less purchases of property, plant, equipment, and intangibles plus proceeds from the sale of property, plant, equipment, and intangibles, which are also presented within investing activities in the Consolidated Statements of Cash Flows. We use this as a measure to gauge our ability to pay cash dividends, fund growth outside of core operations, fund future debt principal repayments, and repurchase shares.
The following table summarizes the calculation of our free cash flow for the nine months ended December 31, 2020 and 2019: 
 Nine Months Ended December 31,
(dollars in thousands)20202019
Net cash provided by operating activities$501,785 $391,326 
Purchases of property, plant, equipment and intangibles, net(164,497)(153,649)
Proceeds from the sale of property, plant, equipment and intangibles417 387 
Free cash flow$337,705 $238,064 
Results of Operations
In the following subsections, we discuss our earnings and the factors affecting them for the third quarter and first nine months of fiscal 2021 compared with the same fiscal 2020 periods. We begin with a general overview of our operating results and then separately discuss earnings for our operating segments.
35

Revenues. The following tables compare our revenues for the three and nine months ended December 31, 2020 to the revenues for the three and nine months ended December 31, 2019:
 Three Months Ended December 31,
(dollars in thousands)20202019ChangePercent Change
Total revenues$808,924 $774,261 $34,663 4.5 %
Revenues by type:
Service revenues433,610 410,466 23,144 5.6 %
Consumable revenues198,466 176,625 21,841 12.4 %
Capital equipment revenues176,848 187,170 (10,322)(5.5)%
Revenues by geography:
Ireland revenues20,316 16,126 4,190 26.0 %
United States revenues572,397 562,502 9,895 1.8 %
Other foreign revenues216,211 195,633 20,578 10.5 %
Revenues increased 4.5%, to $808.9 million for the three months ended December 31, 2020, as compared to $774.3 million for the same period in the prior year. This increase reflects growth in all business segments and favorable fluctuations in currencies. Growth in the Healthcare segment was primarily attributable to the impact of our recent acquisitions. Growth in the Applied Sterilization Technologies segment was primarily due to volume. Growth in the Life Sciences segment was due to increased demand for our products and services from our pharma Customers focused on vaccines and biologics.
Service revenues increased 5.6% for the three months ended December 31, 2020, as compared to the same period in the prior year, reflecting growth in all business segments. Consumable revenues increased by 12.4% for the three months ended December 31, 2020, as compared to the same period in the prior year, reflecting growth in the Healthcare and Life Sciences segments. Capital equipment revenues decreased 5.5%, for the three months ended December 31, 2020, as compared to the same period in the prior year, reflecting declines in the Healthcare and Life Sciences segments. The Healthcare segment's decline was primarily due to reduced capital spending by Customers in response to the uncertainty surrounding the COVID-19 pandemic. The Life Sciences segments's decline was primarily due to the timing of shipments.
Ireland revenues increased 26.0% to $20.3 million for the three months ended December 31, 2020, as compared to $16.1 million for the same period in the prior year, reflecting growth in service, consumable and capital equipment revenues.
United States revenues increased 1.8%, to $572.4 million for the three months ended December 31, 2020, as compared to $562.5 million for the same period in the prior year, reflecting growth in service and consumable revenues, which was partially offset by a decline in capital equipment revenues.
Revenues from other foreign locations, increased 10.5%, to $216.2 million for the three months ended December 31, 2020, as compared to $195.6 million for the same period in the prior year. Growth within Canada and the Europe, Middle East & Africa ("EMEA") and Asia Pacific regions was partially offset by a decline in the Latin American region.
36

 Nine Months Ended December 31,
(dollars in thousands)20202019ChangePercent Change
Total revenues$2,233,988 $2,207,904 $26,084 1.2 %
Revenues by type:
Service revenues1,218,062 1,198,708 19,354 1.6 %
Consumable revenues519,652 495,309 24,343 4.9 %
Capital equipment revenues496,274 513,887 (17,613)(3.4)%
Revenues by geography:
Ireland revenues51,779 46,405 5,374 11.6 %
United States revenues1,613,554 1,611,755 1,799 0.1 %
Other foreign revenues568,655 549,744 18,911 3.4 %
Revenues increased 1.2%, to $2,234.0 million for the nine months ended December 31, 2020, as compared to $2,207.9 million for the same period in the prior year. The increase reflects organic growth in the Applied Sterilization Technologies and Life Sciences segments and favorable fluctuations in currencies, which were partially offset by a decline in the Healthcare segment. Growth in the Applied Sterilization Technologies segment was primarily due to volume. Growth in the Life Sciences segment was due to increased demand for our products and services from our pharma Customers focused on vaccines and biologics. The decline in the Healthcare segment was primarily due to reduced demand for our products and services resulting from the reduction of deferrable surgical procedures as a result of the COVID-19 pandemic and reduced capital spending by Customers in response to the uncertainty surrounding the COVID-19 pandemic. The Healthcare decline was partially offset by the impact of our recent acquisitions and the recognition of $14.6 million of capital equipment revenues that were previously deferred, recorded in the first quarter of fiscal 2021 (for more information regarding this change refer to Note 1 of the consolidated statements, titled "Nature of Operations and Summary of Significant Accounting Policies").
Service revenues increased 1.6% for the nine months ended December 31, 2020, as compared to the same period in the prior year, reflecting growth in the Applied Sterilization and Life Science segments, which was partially offset by decline in the Healthcare segment. Consumable revenues increased by 4.9% for the nine months ended December 31, 2020, as compared to the same period in the prior year, reflecting growth in the Life Sciences segment, which was partially offset by a decline in the Healthcare segment. Capital equipment revenues decreased 3.4% for the nine months ended December 31, 2020, as compared to to the same period in the prior year, reflecting decline in the Healthcare segment, which was partially offset by growth in the Life Sciences segment. In the first quarter of fiscal 2021, we recognized $14.6 million of capital equipment revenues that were previously deferred (for more information regarding this change refer to Note 1 of the consolidated statements, titled "Nature of Operations and Summary of Significant Accounting Policies").
Ireland revenues increased 11.6% to $51.8 million for the nine months ended December 31, 2020, as compared to $46.4 million for the same period in the prior year, reflecting growth in service, consumable and capital equipment revenues.
United States revenues increased 0.1%, to $1,613.6 million for the nine months ended December 31, 2020, as compared to $1,611.8 million for the same period in the prior year, reflecting growth in service and consumable revenues, which was partially offset by a decline in capital equipment revenues. In the first quarter of fiscal 2021, we recognized $14.6 million of capital equipment revenues that were previously deferred (for more information regarding this change refer to Note 1 of the consolidated statements, titled "Nature of Operations and Summary of Significant Accounting Policies").
Revenues from other foreign locations increased 3.4%, to $568.7 million for the nine months ended December 31, 2020, as compared to $549.7 million for the same period in the prior year. Growth within Canada and the EMEA and Asia Pacific regions was partially offset by a decline in the Latin American region.
37

Gross Profit. The following table compares our gross profit for the three and nine months ended December 31, 2020 to the three and nine months ended December 31, 2019:
 Three Months Ended December 31, ChangePercent
Change
(dollars in thousands)20202019
Gross profit:
Product$172,433 $168,690 $3,743 2.2 %
Service173,428 162,663 10,765 6.6 %
Total gross profit$345,861 $331,353 $14,508 4.4 %
Gross profit percentage:
Product45.9 %46.4 %
Service40.0 %39.6 %
Total gross profit percentage42.8 %42.8 %
 Nine Months Ended December 31,ChangePercent
Change
(dollars in thousands)20202019
Gross profit:
Product$480,692 $469,532 $11,160 2.4 %
Service480,774 486,331 (5,557)(1.1)%
Total gross profit$961,466 $955,863 $5,603 0.6 %
Gross profit percentage:
Product47.3 %46.5 %
Service39.5 %40.6 %
Total gross profit percentage43.0 %43.3 %
Our gross profit is affected by the volume, pricing, and mix of sales of our products and services, as well as the costs associated with the products and services that are sold.
Gross profit percentage for the third quarter of fiscal 2021 remained flat at 42.8% compared to the gross profit percentage for the third quarter of fiscal 2020. The favorable impact of improved productivity (90 basis points), favorable pricing (70 basis points), and recent acquisitions (10 basis points), were offset by the unfavorable impact of incremental costs associated with COVID-19 (50 basis points) and mix and other (120 basis points).
Gross profit percentage for the first nine months of fiscal 2021 was 43.0% compared to the gross profit percentage for the first nine months of fiscal 2020 of 43.3%. The unfavorable impact of incremental costs associated with COVID-19 (70 basis points) and mix and other (40 basis points), exceeded the benefits of favorable pricing (60 basis points) and improved productivity (20 basis points).
Operating Expenses. The following table compares our operating expenses for the three and nine months ended December 31, 2020 to the three and nine months ended December 31, 2019:
  
Three Months Ended December 31, ChangePercent
Change
(dollars in thousands)20202019
Operating expenses:
Selling, general, and administrative$182,373 $172,927 $9,446 5.5 %
Research and development16,438 16,487 (49)(0.3)%
Restructuring expenses20 (448)468 NM
Total operating expenses$198,831 $188,966 $9,865 5.2 %
38

  
Nine Months Ended December 31,ChangePercent
Change
(dollars in thousands)20202019
Operating expenses:
Selling, general, and administrative$510,250 $527,667 $(17,417)(3.3)%
Research and development48,812 48,321 491 1.0 %
Restructuring expenses110 667 (557)NM
Total operating expenses$559,172 $576,655 $(17,483)(3.0)%
NM - Not meaningful.
Selling, General, and Administrative Expenses. Significant components of total selling, general, and administrative expenses (“SG&A”) are compensation and benefit costs, fees for professional services, travel and entertainment, facilities costs, and other general and administrative expenses. SG&A increased 5.5% in the third quarter of fiscal 2021 over the same prior year period, largely due to our recent acquisitions. SG&A decreased 3.3% in the first nine months of fiscal 2021, over the same prior year period. Volume and performance driven employee compensation costs and travel and meeting costs have declined in the fiscal 2021 periods over same prior year periods, as a result of the COVID-19 pandemic and measures we have taken in response to it.
Research and Development. Research and development expenses decreased 0.3% and increased 1.0% in the third quarter and first nine months of fiscal 2021, respectively over the same prior year periods. Research and development expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations. During fiscal 2021, our investments in research and development continued to be focused on, but were not limited to, enhancing capabilities of sterile processing combination technologies, procedural products and accessories, and devices and support accessories used in gastrointestinal endoscopy procedures.
Fiscal 2019 Restructuring Plan. Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $44.0 million related to these restructuring actions, of which $31.7 million was recorded as restructuring expenses and $12.3 million was recorded in cost of revenues, with a total of $34.1 million, $7.6 million and $0.7 million related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1.7 million. Additional restructuring expenses related to this plan are not expected to be material to our results of operations. Additional restructuring expenses related to this plan are not expected to be material to our results of operations. For additional information on restructuring see Note17 of our Consolidated Financial Statements, titled "Restructuring".
Non-Operating Expenses, Net. Non-operating expenses, net consists of interest expense on debt, offset by interest earned on cash, cash equivalents, and short-term investment balances, and other miscellaneous income. The following table compares our net non-operating expenses for the three and nine months ended December 31, 2020 and 2019:
 Three Months Ended December 31,  
(dollars in thousands)20202019Change
Non-operating expenses, net:
Interest expense$8,899 $9,813 $(914)
Interest income and miscellaneous expense(1,299)(1,378)79 
Non-operating expenses, net$7,600 $8,435 $(835)
 Nine Months Ended December 31, 
(dollars in thousands)20202019Change
Non-operating expenses, net:
Interest expense$27,056 $30,702 $(3,646)
Interest income and miscellaneous expense(4,776)(2,163)(2,613)
Non-operating expenses, net$22,280 $28,539 $(6,259)
Interest expense decreased $0.9 million and $3.6 million during the third quarter and first nine months of fiscal 2021, respectively over the same prior year periods. These decreases were primarily due to lower interest rates on floating rate debt and an increased amount of capitalized interest expense. Interest (income) and miscellaneous expense changed by $0.1 million and $2.6 million, during the third quarter and first nine months of fiscal 2021, respectively over the same prior year periods, primarily due to movement on our equity investments (refer to our Note 15 to our consolidated financial statements, titled "Fair Value Measurements" for more information).
39

Income Tax Expense. The following table compares our income tax expense and effective income tax rates for the three and nine months ended December 31, 2020 and December 31, 2019:
 Three Months Ended December 31, ChangePercent
Change
(dollars in thousands)20202019
Income tax expense$24,842 $29,285 $(4,443)(15.2)%
Effective income tax rate17.8 %21.9 %
 Nine Months Ended December 31,ChangePercent
Change
(dollars in thousands)20202019
Income tax expense$71,294 $66,083 $5,211 7.9%
Effective income tax rate18.8 %18.8 %
We record income tax expense during interim periods based on our estimate of the annual effective income tax rate,
adjusted each quarter for discrete items. We analyze various factors to determine the estimated annual effective income tax rate, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carryforwards, and available tax planning alternatives.
The effective income tax rates for the three month periods ended December 31, 2020 and 2019 were 17.8% and 21.9%, respectively. The effective income tax rates for the nine month periods ended December 31, 2020 and 2019 were 18.8% and 18.8%, respectively. The fiscal 2021 effective tax rate for the current quarter decreased when compared to fiscal 2020, primarily due to an increase in favorable discrete items.
Business Segment Results of Operations. We operate and report in three reportable business segments: Healthcare, Applied Sterilization Technologies and Life Sciences. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. COVID-19 incremental costs also have been excluded from segment operating income. These costs include payroll costs associated with employees paid but not working as a result of measures taken in response to the COVID-19 pandemic.
Prior to April 1, 2020, we operated and reported our financial information in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products and Healthcare Specialty Services segments were combined and are now reported as one segment, simply called Healthcare, consistent with the way management now operates and views the business. Prior periods have been recast in the financial tables below for comparability.
Our Healthcare segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. The segment also provides a range of specialty services for healthcare providers including hospital sterilization services and instrument and scope repairs.
Our Applied Sterilization Technologies ("AST") segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers.
Our Life Sciences segment designs, manufactures and sells consumable products, equipment maintenance, specialty services and capital equipment primarily to pharmaceutical manufacturers around the world.
We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company.
Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
40

The following table compares business segment revenues, segment operating income and total operating income for the three and nine months ended December 31, 2020 and 2019:

Financial information for each of our segments is presented in the following table:
 Three Months Ended December 31, Nine Months Ended December 31,
(dollars in thousands)2020201920202019
Revenues:
Healthcare $521,662 $509,222 $1,392,247 $1,440,237 
Applied Sterilization Technologies176,462 156,266 498,371 463,459 
Life Sciences110,800 108,773 343,370 304,208 
Total revenues$808,924 $774,261 $2,233,988 $2,207,904 
Operating income (loss):
Healthcare$115,412 $105,227 $302,565 $298,777 
Applied Sterilization Technologies81,626 65,468 222,416 198,889 
Life Sciences41,541 37,731 136,435 103,085 
Corporate(47,941)(45,260)(158,463)(151,613)
Total operating income before adjustments$190,638 $163,166 $502,953 $449,138 
Less: Adjustments
Amortization of acquired intangible assets (1)
$23,194 $17,508 $62,649 $53,407 
Acquisition and integration related charges (2)
11,563 1,721 13,984 5,585 
Redomiciliation and tax restructuring costs (3)
296 487 850 3,274 
(Gain) on fair value adjustment of acquisition related contingent consideration(500)— (500)— 
Net loss on divestiture of businesses (1)
 76 5 2,553 
Amortization of inventory and property "step up" to fair value (1)
1,784 602 3,101 1,783 
COVID-19 incremental costs (4)
7,251 — 20,460 — 
Restructuring charges (5)
20 385 110 3,328 
Total operating income$147,030 $142,387 $402,294 $379,208 
(1) For more information regarding our recent acquisitions and divestitures refer to Note 2 titled" Business Acquisitions and Divestitures" and our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.
(3) Costs incurred in connection with the Redomiciliation and tax restructuring.
(4) COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.
(5) For more information regarding our restructuring efforts refer to Note 17 titled, "Restructuring".

41

Healthcare revenues increased 2.4% to $521.7 million for the three months ended December 31, 2020, as compared to $509.2 million in the same prior year period. Consumables revenues grew 14.3%, as procedure volumes continued to rebound during our third fiscal quarter. Capital equipment revenue declined 4.9%, primarily due to reduced capital spending by Customers in response to the uncertainty surrounding the COVID-19 pandemic. Service revenues remained essentially flat over both periods. Fluctuations in currencies and the impact from our recent acquisitions were favorable during the third quarter of fiscal 2021. Healthcare revenues decreased 3.3% to $1,392.2 million for the nine months ended December 31, 2020, as compared to $1,440.2 million in the same prior year period. This decrease reflects declines capital equipment, service and consumable revenues of 5.0%, 3.0% and 1.9%, respectively. The declines were primarily due to reduced demand for our products and services resulting from the reduction of deferrable surgical procedures as a result of the COVID-19 pandemic and reduced capital spending by Customers in response to the uncertainty surrounding the COVID-19 pandemic. Fluctuations in currencies and the impact from our recent acquisitions were favorable during the first nine months of fiscal 2021. At December 31, 2020, the Healthcare segment’s backlog amounted to $215.5 million, representing a increase of 2.7%, as compared to the backlog of $209.9 million at December 31, 2019. December 31, 2020 backlog was impacted by the recognition of capital equipment revenues that were previously deferred, recorded in the first quarter of fiscal 2021 (for more information regarding this change refer to Note 1 of the consolidated statements, titled "Nature of Operations and Summary of Significant Accounting Policies").
Applied Sterilization Technologies segment revenues increased 12.9% to $176.5 million for the three months ended December 31, 2020, as compared to $156.3 million for the same prior year period. Applied Sterilization Technologies segment revenues increased 7.5% to $498.4 million for the nine months ended December 31, 2020, as compared to $463.5 million for the same prior year period. The fiscal 2021 increases reflect organic growth and favorable fluctuations in currencies.
Life Sciences revenues increased 1.9% to $110.8 million for the three months ended December 31, 2020, as compared to $108.8 million for the same prior year period. This increase reflects growth in consumable and service revenues of 7.0% and 5.0%, respectively, which were partially offset by a 8.7% decline in capital equipment revenues. Life Sciences revenues increased 12.9% to $343.4 million for the nine months ended December 31, 2020, as compared to $304.2 million for the same prior year period. This increase reflects growth in consumable, service and capital equipment of 23.6%, 4.8% and 4.3%, respectively. The fiscal 2021 increases reflect growth due to demand from our pharma Customers focused on vaccines and biologics and favorable fluctuations in currencies. At December 31, 2020, the Life Sciences segment’s backlog amounted to $82.0 million, representing an increase of 14.5%, as compared to the backlog of $71.6 million at December 31, 2019.
The Healthcare segment’s operating income increased 9.7% to $115.4 million for the three months ended December 31, 2020, as compared to $105.2 million in the same prior year period. The Healthcare segment’s operating income increased 1.3% to $302.6 million for the nine months ended December 31, 2020, as compared to $298.8 million in the same prior year period. The segment's operating margins were 22.1% and 20.7% for the third quarter of fiscal 2021 and 2020, respectively. The segment's operating margins were 21.7% and 20.7% for the first nine months of fiscal 2021 and 2020, respectively. These increases in the fiscal 2021 periods were primarily due to favorable impact from our recent acquisitions and reduced expenditures, including reductions in travel and meeting spend due to the COVID-19 pandemic. Employee compensation associated with the Healthcare segment was also reduced due to lower volumes and measures taken in response to the COVID-19 pandemic.
The Applied Sterilization Technologies segment's operating income increased 24.7% to $81.6 million for the three months ended December 31, 2020, as compared to $65.5 million during the same prior year period. The Applied Sterilization Technologies segment's operating income increased 11.8% to $222.4 million for the nine months ended December 31, 2020, as compared to $198.9 million during the same prior year period. The segment's operating margins were 46.3% and 41.9% for the third quarter fiscal 2021 and 2020, respectively. The segment's operating margins were 44.6% and 42.9% for the first nine months of fiscal 2021 and 2020, respectively. These increases in the fiscal 2021 periods were primarily due to higher volumes and reduced expenditures, including reductions in travel and meeting spend due to the COVID-19 pandemic.
The Life Sciences segment’s operating income increased 10.1% to $41.5 million for the three months ended December 31, 2020, as compared to $37.7 million in the same prior year period. The Life Sciences segment’s operating income increased 32.4% to $136.4 million for the nine months ended December 31, 2020, as compared to $103.1 million in the same prior year period. The segment's operating margins were 37.5% and 34.7% for the third quarter of fiscal 2021 and 2020, respectively. The segment's operating margins were 39.7% and 33.9% for the first nine months of fiscal 2021 and 2020, respectively. These increases in the fiscal 2021 periods were primarily due to higher volumes and favorable mix.
Liquidity and Capital Resources
The following table summarizes significant components of our cash flows for the nine months ended December 31, 2020 and 2019:
42

 Nine Months Ended December 31,
(dollars in thousands)20202019
Net cash provided by operating activities$501,785 $391,326 
Net cash (used in) investing activities$(1,035,903)$(259,989)
Net cash provided by (used in) financing activities$442,533 $(153,874)
Debt-to-total capital ratio30.7 %25.2 %
Free cash flow$337,705 $238,064 
Net Cash Provided by Operating Activities – The net cash provided by our operating activities was $501.8 million for the first nine months of fiscal 2021 and $391.3 million for the first nine months of fiscal 2020. The increase in cash from operations was primarily due to higher net income, working capital improvements and deferred tax payments under government COVID-19 relief programs.
Net Cash Used In Investing Activities – The net cash used in investing activities totaled $1,035.9 million for the first nine months of fiscal 2021 and $260.0 million for the first nine months of fiscal 2020. The following discussion summarizes the significant changes in our investing cash flows for the first nine months of fiscal 2021 and fiscal 2020:
Purchases of property, plant, equipment, and intangibles, net – Capital expenditures were $164.5 million for the first nine months of fiscal 2021 and $153.6 million during the same prior year period. The fiscal 2021 increase was primarily due to expansion projects in the Applied Sterilization Technologies segment.
Acquisitions of businesses, net of cash acquired – During the first nine months of fiscal 2021 and 2020, we used $869.4 million and $107.2 million, respectively for the purchases of businesses. For more information on our acquisitions, refer to Note 2 of our consolidated financial statements, titled "Business Acquisitions and Divestitures".
Other – During the first nine months of fiscal 2021, we provided $2.4 million under borrowing agreements. For more information on these loan agreements, refer to Note 18 of our consolidated financial statements, "Loans Receivable".
Net Cash Provided By (Used In) Financing Activities – The net cash provided by financing activities amounted to $442.5 million for the first nine months of fiscal 2021 compared with net cash used in financing activities of $153.9 million for the first nine months of fiscal 2020. The following discussion summarizes the significant changes in our financing cash flows for the first nine months of fiscal 2021 and fiscal 2020:
Payments on long-term obligations – During the second quarter of fiscal 2021, we repaid $35.0 million of principal for private placement notes that matured in August 2020. For more information on our debt refer to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
Proceeds from the issuance of long-term obligations – During the third quarter of fiscal 2021, we received proceeds of $550.0 million under our Term Loan. For more information refer to Note 5 of our consolidated financial statements, titled "Debt".
Proceeds (payments) under credit facility, net – Net proceeds under credit facilities totaled $23.8 million in the first nine months of fiscal 2021 compared to net payments under credit facilities of $48.5 million in the first nine months of fiscal 2020.
Deferred financing fees and debt issuance costs – During the first nine months of fiscal 2021, we paid $3.1 million for financing fees and debt issuance costs in connection with our Term Loan. During the first nine months of fiscal 2020, we paid $1.2 million for financing fees and debt issuance costs related to our Private Placement debt. For more information on our debt, refer to Note 5 of our consolidated financial statements, titled "Debt" or to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
Repurchases of ordinary shares – From the start of fiscal 2021 through April 9, 2020, we purchased 35,000 of our ordinary shares in the aggregate amount of $5.0 million. During the first nine months of fiscal 2021, we obtained 85,574 of our ordinary shares in connection with share-based compensation award programs in the aggregate amount of $9.5 million. During the first nine months of fiscal 2020, we purchased of 205,059 of our ordinary shares in the aggregate amount of $30.0 million. During the first nine months of fiscal 2020, we obtained 100,124 of our ordinary shares in connection with share-based compensation award programs in the aggregate amount of $10.3 million. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020.
Cash dividends paid to ordinary shareholders – During the first nine months of fiscal 2021, we paid total cash dividends of $99.7 million, or $1.17 per outstanding share. During the first nine months of fiscal 2020, we paid total cash dividends of $91.6 million, or $1.08 per outstanding share.
43

Transactions with noncontrolling interest holders – During the first nine months of fiscal 2021, we received $2.3 million of contributions from noncontrolling interest holders and paid $0.6 million in distributions to noncontrolling interest holders. During the first nine months of fiscal 2021, we paid $3.5 million for the acquisition of a subsidiary's interests in noncontrolling interest. During the first nine months of fiscal 2020, we received $6.1 million of contributions from noncontrolling interest holders and paid $0.8 million in distributions to noncontrolling interest holders.
Stock option and other equity transactions, net – We generally receive cash for issuing shares under our stock option programs. During the first nine months of fiscal 2021 and fiscal 2020, we received cash proceeds totaling $26.0 million and $23.0 million, respectively, under these programs.
Cash Flow Measures. Free cash flow was $337.7 million in the first nine months of fiscal 2021 compared to $238.1 million in the first nine months of fiscal 2020 (see the subsection above titled "Non-GAAP Financial Measures" for additional information and related reconciliation of cash flows from operations to free cash flow). The increase in free cash flow was primarily due to working capital improvements and deferred tax payments under government COVID-19 relief programs.
Our debt-to-total capital ratio was 30.7% at December 31, 2020 and 25.2% at December 31, 2019.
Sources of Credit and Contractual and Commercial Commitments. Information related to our sources of credit and contractual and commercial commitments is included in our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020. Our commercial commitments were approximately $76.5 million at December 31, 2020, reflecting a net decrease of $3.7 million in commercial commitments from March 31, 2020. We had $304.6 million of outstanding borrowings under the Credit Agreement as of December 31, 2020. We had $9.0 million of letters of credit outstanding under the Credit Agreement at December 31, 2020.
Cash Requirements. We intend to use our existing cash and cash equivalent balances and cash generated from operations for short-term and long-term capital expenditures and our other liquidity needs. Our capital requirements depend on many uncertain factors, including our rate of sales growth, our Customers’ acceptance of our products and services, the costs of obtaining adequate manufacturing capacities, the timing and extent of our research and development projects, changes in our expenses and other factors. To the extent that existing and anticipated sources of cash are not sufficient to fund our future activities, we may need to raise additional funds through additional borrowings or the sale of equity securities. There can be no assurance that our existing financing arrangements will provide us with sufficient funds or that we will be able to obtain any additional funds on terms favorable to us or at all.
In this regard, we expect to fund the cash portion of the Cantel acquisition consideration and repay or otherwise satisfy a significant amount of Cantel’s existing debt obligations with approximately $2.0 billion of new debt. We have fully committed bridge financing and are working with our lenders and advisors on a long-term plan.
Critical Accounting Policies, Estimates, and Assumptions
Information related to our critical accounting policies, estimates, and assumptions is included in our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020. Our critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2020.
Contingencies
We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief.
44

We record a liability for such contingencies to the extent we conclude that their occurrence is both probable and estimable. We consider many factors in making these assessments, including the professional judgment of experienced members of management and our legal counsel. We have made estimates as to the likelihood of unfavorable outcomes and the amounts of such potential losses. In our opinion, the ultimate outcome of these proceedings and claims is not anticipated to have a material adverse affect on our consolidated financial position, results of operations, or cash flows. However, the ultimate outcome of proceedings, government investigations, and claims is unpredictable and actual results could be materially different from our estimates. We record expected recoveries under applicable insurance contracts when we are assured of recovery. Refer to Note 8 of our consolidated financial statements titled, "Commitments and Contingencies" for additional information and to Item 1A of Part II titled, "Risk factors".
We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual tax jurisdiction or the closing of a statute of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. The IRS routinely conducts audits of our federal income tax returns.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements, that have or are reasonably likely to have, a material current or future impact on our financial condition, changes in financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital.
Forward-Looking Statements
This Form 10-Q contains forward-looking statements within the meaning of the federal securities laws about STERIS, Cantel and the proposed transaction. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend”, and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology. These forward-looking statements are based on current expectations, estimates or forecasts about our businesses, the industries in which we operate and current beliefs and assumptions of management and are subject to uncertainty and changes in circumstances. These statements are not guarantees of performance or results. Many important factors could affect actual financial results and cause them to vary materially from the expectations contained in the forward-looking statements. No assurances can be provided as to any result or the timing of any outcome regarding matters described in STERIS’s securities filings or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, cost reductions, business strategies, earnings or revenue trends or future financial results. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. These risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:
the failure to obtain Cantel stockholder approval of the proposed transaction;
the possibility that the closing conditions to the proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant a necessary regulatory approval and any conditions imposed on the combined entity in connection with consummation of the proposed transaction;
delay in closing the proposed transaction or the possibility of non-consummation of the proposed transaction;
the risk that the cost savings and any other synergies from the proposed transaction may not be fully realized or may take longer to realize than expected, including that the proposed transaction may not be accretive within the expected timeframe or to the extent anticipated;
the occurrence of any event that could give rise to termination of the merger agreement;
the risk that shareholder/stockholder litigation in connection with the proposed transaction may affect the timing or occurrence of the proposed transactions or result in significant costs of defense, indemnification and liability;
risks related to the disruption of the proposed transaction to STERIS, Cantel and our respective managements;
risks relating to the value of the STERIS shares to be issued in the transaction;
the effect of announcement of the proposed transaction on our ability to retain and hire key personnel and maintain relationships with customers, suppliers and other third parties;
the impact of the COVID-19 pandemic on STERIS’s or Cantel’s operations, performance, results, prospects, or value;
STERIS’s ability to achieve the expected benefits regarding the accounting and tax treatments of the redomiciliation to Ireland (“Redomiciliation”);
operating costs, Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected following the Redomiciliation;
45

STERIS’s ability to meet expectations regarding the accounting and tax treatment of the Tax Cuts and Jobs Act (“TCJA”) or the possibility that anticipated benefits resulting from the TCJA will be less than estimated;
changes in tax laws or interpretations that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes;
the potential for increased pressure on pricing or costs that leads to erosion of profit margins;
the possibility that market demand will not develop for new technologies, products or applications or services, or business initiatives will take longer, cost more or produce lower benefits than anticipated;
the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation any of the same relating to FDA, EPA or other regulatory authorities, government investigations, the outcome of any pending or threatened FDA, EPA or other regulatory warning notices, actions, requests, inspections or submissions, or other requirements or standards may delay, limit or prevent new product or service introductions, affect the production, supply and/or marketing of existing products or services or otherwise affect STERIS’s or Cantel’s performance, results, prospects or value;
the potential of international unrest, economic downturn or effects of currencies, tax assessments, tariffs and/or other trade barriers, adjustments or anticipated rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs;
the possibility of reduced demand, or reductions in the rate of growth in demand, for STERIS’s or Cantel’s products and services;
the possibility of delays in receipt of orders, order cancellations, or delays in the manufacture or shipment of ordered products or in the provision of services;
the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with STERIS’s and Cantel’s businesses, industry or initiatives including, without limitation, those matters described in STERIS’s and Cantel’s respective Annual Reports on Form 10-K for the year ended March 31, 2020 and July 31, 2020, respectively, and other securities filings, may adversely impact STERIS’s and/or Cantel’s performance, results, prospects or value;
the impact on STERIS and its operations, or tax liabilities, of Brexit or the exit of other member countries from the EU, and STERIS’s ability to respond to such impacts;
the impact on STERIS, Cantel and their respective operations of any legislation, regulations or orders, including but not limited to any new trade or tax legislation, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto;
the possibility that anticipated financial results or benefits of recent acquisitions, including the acquisition of Key Surgical, or of STERIS’s restructuring efforts, or of recent divestitures, or of restructuring plans will not be realized or will be other than anticipated;
the effects of contractions in credit availability, as well as the ability of STERIS’s and Cantel’s Customers and suppliers to adequately access the credit markets when needed;
STERIS’s ability to complete the acquisition of Cantel, including the fulfillment of closing conditions and obtaining financing, on terms satisfactory to STERIS or at all; and
other risks described in STERIS’s and Cantel’s respective most recent Annual Reports on Form 10-K and other reports filed with the Securities and Exchange Commission.
Availability of Securities and Exchange Commission Filings
We make available free of charge on or through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to these reports as soon as reasonably practicable after we file such material with, or furnish such material to, the Securities Exchange Commission ("SEC.") You may access these documents on the Investor Relations page of our website at http://www.steris-ir.com. The information on our website and the SEC's website is not incorporated by reference into this report.

ITEM 3.     QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

In the ordinary course of business, we are subject to interest rate, currency, and commodity risks. Information related to these risks and our management of these exposures is included in Part II, Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” in our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020. Our exposures to market risks have not changed materially since March 31, 2020.

Fluctuations in currency rates could affect our revenues, cost of revenues and income from operations and could result in currency exchange gains and losses. During the third quarter of fiscal 2021, we entered into forward currency contracts in order to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. These
46

currency exchange contracts will mature during fiscal 2021. We have executed forward currency contracts to hedge a portion of results denominated in euros, Mexican pesos and Canadian dollars. We did not elect hedge accounting for these forward currency contracts; however, we may seek to apply hedge accounting in future scenarios. As a result, we may experience volatility due to (i) the timing mismatch of unrealized hedge gains or losses versus recognition of the underlying hedged earnings, and (ii) the impact of unrealized and realized hedge gains or losses being reported in selling, general and administrative expenses, whereas the offsetting economic gains and losses of the underlying hedged earnings are reported in the various line items of our Consolidated Statements of Income.

ITEM 4.    CONTROLS AND PROCEDURES
Under the supervision of and with the participation of our management, including the Principal Executive Officer (“PEO”) and Principal Financial Officer (“PFO”), we evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as of the end of the period covered by this Quarterly Report. Based on that evaluation, including the assessment and input of our management, the PEO and PFO concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were effective.
There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934, that occurred during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
47

PART II—OTHER INFORMATION
 
ITEM 1.    LEGAL PROCEEDINGS
Information regarding our legal proceedings is included in this Form 10-Q in Note 8 to our consolidated financial statements titled, "Commitments and Contingencies", Item 7 of Part II, titled “Management's Discussion and Analysis of Financial Conditions and Results of Operations," of our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
ITEM 1A.    RISK FACTORS
For a complete discussion of the Company’s risk factors, you should carefully review the risk factors included in Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended March 31, 2020. There have been no material changes to the risk factors set forth in Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, except with regard to the risk factors set forth below related to the proposed acquisition of Cantel.

Risk or uncertaintyDiscussion
Acquisition of Cantel Medical Corp.
Failure to complete the acquisition or delays in completion could negatively impact the price of our shares as well as our future business and financial results.The definitive agreement to acquire Cantel (the “Merger Agreement”) contains a number of conditions that must be satisfied or waived prior to the completion of the acquisition, including, without limitation, regulatory approvals and the approval of the acquisition by Cantel’s stockholders. There can be no assurance that all of the conditions to the acquisition will be so satisfied or waived. If the conditions to the acquisition are not satisfied or waived, we will be unable to complete the acquisition and the Merger Agreement may be terminated. Furthermore, the delay in the fulfillment of such conditions could result in unanticipated expenditures of funds and other resources and/or reduce the benefits of the acquisition of Cantel, even if ultimately consummated.
If the acquisition is delayed or not completed for any reason, we may experience a variety of adverse impacts. These include, without limitation, potential negative impacts to the market price of our shares and potential negative reactions from Customers, employees, vendors, business partners and other third parties. Further, we will have expended time and resources that could otherwise have been spent on our existing business and the pursuit of other opportunities that could have been beneficial to us, and our ongoing business and financial results may be adversely affected.
We will be subject to business uncertainties while the acquisition is pending, which could adversely affect our business.Uncertainty about the effect of the acquisition on employees and Customers may have an adverse effect on our business. These uncertainties may impair our ability to attract, retain and motivate key personnel until the acquisition is completed and for a period of time thereafter, and could cause Customers and others that deal with us or Cantel to seek to change those existing business relationships. In addition, the Merger Agreement restricts us from entering into certain corporate transactions and taking other specified actions without the consent of the other party. These restrictions may prevent us from pursuing attractive business opportunities that may arise prior to the completion of the acquisition.
48

We will incur significant transaction and merger-related costs in connection with the acquisition, which may be in excess of those anticipated.We have incurred substantial expenses in connection with the negotiation and effectuation of the transactions contemplated by the Merger Agreement and we expect to continue to incur a number of associated non-recurring costs. These costs have been, and will continue to be, significant. Non-recurring costs for the time period prior to the completion of the acquisition will include, among others, fees paid to financial, legal and accounting advisors and filing fees. We will also incur costs related to formulating and implementing integration plans.
We will continue to assess the magnitude of these costs. Additional unanticipated costs may be incurred. Although we expect that the elimination of duplicative costs, as well as the realization of other efficiencies related to the integration of the two companies’ businesses, will allow us to offset our costs over time, this net benefit may not be achieved or may not be achieved to the level expected.
The costs described above could have a material adverse effect on our financial condition and operating results. Many of these costs will be borne by us even if the acquisition is not completed.
We expect to incur a substantial amount of debt to complete the acquisition. Increased debt may limit our financial flexibility.
We expect to incur additional long-term debt (which may include debt incurred under term loan and/or “bridge” facilities and/or debt securities) for purposes of funding the payment of the cash portion of the acquisition consideration, the satisfaction of certain Cantel debt obligations, including those that may be accelerated or subject to put or conversion rights in connection with the acquisition, and the payment of certain related fees and expenses. The success of such efforts will depend on, among other things, our and Cantel’s financial position and performance, results of reviews by bond rating agencies, if any, as well as prevailing market conditions and other factors beyond our control. There can be no assurance that we will be able to execute such financing transactions on favorable terms or at all.

Our increased indebtedness could have important consequences to investors, including: increasing our vulnerability to general adverse economic and industry conditions; limiting our ability to obtain additional financing to fund future working capital, capital expenditures and other general corporate requirements and limit our ability to pay dividends or repurchase our stock; requiring the use of a substantial portion of our cash flow from operations for the payment of principal and interest on our indebtedness, thereby reducing our ability to use our cash flow to fund working capital, acquisitions, capital expenditures, dividends, stock repurchases and general corporate requirements; limiting our flexibility in planning for, or reacting to, changes in our business and industry; and putting us at a disadvantage compared to our competitors with less indebtedness.








49

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $79.0 million (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300.0 million (net of taxes, fees and commissions). As of December 31, 2020, there was approximately $333.9 million (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program. The share repurchase program has no specified expiration date.
Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020.
From the start of fiscal 2021 through April 9, 2020, we repurchased 35,000 of our ordinary shares for the aggregate amount of $5.0 million (net of fees and commissions) pursuant to the authorizations.
During the first nine months of fiscal 2021, we obtained 85,574 of our ordinary shares in the aggregate amount of $9.5 million in connection with share based compensation award programs.
The following table summarizes the ordinary shares repurchase activity during the third quarter of fiscal 2021 under our ordinary share repurchase program:
 (a)
Total Number  of
Shares Purchased
 (b)
Average Price Paid
Per Share
 (c)
Total Number  of
Shares Purchased as
Part of Publicly
Announced Plans
(d)
Maximum Dollar Value  of Shares that May Yet Be Purchased Under the
Plans at Period End (in thousands)
October 1-31—   $—   — $333,932 
November 1-30—   —   — 333,932 
December 1-31—   $—   — $333,932 
Total— — — 333,932 
(1) Does not include 7 shares purchased during the quarter at an average price of $186.21 per share by the STERIS Corporation 401(k) Plan on behalf of an executive officer of the Company who may be deemed to be an affiliated purchaser.
50

ITEM 6.    EXHIBITS

Exhibits required by Item 601 of Regulation S-K

Exhibit
Number
Exhibit Description
2.1
2.2
3.1
10.1
10.2
10.3
10.4
10.5
10.6
10.7
15.1
31.1
31.2
32.1
101.SCHInline Schema Document.
101.CALInline Calculation Linkbase Document.
101.DEFInline Definition Linkbase Document.
101.LABInline Labels Linkbase Document.
101.PREInline Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

51

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
STERIS plc
/s/ KAREN L. BURTON
Karen L. Burton

Vice President, Controller and Chief Accounting Officer
February 9, 2021

52
EX-10.2 2 ste12312020exhibit102.htm EX-10.2 Document
EXHIBIT 10.2


GUARANTOR JOINDER AGREEMENT
This Guarantor Joinder Agreement (this “Agreement”) dated as of December 18, 2020 is made by each of the parties on Schedule I hereto (the “Additional Guarantors”), in favor of JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”) for the Lenders under the Credit Agreement referred to below.

RECITALS

WHEREAS, reference is made to the Credit Agreement, dated as of March 23, 2018 (as amended, amended and restated, supplemented or otherwise modified and in effect on the date hereof, the “Credit Agreement”), among STERIS Limited, Synergy Health Limited, STERIS plc (“STERIS plc”) and STERIS Corporation, as Borrowers, the Guarantors parties thereto from time to time, the Lenders parties thereto and the Administrative Agent;

WHEREAS, pursuant to the Credit Agreement, the Lenders have severally agreed to make Advances to the Borrowers upon the terms and subject to the conditions set forth therein;
WHEREAS, each Additional Guarantor is a wholly-owned Subsidiary of STERIS plc;

WHEREAS, the proceeds of the Advances will be used in part to enable the Borrowers to make valuable transfers to the Additional Guarantors in connection with the operation of their respective businesses;

WHEREAS, each Additional Guarantor acknowledges that it will derive a substantial direct or indirect benefit from the making of the Advances; and

Accordingly, the parties hereto agree as follows:

Section 1. Definitions. Except as otherwise defined in this Agreement, terms defined in the Credit Agreement are used herein as defined therein.
Section 2. Joinder. As of the date hereof, each Additional Guarantor hereby agrees that it shall become a “Guarantor” under and for all purposes of the Credit Agreement with the same force and effect as if originally named therein as a Guarantor and, without limiting the generality of the foregoing, hereby expressly assumes all obligations and liabilities of a Guarantor under the Credit Agreement and the other Loan Documents, including those set forth in ARTICLE VIII of the Credit Agreement.
Section 3. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.
Section 4. Execution in Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which



when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by telecopier, facsimile or in a .pdf or similar file shall be effective as delivery of a manually executed counterpart of this Agreement.
Section 5. Miscellaneous. This Agreement shall constitute a “Loan Document” for all purposes of the Credit Agreement and the other Loan Documents.
[SIGNATURE PAGES FOLLOW]






































IN WITNESS WHEREOF, the Additional Guarantors have caused this Guarantor Joinder Agreement to be duly executed and delivered as of the day and year first above written.

                           
KS Apollo Holdings Inc.
/s/ Michael J. Tokich
Name: Michael J. Tokich



Title: President
KS Apollo LLC
/s/ Michael J. Tokich
Name: Michael J. Tokich



Title: President
Key Surgical LLC
/s/ Michael J. Tokich
Name: Michael J. Tokich



Title: President
Acknowledged:

JPMORGAN CHASE BANK, N.A., as Administrative Agent
By:
/s/ Stacey Zoland
Name: Stacey Zoland
Title: Executive Director







[Signature Page to Revolver Guarantor Joinder Agreement]




Schedule I

1. KS Apollo Holdings Inc., a Delaware corporation
2. KS Apollo LLC, a Delaware limited liability company
3. Key Surgical LLC, a Delaware limited liability company


EX-10.3 3 ste12312020exhibit103.htm EX-10.3 Document

EXHIBIT 10.3

GUARANTOR JOINDER AGREEMENT
This Guarantor Joinder Agreement (this “Agreement”) dated as of December 18, 2020 is made by each of the parties on Schedule I hereto (the “Additional Guarantors”), in favor of JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”) for the Lenders under the Credit Agreement referred to below.

RECITALS

WHEREAS, reference is made to the Term Loan Agreement, dated as of November 18, 2020 (as amended, amended and restated, supplemented or otherwise modified and in effect on the date hereof, the “Credit Agreement”), among STERIS plc, STERIS Limited, Synergy Health Limited and STERIS Corporation, as Borrowers, the Guarantors party thereto from time to time, the Lenders parties thereto and the Administrative Agent;

WHEREAS, pursuant to the Credit Agreement, the Lenders have severally agreed to make Advances to the Borrowers upon the terms and subject to the conditions set forth therein;

WHEREAS, each Additional Guarantor is a wholly-owned Subsidiary of the Reporting Entity;

WHEREAS, the proceeds of the Advances will be used in part to enable the Borrowers to make valuable transfers to the Additional Guarantors in connection with the operation of their respective businesses; and

WHEREAS, each Additional Guarantor acknowledges that it will derive a substantial direct or indirect benefit from the making of the Advances.

Accordingly, the parties hereto agree as follows:

Section 1. Definitions. Except as otherwise defined in this Agreement, terms defined in the Credit Agreement are used herein as defined therein.
Section 2. Joinder. As of the date hereof, each Additional Guarantor hereby agrees that it shall become a “Guarantor” under and for all purposes of the Credit Agreement with the same force and effect as if originally named therein as a Guarantor and, without limiting the generality of the foregoing, hereby expressly assumes all obligations and liabilities of a Guarantor under the Credit Agreement and the other Loan Documents, including those set forth in ARTICLE VIII of the Credit Agreement.
Section 3. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.
1


Section 4. Execution in Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement that is an Electronic Signature transmitted by telecopier, facsimile or in a pdf or similar file shall be effective as delivery of a manually executed counterpart of this Agreement; provided, without limiting the foregoing, (i) to the extent the Administrative Agent has agreed to accept any Electronic Signature, the Administrative Agent and each of the Lenders shall be entitled to rely on such Electronic Signature purportedly given by or on behalf of any Additional Guarantors without further verification thereof and without any obligation to review the appearance or form of any such Electronic Signature and (ii) upon the reasonable request of the Administrative Agent or any Lender, any Electronic Signature shall be promptly followed by a manually executed counterpart. Without limiting the generality of the foregoing, each Additional Guarantors hereby (i) agrees that, for all purposes, including without limitation, in connection with any workout, restructuring, enforcement of remedies, bankruptcy proceedings or litigation among the Administrative Agent, the Lenders, and the Borrowers and the other Loan Parties, Electronic Signatures transmitted by telecopy, emailed pdf or any other electronic means that reproduces an image of an actual executed signature page and/or any electronic images of this Agreement shall have the same legal effect, validity and enforceability as any paper original, (ii) each party hereto may, at its option, create one or more copies of this Agreement in the form of an imaged electronic record in any format, which shall be deemed created in the ordinary course of such Person’s business, and destroy the original paper document (and all such electronic records shall be considered an original for all purposes and shall have the same legal effect, validity and enforceability as a paper record), (iii) waives any argument, defense or right to contest the legal effect, validity or enforceability of this Agreement based solely on the lack of paper original copies of this Agreement, including with respect to any signature pages thereto and (iv) waives any claim against any other party hereto or any Related Party of any such Person for any losses, claims (including intraparty claims), demands, damages, penalties or liabilities of any kind arising solely from reliance by any party hereto on or use of Electronic Signatures and/or transmissions by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page, including any losses, claims (including intraparty claims), demands, damages, penalties or liabilities of any kind arising as a result of the failure of any Additional Guarantors to use any available security measures in connection with the execution, delivery or transmission of any Electronic Signature.
Section 5. Miscellaneous. This Agreement shall constitute a “Loan Document” for all purposes of the Credit Agreement and the other Loan Documents.
[SIGNATURE PAGES FOLLOW]




2



IN WITNESS WHEREOF, the Additional Guarantors have caused this Guarantor Joinder Agreement to be duly executed and delivered as of the day and year first above written.

                           
KS Apollo Holdings Inc.
/s/ Michael J. Tokich
Name: Michael J. Tokich



Title: President
KS Apollo LLC
/s/ Michael J. Tokich
Name: Michael J. Tokich



Title: President
Key Surgical LLC
/s/ Michael J. Tokich
Name: Michael J. Tokich



Title: President

Acknowledged:
JPMORGAN CHASE BANK, N.A., as Administrative Agent
By:
/s/ Stacey Zoland
Name: Stacey Zoland
Title: Executive Director









[Signature Page to Term Loan Guarantor Joinder Agreement]

3



Schedule I

1. KS Apollo Holdings Inc., a Delaware corporation
2. KS Apollo LLC, a Delaware limited liability company
3. Key Surgical LLC, a Delaware limited liability company





4
EX-10.4 4 ste12312020exhibit104.htm EX-10.4 Document
EXHIBIT 10.4

image_01.jpg



GUARANTY SUPPLEMENT

December 17, 2020
 
To the Holders of the Series A-1A, A-1B, A-2A, A-2B, A-3A and A-3B Notes, (each, as hereinafter defined) of STERIS Corporation (the “Company”)
 
Ladies and Gentlemen:

    WHEREAS, in order to refinance certain debt and for general corporate purposes, the Company entered into that certain Amended and Restated Note Purchase Agreement, dated as of March 5, 2019 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Note Purchase Agreement”), between the Company and each of the purchasers party thereto providing for, inter alia, the issue and sale by the Company of (a) $47,500,000 aggregate principal amount of 3.20% Senior Notes, Series A-1A, due December 4, 2022 (the “Series A-1A Notes”), (b) $47,500,000 aggregate principal amount of 3.20% Senior Notes, Series A-1B, due December 4, 2022 (the “Series A-1B Notes”), (c) $40,000,000 aggregate principal amount of 3.35% Senior Notes, Series A-2A, due December 4, 2024 (the “Series A-2A Notes”), (d) $40,000,000 aggregate principal amount of 3.35% Senior Notes, Series A-2B, due December 4, 2024 (the “Series A-2B Notes”), (e) $12,500,000 aggregate principal amount of 3.55% Senior Notes, Series A-3A, due December 4, 2027 (the “Series A-3A Notes”) and (f) $12,500,000 aggregate principal amount of 3.55% Senior Notes, Series A-3B, due December 4, 2027 (the “Series A-3B Notes”; the Series A-1A Notes, the Series A-1B Notes, the Series A-2A Notes, the Series A-2B Notes, the Series A-3A Notes and the Series A-3B Notes are hereinafter referred to as the “Notes”; the holders of such notes, the “Holders”).
 
WHEREAS, as a condition precedent to the closing of the Note Purchase Agreement, the Holders required that certain affiliates of the Company enter into an Affiliate Guaranty as security for the Notes (the “Guaranty”).
 
Pursuant to Section 9.7 of the Note Purchase Agreement, the Company has agreed to cause the undersigned, KS Apollo Holdings Inc., a Delaware corporation (“KS HoldCo”), KS Apollo LLC, a Delaware limited liability company (“KS Apollo”) and Key Surgical LLC, a Delaware limited liability company (“Key Surgical” and, together with KS HoldCo and KS Apollo, the “Additional Guarantors”), to join in the Guaranty. In accordance with the requirements of the Guaranty, the Additional Guarantors desire to amend the definition of Guarantor (as the same may have been heretofore amended) set forth in the Guaranty so that at all times from and after the date hereof, the Additional Guarantors shall be jointly and severally liable as set forth in the Guaranty for the obligations of the Company under the Note Purchase Agreement and Notes to the extent and in the manner set forth in the Guaranty.




     The undersigned is the duly elected President of the Additional Guarantors and is duly authorized to execute and deliver this Guaranty Supplement to each of you. The execution by the undersigned of this Guaranty Supplement shall evidence their consent to and acknowledgment and approval of the terms set forth herein and in the Guaranty and by such execution the Additional Guarantors shall be deemed to have made in favor of the Holders the representations and warranties set forth in Sections 5.1, 5.2, 5.6 and 5.7 of the Guaranty.
 
Upon execution of this Guaranty Supplement, the Guaranty shall be deemed to be amended as set forth above. Except as amended herein, the terms and provisions of the Guaranty are hereby ratified, confirmed and approved in all respects.
 
Any and all notices, requests, certificates and other instruments (including the Notes) may refer to the Guaranty without making specific reference to the Guaranty Supplement, but nevertheless all such reference shall be deemed to include this Guaranty Supplement unless the context shall otherwise require.

[Signature Page Follows]































Dated as of the date first written above.

KS Apollo Holdings Inc.
/s/ Michael J. Tokich
Name: Michael J. Tokich
Title: President
KS Apollo LLC
/s/ Michael J. Tokich
Name: Michael J. Tokich
Title: President
KEY Surgical LLC
/s/ Michael J. Tokich
Name: Michael J. Tokich
Title: President


 





















 [Signature Page to Guaranty Supplement – 2012 NPA]

 



ACCEPTED AND AGREED:

 

STERIS Corporation 

By:/s/ Michael J. Tokich
Name:Michael J. Tokich
Title:Director


































[Signature Page to Guaranty Supplement – 2012 NPA]

EX-10.5 5 ste12312020exhibit105.htm EX-10.5 Document
EXHIBIT 10.5

image_01.jpg




GUARANTY SUPPLEMENT

December 17, 2020
 
To the Holders of the Series A-1, A-2 and A-3, (each, as hereinafter defined) of STERIS Corporation (the “Company”)
 
Ladies and Gentlemen:

    WHEREAS, in order to refinance certain debt and for general corporate purposes, the Company entered into that certain Amended and Restated Note Purchase Agreement, dated as of March 5, 2019 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Note Purchase Agreement”), between the Company and each of the purchasers party thereto providing for, inter alia, the issue and sale by the Company of (a) $125,000,000 aggregate principal amount of 3.45% Senior Notes, Series A-1, due May 14, 2025 (the “Series A-1 Notes”), (b) $125,000,000 aggregate principal amount of 3.55% Senior Notes, Series A-2, due May 14, 2027 (the “Series A-2 Notes”) and (c) $100,000,000 aggregate principal amount of 3.70% Senior Notes, Series A-3, due May 14, 2030 (the “Series A-3 Notes”; the Series A-1 Notes, the Series A-2 Notes and the Series A-3 Notes are hereinafter referred to as the “Notes”; the holders of such notes, the “Holders”).
 
WHEREAS, as a condition precedent to the closing of the Note Purchase Agreement, the Holders required that certain affiliates of the Company enter into an Affiliate Guaranty as security for the Notes (the “Guaranty”).
 
Pursuant to Section 9.7 of the Note Purchase Agreement, the Company has agreed to cause the undersigned, KS Apollo Holdings Inc., a Delaware corporation (“KS HoldCo”), KS Apollo LLC, a Delaware limited liability company (“KS Apollo”) and Key Surgical LLC, a Delaware limited liability company (“Key Surgical” and, together with KS HoldCo and KS Apollo, the “Additional Guarantors”), to join in the Guaranty. In accordance with the requirements of the Guaranty, the Additional Guarantors desire to amend the definition of Guarantor (as the same may have been heretofore amended) set forth in the Guaranty so that at all times from and after the date hereof, the Additional Guarantors shall be jointly and severally liable as set forth in the Guaranty for the obligations of the Company under the Note Purchase Agreement and Notes to the extent and in the manner set forth in the Guaranty.

     The undersigned is the duly elected President of the Additional Guarantors and is duly authorized to execute and deliver this Guaranty Supplement to each of you. The execution by the undersigned of this Guaranty Supplement shall evidence their consent to and acknowledgment and approval of the terms set forth herein and in the Guaranty and by such execution the Additional Guarantors shall be deemed to have made in favor of the Holders the representations and warranties set forth in Sections 5.1, 5.2, 5.6 and 5.7 of the Guaranty.



 
Upon execution of this Guaranty Supplement, the Guaranty shall be deemed to be amended as set forth above. Except as amended herein, the terms and provisions of the Guaranty are hereby ratified, confirmed and approved in all respects.
 
Any and all notices, requests, certificates and other instruments (including the Notes) may refer to the Guaranty without making specific reference to the Guaranty Supplement, but nevertheless all such reference shall be deemed to include this Guaranty Supplement unless the context shall otherwise require.

[Signature Page Follows]





































Dated as of the date first written above.

KS Apollo Holdings Inc.

/s/ Michael J. Tokich
Name: Michael J. Tokich
Title: President
KS Apollo LLC
/s/ Michael J. Tokich
Name: Michael J. Tokich
Title: President



Key Surgical LLC
Key Surgical LLC
/s/ Michael J. Tokich
Name: Michael J. Tokich
Title: President


 
 

















 [Signature Page to Guaranty Supplement – 2015 NPA]



ACCEPTED AND AGREED:


STERIS Corporation
 

By:/s/ Michael J. Tokich
Name:Michael J. Tokich
Title:Director


































[Signature Page to Guaranty Supplement – 2015 NPA]

EX-10.6 6 ste12312020exhibit106.htm EX-10.6 Document
EXHIBIT 10.6

image_01.jpg




GUARANTY SUPPLEMENT

December 17, 2020
 
To the Holders of the Series A-1, A-2, A-3, A-4, A-5, A-6 and A-7 Notes, (each, as hereinafter defined) of STERIS Limited (the “Company”)
 
Ladies and Gentlemen:

    WHEREAS, in order to refinance certain debt and for general corporate purposes, the Company entered into that certain Amended and Restated Note Purchase Agreement, dated as of March 5, 2019 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Note Purchase Agreement”), between the Company and each of the purchasers party thereto providing for, inter alia, the issue and sale by the Company of (a) $50,000,000 aggregate principal amount of its 3.93% Senior Notes, Series A-1, due February 27, 2027 (the “Series A-1 Notes”); (b) €60,000,000 aggregate principal amount of its 1.86% Senior Notes, Series A-2, due February 27, 2027 (the “Series A-2 Notes”); (c) $45,000,000 aggregate principal amount of its 4.03% Senior Notes, Series A-3, due February 27, 2029 (the “Series A-3 Notes”); (d) €20,000,000 aggregate principal amount of its 2.04% Senior Notes, Series A-4, due February 27, 2029 (the “Series A-4 Notes”); (e) £45,000,000 aggregate principal amount of its 3.04% Senior Notes, Series A-5, due February 27, 2029 (the “Series A-5 Notes”); (f) €19,000,000 aggregate principal amount of its 2.30% Senior Notes, Series A-6, due February 27, 2032 (the “Series A-6 Notes”); and (g) £30,000,000 aggregate principal amount of its 3.17% Senior Notes, Series A-7, due February 27, 2032 (the “Series A-7 Notes”; the Series A-1 Notes, the Series A-2 Notes, the Series A-3 Notes, the Series A-4 Notes, the Series A-5 Notes, the Series A-6 Notes and the Series A-7 Notes are hereinafter referred to as the “Notes”; the holders of such notes, the “Holders”).
 
WHEREAS, as a condition precedent to the closing of the Note Purchase Agreement, the Holders required that certain affiliates of the Company enter into an Affiliate Guaranty as security for the Notes (the “Guaranty”).
 
Pursuant to Section 9.7 of the Note Purchase Agreement, the Company has agreed to cause the undersigned, KS Apollo Holdings Inc., a Delaware corporation (“KS HoldCo”), KS Apollo LLC, a Delaware limited liability company (“KS Apollo”) and Key Surgical LLC, a Delaware limited liability company (“Key Surgical” and, together with KS HoldCo and KS Apollo, the “Additional Guarantors”), to join in the Guaranty. In accordance with the requirements of the Guaranty, the Additional Guarantors desire to amend the definition of Guarantor (as the same may have been heretofore amended) set forth in the Guaranty so that at all times from and after the date hereof, the Additional Guarantors shall be jointly and severally



liable as set forth in the Guaranty for the obligations of the Company under the Note Purchase Agreement and Notes to the extent and in the manner set forth in the Guaranty.

     The undersigned is the duly elected President of the Additional Guarantors and is duly authorized to execute and deliver this Guaranty Supplement to each of you. The execution by the undersigned of this Guaranty Supplement shall evidence their consent to and acknowledgment and approval of the terms set forth herein and in the Guaranty and by such execution the Additional Guarantors shall be deemed to have made in favor of the Holders the representations and warranties set forth in Sections 5.1, 5.2, 5.6 and 5.7 of the Guaranty.
 
Upon execution of this Guaranty Supplement, the Guaranty shall be deemed to be amended as set forth above. Except as amended herein, the terms and provisions of the Guaranty are hereby ratified, confirmed and approved in all respects.
 
Any and all notices, requests, certificates and other instruments (including the Notes) may refer to the Guaranty without making specific reference to the Guaranty Supplement, but nevertheless all such reference shall be deemed to include this Guaranty Supplement unless the context shall otherwise require.

[Signature Page Follows]




























Dated as of the date first written above.

KS Apollo Holdings Inc.

/s/ Michael J. Tokich
Name: Michael J. Tokich
Title: President
KS Apollo LLC
/s/ Michael J. Tokich
Name: Michael J. Tokich
Title: President



Key Surgical LLC
Key Surgical LLC
/s/ Michael J. Tokich
Name: Michael J. Tokich
Title: President
 




















[Signature Page to Guaranty Supplement – 2017 NPA]





ACCEPTED AND AGREED:

STERIS Limited
 

By:/s/ Michael J. Tokich
Name:Michael J. Tokich
Title:Director


































[Signature Page to Guaranty Supplement – 2017 NPA]

EX-15.1 7 ste12312020ex151.htm EX-15.1 Document

                                                Exhibit 15.1

LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION


Shareholders and Board of Directors
STERIS plc
 
 
We are aware of the incorporation by reference in the following STERIS plc Registration Statements of our review report dated February 9, 2021 relating to the unaudited consolidated interim financial statements of STERIS plc and subsidiaries that are included in its Form 10-Q for the quarter ended December 31, 2020:

Registration
Number
 
Description
 
333-230557Form S-8 Registration Statement of STERIS plc pertaining to the STERIS Corporation 401(k) Plan
333-230558Form S-8 Registration Statement of STERIS plc pertaining to the STERIS plc 2006 Long-Term Equity Incentive Plan (As Assumed, Amended and Restated Effective March 28, 2019)


/s/ Ernst & Young LLP

Cleveland, Ohio
February 9, 2021


EX-31.1 8 ste12312020ex311.htm EX-31.1 Document


Exhibit 31.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
I, Walter M Rosebrough, Jr., certify that:
1.I have reviewed this quarterly report on Form 10-Q of STERIS plc;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date:February 9, 2021
/s/ WALTER M ROSEBROUGH, JR
Walter M Rosebrough, Jr.
President and Chief Executive Officer



EX-31.2 9 ste12312020ex312.htm EX-31.2 Document

 
Exhibit 31.2
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
I, Michael J. Tokich, certify that:
1.I have reviewed this quarterly report on Form 10-Q of STERIS plc;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date:February 9, 2021
/s/ MICHAEL J. TOKICH
Michael J. Tokich
Senior Vice President and Chief Financial Officer



EX-32.1 10 ste12312020ex321.htm EX-32.1 Document

 
Exhibit 32.1
Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, in connection with the filing of the Form 10-Q of STERIS plc (the “Company”) for the quarter ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, that, to such officer's knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report. 
  /s/ WALTER M ROSEBROUGH, JR
Name:  Walter M Rosebrough, Jr.
Title: President and Chief Executive Officer
  /s/ MICHAEL J. TOKICH
Name:  Michael J. Tokich
Title: Senior Vice President and Chief Financial Officer
Dated: February 9, 2021


EX-101.SCH 11 ste-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Statement of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies(Notes) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2105102 - Disclosure - Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes) link:presentationLink link:calculationLink link:definitionLink 2306302 - Disclosure - Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Business Acquisitions and Divestitures Fiscal 2018 Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Business Acquisitions and Divestitures Revenues by Type (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Business Acquisitions and Divestitures (Details) 2020 link:presentationLink link:calculationLink link:definitionLink 2112103 - Disclosure - Inventories, Net (Notes) link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Inventories, Net Inventories, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Inventories, Net Inventories, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2115104 - Disclosure - Property, Plant and Equipment (Notes) link:presentationLink link:calculationLink link:definitionLink 2316304 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2118105 - Disclosure - Debt (Notes) link:presentationLink link:calculationLink link:definitionLink 2219202 - Disclosure - Debt (Policies) link:presentationLink link:calculationLink link:definitionLink 2320305 - Disclosure - Debt Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2421409 - Disclosure - Debt Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2122106 - Disclosure - Additional Consolidated Balance Sheets Information (Notes) link:presentationLink link:calculationLink link:definitionLink 2323306 - Disclosure - Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2424410 - Disclosure - Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) link:presentationLink link:calculationLink link:definitionLink 2125107 - Disclosure - Income Tax Expense (Notes) link:presentationLink link:calculationLink link:definitionLink 2426411 - Disclosure - Income Tax Expense Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Contingencies (Notes) link:presentationLink link:calculationLink link:definitionLink 2128109 - Disclosure - Business Segment Information (Notes) link:presentationLink link:calculationLink link:definitionLink 2329307 - Disclosure - Business Segment Information Business Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2430412 - Disclosure - Business Segment Information Business Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2131110 - Disclosure - Shares and Preferred Shares (Notes) link:presentationLink link:calculationLink link:definitionLink 2332308 - Disclosure - Shares and Preferred Shares Shares and Preferred Shares (Tables) link:presentationLink link:calculationLink link:definitionLink 2433413 - Disclosure - Shares and Preferred Shares Ordinary Shares (Details) link:presentationLink link:calculationLink link:definitionLink 2434414 - Disclosure - Shares and Preferred Shares Preferred Shares (Details) link:presentationLink link:calculationLink link:definitionLink 2135111 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2436415 - Disclosure - Repurchases of Shares (Details) link:presentationLink link:calculationLink link:definitionLink 2137112 - Disclosure - Share-Based Compensation (Notes) link:presentationLink link:calculationLink link:definitionLink 2338309 - Disclosure - Share-Based Compensation Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2439416 - Disclosure - Share-Based Compensation Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2140113 - Disclosure - Financial and Other Guarantees(Notes) link:presentationLink link:calculationLink link:definitionLink 2341310 - Disclosure - Financial and Other Guarantees Financial and Other Gurantees (Tables) link:presentationLink link:calculationLink link:definitionLink 2442417 - Disclosure - Financial and Other Guarantees Financial and Other Guarantees (Details) link:presentationLink link:calculationLink link:definitionLink 2443418 - Disclosure - Financial and Other Guarantees Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2144114 - Disclosure - Derivatives and Hedging (Notes) link:presentationLink link:calculationLink link:definitionLink 2345311 - Disclosure - Derivatives and Hedging Derivatives and Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2446419 - Disclosure - Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) link:presentationLink link:calculationLink link:definitionLink 2447420 - Disclosure - Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) link:presentationLink link:calculationLink link:definitionLink 2148115 - Disclosure - Fair Value Measurements (Notes) link:presentationLink link:calculationLink link:definitionLink 2349312 - Disclosure - Fair Value Measurements Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2450421 - Disclosure - Fair Value Measurements Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 2451422 - Disclosure - Fair Value Measurements Contingent Consideration Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2452423 - Disclosure - Fair Value Measurements Available-for-sale securities (Details) link:presentationLink link:calculationLink link:definitionLink 2153116 - Disclosure - Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes) link:presentationLink link:calculationLink link:definitionLink 2354313 - Disclosure - Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2455424 - Disclosure - Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2156117 - Disclosure - Loans Receivable (Notes) link:presentationLink link:calculationLink link:definitionLink 2357314 - Disclosure - Loans Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 2458425 - Disclosure - Loans Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2159118 - Disclosure - Restructuring (Notes) link:presentationLink link:calculationLink link:definitionLink 2360315 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 2461426 - Disclosure - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 2162119 - Disclosure - Unusual or Infrequently Occurring Items link:presentationLink link:calculationLink link:definitionLink 2363316 - Disclosure - Unusual or Infrequently Occurring Items (Tables) link:presentationLink link:calculationLink link:definitionLink 2464427 - Disclosure - Unusual or Infrequently Occurring Items (Details) link:presentationLink link:calculationLink link:definitionLink 2165120 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2366317 - Disclosure - Subsequent Events (Tables) link:presentationLink link:calculationLink link:definitionLink 2467428 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 ste-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 ste-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 ste-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Number of Restricted Shares, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restatement [Axis] Revision of Prior Period [Axis] Document Type Document Type Receivable Type [Axis] Receivable Type [Axis] Aggregate Intrinsic Value, Outstanding at June 30, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Interest income and miscellaneous expense Other Nonoperating Income (Expense) Schedule of Product Warranty Liability Schedule of Product Warranty Liability [Table Text Block] Service [Member] Service [Member] Business Segments [Axis] Segments [Axis] Segments [Axis] Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Investment Owned, at Cost Investments Investment Owned, at Cost Weighted-Average Grant Date Fair Value, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Shares repurchased during period, number Stock Repurchased During Period, Shares Subsequent Event - Acquisition Acquiree Closing Share Price Subsequent Event - Acquisition Acquiree Closing Share Price Subsequent Event - Acquisition Acquiree Closing Share Price Amortization of pension and postretirement benefits plans costs, (net of taxes of $173 ,$171, $520 and $512, respectively) Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Asset derivatives Forward and swap contracts Derivative Asset Product Warranty Disclosure Product Warranty Disclosure [Text Block] Approximate purchase price of entity Approximate aggregate purchase price of acquisitions Approximate aggregate purchase price of acquisitions Range [Domain] Statistical Measurement [Domain] Liabilities and equity Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Item] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Derivative Instruments and Hedging Activities Disclosure Derivative Instruments and Hedging Activities Disclosure [Text Block] Proceeds from Issuance of Private Placement Proceeds from Issuance of Debt Security Exchange Name Security Exchange Name Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Balance under credit facility expected to be forgiven in acquisition Balance under credit facility expected to be forgiven in acquisition Balance under credit facility expected to be forgiven in acquisition Capital equipment revenues [Member] Capital equipment revenues [Member] Capital equipment revenues [Member] Income from operations Segment operating income Operating Income (Loss) Total current liabilities Liabilities, Current Payments for Repurchase of Other Equity Payments for acquisition of subsidiary interests in noncontrolling interest Payments for acquisition of subsidiary interests in noncontrolling interest Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period Weighted-Average Grant Date Fair Value, Non-vested at End of Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Commitments and contingencies (see Note 8) Commitments and Contingencies Repurchases of ordinary shares Payments for Repurchase of Common Stock Payments for Repurchase of Common Stock Payments for Repurchase of Common Stock Assets Assets [Abstract] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Payments Reductions and Payout [Member] Reductions and Payout [Member] Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Number of Restricted Shares, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Interest rate [Domain] Interest rate [Domain] [Domain] for Interest rate [Axis] Accounts payable Accounts Payable, Current Stock Appreciation Rights (SARs) [Member] Stock Appreciation Rights (SARs) [Member] Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Note [Text Block] Segment operating income OperatingSegmentAll [Member] OperatingSegmentAll [Member] Change in cumulative foreign current translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Retained earnings Retained Earnings (Accumulated Deficit) Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset UK Linen Management Services UK Linen Management Services [Member] UK Linen Management Services [Member] Entity Address, Country Entity Address, Country Accounting Standards Update 2016-01 [Member] Accounting Standards Update 2016-01 [Member] Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Outstanding at March 31, 2017 Outstanding at June 30, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Property, plant, and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Unrecognized compensation cost related to nonvested share-based compensation granted Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Preferred Stock, Value, issued Preferred Stock, Value, Issued Deferred revenues Deferred Revenue Principal repayment rate year 1 Term loan quarterly principal repayment rate year 2022 Term loan quarterly principal repayment rate year 2022 Total operating expenses Operating Expenses Term loan quarterly principal repayment rate year 2023 Term loan quarterly principal repayment rate year 2023 Term loan quarterly principal repayment rate year 2023 Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax [Abstract] Exercisable at June 30, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Subsequent Event - Acquisition Amount of New Borrowing Arrangements Subsequent Event - Business Acquisition Amount of New Borrowing Arrangements Subsequent Event - Business Acquisition Amount of New Borrowing Arrangements Investment Secondary Categorization [Axis] Investment Secondary Categorization [Axis] Non-derivative Net Investment Hedge Non-derivative Net Investment Hedge Non-derivative Net Investment Hedge Deferred financing fees and debt issuance costs Payments of Financing Costs Other Liabilities, Noncurrent Other Liabilities, Noncurrent Machinery and equipment Machinery and Equipment, Gross Payments for (Proceeds from) Other Investing Activities Payments for (Proceeds from) Other Investing Activities Cost of revenues: Cost of Revenue [Abstract] Reversal of Liability Balance Reversal of Liability Balance [Member] Reversal of Liability Balance Uncertain Tax Liability Resulting From IRS Notice Uncertain Tax Liability Resulting From IRS Notice Uncertain Tax Liability Resulting From IRS Notice Years 5-6,8% Int Rate [Member] [Member] Years 5-6,8% Int Rate [Member] [Member] Years 5-6,8% Int Rate [Member] [Member] Construction in progress Construction in Progress, Gross Inventories, net Inventories, net Inventory, Net Business Acquisition [Axis] Business Acquisition [Axis] Contingent Consideration Rollforward [Abstract] Contingent Consideration Rollforward [Abstract] Contingent Consideration Rollforward [Abstract] Geographical [Domain] Geographical [Domain] Financing Receivable Portfolio Segment [Axis] Financing Receivable Portfolio Segment [Axis] Inventory [Axis] Inventory [Axis] Statement [Line Items] Statement [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Purchase price of acquired entity Purchase price of acquired entity Purchase price of acquired entity Class of Stock [Domain] Class of Stock [Domain] Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Non-current liabilities Non-current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities Business Combination, Acquisition Related Costs Business Combination, Acquisition Related Costs Statement [Table] Statement [Table] Type of Restructuring [Domain] Type of Restructuring [Domain] Range [Axis] Statistical Measurement [Axis] Foreign currency translation adjustment Foreign Currency Gain (Loss) [Member] Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure UNITED KINGDOM IRELAND Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Preferred Stock, Shares Issued Preferred shares, shares issued Preferred Stock, Shares Issued Land and land improvements Land Industry Sector [Axis] Industry Sector [Axis] Unusual or Infrequent Items, or Both [Abstract] Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of Weighted Average Number of Shares [Table Text Block] Deferred compensation plans Deferred Compensation Liability, Current and Noncurrent Business Combinations [Abstract] Business Combinations [Abstract] Entity Small Business Entity Small Business Principles of Consolidation Consolidation, Policy [Policy Text Block] Amortization of acquired intangible assets amortization and impairment of acquired intangible assets amortization and impairment of acquired intangible assets Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Debt Debt Disclosure [Text Block] Average Remaining Contractual Term, Exercisable at June 30, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Asset retirement obligation-current portion Asset Retirement Obligation, Current Total cost of revenues Cost of Revenue Share Repurchase Program [Domain] Share Repurchase Program [Domain] Selling, general, and administrative expense Selling, General and Administrative Expenses [Member] Class of Financing Receivable, Type of Borrower [Axis] Type of Borrower [Axis] Amendment Flag Amendment Flag COVID-19 Pandemic COVID-19 Pandemic [Text Block] COVID-19 Pandemic Weighted-average assumptions used for options granted: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Remaining shares available for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Credit Agreement Long-term Line of Credit Product Warranty Liability [Line Items] Product Warranty Liability [Line Items] Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Additional Consolidated Balance Sheets Information Supplemental Balance Sheet Disclosures [Text Block] Line of Credit Provide Line of Credit Provided to Investee Line of Credit Provided to Investee New Accounting Pronouncement, Early Adoption New Accounting Pronouncement, Early Adoption [Table Text Block] Self-insured risk reserves-long-term portion Self Insurance Reserve, Noncurrent Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Other liabilities: Other Liabilities, Noncurrent [Abstract] Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Payments of Ordinary Dividends, Noncontrolling Interest Billing Status, Type [Axis] Billing Status, Type [Axis] Accrued employee commissions Accrued Liabilities for Commissions, Expense and Taxes Entity Central Index Key Entity Central Index Key Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] US Linen Management Services US Linen Management Services [Member] US Linen Management Services [Member] Financing Receivable [Member] Financing Receivable [Member] Accrued expenses and other: Accrued Liabilities, Current [Abstract] Years 5-15, 12% Int Rate Years 5-15, 12% Int Rate [Member] Years 5-15, 12% Int Rate [Member] Years 5-15, 12% Int Rate [Member] - Interest rate for years 5-15 of the agreement Derivative Instrument [Axis] Derivative Instrument [Axis] Accrued dealer commissions Accrued Sales Commission Mexican peso Mexico, Pesos Fair Value Measurement [Domain] Fair Value Measurement [Domain] Geographical [Axis] Geographical [Axis] Subsequent Events Subsequent Events [Text Block] Business Segment [Domain] Segments [Domain] Segments [Domain] Interest rate on loan receivable Interest rate on loan receivable Interest rate on loan receivable Accrued long-term income taxes Accrued Income Taxes, Noncurrent Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Dilutive effect of share equivalents Weighted Average Number Diluted Shares Outstanding Adjustment Property, Plant and Equipment by Type [Axis] Long-Lived Tangible Asset [Axis] Additions Additions [Member] Additions [Member] Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Loss on sale of HSS China Operations Loss on sale of HSS China Operations Loss on sale of HSS China Operations Revenue from External Customers by Products and Services [Table Text Block] Revenue from External Customers by Products and Services [Table Text Block] Other Other Accrued Liabilities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Income Statement Location [Axis] Income Statement Location [Axis] Allowance for Doubtful Accounts Receivable, Current Accounts Receivable, Allowance for Credit Loss, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Compass Medical Inc. Compass Medical [Member] Compass Medical [Member] Other Comprehensive Income (Loss), Net of Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Selling, general, and administrative Selling, General and Administrative Expense Adjustments for Change in Accounting Principle [Domain] Change in Accounting Principle, Type [Domain] Capitalized Computer Hardware/Software, Gross Capitalized Computer Hardware/Software, Gross Capitalized Computer Hardware/Software, Gross Other assets Other Assets, Noncurrent Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Other Other Liabilities Business Segment Information Segment Reporting Disclosure [Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Assets Assets Assets Scenario [Axis] Scenario [Axis] Equity Investee Loan [Domain] Equity Investee Loan [Domain] Equity Investee Loan [Domain] Number of Restricted Shares, Non-vested at Beginning of Period Number of Restricted Shares, Non-vested at End of Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Corporate Segment [Member] Corporate Segment [Member] Title of 12(b) Security Title of 12(b) Security Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] Debt and Equity Securities, Gain (Loss) Equity Securities, FV-NI, Gain (Loss) Equity Securities, FV-NI, Gain (Loss) Industry of Counterparty, Type [Axis] Industry of Counterparty, Type [Axis] Weighted average grant date fair value of stock option grants, per share Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Accrued income taxes Accrued Income Taxes, Current Subsequent Event Type [Axis] Subsequent Event Type [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Geographic Distribution [Axis] Geographic Distribution [Axis] Cost of Sales [Member] Cost of revenues Cost of Sales [Member] Approximate annual revenues of divested entity Approximate annual revenues of divested entity Approximate annual revenues of divested entity Business Acquisition, Effective Date of Acquisition Business Acquisition, Effective Date of Acquisition Capital Lease Obligations, Noncurrent Capital Lease Obligations, Noncurrent Interest expense Interest Expense Business acquisitions and divestitures Mergers, Acquisitions and Dispositions Disclosures [Text Block] Depreciation, depletion, and amortization Depreciation, Depletion and Amortization Financing Receivable Portfolio Segment [Domain] Financing Receivable Portfolio Segment [Domain] Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Unrealized Gain (Loss) on Investments [Table Text Block] Unrealized Gain (Loss) on Investments [Table Text Block] Total accrued expenses and other Accrued Liabilities Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Canadian dollar Canada, Dollars Weighted Average Period For Total Compensation Expense Not Yet Recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Other Long-term Debt Other Long-term Debt Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Fiscal 2017 Divestitures [Abstract] Fiscal 2017 Divestitures [Abstract] Fiscal 2017 Divestitures [Abstract] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Inventories, net Increase (Decrease) in Inventories Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Accounts payable Increase (Decrease) in Accounts Payable Summary of non-vested restricted share activity: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Capital Lease Obligations, Current Capital Lease Obligations, Current Common Stock, Dividends, Per Share, Cash Paid Common Stock, Dividends, Per Share, Cash Paid Subsequent Event - Acquisition Acquirer Stock Price Subsequent Event - Acquisition Acquirer Stock Price Subsequent Event - Acquisition Acquirer Stock Price Accrued Payroll and Other Liabilities Accrued Payroll and Other Liabilities Accrued Payroll and Other Liabilities Assets: Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Total other liabilities Total Other Long Term Liabilities Total Other Long Term Liabilities Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Class of Stock [Line Items] Class of Stock [Line Items] Assets [Member] Assets [Member] Accruals and other, net Increase (Decrease) in Accrued Liabilities Liability derivatives Forward and swap contracts Derivative Liability Shares, Issued Shares, Issued Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Proceeds from Sales of Business, Affiliate and Productive Assets Proceeds from Sales of Business, Affiliate and Productive Assets HCS [Member] HCS [Member] HCS [Member] Other Receivables Other Receivables Payments for Repurchase of Other Equity Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Entity Information [Line Items] Entity Information [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Accrued payroll and other related liabilities: Employee-related Liabilities, Current [Abstract] Income before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development Research and Development Expense Dutch Linen Loan [Domain] Dutch Linen Loan [Domain] Dutch Linen Loan [Domain] Subsequent Event [Member] Subsequent Event [Member] Restructuring [Abstract] Restructuring [Abstract] Restructuring [Abstract] Outstanding at March 31, 2017 Outstanding at June 30, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Acquisition of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Common Stock, Shares Authorized Common Stock, Shares Authorized Concentration Risk Type [Axis] Concentration Risk Type [Axis] Percent of shares acquired Business Acquisition, Percentage of Voting Interests Acquired Net cash proceeds from the exercise of stock options Proceeds from Stock Options Exercised Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Total property, plant, and equipment Property, Plant and Equipment, Gross Subsequent event- Forgiveness of Loan Receivable Subsequent event- Forgiveness of Loan Receivable Subsequent event- Forgiveness of Loan Receivable Revenue Revenue [Policy Text Block] Operating Expense [Member] Operating Expense [Member] Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Loan Rate 4% [Member] [Domain] Loan Rate 4% [Member] [Domain] Loan Rate 4% [Member] [Domain] Entity [Abstract] Entity [Abstract] Entity [Abstract] Radioisotope Materials, Supplies, and Other Accrued vacation/paid time off Accrued Vacation, Current Income Statement [Abstract] Income Statement [Abstract] AOCI Attributable to Parent [Member] AOCI Attributable to Parent [Member] Other employee benefit plans obligations-long-term portion Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent Notes To Financial Statements [Abstract] Notes To Financial Statements [Abstract] Notes to Financial Statements [Abstract] Other current assets Increase (Decrease) in Prepaid Expense and Other Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Amortization of pension and postretirement benefits plans costs, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Adjustments for Change in Accounting Principle [Axis] Change in Accounting Principle, Type [Axis] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Use of Estimates Use of Estimates, Policy [Policy Text Block] Sales Revenue, Services, Net [Member] Service revenues [Member] Service revenues [Member] Current assets: Assets, Current [Abstract] Business Acquisition, Goodwill, Expected Tax Deductible Amount Business Acquisition, Goodwill, Expected Tax Deductible Amount Fair Value Option, Disclosures Fair Value Option, Disclosures [Table Text Block] Expected recognition beyond the next year [Member] [Member] Expected recognition beyond the next year [Member] [Member] Expected recognition beyond the next year [Member] [Member] Investments Fair value Investments, Fair Value Disclosure Deferred Ordinary Shares Deferred Ordinary Shares Deferred Ordinary Shares Schedule of Assumptions Used Defined Benefit Plan, Assumptions [Table Text Block] Subsegments [Domain] Subsegments [Domain] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Exptected dividend yield of stock Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Preferred Stock, Par or Stated Value Per Share Preferred shares, par value Preferred Stock, Par or Stated Value Per Share Reclassification from AOCI, Current Period, Tax [Abstract] Reclassification from AOCI, Current Period, Tax [Abstract] Collateral [Axis] Collateral Held [Axis] Scenario, Unspecified [Domain] Scenario [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Legal Entity [Axis] Legal Entity [Axis] Purchases of property, plant, equipment, and intangibles, net Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Consolidation Items [Domain] Consolidation Items [Domain] Deferred Revenue [Abstract] Deferred Revenue [Abstract] Subsequent Event - Business Acquisition Enterprise Value of Acquiree Subsequent Event - Business Acquisition Enterprise Value of Acquiree Subsequent Event - Business Acquisition Enterprise Value of Acquiree Document Period End Date Document Period End Date Subsequent Event, Date Subsequent Event, Date Contingent consideration Contingent consideration obligations Business Combination, Contingent Consideration, Liability Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Revenue, Remaining Performance Obligation, Percentage Revenue, Remaining Performance Obligation, Percentage Preferred shares, redemption price per share Preferred Stock, Redemption Price Per Share Gain (Loss) on Derivative Instruments, Net, Pretax Amount of gain (loss) recognized in income Gain (Loss) on Derivative Instruments, Net, Pretax Share repurchase program, number of shares authorized Stock Repurchase Program, Authorized Amount Net Income Net Income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Compensation and related items Employee-related Liabilities Current liabilities Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Product Warranties Disclosures [Abstract] Product Warranties Disclosures [Abstract] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Share-based compensation Share-based Payment Arrangement, Noncash Expense Equity Securities, FV-NI Equity Securities, FV-NI Term of interest rate first for years Term of interest rate first for years Term of interest rate first for years Entity [Domain] Entity [Domain] Restructuring expense incurred since Plan inception Restructuring expense incurred since Plan inception Restructuring expense incurred since Plan inception FairValueOfOutstandingStockAppreciationRights FairValueOfOutstandingStockAppreciationRights FairValueOfOutstandingStockAppreciationRights Payments for shares obtained in connection with share based compensation programs Payment, Tax Withholding, Share-based Payment Arrangement Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Proceeds from (Payments for) Other Financing Activities Proceeds from (Payments for) Other Financing Activities Restructuring and Related Costs [Table Text Block] Restructuring and Related Costs [Table Text Block] Estimated forfeiture rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate The estimated forfeiture rate is based upon historical activity and represents an estimate of the granted options not exptected to vest. Other employee benefit plans obligations-current portion Liability, Retirement and Postemployment Benefits Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Value (EUROS) Ordinary Shares Deferred Value (EUROS) Ordinary Shares Deferred Value (EUROS) Ordinary Shares Deferred Inventories [Member] Inventories [Member] Total long term debt Long-term Debt Key Surgical [Domain] Key Surgical [Domain] Key Surgical Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Amortization of inventory and property step-up to fair value amortization of inventory and property step up to fair value amortization of inventory and property step up to fair value Investments Investments Payment for Pension Benefits Payment for Pension Benefits Asset retirement obligation-long-term portion Asset Retirement Obligations, Noncurrent Applied Sterilization Technologies Applied Sterilization Technologies [Member] Applied Sterilization Technologies [Member] Applied Sterilization Technologies [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Cost of Goods and Services Sold Cost of Goods and Services Sold Series of Individually Immaterial Business Acquisitions Series of Individually Immaterial Business Acquisitions [Member] Equity Components [Axis] Equity Components [Axis] Restricted Stock Restricted Stock [Member] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Reclassifications out of AOCI [Abstract] Reclassifications out of AOCI [Abstract] Reclassifications out of AOCI [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-based Payment Arrangement [Abstract] Proceeds (Payments) under credit facilities, net Proceeds from (Repayments of) Lines of Credit Receivables [Abstract] Receivables [Abstract] Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Total Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accrued warranty Balance, March 31, 2017 Balance, June 30, 2017 Standard and Extended Product Warranty Accrual Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Industry Sector [Domain] Industry Sector [Domain] Less: Net Income Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest Class of Financing Receivable, Type [Domain] Class of Financing Receivable [Domain] Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance Derivative Instruments, Gain (Loss) [Table Text Block] Weighted-Average Grant Date Fair Value, Canceled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] UNITED STATES UNITED STATES Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Revenues: Revenues [Abstract] Other Investments Level 3 table Other Investments Level 3 table Other Investments Level 3 table Fair Value Disclosures Fair Value Disclosures [Text Block] Acquisition related deferred or contingent consideration Payments of Merger Related Costs, Financing Activities Impact of TCJA redomiciliaton and tax restructuring costs ax restructuring redomiciliaton and tax restructuring costs ax restructuring Accounts Receivable [Member] Accounts Receivable [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Commodity swap contracts Commodity Contract [Member] Industry of Counterparty [Domain] Industry of Counterparty [Domain] United Kingdom, Pounds British pounds sterling United Kingdom, Pounds Life Sciences Life Science Member [Member] Life Science Member [Member] Life Science Member [Member] Loan Agreement Max Borrowing Amount Dutch Linen Sale Loan Agreement Max Borrowing Amount Dutch Linen Sale Loan Agreement Max Borrowing Amount Dutch Linen Sale Deferred Cost of Revenues, Amount recognized in period from certain capital contracts Deferred Cost of Revenues, Amount recognized in period from certain capital contracts Deferred Cost of Revenues, Amount recognized in period from certain capital contracts Entity Registrant Name Entity Registrant Name Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Subsequent Event Type [Domain] Subsequent Event Type [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Healthcare Healthcare [Member] Healthcare Proceeds from the sale of property, plant, equipment, and intangibles Proceeds from Sale of Property, Plant, and Equipment Deferred financing costs Debt Issuance Costs, Net Weighted average exercise price: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Contract Termination [Member] Contract Termination [Member] Change in contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Service liabilities Service liabilities Service liabilities Restructuring, Impairment, and Other Activities Disclosure Restructuring, Impairment, and Other Activities Disclosure [Text Block] Warranties issued during the period Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Cash dividends paid to ordinary shareholders Payments of Ordinary Dividends, Common Stock Equity Investment [Domain] Equity Investment [Domain] Equity Investment Consolidation Items [Axis] Consolidation Items [Axis] Deferred Service Revenue Deferred Service Revenue Deferred Service Revenue Marketable equity securities Equity Securities [Member] Accrued Liabilities [Member] Accrued expenses and other Accrued Liabilities [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable (net of allowances of $11,605 and $12,051 respectively) Accounts Receivable, after Allowance for Credit Loss, Current Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Finished goods Inventory, Finished Goods, Gross Treasury Stock Treasury Stock [Text Block] Investments by Secondary Categorization [Domain] Investments by Secondary Categorization [Domain] Restructuring Reserve Restructuring Reserve Other foreign locations [Member] Other foreign locations [Member] Other foreign locations [Member] Principal outstanding on loan receivable Principal outstanding on loan receivable Principal outstanding on loan receivable - amount outstanding on loans receivable Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restructuring Costs Restructuring Costs Restructuring Type [Axis] Restructuring Type [Axis] Prepaid expenses and other current assets Other Prepaid Expense, Current Goodwill Goodwill Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Total other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Document Transition Report Document Transition Report Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Expected recognition within the next year [Member] Expected recognition within the next year [Member] Expected recognition within the next year [Member] Aggregate value of shares repurchased pursuant to authorization Stock Repurchased and Retired During Period, Value Product Rationalization [Member] Product Rationalization [Member] Product Rationalization [Member] Non-operating expenses, net: Nonoperating Income (Expense) [Abstract] Cash dividends declared per common share outstanding Common Stock, Dividends, Per Share, Declared Applied Infection Control Applied Infection Control [Member] Applied Infection Control [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Document Quarterly Report Document Quarterly Report LIFO reserve Inventory, LIFO Reserve Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Equity [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Interest Rate Period Term of Loan Agreement Term of Loan Agreement Derivative Asset, Notional Amount Derivative Asset, Notional Amount Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Entities [Table] Entities [Table] Non-vested stock options outstanding expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Derivative Contract [Domain] Derivative Contract [Domain] Weighted average shares outstanding and share equivalents - diluted Weighted Average Number of Shares Outstanding, Diluted Loans Payable to Bank Loans Payable to Bank Basic Earnings Per Share, Basic Contingencies Contingencies Disclosure [Text Block] Contingent consideration gain loss [Member] Contingent consideration assumed in acquisition of Key [Member] Contingent consideration assumed in acquisition of Key Restructuring and Related Cost, Expected Cost Remaining Restructuring and Related Cost, Expected Cost Remaining Expected life of options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Entity File Number Entity File Number Number of Restricted Shares, Canceled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Canceled Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Collateral [Domain] Collateral Held [Domain] Inventory, Current [Table] Inventory, Current [Table] Geographic Distribution [Domain] Geographic Distribution [Domain] Healthcare and Life Sciences [Member] Healthcare and Life Sciences [Member] Healthcare and Life Sciences [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Proceeds from issuance of equity to minority shareholders Proceeds from Noncontrolling Interests Payments on long-term obligations Repayments of Long-term Debt Deferred Revenue [Domain] Deferred Revenue [Domain] Reserve for excess and obsolete inventory Inventory Valuation Reserves Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Amount Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Common shares, with $0.001 par value; 500,000 authorized; 85,337 shares issued; and 84,924 shares outstanding Common Stock, Value, Issued Disposal Group Name [Axis] Disposal Group Name [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Business Combination, Acquisition Related Costs acquisition and integration costs acquisition and integration costs Aggregate Intrinsic Value, Exercisable at June 30, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Subsequent Event - Purchase Price of Entity Net of Tax Benefits Subsequent Event - Purchase Price of Entity Net of Tax Benefits Subsequent Event - Purchase Price of Entity Net of Tax Benefits Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Business Acquisition, Date of Acquisition [Abstract] Business Acquisition, Date of Acquisition [Abstract] All Currencies [Domain] All Currencies [Domain] Receivable [Domain] Receivable [Domain] Subsequent Event [Table] Subsequent Event [Table] Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Net Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Stockholders' Equity Attributable to Noncontrolling Interest Weighted-Average Grant Date Fair Value, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Business Acquisition, Share Price Business Acquisition, Share Price Ordinary shares, closing price Common Stock, Fair Market Value Per Share Common Stock, Fair Market Value Per Share Years 1-4, 4% Int Rate Years 1-4, 4% Int Rate [Member] Years 1-4, 4% Int Rate [Member] Years 1-4, 4% Int Rate [Member] - Interest rate for first four years Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common Stock, Shares, Issued Common Stock, Shares, Issued Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and Cash Equivalents, at Carrying Value Subsequent Event - Business Acquisition Purchase Price of Entity Subsequent Event - Business Acquisition Purchase Price of Entity Subsequent Event - Business Acquisition Purchase Price of Entity Foreign currency forward contracts Foreign Exchange Forward [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Long-term indebtedness Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] Consumable revenues [Member] Consumable revenues [Member] Consumable revenues [Member] Business Acquisitions and Divestitures [Abstract] Business Acquisitions and Divestitures [Abstract] Business Acquisitions and Divestitures [Abstract] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Accounts receivable, net Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Accelerated depreciation and amortization [Member] Accelerated depreciation and amortization [Member] Accelerated depreciation and amortization [Member] Statement of Comprehensive Income [Abstract] Total shareholders' equity Stockholders' Equity Attributable to Parent Stockholders' Equity Attributable to Parent Nature of Operations Nature of Operations [Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Business Combination, Consideration Transferred Business Combination, Consideration Transferred Total liabilities and equity Liabilities and Equity Buildings and leasehold improvements Buildings and Improvements, Gross Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Income Tax Expense Income Tax Disclosure [Text Block] Raw materials Inventory, Raw Materials, Gross Entity Address, City or Town Entity Address, City or Town Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Brazilian reals Brazil, Brazil Real Accrued payroll and other related liabilities Employee-related Liabilities, Current Employee-related Liabilities, Current Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Phoenix Surgical Holdings, Ltd. and Endo-Tel LLP Phoenix and Endo-Tek [Member] Phoenix and Endo-Tek [Member] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Total Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Loans Receivable, Net Financing Receivable, after Allowance for Credit Loss Other Assets [Member] Other Assets [Member] Type of Adoption [Domain] Including Impact of Adoption of ASU 2016-01 [Domain] Accounting Standards Update [Domain] Number of share options that are antidilutive Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Long-term liabilities, other Long-term liabilities, other Long-term liabilities, other Consolidated Statements of Comprehensive Income [Abstract] Consolidated Statements of Comprehensive Income [Abstract] Consolidated Statements of Comprehensive Income [Abstract] Other items Other Noncash Income (Expense) Product [Member] Product [Member] (Gain) loss on the disposal of property, plant, and equipment, and intangibles, net Gain (Loss) on Disposition of Property Plant Equipment Other Receivable type [Axis] Other Receivable type [Axis] Other Receivable type [Axis] Equity Component [Domain] Equity Component [Domain] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Other Comprehensive (Loss) Income, Available-for-sale Securities Adjustment, Net of Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Gross Profit Gross Profit Synergy Health Labs Synergy Health Labs [Member] Synergy Health Labs [Member] Property, plant, and equipment, net Property, plant, and equipment, net Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number loss (gain) on fair value contingent consideration adjustments loss (gain) on fair value contingent consideration adjustments loss (gain) on fair value contingent consideration adjustments Revenue from Contract with Customer [Policy Text Block] Revenue from Contract with Customer [Policy Text Block] Accounting Guidance [Domain] Accounting Guidance [Domain] Share-Based Compensation Share-based Payment Arrangement [Text Block] Net income (loss) attributable to shareholders Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Receivables Billing Status [Domain] Receivables Billing Status [Domain] Changes in operating assets and liabilities, net of effects of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Netherlands Linen Management Services Netherlands Linen Management [Domain] Netherlands Linen Management [Domain] Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Inventories, Net Inventory Disclosure [Text Block] Work in process Inventory, Work in Process, Gross Derivative, notional amount, weight Derivative, Nonmonetary Notional Amount, Mass Deferred consideration Deferred consideration Deferred consideration Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Self-insured risk reserves-current portion Self Insurance Reserve, Current Operating expenses: Operating Expenses [Abstract] Net income per common share [Abstract] Earnings Per Share [Abstract] Restructuring Charges Restructuring Charges Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Loss on sale of businesses, net Gain (Loss) on Disposition of Business Pre-tax gain or loss on sale of business Net loss on divestiture of businesses Gain (Loss) on Disposition of Business Operating Income (Loss) [Member] Operating Income (Loss) [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Interest rate Interest rate [Axis] Interest rate [Axis] Interest rate [Axis] Information systems Capitalized Computer Software, Gross Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Pension Cost (Reversal of Cost) Pension Cost (Reversal of Cost) Summary of share option activity: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Non controlling interest period increase (decrease) from translation and other Non controlling interest period increase (decrease) from translation and other Non controlling interest period increase (decrease) from translation and other Document Fiscal Period Focus Document Fiscal Period Focus Liabilities: Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Equity [Member] Equity [Member] Other postretirement benefit obligations-long-term portion Liability, Other Retirement Benefits, Noncurrent Euro Member Countries, Euro euro Euro Member Countries, Euro Healthcare Products Healthcare Products [Member] [Member] Healthcare Products [Member] [Member] Defined benefit pension plans obligations-long-term portion Liability, Defined Benefit Pension Plan, Noncurrent Class of Financing Receivable, Type of Borrower [Domain] Class of Financing Receivable, Type of Borrower [Domain] Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Loans Receivable [Member] Loans Receivable [Member] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] COVID-19 incremental costs COVID-19 incremental costs COVID-19 incremental costs Entity Filer Category Entity Filer Category Common Stock [Member] Common Stock [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product and Service [Domain] Product and Service [Domain] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Liability [Member] Liabilities, Total [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Inventory [Domain] Inventory [Domain] Expected volatility of stock Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Preferred shares, annual dividend rate Preferred Stock, Dividend Rate, Percentage Loan agreement principal amount, maximum Loans and Leases Receivable, Gross Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Scenario [Axis] Prospective Adoption of New Accounting Pronouncements [Axis] Prospective Adoption of New Accounting Pronouncements [Axis] Share repurchases Class of Treasury Stock [Table] Private Placement Senior Notes Restatement [Domain] Revision of Prior Period [Domain] Interest rate Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Restructuring and Related Cost, Expected Number of Positions Eliminated Restructuring and Related Cost, Expected Number of Positions Eliminated Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Less: accumulated depreciation and depletion Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Product Warranty Liability [Table] Product Warranty Liability [Table] Currency [Axis] Currency [Axis] Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cost Available-for-sale Securities, Amortized Cost Basis Business Combination Disclosure Business Combination Disclosure [Text Block] Total non-operating expenses, net Nonoperating Income (Expense) Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Employee share option Share-based Payment Arrangement, Option [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Weighted average shares outstanding - basic Weighted Average Number of Shares Outstanding, Basic Debt Securities, Available-for-sale [Abstract] Debt Securities, Available-for-sale [Abstract] Mutual funds Mutual Funds [Member] Mutual Funds [Member] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate United States of America, Dollars United States of America, Dollars Subsequent Events [Abstract] Forfeited Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Healthcare [Member] [Member] Healthcare [Member] [Member] Healthcare [Member] Employee Severance [Member] Employee Severance [Member] Deferred Revenues, Amount recognized in period from certain capital contracts Deferred Revenues, Amount recognized in period from certain capital contracts Deferred Revenues, Amount recognized in period from certain capital contracts Reported Value Measurement [Member] Reported Value Measurement [Member] Including Impact of Adoption of ASU 2016-01 [Domain] Including Impact of Adoption of ASU 2016-01 [Domain] Including Impact of Adoption of ASU 2016-01 [Domain] Total equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Subsequent Event - Business Acquisition Equity Value of Acquiree Subsequent Event - Business Acquisition Equity Value of Acquiree Subsequent Event - Business Acquisition Equity Value of Acquiree Long term debt Long-term Debt, Fair Value Total revenues Revenues Revenues Class of Stock [Axis] Class of Stock [Axis] Income tax expense Income Tax Expense (Benefit) Proceeds from sale of business Proceeds from Divestiture of Businesses Cantel [Domain] Cantel [Domain] Cantel Accrued bonuses Accrued Bonuses Unrealized gains Available-for-sale Equity Securities, Accumulated Gross Unrealized Gain, before Tax Accrued expenses and other Accrued Liabilities, Current Diluted Earnings Per Share, Diluted Local Phone Number Local Phone Number Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Unrealized losses Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Reconciliation of Assets from Segment to Consolidated Reconciliation of Assets from Segment to Consolidated [Table Text Block] Total intrinsic value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Schedule of Debt Schedule of Debt [Table Text Block] Additional Consolidated Balance Sheet Information [Table] Additional Consolidated Balance Sheet Information [Table] Additional Consolidated Balance Sheet Information [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Derivative [Line Items] Derivative [Line Items] Entity Address, Address Line One Entity Address, Address Line One Proceeds from Divestiture of Businesses, Net of Cash Divested Proceeds from Divestiture of Businesses, Net of Cash Divested Entity Emerging Growth Company Entity Emerging Growth Company Type of other receivable [Axis] Type of other receivable [Axis] type of other receivable [Axis] Medisafe Medisafe [Member] Medisafe [Member] Deferred income taxes Deferred Income Tax Expense (Benefit) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Award Type [Axis] Award Type [Axis] Deferred Income Taxes and Other Tax Liabilities, Noncurrent Deferred Income Taxes and Other Tax Liabilities, Noncurrent Prepaid Expenses and Other Current Assets [Member] Prepaid & Other Prepaid Expenses and Other Current Assets [Member] Class of Financing Receivable, Type [Axis] Class of Financing Receivable [Axis] Credit facility term Credit facility term Credit facility term Fair Value, Share-based Payment Awards, Other than Options Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Maximum Maximum [Member] Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Noncontrolling Interest [Member] Noncontrolling Interest [Member] Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Dividends, Common Stock, Cash Dividends, Common Stock, Cash Dividends, Common Stock, Cash Loans and Leases Receivable, Related Parties, Additions Loans and Leases Receivable, Related Parties, Additions Retained Earnings [Member] Retained Earnings [Member] Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Measurement Basis [Axis] Measurement Basis [Axis] Effective Income Tax Rate, Continuing Operations Effective Income Tax Rate Reconciliation, Percent Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Purchase of investments Payments to Acquire Investments Average Remaining Contractual Term, Outstanding at June 30, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Share-based CompensationArrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Equity Award [Domain] Award Type [Domain] Increase (Decrease) in Restructuring Reserve Increase (Decrease) in Restructuring Reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Trading Symbol Trading Symbol Restructuring Costs LTD Since Plan Inception Restructuring Costs LTD Since Plan Inception Restructuring Costs LTD Since Plan Inception Exercisable at June 30, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Settlement made during the period Standard Product Warranty Accrual, Decrease for Payments Par Value (Euros) of Deferred Ordinary Shares Par Value (Euros) of Deferred Ordinary Shares Par Value (Euros) of Deferred Ordinary Shares Earnings Per Share Earnings Per Share [Text Block] Asset impairment charges [Member] Asset impairment charges [Member] Asset impairment charges [Member] Current liabilities: Liabilities, Current [Abstract] Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Entity Shell Company Entity Shell Company Cost of Goods, Total [Member] Cost of Goods and Service Benchmark [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Shares obtained in connection with share based compensation award programs Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Other postretirement benefit obligations-current portion Liability, Other Retirement Benefits Canceled Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Recently Issued Accounting Standards Impacting the Company New Accounting Pronouncements, Policy [Policy Text Block] Derivative, Gain (Loss) on Derivative, Net [Abstract] Derivative, Gain (Loss) on Derivative, Net [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Subsequent Event - Unsecured Term Loan Credit Facility Subsequent Event - Unsecured Term Loan Credit Facility Subsequent Event - Unsecured Term Loan Credit Facility Subsegments [Axis] Subsegments [Axis] EX-101.PRE 15 ste-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 image_01.jpg GRAPHIC begin 644 image_01.jpg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end XML 17 ste-20201231_htm.xml IDEA: XBRL DOCUMENT 0001757898 2020-04-01 2020-12-31 0001757898 2021-02-05 0001757898 2020-12-31 0001757898 2020-03-31 0001757898 us-gaap:ProductMember 2020-10-01 2020-12-31 0001757898 us-gaap:ProductMember 2019-10-01 2019-12-31 0001757898 us-gaap:ProductMember 2020-04-01 2020-12-31 0001757898 us-gaap:ProductMember 2019-04-01 2019-12-31 0001757898 us-gaap:ServiceMember 2020-10-01 2020-12-31 0001757898 us-gaap:ServiceMember 2019-10-01 2019-12-31 0001757898 us-gaap:ServiceMember 2020-04-01 2020-12-31 0001757898 us-gaap:ServiceMember 2019-04-01 2019-12-31 0001757898 2020-10-01 2020-12-31 0001757898 2019-10-01 2019-12-31 0001757898 2019-04-01 2019-12-31 0001757898 2019-03-31 0001757898 2019-12-31 0001757898 us-gaap:CommonStockMember 2020-09-30 0001757898 us-gaap:RetainedEarningsMember 2020-09-30 0001757898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001757898 us-gaap:NoncontrollingInterestMember 2020-09-30 0001757898 2020-09-30 0001757898 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001757898 us-gaap:NoncontrollingInterestMember 2020-10-01 2020-12-31 0001757898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2020-12-31 0001757898 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001757898 us-gaap:CommonStockMember 2020-12-31 0001757898 us-gaap:RetainedEarningsMember 2020-12-31 0001757898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001757898 us-gaap:NoncontrollingInterestMember 2020-12-31 0001757898 us-gaap:CommonStockMember 2020-03-31 0001757898 us-gaap:RetainedEarningsMember 2020-03-31 0001757898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001757898 us-gaap:NoncontrollingInterestMember 2020-03-31 0001757898 us-gaap:RetainedEarningsMember 2020-04-01 2020-12-31 0001757898 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-12-31 0001757898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-12-31 0001757898 us-gaap:CommonStockMember 2020-04-01 2020-12-31 0001757898 us-gaap:CommonStockMember 2019-09-30 0001757898 us-gaap:RetainedEarningsMember 2019-09-30 0001757898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001757898 us-gaap:NoncontrollingInterestMember 2019-09-30 0001757898 2019-09-30 0001757898 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001757898 us-gaap:NoncontrollingInterestMember 2019-10-01 2019-12-31 0001757898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-01 2019-12-31 0001757898 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001757898 us-gaap:CommonStockMember 2019-12-31 0001757898 us-gaap:RetainedEarningsMember 2019-12-31 0001757898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001757898 us-gaap:NoncontrollingInterestMember 2019-12-31 0001757898 us-gaap:CommonStockMember 2019-03-31 0001757898 us-gaap:RetainedEarningsMember 2019-03-31 0001757898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001757898 us-gaap:NoncontrollingInterestMember 2019-03-31 0001757898 us-gaap:RetainedEarningsMember 2019-04-01 2019-12-31 0001757898 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-12-31 0001757898 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-12-31 0001757898 us-gaap:CommonStockMember 2019-04-01 2019-12-31 0001757898 2020-04-01 2020-06-30 0001757898 ste:ExpectedrecognitionwithinthenextyearMember 2020-12-31 0001757898 ste:ExpectedrecognitionbeyondthenextyearMemberMember 2020-12-31 0001757898 ste:KeySurgicalDomain 2020-04-01 2020-12-31 0001757898 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2020-04-01 2020-12-31 0001757898 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2019-04-01 2019-12-31 0001757898 ste:HealthcareMemberMember 2020-10-01 2020-12-31 0001757898 ste:HealthcareMemberMember 2019-10-01 2019-12-31 0001757898 ste:HealthcareMemberMember 2020-04-01 2020-12-31 0001757898 ste:HealthcareMemberMember 2019-04-01 2019-12-31 0001757898 ste:AppliedSterilizationTechnologiesMember 2020-10-01 2020-12-31 0001757898 ste:AppliedSterilizationTechnologiesMember 2019-10-01 2019-12-31 0001757898 ste:AppliedSterilizationTechnologiesMember 2020-04-01 2020-12-31 0001757898 ste:AppliedSterilizationTechnologiesMember 2019-04-01 2019-12-31 0001757898 ste:LifeScienceMemberMember 2020-10-01 2020-12-31 0001757898 ste:LifeScienceMemberMember 2019-10-01 2019-12-31 0001757898 ste:LifeScienceMemberMember 2020-04-01 2020-12-31 0001757898 ste:LifeScienceMemberMember 2019-04-01 2019-12-31 0001757898 ste:OperatingsegmentallMember 2020-10-01 2020-12-31 0001757898 ste:OperatingsegmentallMember 2019-10-01 2019-12-31 0001757898 ste:OperatingsegmentallMember 2020-04-01 2020-12-31 0001757898 ste:OperatingsegmentallMember 2019-04-01 2019-12-31 0001757898 us-gaap:CorporateMember 2020-10-01 2020-12-31 0001757898 us-gaap:CorporateMember 2019-10-01 2019-12-31 0001757898 us-gaap:CorporateMember 2020-04-01 2020-12-31 0001757898 us-gaap:CorporateMember 2019-04-01 2019-12-31 0001757898 ste:CapitalequipmentrevenuesMember ste:HealthcareMemberMember 2020-10-01 2020-12-31 0001757898 ste:CapitalequipmentrevenuesMember ste:HealthcareMemberMember 2019-10-01 2019-12-31 0001757898 ste:CapitalequipmentrevenuesMember ste:HealthcareMemberMember 2020-04-01 2020-12-31 0001757898 ste:CapitalequipmentrevenuesMember ste:HealthcareMemberMember 2019-04-01 2019-12-31 0001757898 ste:ConsumablerevenuesMember ste:HealthcareMemberMember 2020-10-01 2020-12-31 0001757898 ste:ConsumablerevenuesMember ste:HealthcareMemberMember 2019-10-01 2019-12-31 0001757898 ste:ConsumablerevenuesMember ste:HealthcareMemberMember 2020-04-01 2020-12-31 0001757898 ste:ConsumablerevenuesMember ste:HealthcareMemberMember 2019-04-01 2019-12-31 0001757898 ste:ServicerevenuesMember ste:HealthcareMemberMember 2020-10-01 2020-12-31 0001757898 ste:ServicerevenuesMember ste:HealthcareMemberMember 2019-10-01 2019-12-31 0001757898 ste:ServicerevenuesMember ste:HealthcareMemberMember 2020-04-01 2020-12-31 0001757898 ste:ServicerevenuesMember ste:HealthcareMemberMember 2019-04-01 2019-12-31 0001757898 ste:CapitalequipmentrevenuesMember ste:LifeScienceMemberMember 2020-10-01 2020-12-31 0001757898 ste:CapitalequipmentrevenuesMember ste:LifeScienceMemberMember 2019-10-01 2019-12-31 0001757898 ste:CapitalequipmentrevenuesMember ste:LifeScienceMemberMember 2020-04-01 2020-12-31 0001757898 ste:CapitalequipmentrevenuesMember ste:LifeScienceMemberMember 2019-04-01 2019-12-31 0001757898 ste:ConsumablerevenuesMember ste:LifeScienceMemberMember 2020-10-01 2020-12-31 0001757898 ste:ConsumablerevenuesMember ste:LifeScienceMemberMember 2019-10-01 2019-12-31 0001757898 ste:ConsumablerevenuesMember ste:LifeScienceMemberMember 2020-04-01 2020-12-31 0001757898 ste:ConsumablerevenuesMember ste:LifeScienceMemberMember 2019-04-01 2019-12-31 0001757898 ste:ServicerevenuesMember ste:LifeScienceMemberMember 2020-10-01 2020-12-31 0001757898 ste:ServicerevenuesMember ste:LifeScienceMemberMember 2019-10-01 2019-12-31 0001757898 ste:ServicerevenuesMember ste:LifeScienceMemberMember 2020-04-01 2020-12-31 0001757898 ste:ServicerevenuesMember ste:LifeScienceMemberMember 2019-04-01 2019-12-31 0001757898 country:IE 2020-10-01 2020-12-31 0001757898 country:IE 2019-10-01 2019-12-31 0001757898 country:IE 2020-04-01 2020-12-31 0001757898 country:IE 2019-04-01 2019-12-31 0001757898 country:US 2020-10-01 2020-12-31 0001757898 country:US 2019-10-01 2019-12-31 0001757898 country:US 2020-04-01 2020-12-31 0001757898 country:US 2019-04-01 2019-12-31 0001757898 ste:OtherforeignlocationsMember 2020-10-01 2020-12-31 0001757898 ste:OtherforeignlocationsMember 2019-10-01 2019-12-31 0001757898 ste:OtherforeignlocationsMember 2020-04-01 2020-12-31 0001757898 ste:OtherforeignlocationsMember 2019-04-01 2019-12-31 0001757898 ste:HealthcareandLifeSciencesMember 2020-12-31 0001757898 ste:HealthcareandLifeSciencesMember 2020-03-31 0001757898 ste:AppliedSterilizationTechnologiesMember 2020-12-31 0001757898 ste:AppliedSterilizationTechnologiesMember 2020-03-31 0001757898 us-gaap:EmployeeStockOptionMember 2020-10-01 2020-12-31 0001757898 us-gaap:EmployeeStockOptionMember 2019-10-01 2019-12-31 0001757898 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-12-31 0001757898 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-12-31 0001757898 currency:EUR 2020-12-31 0001757898 2019-05-07 0001757898 2019-07-30 0001757898 us-gaap:StockAppreciationRightsSARSMember 2020-12-31 0001757898 us-gaap:StockAppreciationRightsSARSMember 2019-12-31 0001757898 us-gaap:RestrictedStockMember 2020-03-31 0001757898 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001757898 us-gaap:RestrictedStockMember 2020-04-01 2020-12-31 0001757898 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-12-31 0001757898 us-gaap:RestrictedStockMember 2020-12-31 0001757898 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001757898 currency:GBP us-gaap:ForeignExchangeForwardMember 2020-12-31 0001757898 currency:MXN us-gaap:ForeignExchangeForwardMember 2020-12-31 0001757898 currency:CAD us-gaap:ForeignExchangeForwardMember 2020-12-31 0001757898 currency:EUR us-gaap:ForeignExchangeForwardMember 2020-12-31 0001757898 us-gaap:CommodityContractMember 2020-04-01 2020-12-31 0001757898 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0001757898 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-03-31 0001757898 us-gaap:AccruedLiabilitiesMember 2020-12-31 0001757898 us-gaap:AccruedLiabilitiesMember 2020-03-31 0001757898 us-gaap:ForeignExchangeForwardMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-10-01 2020-12-31 0001757898 us-gaap:ForeignExchangeForwardMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-10-01 2019-12-31 0001757898 us-gaap:ForeignExchangeForwardMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-04-01 2020-12-31 0001757898 us-gaap:ForeignExchangeForwardMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-12-31 0001757898 us-gaap:CommodityContractMember us-gaap:CostOfSalesMember 2020-10-01 2020-12-31 0001757898 us-gaap:CommodityContractMember us-gaap:CostOfSalesMember 2019-10-01 2019-12-31 0001757898 us-gaap:CommodityContractMember us-gaap:CostOfSalesMember 2020-04-01 2020-12-31 0001757898 us-gaap:CommodityContractMember us-gaap:CostOfSalesMember 2019-04-01 2019-12-31 0001757898 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001757898 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001757898 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001757898 us-gaap:FairValueInputsLevel1Member 2020-03-31 0001757898 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001757898 us-gaap:FairValueInputsLevel2Member 2020-03-31 0001757898 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001757898 us-gaap:FairValueInputsLevel3Member 2020-03-31 0001757898 ste:AdditionsMember 2020-04-01 2020-12-31 0001757898 ste:ContingentConsiderationAssumedInAcquisitionOfKeyMember 2020-04-01 2020-12-31 0001757898 ste:ReductionsandPayoutMember 2020-04-01 2020-12-31 0001757898 ste:ReversalOfLiabilityBalanceMember 2020-04-01 2020-12-31 0001757898 us-gaap:ForeignCurrencyGainLossMember 2020-04-01 2020-12-31 0001757898 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0001757898 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0001757898 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0001757898 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0001757898 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-10-01 2020-12-31 0001757898 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-04-01 2020-12-31 0001757898 us-gaap:AccumulatedTranslationAdjustmentMember 2020-10-01 2020-12-31 0001757898 us-gaap:AccumulatedTranslationAdjustmentMember 2020-04-01 2020-12-31 0001757898 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0001757898 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001757898 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0001757898 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0001757898 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0001757898 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0001757898 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-10-01 2019-12-31 0001757898 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-04-01 2019-12-31 0001757898 us-gaap:AccumulatedTranslationAdjustmentMember 2019-10-01 2019-12-31 0001757898 us-gaap:AccumulatedTranslationAdjustmentMember 2019-04-01 2019-12-31 0001757898 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0001757898 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001757898 us-gaap:OperatingIncomeLossMember 2020-04-01 2020-12-31 0001757898 us-gaap:CostOfSalesMember 2020-04-01 2020-12-31 0001757898 ste:HealthcareMember 2020-04-01 2020-12-31 0001757898 ste:LoanRate4MemberDomain 2020-12-31 0001757898 us-gaap:FinanceReceivablesMember 2020-12-31 0001757898 us-gaap:FinanceReceivablesMember 2020-03-31 0001757898 2017-03-31 0001757898 us-gaap:LoansReceivableMember 2017-04-01 2017-06-30 0001757898 ste:Years144IntRateMember 2017-03-31 0001757898 ste:Years51512IntRateMember 2017-03-31 0001757898 us-gaap:LoansReceivableMember 2019-10-31 0001757898 ste:Years144IntRateMember 2019-10-31 0001757898 ste:Years568IntRateMemberMember 2019-10-31 0001757898 us-gaap:LoansReceivableMember 2020-12-31 0001757898 us-gaap:LoansReceivableMember 2020-03-31 0001757898 ste:CantelDomain us-gaap:SubsequentEventMember 2020-04-01 2021-03-31 0001757898 ste:CantelDomain us-gaap:SubsequentEventMember 2021-03-31 0001757898 us-gaap:SubsequentEventMember 2021-03-31 0001757898 us-gaap:SubsequentEventMember 2020-04-01 2021-03-31 0001757898 ste:EquityInvestmentDomain us-gaap:SubsequentEventMember 2020-04-01 2021-03-31 shares iso4217:USD iso4217:USD shares pure iso4217:EUR iso4217:GBP iso4217:MXN iso4217:CAD utr:lb ste:plan STERIS plc 0001757898 10-Q 2020-12-31 false 2021 Q3 --03-31 Large Accelerated Filer 85352713 false false L2 1 232 2000 353 false true false 11605000 12051000 500000000 500000000 85337000 84924000 85337000 84924000 0.001 0.001 173000 171000 520000 512000 0.40 0.37 1.17 1.08 10-Q true 2020-12-31 false 001-38848 STERIS plc L2 98-1455064 70 Sir John Rogerson's Quay, Dublin 2, IE D02 R296 353 1 232 2000 Ordinary Shares, $0.001 par value STE NYSE Yes Yes Large Accelerated Filer false 85352713 252502000 319581000 11605000 12051000 556117000 586481000 294132000 248259000 73324000 54430000 1176075000 1208751000 1226895000 1111855000 149741000 131837000 2926551000 2356085000 1043904000 565473000 57614000 51581000 6580780000 5425582000 134471000 149341000 13068000 14013000 152331000 128261000 21364000 19809000 184633000 192183000 505867000 503607000 1713199000 1150521000 264041000 160270000 130217000 114114000 89264000 90346000 2702588000 2018858000 0.001 500000000 85337000 84924000 1996843000 1982164000 1872533000 1647175000 -2386000 -235463000 3866990000 3393876000 11202000 12848000 3878192000 3406724000 6580780000 5425582000 375314000 363795000 1015926000 1009196000 433610000 410466000 1218062000 1198708000 808924000 774261000 2233988000 2207904000 202881000 195105000 535234000 539664000 260182000 247803000 737288000 712377000 463063000 442908000 1272522000 1252041000 345861000 331353000 961466000 955863000 182373000 172927000 510250000 527667000 16438000 16487000 48812000 48321000 20000 -448000 110000 667000 198831000 188966000 559172000 576655000 147030000 142387000 402294000 379208000 8899000 9813000 27056000 30702000 1299000 1378000 4776000 2163000 -7600000 -8435000 -22280000 -28539000 139430000 133952000 380014000 350669000 24842000 29285000 71294000 66083000 114588000 104667000 308720000 284586000 87000 -263000 171000 297000 114501000 104930000 308549000 284289000 1.34 1.24 3.62 3.35 1.33 1.23 3.59 3.32 0.40 0.37 1.17 1.08 114588000 104667000 308720000 284586000 87000 -263000 171000 297000 114501000 104930000 308549000 284289000 173000 171000 520000 512000 -510000 -504000 -1530000 -1515000 128737000 77299000 234607000 12371000 128227000 76795000 233077000 10856000 242728000 181725000 541626000 295145000 308720000 284586000 160193000 146294000 783000 -1139000 19924000 18862000 -865000 540000 -5000 -2553000 -4494000 2506000 -60574000 -29860000 7520000 32816000 8906000 -3615000 -30974000 -18610000 -6373000 -38833000 501785000 391326000 164497000 153649000 417000 387000 0 439000 869431000 107166000 2392000 0 -1035903000 -259989000 550000000 0 35000000 0 23782000 -48467000 3122000 1206000 2968000 452000 14560000 40322000 99696000 91595000 2258000 6050000 627000 840000 3552000 0 26018000 22958000 442533000 -153874000 24506000 1134000 -67079000 -21403000 319581000 220633000 252502000 199230000 85251000 1990880000 1786878000 -130613000 15310000 3662455000 114501000 87000 114588000 128227000 128227000 9000 5417000 -5290000 127000 95000 11380000 11380000 0.40 34136000 34136000 627000 627000 -3552000 -3552000 -16000 -16000 85337000 1996843000 1872533000 -2386000 11202000 3878192000 84924000 1982164000 1647175000 -235463000 12848000 3406724000 308549000 171000 308720000 233077000 233077000 121000 31065000 -16505000 14560000 534000 45744000 45744000 1.17 99696000 99696000 2258000 2258000 627000 627000 3552000 3552000 104000 104000 85337000 1996843000 1872533000 -2386000 11202000 3878192000 84797000 1981660000 1472725000 -225717000 8977000 3237645000 104930000 -263000 104667000 76795000 76795000 25000 669000 1785000 2454000 19000 6116000 6116000 0.37 31375000 31375000 840000 840000 6050000 6050000 -538000 -538000 84791000 1987107000 1544495000 -148922000 13386000 3396066000 84517000 1998564000 1339024000 -159778000 7988000 3185798000 284289000 297000 284586000 10856000 10856000 304000 53099000 -12777000 40322000 578000 41642000 41642000 1.08 91595000 91595000 840000 840000 6050000 6050000 -109000 -109000 84791000 1987107000 1544495000 -148922000 13386000 3396066000 Nature of Operations and Summary of Significant Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STERIS plc is a leading provider of infection prevention and other procedural products and services. Our MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal ("GI") endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory testing services, on-site and off-site reprocessing, and capital equipment products, such as sterilizers and surgical tables, and connectivity solutions such as operating room (“OR”) integration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. The Consolidated Balance Sheet at March 31, 2020 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2020 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition and Associated Liabilities</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018. At the time of adoption, certain of our capital equipment contracts were comprised of a single integrated performance obligation, which resulted in the deferral of the corresponding capital equipment revenue and cost of revenues until installation was complete. Since the adoption of the standard, there have been changes made in our selling philosophy, product architecture, and manufacturing processes with respect to this product line, that impact whether the promises to transfer the individual goods or services to the Customer are separately identifiable from other promises in the contract. After review of these changes, we have concluded that these contracts consist of multiple performance obligations that are capable of being distinct and meet the criteria for revenue to be recognized when the Customer obtains control of the asset, which is upon delivery of each performance obligation. Revenues and costs of revenues related to these </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts totaling $14,609 and $7,560, respectively, that had previously been deferred were recognized in our fiscal 2021 first quarter.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2020, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our Healthcare and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2021, $38,181 of the March 31, 2020 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2020, $46,744 of the March 31, 2019 deferred revenue balance was recorded as revenue.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31 2020, the transaction price allocated to remaining performance obligations was approximately $1,014,800. We expect to recognize approximately 50% of the transaction price within one year and approximately 42% beyond one year. The remainder has yet to be scheduled for delivery. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Impacting the Company</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently Issued Accounting Standards Impacting the Company are presented in the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Adoption</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="27" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standards that have been adopted in fiscal 2021</span></td></tr><tr style="height:5pt"><td colspan="27" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2016-13, "Measurement of Credit Losses on Financial Instruments"</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2016</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard required a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard was effective for annual periods beginning after December 15, 2019. </span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard effective April 1, 2020 with no material impact to our consolidated financial statements.</span></div></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement”<br/></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy.  The standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.<br/></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans"</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans.  The standard also clarified disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation.  The standard was effective for fiscal years ending after December 15, 2019.<br/></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract"</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard aligned the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or<br/>obtain internal-use software. The standard was effective for fiscal years beginning after December 15, 2019.<br/></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard on April 1, 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></td></tr><tr style="height:179pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.609%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="27" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standards that have not yet been adopted</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)"</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This standard simplifies the accounting for convertible instruments and its application of the derivatives scope exception for contracts in an entity’s own equity. The standard reduces the number of accounting models that require separating embedded conversion features from convertible instruments. As a result, only conversion features accounted for under the substantial premium model and those that require bifurcation will be accounted for separately. For contracts in an entity’s own equity, the new standard eliminates some of the current requirements for equity classification. The standard also addresses how convertible instruments are accounted for in the diluted earnings per share calculation and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity’s own equity. The standard is effective for annual periods beginning after December 15, 2021 and interim periods within that year. Early adoption is permitted for annual periods beginning after December 15, 2020 and interim periods within that year.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2019-12 "Income Taxes (Topic 740)"</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard provides final guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance simplifies accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table>A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2020 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2020 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2021.</span></div> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition and Associated Liabilities</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018. At the time of adoption, certain of our capital equipment contracts were comprised of a single integrated performance obligation, which resulted in the deferral of the corresponding capital equipment revenue and cost of revenues until installation was complete. Since the adoption of the standard, there have been changes made in our selling philosophy, product architecture, and manufacturing processes with respect to this product line, that impact whether the promises to transfer the individual goods or services to the Customer are separately identifiable from other promises in the contract. After review of these changes, we have concluded that these contracts consist of multiple performance obligations that are capable of being distinct and meet the criteria for revenue to be recognized when the Customer obtains control of the asset, which is upon delivery of each performance obligation. Revenues and costs of revenues related to these </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts totaling $14,609 and $7,560, respectively, that had previously been deferred were recognized in our fiscal 2021 first quarter.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2020, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our Healthcare and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2021, $38,181 of the March 31, 2020 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2020, $46,744 of the March 31, 2019 deferred revenue balance was recorded as revenue.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Performance Obligations</span></div>Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31 2020, the transaction price allocated to remaining performance obligations was approximately $1,014,800. We expect to recognize approximately 50% of the transaction price within one year and approximately 42% beyond one year. The remainder has yet to be scheduled for delivery 14609000 7560000 38181000 46744000 1014800000 0.50 0.42 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently Issued Accounting Standards Impacting the Company are presented in the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Adoption</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="27" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standards that have been adopted in fiscal 2021</span></td></tr><tr style="height:5pt"><td colspan="27" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2016-13, "Measurement of Credit Losses on Financial Instruments"</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2016</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard required a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard was effective for annual periods beginning after December 15, 2019. </span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard effective April 1, 2020 with no material impact to our consolidated financial statements.</span></div></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement”<br/></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy.  The standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.<br/></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans"</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans.  The standard also clarified disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation.  The standard was effective for fiscal years ending after December 15, 2019.<br/></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract"</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard aligned the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or<br/>obtain internal-use software. The standard was effective for fiscal years beginning after December 15, 2019.<br/></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard on April 1, 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></td></tr><tr style="height:179pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.609%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="27" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standards that have not yet been adopted</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)"</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This standard simplifies the accounting for convertible instruments and its application of the derivatives scope exception for contracts in an entity’s own equity. The standard reduces the number of accounting models that require separating embedded conversion features from convertible instruments. As a result, only conversion features accounted for under the substantial premium model and those that require bifurcation will be accounted for separately. For contracts in an entity’s own equity, the new standard eliminates some of the current requirements for equity classification. The standard also addresses how convertible instruments are accounted for in the diluted earnings per share calculation and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity’s own equity. The standard is effective for annual periods beginning after December 15, 2021 and interim periods within that year. Early adoption is permitted for annual periods beginning after December 15, 2020 and interim periods within that year.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2019-12 "Income Taxes (Topic 740)"</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard provides final guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance simplifies accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table> Business Acquisitions and Divestitures <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal 2021</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2020, we acquired all of the outstanding units and equity of Key Surgical, LLC ("Key Surgical"). Key Surgical is a global provider of sterile processing, operating room and endoscopy consumable products serving hospitals and surgical facilities. Key Surgical is being integrated into our Healthcare segment. The total purchase price of the acquisition was $849,717, net of cash acquired and remains subject to customary working capital adjustments. Acquisition related costs of $10,842 are reported in the selling, general, and administrative expense line of the Consolidated Statements of Income. The purchase price for the acquisition was financed with a combination of cash on hand, credit facility borrowings and proceeds from the issuance of new long-term obligations. Please refer to note 5 titled, "Debt" for more information. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the preliminary allocation of the purchase price to the net assets acquired for the Key Surgical acquisition based on fair values at the acquisition date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Key Surgical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,967</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,167</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">491,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">975,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,683)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(95,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(113,377)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">862,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">urchase price allocation is still preliminary as of December 31, 2020, as valuation has not been finalized. </span></div><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets resulting from the Key Surgical acquisition may consists of patents, trade names, Customer Relationships, non-compete agreements, and technologies, pending the outcome of the final valuation.</span></div><div style="margin-bottom:1pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Key Surgical, we also completed two tuck-in acquisitions during the third quarter fiscal 2021, which continued to expand our product and service offerings in the Healthcare segment. The aggregate purchase price associated with these transactions was approximately $20,908, net of cash acquired and including deferred consideration of $1,194. Acquisition related costs are reported in the selling, general, and administrative expense line of the Consolidated Statements of Income and amounts are not mate</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rial.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price allocations will be finalized within a measurement period not to exceed one year from closing. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal 2020 </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of fiscal 2020, we completed several tuck-in acquisitions which continued to expand our product and service offerings in the Healthcare and Applied Sterilization Technologies segments. The aggregate purchase price associated with these transactions was approximately $117,259, net of cash acquired and including deferred consideration of $894. Acquisition related costs are reported in the selling, general, and administrative expense line of the Consolidated Statements of Income and amounts are not material. The purchase price for the acquisitions was financed with both cash on hand and with credit facility borrowings.</span></div> Purchase price allocations were finalized within a measurement period not to exceed one year from closing. Any final adjustments recorded were not material. During the first quarter of fiscal 2020, we sold the operations of our hospital sterilization services business that was located in China. We recorded proceeds of $439, net of cash divested, and recognized a pre-tax loss on the sale of $2,330 in the selling, general and administrative expense line of the Consolidated Statements of Income. The business generated annual revenues of approximately $5,000. 2020-11-18 849717000 10842000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the preliminary allocation of the purchase price to the net assets acquired for the Key Surgical acquisition based on fair values at the acquisition date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Key Surgical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,967</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,167</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">491,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">975,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,683)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(95,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(113,377)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">862,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">urchase price allocation is still preliminary as of December 31, 2020, as valuation has not been finalized. </span></div>(2) Intangible assets resulting from the Key Surgical acquisition may consists of patents, trade names, Customer Relationships, non-compete agreements, and technologies, pending the outcome of the final valuation 12615000 13967000 22167000 6032000 6680000 491009000 423239000 975709000 17683000 95694000 113377000 862332000 20908000 1194000 117259000 894000 439000 2330000 5000000 Inventories, Net<div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the last-in, first-out (“LIFO”) and first-in, first-out (“FIFO”) cost methods to value inventory. Inventory valued using the LIFO cost method is stated at the lower of cost or market. Inventory valued using the FIFO cost method is stated at the lower of cost or net realizable value. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,321 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42,109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">185,762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO reserve</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for excess and obsolete inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">294,132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,259 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,321 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42,109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">185,762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO reserve</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for excess and obsolete inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">294,132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,259 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 102212000 94321000 42109000 35643000 185762000 151381000 18753000 16937000 17198000 16149000 294132000 248259000 Property, Plant and Equipment <div style="text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the major categories of our depreciable assets is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69,591</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">753,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information systems</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Radioisotope</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total property, plant, and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,355,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129,185 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and depletion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,128,617)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,017,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,226,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111,855 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:2.2pt">Land is not depreciated. Construction in progress is not depreciated until placed in service.</span></div> <div style="text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the major categories of our depreciable assets is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69,591</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">753,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information systems</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Radioisotope</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total property, plant, and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,355,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129,185 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and depletion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,128,617)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,017,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,226,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111,855 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:2.2pt">Land is not depreciated. Construction in progress is not depreciated until placed in service.</span></div> 69591000 65994000 567113000 531267000 753851000 682488000 186421000 181112000 567353000 508593000 211183000 159731000 2355512000 2129185000 1128617000 1017330000 1226895000 1111855000 Debt<div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indebtedness was as follows:</span></div><div style="margin-bottom:11pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">550,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">864,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,844)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,713,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,521 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2020, we entered into a Term Loan Agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Credit Agreement”) providing for a $550,000 Term Loan (the “Term Loan”) in connection with our acquisition of Key Surgical. The proceeds of the Term Loan were used to fund a portion of the purchase price, to prepay and terminate existing indebtedness of Key Surgical and to pay fees and expenses incurred in connection with the Key Surgical acquisition and entry into the Credit Agreement. For more information on the Key Surgical acquisition refer to Note 2 titled, "Business Acquisitions and Divestitures". </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan matures on November 20, 2023. No principal payments are due on the Term Loan for the period ending December 31, 2021. For the period beginning January 1, 2022 through December 31, 2022, quarterly principal payments, each in the amount of 1.25% of the original principal amount of the Term Loan, are due on the last business day of each fiscal quarter. For the period beginning January 1, 2023 through September 30, 2023, quarterly principal payments, each in the amount of 1.875% of the original principal amount of the Term Loan, are due on the last business day of each fiscal quarter. The remaining unpaid principal balance of the Term Loan, together with accrued and unpaid interest thereon, is due and payable on November 20, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan bears interest from time to time at either the Base Rate or the Eurocurrency Rate, plus the Applicable Margin, as calculated and defined in the Credit Agreement. The Applicable Margin is determined based on the ratio of Consolidated Total Debt to Consolidated EBITDA, each as defined in the Credit Agreement. Interest on borrowings made at the Base Rate (“Base Rate Advances”) is payable quarterly in arrears and interest on borrowings made at the Eurocurrency Rate (“Eurocurrency Rate Advances”) is payable at the end of the relevant interest period therefor, but in no event less frequently than every three months. There is no premium or penalty for prepayment of Base Rate Advances, but prepayments of Eurocurrency Rate Advances are subject to a breakage fee.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the lenders under the Credit Agreement are also lenders under our revolving credit agreement dated as of March 23, 2018. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indebtedness was as follows:</span></div><div style="margin-bottom:11pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">550,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">864,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,844)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,713,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,521 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 304618000 275449000 550000000 0 864425000 878409000 5844000 3337000 1713199000 1150521000 550000000 0.0125 0.01875 Additional Consolidated Balance Sheet Information <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information related to our Consolidated Balance Sheets is as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued payroll and other related liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation/paid time off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,041 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee commissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,591</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other postretirement benefit obligations-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,488</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other employee benefit plans obligations-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued payroll and other related liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,261 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued expenses and other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,948</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured risk reserves-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued dealer commissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,796</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured risk reserves-long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,452</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other postretirement benefit obligations-long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans obligations-long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other employee benefit plans obligations-long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued long-term income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation-long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89,264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,346 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> Additional Consolidated Balance Sheet Information <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information related to our Consolidated Balance Sheets is as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued payroll and other related liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation/paid time off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,041 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee commissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,591</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other postretirement benefit obligations-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,488</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other employee benefit plans obligations-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued payroll and other related liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,261 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued expenses and other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,948</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured risk reserves-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued dealer commissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,796</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured risk reserves-long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,452</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other postretirement benefit obligations-long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans obligations-long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other employee benefit plans obligations-long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued long-term income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation-long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89,264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,346 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information related to our Consolidated Balance Sheets is as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued payroll and other related liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation/paid time off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,041 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee commissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,591</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other postretirement benefit obligations-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,488</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other employee benefit plans obligations-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued payroll and other related liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,261 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued expenses and other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,948</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured risk reserves-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued dealer commissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,796</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured risk reserves-long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,452</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other postretirement benefit obligations-long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans obligations-long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other employee benefit plans obligations-long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued long-term income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation-long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89,264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,346 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 67883000 42205000 14663000 9917000 51100000 53041000 14591000 19298000 1488000 1488000 2606000 2312000 152331000 128261000 44308000 53299000 38948000 47505000 9711000 7342000 25174000 15827000 6796000 7381000 1202000 2671000 58494000 58158000 184633000 192183000 17452000 17452000 8587000 9880000 10152000 10987000 2341000 2333000 10841000 11959000 12379000 9843000 27512000 27892000 89264000 90346000 Income Tax Expense <div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The TCJA reduced the U.S. federal corporate income tax rate to 21.0%, required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and created new taxes on certain foreign sourced earnings. The Company applied the guidance in Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cut and Jobs Act when accounting for the enactment-date effects of the TCJA. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the tax expense recorded for the TCJA to be complete at this time. However, it is possible that additional legislation, regulations and/or guidance may be issued in the future that may result in additional adjustments to the tax expense recorded related to the TCJA. We will continue to monitor and assess the impact of any new developments. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective income tax rates for the three month periods ended December 31, 2020 and 2019 were 17.8% and 21.9%, respectively. The effective income tax rates for the nine month periods ended December 31, 2020 and 2019 were 18.8% and 18.8%, respectively. The fiscal 2021 effective tax rate for the current quarter decreased when compared to fiscal 2020, primarily due to an increase in favorable discrete items.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2016 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2015. We remain subject to tax authority audits in various jurisdictions wherever we do business.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, we received two notices of proposed tax adjustment from the U.S. Internal Revenue Service (the “IRS”) regarding the deductibility of interest paid on certain intercompany debt. The notices relate to fiscal years 2016 and 2017. In September 2019, we received another notice of proposed adjustment for the same issue, for the 2018 fiscal year. The IRS adjustments would result in a cumulative tax liability of approximately $40,000. Notices have not been received for subsequent periods. We are contesting the IRS’s assertions. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but could be material to our consolidated results of operations and cash flows for any one period.</span></div> 0.210 0.178 0.219 0.188 0.188 40000000 Commitments and Contingencies <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020: Item 1 titled “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factors” in Item 1A titled "Product related regulations and claims".</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q.</span></div> Business Segment Information<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies and Life Sciences. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior to April 1, 2020, we operated and reported our financial information in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products and Healthcare Specialty Services segments were combined and are now reported as one segment, simply called Healthcare, consistent with the way management now operates and views the business. Prior periods have been recast in the financial tables below for comparability. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Healthcare segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. The segment also provides a range of specialty services for healthcare providers including hospital sterilization services and instrument and scope repairs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Applied Sterilization Technologies ("AST") segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Life Sciences segment designs, manufactures and sells consumable products, equipment maintenance, specialty services and capital equipment primarily to pharmaceutical manufacturers around the world.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended December 31, 2020, revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information for each of our segments is presented in the following table:</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">521,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,392,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,237 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applied Sterilization Technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176,462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">498,371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,459 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Sciences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">343,370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,208 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">808,924</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,233,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207,904 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115,412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">302,565</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applied Sterilization Technologies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,626</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222,416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Sciences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(158,463)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,613)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating income before adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration related charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,585 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redomiciliation and tax restructuring costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) on fair value adjustment of acquisition related contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss on divestiture of businesses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of inventory and property "step up" to fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,784</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 incremental costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,460</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147,030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,387 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">402,294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,208 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For more information regarding our recent acquisitions and divestitures refer to Note 2 titled" Business Acquisitions and Divestitures" and our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Costs incurred in connection with the Redomiciliation and tax restructuring. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For more information regarding our restructuring efforts refer to Note 17 titled, "Restructuring".</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding our fiscal 2021 and fiscal 2020 revenue is disclosed in the following tables:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,894</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">148,839</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,255 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">355,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,370</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,968</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">629,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Healthcare Revenues </span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">521,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,222 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,392,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,237 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applied Sterilization Technologies Service Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176,462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">498,371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Sciences:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital equipment<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,664</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,627</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,370 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164,262</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,939 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Life Sciences Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,773 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">343,370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,208 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">808,924</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,261 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,233,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207,904 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">572,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,613,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other locations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">568,655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">808,924</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,261 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,233,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207,904 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments. </span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare and Life Sciences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,595,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,705,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applied Sterilization Technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,985,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,580,780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,425,582 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal 2021 increase in Healthcare and Life Sciences was primarily due to the acquisition of Key Surgical.</span></div> <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information for each of our segments is presented in the following table:</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">521,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,392,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,237 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applied Sterilization Technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176,462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">498,371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,459 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Sciences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">343,370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,208 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">808,924</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,233,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207,904 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115,412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">302,565</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applied Sterilization Technologies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,626</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222,416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Sciences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(158,463)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,613)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating income before adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration related charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,585 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redomiciliation and tax restructuring costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) on fair value adjustment of acquisition related contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss on divestiture of businesses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of inventory and property "step up" to fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,784</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 incremental costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,460</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147,030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,387 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">402,294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,208 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 521662000 509222000 1392247000 1440237000 176462000 156266000 498371000 463459000 110800000 108773000 343370000 304208000 808924000 774261000 2233988000 2207904000 115412000 105227000 302565000 298777000 81626000 65468000 222416000 198889000 41541000 37731000 136435000 103085000 -47941000 -45260000 -158463000 -151613000 190638000 163166000 502953000 449138000 23194000 17508000 62649000 53407000 11563000 1721000 13984000 5585000 296000 487000 850000 3274000 -500000 0 -500000 0 0 -76000 -5000 -2553000 1784000 602000 3101000 1783000 7251000 0 20460000 0 20000 385000 110000 3328000 147030000 142387000 402294000 379208000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,894</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">148,839</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,255 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">355,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,370</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,968</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">629,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Healthcare Revenues </span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">521,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,222 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,392,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,237 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applied Sterilization Technologies Service Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176,462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">498,371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Sciences:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital equipment<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,664</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,627</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,370 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164,262</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,939 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Life Sciences Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,773 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">343,370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,208 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">808,924</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,261 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,233,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207,904 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 147855000 155408000 407610000 428894000 148839000 130255000 355390000 362370000 224968000 223559000 629247000 648973000 521662000 509222000 1392247000 1440237000 176462000 156266000 498371000 463459000 28993000 31762000 88664000 84993000 49627000 46370000 164262000 132939000 32180000 30641000 90444000 86276000 110800000 108773000 343370000 304208000 808924000 774261000 2233988000 2207904000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">572,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,613,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other locations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">568,655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">808,924</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,261 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,233,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207,904 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 20316000 16126000 51779000 46405000 572397000 562502000 1613554000 1611755000 216211000 195633000 568655000 549744000 808924000 774261000 2233988000 2207904000 <div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments. </span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare and Life Sciences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,595,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,705,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applied Sterilization Technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,985,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,580,780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,425,582 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3595753000 2705377000 2985027000 2720205000 6580780000 5425582000 Shares and Preferred Shares<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ordinary shares</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.140%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Denominator (shares in thousands):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding—basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85,330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85,153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of share equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">702</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding and share equivalents—diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,628 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,630 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">(shares in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of share options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Authorized Shares</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.</span></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.140%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Denominator (shares in thousands):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding—basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85,330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85,153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of share equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">702</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding and share equivalents—diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,628 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,630 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 85330000 84788000 85153000 84740000 702000 840000 698000 890000 86032000 85628000 85851000 85630000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">(shares in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of share options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 278000 347000 370000 270000 50000000 0.001 25000 1.00 Repurchases of Ordinary Shares<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $78,979 (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). As of December 31, 2020, there was approximately $333,932 (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program. The share repurchase program has no specified expiration date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the start of fiscal 2021 through April 9, 2020, we repurchased 35,000 of our ordinary shares for the aggregate amount of $5,047 (net of fees and commissions) pursuant to the authorizations. During the first nine months of fiscal 2020, we repurchased 205,059 of our ordinary shares for the aggregate amount of $30,000 (net of fees and commissions) pursuant to the authorizations.</span></div> During the first nine months of fiscal 2021 we obtained 85,574 of our ordinary shares in the aggregate amount of $9,512 in connection with share based compensation award programs. During the first nine months of fiscal 2020, we obtained 100,124 of our ordinary shares in the aggregate amount of $10,318 in connection with share based compensation award programs. Repurchases of Ordinary Shares<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $78,979 (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). As of December 31, 2020, there was approximately $333,932 (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program. The share repurchase program has no specified expiration date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the start of fiscal 2021 through April 9, 2020, we repurchased 35,000 of our ordinary shares for the aggregate amount of $5,047 (net of fees and commissions) pursuant to the authorizations. During the first nine months of fiscal 2020, we repurchased 205,059 of our ordinary shares for the aggregate amount of $30,000 (net of fees and commissions) pursuant to the authorizations.</span></div> During the first nine months of fiscal 2021 we obtained 85,574 of our ordinary shares in the aggregate amount of $9,512 in connection with share based compensation award programs. During the first nine months of fiscal 2020, we obtained 100,124 of our ordinary shares in the aggregate amount of $10,318 in connection with share based compensation award programs. 78979000 300000000 333932000 35000 5047000 205059 30000000 85574 9512000 100124 10318000 Share-Based Compensation<div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Board of Directors or the Compensation and Organizational Development Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of December 31, 2020, 3,592,261 ordinary shares remained available for grant under the long-term incentive plan. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2021 and 2020:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:74.817%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield of stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.78% and 2.77% was applied in fiscal 2021 and 2020, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of share option activity is as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:50.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.460%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,652,017</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111.43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">897,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that 736,801 of the non-vested stock options outstanding at December 31, 2020 will ultimately vest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above represents the total pre-tax difference between the $189.54 closing price of our ordinary shares on December 31, 2020 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the first nine months of fiscal 2021 and fiscal 2020 was $36,850 and $36,939, respectively. Net cash proceeds from the exercise of stock options were $26,018 and $22,958 for the first nine months of fiscal 2021 and fiscal 2020, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of stock option grants was $27.66 and $23.52 for the first nine months of fiscal 2021 and fiscal 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of December 31, 2020 and 2019 was $491 and $629, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the non-vested restricted share and share unit activity is presented below:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of<br/>Restricted<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-vested at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,830 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,997)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">532,812</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during the first nine months of fiscal 2021 at the time of grant was $14,764. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, there was a total of $51,583 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plan. We expect to recognize the cost over a weighted average period of 2.1 years.</span></div> 3592261 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2021 and 2020:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:74.817%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield of stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.0046 0.0226 P6Y P6Y2M12D 0.0096 0.0122 0.2304 0.2027 0.0278 0.0277 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of share option activity is as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:50.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.460%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,652,017</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111.43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">897,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1796126 91.29 288936 181.33 385090 68.75 47955 121.18 1652017 111.43 P6Y10M24D 129044000 897953 83.41 P5Y7M6D 95303000 736801 189.54 36850000 36939000 26018000 22958000 27.66 23.52 491000 629000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the non-vested restricted share and share unit activity is presented below:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of<br/>Restricted<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-vested at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,830 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,997)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">532,812</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 575830 30894 98.07 139229 14208 164.58 158250 16238 84.61 23997 228 103.36 532812 28636 120.26 14764000 51583000 P2Y1M6D Financial and Other Guarantees<div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our warranty liability during the first nine months of fiscal 2021 were as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:85.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranties</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranties issued during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements made during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,796</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our warranty liability during the first nine months of fiscal 2021 were as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:85.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranties</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranties issued during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements made during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,796</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7381000 7411000 7996000 6796000 Derivatives and HedgingFrom time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. During the third quarter of <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal 2021, we also held forward foreign currency contracts to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature during fiscal 2021. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of these contracts are designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At December 31, 2020, we held foreign currency forward contracts to buy 30.5 million British pounds, 35.0 million Mexican pesos and 2.2 million Canadian dollars; and to sell 4.0 million euros. At December 31, 2020 we held commodity swap contracts to buy 946.8 thousand pounds of nickel. </span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:34.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.343%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value at</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value at</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance sheet location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid &amp; Other</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,377</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">659</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Location of gain (loss)<br/>recognized in income</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in income</span></td></tr><tr style="height:21pt"><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">661</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity swap contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $51,323 at December 31, 2020. These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.</span></div> 30500000 35000000.0 2200000 4000000.0 946800 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:34.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.343%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value at</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value at</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance sheet location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid &amp; Other</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,377</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">659</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1377000 124000 0 0 0 0 659000 912000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Location of gain (loss)<br/>recognized in income</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in income</span></td></tr><tr style="height:21pt"><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">661</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity swap contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -741000 -79000 -661000 -784000 153000 -398000 904000 271000 51323000 . Fair Value Measurements <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of our financial assets and liabilities at December 31, 2020 and March 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.967%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:32pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted Prices<br/>in Active Markets<br/>for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant Other<br/>Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward and swap contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,377</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,377</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investments </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward and swap contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">659</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">659</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,713,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,781,304</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,143,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,988 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,988 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the third quarter and first nine months of fiscal 2021, we recorded gains of $210 and $138, respectively, related to these investments. During the third quarter and first nine months of fiscal 2020, we recorded gains (losses) of $636 and $(1,843), respectively, related to these investments.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2020 are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed in acquisition of Key Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversal </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of our financial assets and liabilities at December 31, 2020 and March 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.967%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:32pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted Prices<br/>in Active Markets<br/>for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant Other<br/>Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward and swap contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,377</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,377</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investments </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward and swap contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">659</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">659</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,713,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,781,304</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,143,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,988 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,988 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 252502000 319581000 252502000 319581000 0 0 0 0 1377000 124000 0 0 1377000 124000 0 0 10484000 9624000 10484000 9624000 0 0 0 0 2785000 2507000 2785000 2507000 0 0 0 0 659000 912000 0 0 659000 912000 0 0 1822000 1475000 1822000 1475000 0 0 0 0 1713199000 1150521000 0 0 1781304000 1143978000 0 0 17931000 15988000 0 0 0 0 17931000 15988000 210000 138000 636000 -1843000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2020 are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed in acquisition of Key Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversal </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15988000 334000 2940000 -917000 -500000 86000 17931000 Reclassifications Out of Accumulated Other Comprehensive Income (Loss)<div style="margin-bottom:6pt;margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended December 31, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defined Benefit Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency Translation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,833)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,813)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,780)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228,650)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130,613)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,463)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive Income before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">972</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234,607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129,060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235,579</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated Other Comprehensive (Loss) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period Other Comprehensive (Loss) Income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(510)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,530)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234,607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,227</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">233,077</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,343)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,343)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,386)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,386)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. </span></div><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. </span></div><div style="margin-bottom:11pt;margin-top:11pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defined Benefit Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency Translation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220,502)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,574)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,778)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive Income (Loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,299 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,371 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,494 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,947 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated Other Comprehensive (Loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period Other Comprehensive (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(504)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,515)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,299 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,371 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,795 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,856 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,719)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,719)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,203)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,203)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. </span></div>(2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended December 31, 2020 and 2019 were as follows:<div style="margin-bottom:11pt;margin-top:11pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defined Benefit Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency Translation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,833)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,813)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,780)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228,650)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130,613)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,463)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive Income before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">972</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234,607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129,060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235,579</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated Other Comprehensive (Loss) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period Other Comprehensive (Loss) Income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(510)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,530)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234,607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,227</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">233,077</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,343)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,343)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,386)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,386)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. </span></div><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. </span></div><div style="margin-bottom:11pt;margin-top:11pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defined Benefit Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency Translation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220,502)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,574)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,778)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive Income (Loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,299 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,371 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,494 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,947 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated Other Comprehensive (Loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period Other Comprehensive (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(504)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,515)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,299 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,371 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,795 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,856 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,719)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,719)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,203)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,203)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. </span></div>(2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. -7833000 -6813000 -122780000 -228650000 -130613000 -235463000 323000 972000 128737000 234607000 129060000 235579000 -833000 -2502000 0 0 -833000 -2502000 -510000 -1530000 128737000 234607000 128227000 233077000 -8343000 -8343000 5957000 5957000 -2386000 -2386000 -5215000 -4204000 -220502000 -155574000 -225717000 -159778000 195000 576000 77299000 12371000 77494000 12947000 -699000 -2091000 0 0 -699000 -2091000 -504000 -1515000 77299000 12371000 76795000 10856000 -5719000 -5719000 -143203000 -143203000 -148922000 -148922000 Restructuring<div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal 2019 Restructuring Plan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions were eliminated. The Company relocated the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions were designed to enhance profitability and improve efficiency. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $43,961 related to these restructuring actions, of which $31,660 was recorded as restructuring expenses and $12,301 was recorded in cost of revenues, with a total of $34,062, $7,568 and $668 related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1,663. Additional restructuring expenses related to this plan are not expected to be material to our results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The remaining liability balances at December 31, 2020 and March 31, 2020 are not material. </span></div>For more information relating to our restructuring efforts, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. 200 43961000 31660000 12301000 34062000 7568000 668000 1663000 Loans Receivable<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with an equity investment </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of $4,955, we agreed to provide a credit facility of up to approximately $11,606 for a term of up to seven years ending in 2025. The loan carries an interest rate of 4% compounded daily and payable annually. Outstanding principal borrowings under the agreement totaled $10,326 at December 31, 2020 and $7,084 at March 31, 2020. On January 4, 2021, we purchased the remaining outstanding shares of this equity investment. The acquisition agreement included the capitalization of the outstanding principal and interest borrowings of this credit facility in the amount of $10,536. For more information refer to Note 20, titled, "Subsequent Events". </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the fiscal 2017 divestiture of Synergy Health Netherlands Linen Management Services, we entered into a loan agreement to provide financing of up to €15,000 for a term of up to 15 years. The loan carried an interest rate of 4% for the first four years and 12% thereafter. The loan was renegotiated during the third quarter of fiscal 2020. According to the new terms of the loan agreement, the outstanding balance at October 31, 2019, of €7,300, will be repaid in six equal annual installments beginning on October 18, 2022. The loan carries an interest rate of 4% for the first four years and 8% thereafter. Outstan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ding principal bo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rrowings under the agreement totaled $8,966 (or €7,300) at December 31, 2020 and $8,072 (or €7,300) at March 31, 2020.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts for loan receivables as noted above are recorded in the "Other assets" line of our Consolidated balance sheets. Interest income is not material.</span></div> 4955000 11606000 0.04 10326000 7084000 10536000 15000000 15 years 0.04 0.12 7300000 0.04 0.08 8966000 7300000 8072000 7300000 COVID-19 PandemicThe COVID-19 pandemic began to impact our business late in fiscal 2020. The pandemic and related public health recommendations and mandated precautions to mitigate the spread of COVID-19, including deferral of medical procedures and treatments and shelter-in-place orders or similar measures, have negatively affected and are expected to continue to negatively affect some of our operations, which may impact our financial position and cash flows. We have experienced and expect to continue to experience unpredictable fluctuations in demand for certain of our products and services, including some products and services that are experiencing increased demand. To date, we do not believe that the COVID-19 pandemic has had a significant impact on our operations, as we have been able to continue to operate our manufacturing facilities and meet the demand for essential products and services of our Customers. In response to the pandemic, we have implemented several measures that we believe will help us to protect the health and safety of our employees, preserve liquidity and enhance our financial flexibility. For our employees, we allowed employees to work remotely when possible and have implemented additional safety measures in compliance with applicable regulations to allow personnel to continue to work in our facilities. We suspended all non-essential travel and enacted a temporary hiring freeze on certain positions. To manage liquidity, we have suspended our stock repurchase program and deferred certain planned capital expenditures; however, we have continued to invest in expansion projects as planned. We do not believe that these actions will negatively impact our long-term ability to generate revenues or meet existing and future financial obligations. While we have been impacted and expect this situation to continue to have an impact on our business, the full impact to our results of operations and financial position cannot be reasonably estimated at this time. For additional information and our risk factors related to the COVID-19 pandemic, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. Subsequent Events<div style="margin-bottom:3pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2021, we announced the signing of a definitive agreement to acquire Cantel Medical Corp. (NYSE: CMD "Cantel"), through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and dental Customers. Under the terms of the agreement, we will acquire Cantel in a cash and stock transaction valued at $84.66 per Cantel common share, based on STERIS’s closing share price of $200.46 on January 11, 2021. This represents a total equity value of approximately $3.6 billion and a total enterprise value of approximately $4.6 billion. The agreement has been unanimously approved by the Boards of Directors of both companies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition is subject to certain closing conditions, including Cantel shareholder vote and regulatory approvals.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to fund the cash portion of the transaction consideration and repay or otherwise satisfy a significant amount of Cantel’s existing debt obligations with approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$2.0 billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of new debt. We have fully committed bridge financing and are working with our lenders and advisors on a long-term plan. </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 4, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we purchased the remaining outstanding shares of an equity investment that we made in fiscal 2019, for approximately $44,255, subject to any working capital adjustments. In addition to the purchase price, the acquisition agreement included the capitalization of the outstanding principal and accumulated interest under a credit facility in the amount of $10,536. For more information refer to Note 18 titled, "Loans Receivable". We plan to integrate the business into our Applied Sterilization Technologies business segment and to fund the transaction through a combination of </span>cash on hand and credit facility borrowings. 2021-01-12 84.66 200.46 3600000000 4600000000 2000000000.0 2021-01-04 44255000 10536000 Purchase price allocation is still preliminary as of December 31, 2020, as valuation has not been finalized. Intangible assets resulting from the Key Surgical acquisition may consists of patents, trade names, Customer Relationships, non-compete agreements, and technologies, pending the outcome of the final valuation Costs incurred in connection with the Redomiciliation and tax restructuring. We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the third quarter and first nine months of fiscal 2021, we recorded gains of $210 and $138, respectively, related to these investments The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available. Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates Land is not depreciated. Construction in progress is not depreciated until placed in service. The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. For more information regarding our restructuring efforts refer to Note 17 titled, "Restructuring" For more information regarding our recent acquisitions and divestitures refer to Note 2 titled" Business Acquisitions and Divestitures" and our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020. XML 18 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information Document - shares
9 Months Ended
Dec. 31, 2020
Feb. 05, 2021
Entity Information [Line Items]    
Entity Registrant Name STERIS plc  
Entity Central Index Key 0001757898  
Document Type 10-Q  
Document Period End Date Dec. 31, 2020  
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Current Fiscal Year End Date --03-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   85,352,713
Entity Small Business false  
Entity Emerging Growth Company false  
Entity File Number 001-38848  
Entity Incorporation, State or Country Code L2  
Entity Tax Identification Number 98-1455064  
Local Phone Number 1 232 2000  
City Area Code 353  
Document Transition Report false  
Document Quarterly Report true  
Entity Address, Address Line One 70 Sir John Rogerson's Quay,  
Entity Address, City or Town Dublin 2,  
Entity Address, Country IE  
Entity Address, Postal Zip Code D02 R296  
Title of 12(b) Security Ordinary Shares, $0.001 par value  
Trading Symbol STE  
Security Exchange Name NYSE  
Entity Shell Company false  
XML 19 R2.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Dec. 31, 2020
Mar. 31, 2020
Current assets:    
Cash and cash equivalents $ 252,502 $ 319,581
Accounts receivable (net of allowances of $11,605 and $12,051 respectively) 556,117 586,481
Inventories, net 294,132 248,259
Prepaid expenses and other current assets 73,324 54,430
Total current assets 1,176,075 1,208,751
Property, plant, and equipment, net 1,226,895 1,111,855
Other assets 57,614 51,581
Assets 6,580,780 5,425,582
Current liabilities:    
Accounts payable 134,471 149,341
Accrued income taxes 13,068 14,013
Accrued payroll and other related liabilities 152,331 128,261
Accrued expenses and other 184,633 192,183
Total current liabilities 505,867 503,607
Long-term indebtedness 1,713,199 1,150,521
Deferred Income Taxes and Other Tax Liabilities, Noncurrent 264,041 160,270
Other Liabilities, Noncurrent 89,264 90,346
Total liabilities 2,702,588 2,018,858
Commitments and contingencies (see Note 8)
Common shares, with $0.001 par value; 500,000 authorized; 85,337 shares issued; and 84,924 shares outstanding 1,996,843 1,982,164
Retained earnings 1,872,533 1,647,175
Accumulated other comprehensive income (2,386) (235,463)
Total shareholders' equity 3,866,990 3,393,876
Noncontrolling interest 11,202 12,848
Total equity 3,878,192 3,406,724
Total liabilities and equity 6,580,780 5,425,582
Operating Lease, Right-of-Use Asset 149,741 131,837
Goodwill 2,926,551 2,356,085
Intangible Assets, Net (Excluding Goodwill) 1,043,904 565,473
Capital Lease Obligations, Current 21,364 19,809
Capital Lease Obligations, Noncurrent $ 130,217 $ 114,114
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2020
Mar. 31, 2020
Capital Lease Obligations, Noncurrent $ 130,217 $ 114,114
Capital Lease Obligations, Current 21,364 19,809
Operating Lease, Right-of-Use Asset 149,741 131,837
Goodwill 2,926,551 2,356,085
Allowance for Doubtful Accounts Receivable, Current $ 11,605 $ 12,051
Preferred Stock, Shares Authorized 50,000,000  
Preferred Stock, Par or Stated Value Per Share $ 0.001  
Common Stock, Shares Authorized 500,000,000 500,000,000
Common Stock, Shares, Issued 85,337,000 84,924,000
Common Stock, Shares, Outstanding 85,337,000 84,924,000
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Intangible Assets, Net (Excluding Goodwill) $ 1,043,904 $ 565,473
Deferred Income Taxes and Other Tax Liabilities, Noncurrent $ 264,041 $ 160,270
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Revenues:        
Total revenues $ 808,924 $ 774,261 $ 2,233,988 $ 2,207,904
Cost of revenues:        
Total cost of revenues 463,063 442,908 1,272,522 1,252,041
Gross Profit 345,861 331,353 961,466 955,863
Operating expenses:        
Selling, general, and administrative 182,373 172,927 510,250 527,667
Research and development 16,438 16,487 48,812 48,321
Restructuring Costs 20 (448) 110 667
Total operating expenses 198,831 188,966 559,172 576,655
Income from operations 147,030 142,387 402,294 379,208
Non-operating expenses, net:        
Interest expense 8,899 9,813 27,056 30,702
Interest income and miscellaneous expense (1,299) (1,378) (4,776) (2,163)
Total non-operating expenses, net 7,600 8,435 22,280 28,539
Income before income tax expense 139,430 133,952 380,014 350,669
Income tax expense 24,842 29,285 71,294 66,083
Net Income 114,588 104,667 308,720 284,586
Less: Net Income Attributable to Noncontrolling Interest 87 (263) 171 297
Net income (loss) attributable to shareholders $ 114,501 $ 104,930 $ 308,549 $ 284,289
Net income per common share [Abstract]        
Basic $ 1.34 $ 1.24 $ 3.62 $ 3.35
Diluted 1.33 1.23 3.59 3.32
Cash dividends declared per common share outstanding $ 0.40 $ 0.37 $ 1.17 $ 1.08
Product [Member]        
Revenues:        
Total revenues $ 375,314 $ 363,795 $ 1,015,926 $ 1,009,196
Cost of revenues:        
Cost of Goods and Services Sold 202,881 195,105 535,234 539,664
Service [Member]        
Revenues:        
Total revenues 433,610 410,466 1,218,062 1,198,708
Cost of revenues:        
Cost of Goods and Services Sold $ 260,182 $ 247,803 $ 737,288 $ 712,377
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Net Income $ 114,588 $ 104,667 $ 308,720 $ 284,586
Less: Net Income Attributable to Noncontrolling Interest 87 (263) 171 297
Net Income (Loss) Attributable to Parent 114,501 104,930 308,549 284,289
Other comprehensive (loss) income        
Amortization of pension and postretirement benefits plans costs, (net of taxes of $173 ,$171, $520 and $512, respectively) (510) (504) (1,530) (1,515)
Change in cumulative foreign current translation adjustment 128,737 77,299 234,607 12,371
Total other comprehensive (loss) income 128,227 76,795 233,077 10,856
Comprehensive income $ 242,728 $ 181,725 $ 541,626 $ 295,145
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Statement of Comprehensive Income (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Statement of Comprehensive Income [Abstract]        
Amortization of pension and postretirement benefits plans costs, tax $ 173 $ 171 $ 520 $ 512
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Net Income $ 308,720 $ 284,586
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation, depletion, and amortization 160,193 146,294
Deferred income taxes 783 (1,139)
Share-based compensation 19,924 18,862
(Gain) loss on the disposal of property, plant, and equipment, and intangibles, net 865 (540)
Loss on sale of businesses, net [1] 5 2,553
Other items 4,494 (2,506)
Changes in operating assets and liabilities, net of effects of acquisitions:    
Accounts receivable, net 60,574 29,860
Inventories, net (7,520) (32,816)
Other current assets (8,906) 3,615
Accounts payable (30,974) (18,610)
Accruals and other, net (6,373) (38,833)
Net cash provided by operating activities 501,785 391,326
Investing activities:    
Purchases of property, plant, equipment, and intangibles, net (164,497) (153,649)
Proceeds from the sale of property, plant, equipment, and intangibles 417 387
Proceeds from Divestiture of Businesses, Net of Cash Divested 0 439
Acquisition of businesses, net of cash acquired (869,431) (107,166)
Payments for (Proceeds from) Other Investing Activities (2,392) 0
Net cash used in investing activities (1,035,903) (259,989)
Financing activities:    
Proceeds from Issuance of Private Placement 550,000 0
Payments on long-term obligations (35,000) 0
Proceeds (Payments) under credit facilities, net 23,782 (48,467)
Deferred financing fees and debt issuance costs (3,122) (1,206)
Acquisition related deferred or contingent consideration (2,968) (452)
Repurchases of ordinary shares (14,560) (40,322)
Cash dividends paid to ordinary shareholders (99,696) (91,595)
Proceeds from issuance of equity to minority shareholders 2,258 6,050
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders (627) (840)
Payments for Repurchase of Other Equity (3,552) 0
Net cash used in financing activities 442,533 (153,874)
Effect of exchange rate changes on cash and cash equivalents 24,506 1,134
Cash and cash equivalents at beginning of period 319,581 220,633
Cash and cash equivalents at end of period 252,502 199,230
Proceeds from (Payments for) Other Financing Activities 26,018 22,958
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $ (67,079) $ (21,403)
[1] For more information regarding our recent acquisitions and divestitures refer to Note 2 titled" Business Acquisitions and Divestitures" and our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement - USD ($)
shares in Thousands, $ in Thousands
Total
Noncontrolling Interest [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Common Stock [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $ 3,185,798 $ 7,988 $ (159,778) $ 1,339,024 $ 1,998,564
Shares, Issued         84,517
Net Income (Loss) Attributable to Parent 284,289     284,289  
Net Income (Loss) Attributable to Noncontrolling Interest 297 297      
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 284,586        
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 10,856   10,856    
Treasury Stock, Shares, Acquired         304
Payments for Repurchase of Common Stock 40,322     (12,777) $ 53,099
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures         578
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 41,642       $ 41,642
Dividends, Common Stock, Cash 91,595     91,595  
Proceeds from issuance of equity to minority shareholders 6,050 6,050      
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders (840) (840)      
Non controlling interest period increase (decrease) from translation and other $ (109) (109)      
Common Stock, Dividends, Per Share, Cash Paid $ 1.08        
Net Income (Loss) Attributable to Parent $ 284,289     284,289  
Net Income (Loss) Attributable to Noncontrolling Interest 297 297      
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 284,586        
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 10,856   10,856    
Treasury Stock, Shares, Acquired         (304)
Payments for Repurchase of Common Stock (40,322)     12,777 $ (53,099)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures         578
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 41,642       $ 41,642
Dividends, Common Stock, Cash (91,595)     (91,595)  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3,237,645 8,977 (225,717) 1,472,725 $ 1,981,660
Shares, Issued         84,797
Net Income (Loss) Attributable to Parent 104,930     104,930  
Net Income (Loss) Attributable to Noncontrolling Interest (263) (263)      
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 104,667        
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 76,795   76,795    
Treasury Stock, Shares, Acquired         25
Payments for Repurchase of Common Stock 2,454     1,785 $ 669
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures         19
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 6,116       $ 6,116
Dividends, Common Stock, Cash 31,375     31,375  
Proceeds from issuance of equity to minority shareholders 6,050 6,050      
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders (840) (840)      
Non controlling interest period increase (decrease) from translation and other $ (538) (538)      
Common Stock, Dividends, Per Share, Cash Paid $ 0.37        
Net Income (Loss) Attributable to Parent $ 104,930     104,930  
Net Income (Loss) Attributable to Noncontrolling Interest (263) (263)      
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 104,667        
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 76,795   76,795    
Treasury Stock, Shares, Acquired         (25)
Payments for Repurchase of Common Stock (2,454)     (1,785) $ (669)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures         19
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 6,116       $ 6,116
Dividends, Common Stock, Cash (31,375)     (31,375)  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3,396,066        
Stockholders' Equity Attributable to Parent     (148,922) 1,544,495 $ 1,987,107
Noncontrolling interest   13,386      
Shares, Issued         84,791
Stockholders' Equity Attributable to Parent     (148,922) 1,544,495 $ 1,987,107
Stockholders' Equity Attributable to Noncontrolling Interest   13,386      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3,406,724 12,848 (235,463) 1,647,175 $ 1,982,164
Stockholders' Equity Attributable to Parent 3,393,876        
Noncontrolling interest 12,848        
Shares, Issued         84,924
Stockholders' Equity Attributable to Parent 3,393,876        
Stockholders' Equity Attributable to Noncontrolling Interest 12,848        
Net Income (Loss) Attributable to Parent 308,549     308,549  
Net Income (Loss) Attributable to Noncontrolling Interest 171 171      
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 308,720        
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 233,077   233,077    
Treasury Stock, Shares, Acquired         121
Payments for Repurchase of Common Stock 14,560     (16,505) $ 31,065
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures         534
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 45,744       $ 45,744
Dividends, Common Stock, Cash 99,696     99,696  
Proceeds from issuance of equity to minority shareholders 2,258 2,258      
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders (627) (627)      
Payments for Repurchase of Other Equity (3,552) (3,552)      
Non controlling interest period increase (decrease) from translation and other $ 104 104      
Common Stock, Dividends, Per Share, Cash Paid $ 1.17        
Net Income (Loss) Attributable to Parent $ 308,549     308,549  
Net Income (Loss) Attributable to Noncontrolling Interest 171 171      
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 308,720        
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 233,077   233,077    
Treasury Stock, Shares, Acquired         (121)
Payments for Repurchase of Common Stock (14,560)     16,505 $ (31,065)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures         534
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 45,744       $ 45,744
Dividends, Common Stock, Cash (99,696)     (99,696)  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3,662,455 15,310 (130,613) 1,786,878 $ 1,990,880
Shares, Issued         85,251
Net Income (Loss) Attributable to Parent 114,501     114,501  
Net Income (Loss) Attributable to Noncontrolling Interest 87 87      
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 114,588        
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 128,227   128,227    
Treasury Stock, Shares, Acquired         9
Payments for Repurchase of Common Stock 127     (5,290) $ 5,417
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures         95
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 11,380       $ 11,380
Dividends, Common Stock, Cash 34,136     34,136  
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders (627) (627)      
Payments for Repurchase of Other Equity 3,552 3,552      
Non controlling interest period increase (decrease) from translation and other $ (16) (16)      
Common Stock, Dividends, Per Share, Cash Paid $ 0.40        
Net Income (Loss) Attributable to Parent $ 114,501     114,501  
Net Income (Loss) Attributable to Noncontrolling Interest 87 87      
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 114,588        
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 128,227   128,227    
Treasury Stock, Shares, Acquired         (9)
Payments for Repurchase of Common Stock (127)     5,290 $ (5,417)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures         95
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 11,380       $ 11,380
Dividends, Common Stock, Cash (34,136)     (34,136)  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3,878,192        
Stockholders' Equity Attributable to Parent 3,866,990   (2,386) 1,872,533 $ 1,996,843
Noncontrolling interest 11,202 11,202      
Shares, Issued         85,337
Stockholders' Equity Attributable to Parent 3,866,990   $ (2,386) $ 1,872,533 $ 1,996,843
Stockholders' Equity Attributable to Noncontrolling Interest $ 11,202 $ 11,202      
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Nature of Operations and Summary of Significant Accounting Policies(Notes)
9 Months Ended
Dec. 31, 2020
Notes To Financial Statements [Abstract]  
Significant Accounting Policies Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
STERIS plc is a leading provider of infection prevention and other procedural products and services. Our MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal ("GI") endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory testing services, on-site and off-site reprocessing, and capital equipment products, such as sterilizers and surgical tables, and connectivity solutions such as operating room (“OR”) integration.
Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below:
Interim Financial Statements
We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented.
These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. The Consolidated Balance Sheet at March 31, 2020 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.
Principles of Consolidation
We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.
Use of Estimates
We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2020 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2021.
Revenue Recognition and Associated Liabilities
We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018. At the time of adoption, certain of our capital equipment contracts were comprised of a single integrated performance obligation, which resulted in the deferral of the corresponding capital equipment revenue and cost of revenues until installation was complete. Since the adoption of the standard, there have been changes made in our selling philosophy, product architecture, and manufacturing processes with respect to this product line, that impact whether the promises to transfer the individual goods or services to the Customer are separately identifiable from other promises in the contract. After review of these changes, we have concluded that these contracts consist of multiple performance obligations that are capable of being distinct and meet the criteria for revenue to be recognized when the Customer obtains control of the asset, which is upon delivery of each performance obligation. Revenues and costs of revenues related to these
contracts totaling $14,609 and $7,560, respectively, that had previously been deferred were recognized in our fiscal 2021 first quarter.
Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers.
We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets.
In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately.
Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.
We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.
Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2020, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements.
Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue.
Product Revenue
Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation.
Service Revenue
Within our Healthcare and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair.
We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure.
Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service.
Contract Liabilities
Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2021, $38,181 of the March 31, 2020 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2020, $46,744 of the March 31, 2019 deferred revenue balance was recorded as revenue.
Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances.
Service Liabilities
Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract.
Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances.
Remaining Performance Obligations
Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31 2020, the transaction price allocated to remaining performance obligations was approximately $1,014,800. We expect to recognize approximately 50% of the transaction price within one year and approximately 42% beyond one year. The remainder has yet to be scheduled for delivery.
Recently Issued Accounting Standards Impacting the Company

Recently Issued Accounting Standards Impacting the Company are presented in the following table:
StandardDate of IssuanceDescriptionDate of AdoptionEffect on the financial statements or other significant matters
Standards that have been adopted in fiscal 2021
ASU 2016-13, "Measurement of Credit Losses on Financial Instruments"June 2016The standard required a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard was effective for annual periods beginning after December 15, 2019. First Quarter Fiscal 2021
We adopted this standard effective April 1, 2020 with no material impact to our consolidated financial statements.
ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement”
August 2018The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy.  The standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.
First Quarter Fiscal 2021We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.
ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans"August 2018The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans.  The standard also clarified disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation.  The standard was effective for fiscal years ending after December 15, 2019.
First Quarter Fiscal 2021
We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.
ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract"August 2018The standard aligned the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or
obtain internal-use software. The standard was effective for fiscal years beginning after December 15, 2019.
First Quarter Fiscal 2021We adopted this standard on April 1, 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.
Standards that have not yet been adopted
ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)"August 2020
This standard simplifies the accounting for convertible instruments and its application of the derivatives scope exception for contracts in an entity’s own equity. The standard reduces the number of accounting models that require separating embedded conversion features from convertible instruments. As a result, only conversion features accounted for under the substantial premium model and those that require bifurcation will be accounted for separately. For contracts in an entity’s own equity, the new standard eliminates some of the current requirements for equity classification. The standard also addresses how convertible instruments are accounted for in the diluted earnings per share calculation and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity’s own equity. The standard is effective for annual periods beginning after December 15, 2021 and interim periods within that year. Early adoption is permitted for annual periods beginning after December 15, 2020 and interim periods within that year.
N/AWe are in the process of evaluating the impact that the standard will have on our consolidated financial statements.
ASU 2019-12 "Income Taxes (Topic 740)"December 2019The standard provides final guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance simplifies accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted.N/AWe are in the process of evaluating the impact that the standard will have on our consolidated financial statements.
A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2020
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.20.4
Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)
9 Months Ended
Dec. 31, 2020
Business Acquisitions and Divestitures [Abstract]  
Business Combination Disclosure Business Acquisitions and Divestitures
Fiscal 2021
On November 18, 2020, we acquired all of the outstanding units and equity of Key Surgical, LLC ("Key Surgical"). Key Surgical is a global provider of sterile processing, operating room and endoscopy consumable products serving hospitals and surgical facilities. Key Surgical is being integrated into our Healthcare segment. The total purchase price of the acquisition was $849,717, net of cash acquired and remains subject to customary working capital adjustments. Acquisition related costs of $10,842 are reported in the selling, general, and administrative expense line of the Consolidated Statements of Income. The purchase price for the acquisition was financed with a combination of cash on hand, credit facility borrowings and proceeds from the issuance of new long-term obligations. Please refer to note 5 titled, "Debt" for more information.
The table below summarizes the preliminary allocation of the purchase price to the net assets acquired for the Key Surgical acquisition based on fair values at the acquisition date.
(dollars in thousands)
Key Surgical (1)
Cash$12,615 
Accounts receivable13,967 
Inventory22,167 
Property, plant and equipment6,032 
Other assets6,680 
Intangible assets (2)
491,009 
Goodwill423,239 
Total Assets$975,709 
Current liabilities(17,683)
Non-current liabilities(95,694)
Total Liabilities(113,377)
Net Assets$862,332 
(1) Purchase price allocation is still preliminary as of December 31, 2020, as valuation has not been finalized.
(2) Intangible assets resulting from the Key Surgical acquisition may consists of patents, trade names, Customer Relationships, non-compete agreements, and technologies, pending the outcome of the final valuation.

In addition to Key Surgical, we also completed two tuck-in acquisitions during the third quarter fiscal 2021, which continued to expand our product and service offerings in the Healthcare segment. The aggregate purchase price associated with these transactions was approximately $20,908, net of cash acquired and including deferred consideration of $1,194. Acquisition related costs are reported in the selling, general, and administrative expense line of the Consolidated Statements of Income and amounts are not material.
Purchase price allocations will be finalized within a measurement period not to exceed one year from closing.
Fiscal 2020
During the first nine months of fiscal 2020, we completed several tuck-in acquisitions which continued to expand our product and service offerings in the Healthcare and Applied Sterilization Technologies segments. The aggregate purchase price associated with these transactions was approximately $117,259, net of cash acquired and including deferred consideration of $894. Acquisition related costs are reported in the selling, general, and administrative expense line of the Consolidated Statements of Income and amounts are not material. The purchase price for the acquisitions was financed with both cash on hand and with credit facility borrowings.
Purchase price allocations were finalized within a measurement period not to exceed one year from closing. Any final adjustments recorded were not material. During the first quarter of fiscal 2020, we sold the operations of our hospital sterilization services business that was located in China. We recorded proceeds of $439, net of cash divested, and recognized a pre-tax loss on the sale of $2,330 in the selling, general and administrative expense line of the Consolidated Statements of Income. The business generated annual revenues of approximately $5,000.
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Inventories, Net (Notes)
9 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
Inventories, Net Inventories, Net
We use the last-in, first-out (“LIFO”) and first-in, first-out (“FIFO”) cost methods to value inventory. Inventory valued using the LIFO cost method is stated at the lower of cost or market. Inventory valued using the FIFO cost method is stated at the lower of cost or net realizable value. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:
 December 31,
2020
March 31,
2020
Raw materials$102,212 $94,321 
Work in process42,109 35,643 
Finished goods185,762 151,381 
LIFO reserve(18,753)(16,937)
Reserve for excess and obsolete inventory(17,198)(16,149)
Inventories, net$294,132 $248,259 
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.20.4
Property, Plant and Equipment (Notes)
9 Months Ended
Dec. 31, 2020
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment Property, Plant and Equipment
Information related to the major categories of our depreciable assets is as follows:
 December 31,
2020
March 31,
2020
Land and land improvements (1)
$69,591 $65,994 
Buildings and leasehold improvements567,113 531,267 
Machinery and equipment753,851 682,488 
Information systems186,421 181,112 
Radioisotope567,353 508,593 
Construction in progress (1)
211,183 159,731 
Total property, plant, and equipment2,355,512 2,129,185 
Less: accumulated depreciation and depletion(1,128,617)(1,017,330)
Property, plant, and equipment, net$1,226,895 $1,111,855 
(1)Land is not depreciated. Construction in progress is not depreciated until placed in service.
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.20.4
Debt (Notes)
9 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Debt Debt
Indebtedness was as follows:
 December 31,
2020
March 31,
2020
Credit Agreement$304,618 $275,449 
Term Loan550,000 — 
Private Placement 864,425 878,409 
Deferred financing costs(5,844)(3,337)
Total long term debt$1,713,199 $1,150,521 
On November 18, 2020, we entered into a Term Loan Agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Credit Agreement”) providing for a $550,000 Term Loan (the “Term Loan”) in connection with our acquisition of Key Surgical. The proceeds of the Term Loan were used to fund a portion of the purchase price, to prepay and terminate existing indebtedness of Key Surgical and to pay fees and expenses incurred in connection with the Key Surgical acquisition and entry into the Credit Agreement. For more information on the Key Surgical acquisition refer to Note 2 titled, "Business Acquisitions and Divestitures".
The Term Loan matures on November 20, 2023. No principal payments are due on the Term Loan for the period ending December 31, 2021. For the period beginning January 1, 2022 through December 31, 2022, quarterly principal payments, each in the amount of 1.25% of the original principal amount of the Term Loan, are due on the last business day of each fiscal quarter. For the period beginning January 1, 2023 through September 30, 2023, quarterly principal payments, each in the amount of 1.875% of the original principal amount of the Term Loan, are due on the last business day of each fiscal quarter. The remaining unpaid principal balance of the Term Loan, together with accrued and unpaid interest thereon, is due and payable on November 20, 2023.
The Term Loan bears interest from time to time at either the Base Rate or the Eurocurrency Rate, plus the Applicable Margin, as calculated and defined in the Credit Agreement. The Applicable Margin is determined based on the ratio of Consolidated Total Debt to Consolidated EBITDA, each as defined in the Credit Agreement. Interest on borrowings made at the Base Rate (“Base Rate Advances”) is payable quarterly in arrears and interest on borrowings made at the Eurocurrency Rate (“Eurocurrency Rate Advances”) is payable at the end of the relevant interest period therefor, but in no event less frequently than every three months. There is no premium or penalty for prepayment of Base Rate Advances, but prepayments of Eurocurrency Rate Advances are subject to a breakage fee.
All of the lenders under the Credit Agreement are also lenders under our revolving credit agreement dated as of March 23, 2018.
Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Additional Consolidated Balance Sheets Information (Notes)
9 Months Ended
Dec. 31, 2020
Notes To Financial Statements [Abstract]  
Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheet Information
Additional information related to our Consolidated Balance Sheets is as follows:
 December 31,
2020
March 31,
2020
Accrued payroll and other related liabilities:
Compensation and related items$67,883 $42,205 
Accrued vacation/paid time off14,663 9,917 
Accrued bonuses51,100 53,041 
Accrued employee commissions14,591 19,298 
Other postretirement benefit obligations-current portion1,488 1,488 
Other employee benefit plans obligations-current portion2,606 2,312 
Total accrued payroll and other related liabilities$152,331 $128,261 
Accrued expenses and other:
Deferred revenues$44,308 $53,299 
Service liabilities38,948 47,505 
Self-insured risk reserves-current portion9,711 7,342 
Accrued dealer commissions25,174 15,827 
Accrued warranty6,796 7,381 
Asset retirement obligation-current portion1,202 2,671 
Other58,494 58,158 
Total accrued expenses and other$184,633 $192,183 
Other liabilities:
Self-insured risk reserves-long-term portion$17,452 $17,452 
Other postretirement benefit obligations-long-term portion8,587 9,880 
Defined benefit pension plans obligations-long-term portion10,152 10,987 
Other employee benefit plans obligations-long-term portion2,341 2,333 
Accrued long-term income taxes10,841 11,959 
Asset retirement obligation-long-term portion12,379 9,843 
Other27,512 27,892 
Total other liabilities$89,264 $90,346 
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Income Tax Expense (Notes)
9 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Income Tax Expense Income Tax Expense
The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The TCJA reduced the U.S. federal corporate income tax rate to 21.0%, required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and created new taxes on certain foreign sourced earnings. The Company applied the guidance in Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cut and Jobs Act when accounting for the enactment-date effects of the TCJA.
We consider the tax expense recorded for the TCJA to be complete at this time. However, it is possible that additional legislation, regulations and/or guidance may be issued in the future that may result in additional adjustments to the tax expense recorded related to the TCJA. We will continue to monitor and assess the impact of any new developments.
The effective income tax rates for the three month periods ended December 31, 2020 and 2019 were 17.8% and 21.9%, respectively. The effective income tax rates for the nine month periods ended December 31, 2020 and 2019 were 18.8% and 18.8%, respectively. The fiscal 2021 effective tax rate for the current quarter decreased when compared to fiscal 2020, primarily due to an increase in favorable discrete items.
Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various
factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.
We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2016 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2015. We remain subject to tax authority audits in various jurisdictions wherever we do business.
In May 2019, we received two notices of proposed tax adjustment from the U.S. Internal Revenue Service (the “IRS”) regarding the deductibility of interest paid on certain intercompany debt. The notices relate to fiscal years 2016 and 2017. In September 2019, we received another notice of proposed adjustment for the same issue, for the 2018 fiscal year. The IRS adjustments would result in a cumulative tax liability of approximately $40,000. Notices have not been received for subsequent periods. We are contesting the IRS’s assertions. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but could be material to our consolidated results of operations and cash flows for any one period.
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.20.4
Contingencies (Notes)
9 Months Ended
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Commitments and Contingencies
We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief.
We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us.
Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations.
For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020: Item 1 titled “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factors” in Item 1A titled "Product related regulations and claims".
From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized.
We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q.
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.20.4
Business Segment Information (Notes)
9 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Business Segment Information Business Segment Information
We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies and Life Sciences. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income.
Prior to April 1, 2020, we operated and reported our financial information in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products and Healthcare Specialty Services segments were combined and are now reported as one segment, simply called Healthcare, consistent with the way management now operates and views the business. Prior periods have been recast in the financial tables below for comparability.
Our Healthcare segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. The segment also provides a range of specialty services for healthcare providers including hospital sterilization services and instrument and scope repairs.
Our Applied Sterilization Technologies ("AST") segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers.
Our Life Sciences segment designs, manufactures and sells consumable products, equipment maintenance, specialty services and capital equipment primarily to pharmaceutical manufacturers around the world.
We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company.
For the three and nine months ended December 31, 2020, revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
Financial information for each of our segments is presented in the following table:
 Three Months Ended December 31, Nine Months Ended December 31,
 2020201920202019
Revenues:
Healthcare $521,662 $509,222 $1,392,247 $1,440,237 
Applied Sterilization Technologies176,462 156,266 498,371 463,459 
Life Sciences110,800 108,773 343,370 304,208 
Total revenues$808,924 $774,261 $2,233,988 $2,207,904 
Operating income (loss):
Healthcare$115,412 $105,227 $302,565 $298,777 
Applied Sterilization Technologies81,626 65,468 222,416 198,889 
Life Sciences41,541 37,731 136,435 103,085 
Corporate(47,941)(45,260)(158,463)(151,613)
Total operating income before adjustments$190,638 $163,166 $502,953 $449,138 
Less: Adjustments
Amortization of acquired intangible assets (1)
$23,194 $17,508 $62,649 $53,407 
Acquisition and integration related charges (2)
11,563 1,721 13,984 5,585 
Redomiciliation and tax restructuring costs (3)
296 487 850 3,274 
(Gain) on fair value adjustment of acquisition related contingent consideration(500)— (500)— 
Net loss on divestiture of businesses (1)
 76 5 2,553 
Amortization of inventory and property "step up" to fair value (1)
1,784 602 3,101 1,783 
COVID-19 incremental costs (4)
7,251 — 20,460 — 
Restructuring charges (5)
20 385 110 3,328 
Total operating income$147,030 $142,387 $402,294 $379,208 
(1) For more information regarding our recent acquisitions and divestitures refer to Note 2 titled" Business Acquisitions and Divestitures" and our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.
(3) Costs incurred in connection with the Redomiciliation and tax restructuring.
(4) COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.
(5) For more information regarding our restructuring efforts refer to Note 17 titled, "Restructuring".

Additional information regarding our fiscal 2021 and fiscal 2020 revenue is disclosed in the following tables:
 Three Months Ended December 31, Nine Months Ended December 31,
 2020201920202019
Healthcare:
Capital equipment$147,855 $155,408 $407,610 428,894
Consumables148,839 130,255 355,390 362,370
Service224,968 223,559 629,247 648,973 
Total Healthcare Revenues $521,662 $509,222 $1,392,247 $1,440,237 
Applied Sterilization Technologies Service Revenues$176,462 $156,266 $498,371 $463,459 
Life Sciences:
Capital equipment
$28,993 $31,762 $88,664 $84,993 
Consumables49,627 46,370 164,262 132,939 
Service32,180 30,641 90,444 86,276 
Total Life Sciences Revenues$110,800 $108,773 $343,370 $304,208 
Total Revenues$808,924 $774,261 $2,233,988 $2,207,904 
Three Months Ended December 31, Nine Months Ended December 31,
2020201920202019
Revenues:
Ireland$20,316 $16,126 $51,779 $46,405 
United States572,397 562,502 1,613,554 1,611,755 
Other locations216,211 195,633 568,655 549,744 
Total Revenues
$808,924 $774,261 $2,233,988 $2,207,904 
Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments.
Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.
December 31, 2020March 31, 2020
Assets:
Healthcare and Life Sciences$3,595,753 $2,705,377 
Applied Sterilization Technologies2,985,027 2,720,205 
Total assets
$6,580,780 $5,425,582 

The fiscal 2021 increase in Healthcare and Life Sciences was primarily due to the acquisition of Key Surgical.
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.20.4
Shares and Preferred Shares (Notes)
9 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Earnings Per Share Shares and Preferred Shares
Ordinary shares
We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method.
The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share:
 Three Months Ended December 31, Nine Months Ended December 31,
Denominator (shares in thousands):2020201920202019
Weighted average shares outstanding—basic85,330 84,788 85,153 84,740 
Dilutive effect of share equivalents702 840 698 890 
Weighted average shares outstanding and share equivalents—diluted86,032 85,628 85,851 85,630 
Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:
 Three Months Ended December 31, Nine Months Ended December 31,
(shares in thousands)2020201920202019
Number of share options278 347 370 270 
Additional Authorized Shares
 The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Equity
9 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Treasury Stock Repurchases of Ordinary Shares
On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $78,979 (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). As of December 31, 2020, there was approximately $333,932 (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program. The share repurchase program has no specified expiration date.
Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020.
From the start of fiscal 2021 through April 9, 2020, we repurchased 35,000 of our ordinary shares for the aggregate amount of $5,047 (net of fees and commissions) pursuant to the authorizations. During the first nine months of fiscal 2020, we repurchased 205,059 of our ordinary shares for the aggregate amount of $30,000 (net of fees and commissions) pursuant to the authorizations.
During the first nine months of fiscal 2021 we obtained 85,574 of our ordinary shares in the aggregate amount of $9,512 in connection with share based compensation award programs. During the first nine months of fiscal 2020, we obtained 100,124 of our ordinary shares in the aggregate amount of $10,318 in connection with share based compensation award programs.
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation (Notes)
9 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Board of Directors or the Compensation and Organizational Development Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares.
Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of December 31, 2020, 3,592,261 ordinary shares remained available for grant under the long-term incentive plan.
The fair value of stock option awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits.
The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2021 and 2020:
 Fiscal 2021Fiscal 2020
Risk-free interest rate0.46 %2.26 %
Expected life of options6.0 years6.2 years
Expected dividend yield of stock0.96 %1.22 %
Expected volatility of stock23.04 %20.27 %
The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.78% and 2.77% was applied in fiscal 2021 and 2020, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually.
A summary of share option activity is as follows:
 Number of
Options
Weighted
Average
Exercise
Price Per Share
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at March 31, 20201,796,126 $91.29 
Granted288,936 181.33 
Exercised(385,090)68.75 
Forfeited(47,955)121.18 
Outstanding at December 31, 20201,652,017 $111.43 6.9 years$129,044 
Exercisable at December 31, 2020897,953 $83.41 5.6 years$95,303 
We estimate that 736,801 of the non-vested stock options outstanding at December 31, 2020 will ultimately vest.
The aggregate intrinsic value in the table above represents the total pre-tax difference between the $189.54 closing price of our ordinary shares on December 31, 2020 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares.
The total intrinsic value of stock options exercised during the first nine months of fiscal 2021 and fiscal 2020 was $36,850 and $36,939, respectively. Net cash proceeds from the exercise of stock options were $26,018 and $22,958 for the first nine months of fiscal 2021 and fiscal 2020, respectively.
The weighted average grant date fair value of stock option grants was $27.66 and $23.52 for the first nine months of fiscal 2021 and fiscal 2020, respectively.
Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of December 31, 2020 and 2019 was $491 and $629, respectively.
A summary of the non-vested restricted share and share unit activity is presented below:
 Number of
Restricted
Shares
Number of Restricted Share UnitsWeighted-Average
Grant Date
Fair Value
Non-vested at March 31, 2020575,830 30,894 $98.07 
Granted139,229 14,208 164.58 
Vested(158,250)(16,238)84.61 
Forfeited(23,997)(228)103.36 
Non-vested at December 31, 2020532,812 28,636 $120.26 
Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during the first nine months of fiscal 2021 at the time of grant was $14,764.
As of December 31, 2020, there was a total of $51,583 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plan. We expect to recognize the cost over a weighted average period of 2.1 years.
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Financial and Other Guarantees(Notes)
9 Months Ended
Dec. 31, 2020
Product Warranties Disclosures [Abstract]  
Product Warranty Disclosure Financial and Other Guarantees
We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.
Changes in our warranty liability during the first nine months of fiscal 2021 were as follows:
Warranties
Balance, March 31, 2020$7,381 
Warranties issued during the period7,411 
Settlements made during the period(7,996)
Balance, December 31, 2020$6,796 
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.20.4
Derivatives and Hedging (Notes)
9 Months Ended
Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments and Hedging Activities Disclosure Derivatives and HedgingFrom time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. During the third quarter of
fiscal 2021, we also held forward foreign currency contracts to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature during fiscal 2021. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes.
None of these contracts are designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At December 31, 2020, we held foreign currency forward contracts to buy 30.5 million British pounds, 35.0 million Mexican pesos and 2.2 million Canadian dollars; and to sell 4.0 million euros. At December 31, 2020 we held commodity swap contracts to buy 946.8 thousand pounds of nickel.
 Asset DerivativesLiability Derivatives
Fair Value atFair Value atFair Value atFair Value at
Balance sheet locationDecember 31, 2020March 31, 2020December 31, 2020March 31, 2020
Prepaid & Other$1,377 $124 $ $ 
Accrued expenses and other$— $— $659 $912 
The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:
 Location of gain (loss)
recognized in income
Amount of gain (loss) recognized in income
Three Months Ended December 31, Nine Months Ended December 31,
2020201920202019
Foreign currency forward contractsSelling, general and administrative$741 $79 $661 $784 
Commodity swap contractsCost of revenues$153 $(398)$904 $271 
Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $51,323 at December 31, 2020. These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements (Notes)
9 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Disclosures . Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions.
The following table shows the fair value of our financial assets and liabilities at December 31, 2020 and March 31, 2020:
  Fair Value Measurements
 Carrying ValueQuoted Prices
in Active Markets
for Identical Assets
Significant Other
Observable Inputs
Significant
Unobservable
Inputs
Level 1Level 2Level 3
December 31,March 31,December 31,March 31,December 31,March 31,December 31,March 31,
Assets:
Cash and cash equivalents$252,502 $319,581 $252,502 $319,581 $ $— $ $— 
Forward and swap contracts (1)
1,377 124  — 1,377 124  — 
Equity investments(2)
10,484 9,624 10,484 9,624  —  — 
Other investments 2,785 2,507 2,785 2,507  —  — 
Liabilities:
Forward and swap contracts (1)
$659 $912 $ $— $659 $912 $ $— 
Deferred compensation plans (2)
1,822 1,475 1,822 1,475  —  — 
Long term debt (3)
1,713,199 1,150,521  — 1,781,304 1,143,978  — 
Contingent consideration obligations (4)
17,931 15,988  —  — 17,931 15,988 
(1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
(2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the third quarter and first nine months of fiscal 2021, we recorded gains of $210 and $138, respectively, related to these investments. During the third quarter and first nine months of fiscal 2020, we recorded gains (losses) of $636 and $(1,843), respectively, related to these investments.
(3) We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
(4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2020 are summarized as follows:
Contingent Consideration
Balance at March 31, 2020$15,988 
Additions334 
Assumed in acquisition of Key Surgical2,940 
Payments(917)
Reversal (500)
Currency translation adjustments86 
Balance at December 31, 2020$17,931 
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes)
9 Months Ended
Dec. 31, 2020
Reclassifications out of AOCI [Abstract]  
Comprehensive Income (Loss) Note [Text Block] Reclassifications Out of Accumulated Other Comprehensive Income (Loss)
Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended December 31, 2020 and 2019 were as follows:
Defined Benefit Plans (1)
Currency Translation (2)
Total Accumulated Other Comprehensive Income (Loss)
Three MonthsNine MonthsThree MonthsNine MonthsThree MonthsNine Months
Beginning Balance$(7,833)$(6,813)$(122,780)$(228,650)$(130,613)$(235,463)
Other Comprehensive Income before reclassifications323 972 128,737 234,607 129,060 235,579 
Amounts reclassified from Accumulated Other Comprehensive (Loss) (833)(2,502)  (833)(2,502)
Net current-period Other Comprehensive (Loss) Income(510)(1,530)128,737 234,607 128,227 233,077 
Balance at December 31, 2020$(8,343)$(8,343)$5,957 $5,957 $(2,386)$(2,386)
(1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.
(2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
Defined Benefit Plans (1)
Currency Translation (2)
Total Accumulated Other Comprehensive Income (Loss)
Three MonthsNine MonthsThree MonthsNine MonthsThree MonthsNine Months
Beginning Balance$(5,215)$(4,204)$(220,502)$(155,574)$(225,717)$(159,778)
Other Comprehensive Income (Loss) before reclassifications195 576 77,299 12,371 77,494 12,947 
Amounts reclassified from Accumulated Other Comprehensive (Loss)(699)(2,091)— — (699)(2,091)
Net current-period Other Comprehensive (Loss)(504)(1,515)77,299 12,371 76,795 10,856 
Balance at December 31, 2019$(5,719)$(5,719)$(143,203)$(143,203)$(148,922)$(148,922)
(1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.
(2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.20.4
Loans Receivable (Notes)
9 Months Ended
Dec. 31, 2020
Receivables [Abstract]  
Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Loans Receivable
In connection with an equity investment of $4,955, we agreed to provide a credit facility of up to approximately $11,606 for a term of up to seven years ending in 2025. The loan carries an interest rate of 4% compounded daily and payable annually. Outstanding principal borrowings under the agreement totaled $10,326 at December 31, 2020 and $7,084 at March 31, 2020. On January 4, 2021, we purchased the remaining outstanding shares of this equity investment. The acquisition agreement included the capitalization of the outstanding principal and interest borrowings of this credit facility in the amount of $10,536. For more information refer to Note 20, titled, "Subsequent Events".

In connection with the fiscal 2017 divestiture of Synergy Health Netherlands Linen Management Services, we entered into a loan agreement to provide financing of up to €15,000 for a term of up to 15 years. The loan carried an interest rate of 4% for the first four years and 12% thereafter. The loan was renegotiated during the third quarter of fiscal 2020. According to the new terms of the loan agreement, the outstanding balance at October 31, 2019, of €7,300, will be repaid in six equal annual installments beginning on October 18, 2022. The loan carries an interest rate of 4% for the first four years and 8% thereafter. Outstanding principal borrowings under the agreement totaled $8,966 (or €7,300) at December 31, 2020 and $8,072 (or €7,300) at March 31, 2020.
Amounts for loan receivables as noted above are recorded in the "Other assets" line of our Consolidated balance sheets. Interest income is not material.
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Restructuring (Notes)
9 Months Ended
Dec. 31, 2020
Restructuring [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] Restructuring
Fiscal 2019 Restructuring Plan. During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions were eliminated. The Company relocated the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions were designed to enhance profitability and improve efficiency.
Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $43,961 related to these restructuring actions, of which $31,660 was recorded as restructuring expenses and $12,301 was recorded in cost of revenues, with a total of $34,062, $7,568 and $668 related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1,663. Additional restructuring expenses related to this plan are not expected to be material to our results of operations.
Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The remaining liability balances at December 31, 2020 and March 31, 2020 are not material.
For more information relating to our restructuring efforts, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Unusual or Infrequently Occurring Items
9 Months Ended
Dec. 31, 2020
Unusual or Infrequent Items, or Both [Abstract]  
COVID-19 Pandemic COVID-19 PandemicThe COVID-19 pandemic began to impact our business late in fiscal 2020. The pandemic and related public health recommendations and mandated precautions to mitigate the spread of COVID-19, including deferral of medical procedures and treatments and shelter-in-place orders or similar measures, have negatively affected and are expected to continue to negatively affect some of our operations, which may impact our financial position and cash flows. We have experienced and expect to continue to experience unpredictable fluctuations in demand for certain of our products and services, including some products and services that are experiencing increased demand. To date, we do not believe that the COVID-19 pandemic has had a significant impact on our operations, as we have been able to continue to operate our manufacturing facilities and meet the demand for essential products and services of our Customers. In response to the pandemic, we have implemented several measures that we believe will help us to protect the health and safety of our employees, preserve liquidity and enhance our financial flexibility. For our employees, we allowed employees to work remotely when possible and have implemented additional safety measures in compliance with applicable regulations to allow personnel to continue to work in our facilities. We suspended all non-essential travel and enacted a temporary hiring freeze on certain positions. To manage liquidity, we have suspended our stock repurchase program and deferred certain planned capital expenditures; however, we have continued to invest in expansion projects as planned. We do not believe that these actions will negatively impact our long-term ability to generate revenues or meet existing and future financial obligations. While we have been impacted and expect this situation to continue to have an impact on our business, the full impact to our results of operations and financial position cannot be reasonably estimated at this time. For additional information and our risk factors related to the COVID-19 pandemic, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.20.4
Subsequent Events
9 Months Ended
Dec. 31, 2020
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
On January 12, 2021, we announced the signing of a definitive agreement to acquire Cantel Medical Corp. (NYSE: CMD "Cantel"), through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and dental Customers. Under the terms of the agreement, we will acquire Cantel in a cash and stock transaction valued at $84.66 per Cantel common share, based on STERIS’s closing share price of $200.46 on January 11, 2021. This represents a total equity value of approximately $3.6 billion and a total enterprise value of approximately $4.6 billion. The agreement has been unanimously approved by the Boards of Directors of both companies. The acquisition is subject to certain closing conditions, including Cantel shareholder vote and regulatory approvals.
We expect to fund the cash portion of the transaction consideration and repay or otherwise satisfy a significant amount of Cantel’s existing debt obligations with approximately $2.0 billion of new debt. We have fully committed bridge financing and are working with our lenders and advisors on a long-term plan.
On January 4, 2021, we purchased the remaining outstanding shares of an equity investment that we made in fiscal 2019, for approximately $44,255, subject to any working capital adjustments. In addition to the purchase price, the acquisition agreement included the capitalization of the outstanding principal and accumulated interest under a credit facility in the amount of $10,536. For more information refer to Note 18 titled, "Loans Receivable". We plan to integrate the business into our Applied Sterilization Technologies business segment and to fund the transaction through a combination of cash on hand and credit facility borrowings.
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.20.4
Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)
9 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation
We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.
Use of Estimates
Use of Estimates
We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2020 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2021.
Revenue
Revenue Recognition and Associated Liabilities
We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018. At the time of adoption, certain of our capital equipment contracts were comprised of a single integrated performance obligation, which resulted in the deferral of the corresponding capital equipment revenue and cost of revenues until installation was complete. Since the adoption of the standard, there have been changes made in our selling philosophy, product architecture, and manufacturing processes with respect to this product line, that impact whether the promises to transfer the individual goods or services to the Customer are separately identifiable from other promises in the contract. After review of these changes, we have concluded that these contracts consist of multiple performance obligations that are capable of being distinct and meet the criteria for revenue to be recognized when the Customer obtains control of the asset, which is upon delivery of each performance obligation. Revenues and costs of revenues related to these
contracts totaling $14,609 and $7,560, respectively, that had previously been deferred were recognized in our fiscal 2021 first quarter.
Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers.
We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets.
In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately.
Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.
We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.
Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2020, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements.
Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue.
Product Revenue
Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation.
Service Revenue
Within our Healthcare and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair.
We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure.
Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service.
Contract Liabilities
Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2021, $38,181 of the March 31, 2020 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2020, $46,744 of the March 31, 2019 deferred revenue balance was recorded as revenue.
Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances.
Service Liabilities
Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract.
Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances.
Remaining Performance Obligations
Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31 2020, the transaction price allocated to remaining performance obligations was approximately $1,014,800. We expect to recognize approximately 50% of the transaction price within one year and approximately 42% beyond one year. The remainder has yet to be scheduled for delivery
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.20.4
Accounting Policies (Tables)
9 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
New Accounting Pronouncement, Early Adoption
Recently Issued Accounting Standards Impacting the Company are presented in the following table:
StandardDate of IssuanceDescriptionDate of AdoptionEffect on the financial statements or other significant matters
Standards that have been adopted in fiscal 2021
ASU 2016-13, "Measurement of Credit Losses on Financial Instruments"June 2016The standard required a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard was effective for annual periods beginning after December 15, 2019. First Quarter Fiscal 2021
We adopted this standard effective April 1, 2020 with no material impact to our consolidated financial statements.
ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement”
August 2018The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy.  The standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.
First Quarter Fiscal 2021We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.
ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans"August 2018The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans.  The standard also clarified disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation.  The standard was effective for fiscal years ending after December 15, 2019.
First Quarter Fiscal 2021
We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.
ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract"August 2018The standard aligned the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or
obtain internal-use software. The standard was effective for fiscal years beginning after December 15, 2019.
First Quarter Fiscal 2021We adopted this standard on April 1, 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.
Standards that have not yet been adopted
ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)"August 2020
This standard simplifies the accounting for convertible instruments and its application of the derivatives scope exception for contracts in an entity’s own equity. The standard reduces the number of accounting models that require separating embedded conversion features from convertible instruments. As a result, only conversion features accounted for under the substantial premium model and those that require bifurcation will be accounted for separately. For contracts in an entity’s own equity, the new standard eliminates some of the current requirements for equity classification. The standard also addresses how convertible instruments are accounted for in the diluted earnings per share calculation and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity’s own equity. The standard is effective for annual periods beginning after December 15, 2021 and interim periods within that year. Early adoption is permitted for annual periods beginning after December 15, 2020 and interim periods within that year.
N/AWe are in the process of evaluating the impact that the standard will have on our consolidated financial statements.
ASU 2019-12 "Income Taxes (Topic 740)"December 2019The standard provides final guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance simplifies accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted.N/AWe are in the process of evaluating the impact that the standard will have on our consolidated financial statements.
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables)
9 Months Ended
Dec. 31, 2020
Business Acquisitions and Divestitures [Abstract]  
Schedule of Business Acquisitions, by Acquisition
The table below summarizes the preliminary allocation of the purchase price to the net assets acquired for the Key Surgical acquisition based on fair values at the acquisition date.
(dollars in thousands)
Key Surgical (1)
Cash$12,615 
Accounts receivable13,967 
Inventory22,167 
Property, plant and equipment6,032 
Other assets6,680 
Intangible assets (2)
491,009 
Goodwill423,239 
Total Assets$975,709 
Current liabilities(17,683)
Non-current liabilities(95,694)
Total Liabilities(113,377)
Net Assets$862,332 
(1) Purchase price allocation is still preliminary as of December 31, 2020, as valuation has not been finalized.
(2) Intangible assets resulting from the Key Surgical acquisition may consists of patents, trade names, Customer Relationships, non-compete agreements, and technologies, pending the outcome of the final valuation
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Inventories, Net Inventories, Net (Tables)
9 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
Schedule of Inventory Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:
 December 31,
2020
March 31,
2020
Raw materials$102,212 $94,321 
Work in process42,109 35,643 
Finished goods185,762 151,381 
LIFO reserve(18,753)(16,937)
Reserve for excess and obsolete inventory(17,198)(16,149)
Inventories, net$294,132 $248,259 
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.20.4
Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables)
9 Months Ended
Dec. 31, 2020
Notes To Financial Statements [Abstract]  
Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheet Information
Additional information related to our Consolidated Balance Sheets is as follows:
 December 31,
2020
March 31,
2020
Accrued payroll and other related liabilities:
Compensation and related items$67,883 $42,205 
Accrued vacation/paid time off14,663 9,917 
Accrued bonuses51,100 53,041 
Accrued employee commissions14,591 19,298 
Other postretirement benefit obligations-current portion1,488 1,488 
Other employee benefit plans obligations-current portion2,606 2,312 
Total accrued payroll and other related liabilities$152,331 $128,261 
Accrued expenses and other:
Deferred revenues$44,308 $53,299 
Service liabilities38,948 47,505 
Self-insured risk reserves-current portion9,711 7,342 
Accrued dealer commissions25,174 15,827 
Accrued warranty6,796 7,381 
Asset retirement obligation-current portion1,202 2,671 
Other58,494 58,158 
Total accrued expenses and other$184,633 $192,183 
Other liabilities:
Self-insured risk reserves-long-term portion$17,452 $17,452 
Other postretirement benefit obligations-long-term portion8,587 9,880 
Defined benefit pension plans obligations-long-term portion10,152 10,987 
Other employee benefit plans obligations-long-term portion2,341 2,333 
Accrued long-term income taxes10,841 11,959 
Asset retirement obligation-long-term portion12,379 9,843 
Other27,512 27,892 
Total other liabilities$89,264 $90,346 
Schedule of Accrued Liabilities [Table Text Block]
Additional information related to our Consolidated Balance Sheets is as follows:
 December 31,
2020
March 31,
2020
Accrued payroll and other related liabilities:
Compensation and related items$67,883 $42,205 
Accrued vacation/paid time off14,663 9,917 
Accrued bonuses51,100 53,041 
Accrued employee commissions14,591 19,298 
Other postretirement benefit obligations-current portion1,488 1,488 
Other employee benefit plans obligations-current portion2,606 2,312 
Total accrued payroll and other related liabilities$152,331 $128,261 
Accrued expenses and other:
Deferred revenues$44,308 $53,299 
Service liabilities38,948 47,505 
Self-insured risk reserves-current portion9,711 7,342 
Accrued dealer commissions25,174 15,827 
Accrued warranty6,796 7,381 
Asset retirement obligation-current portion1,202 2,671 
Other58,494 58,158 
Total accrued expenses and other$184,633 $192,183 
Other liabilities:
Self-insured risk reserves-long-term portion$17,452 $17,452 
Other postretirement benefit obligations-long-term portion8,587 9,880 
Defined benefit pension plans obligations-long-term portion10,152 10,987 
Other employee benefit plans obligations-long-term portion2,341 2,333 
Accrued long-term income taxes10,841 11,959 
Asset retirement obligation-long-term portion12,379 9,843 
Other27,512 27,892 
Total other liabilities$89,264 $90,346 
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Business Segment Information Business Segment Information (Tables)
9 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Financial information for each of our segments is presented in the following table:
 Three Months Ended December 31, Nine Months Ended December 31,
 2020201920202019
Revenues:
Healthcare $521,662 $509,222 $1,392,247 $1,440,237 
Applied Sterilization Technologies176,462 156,266 498,371 463,459 
Life Sciences110,800 108,773 343,370 304,208 
Total revenues$808,924 $774,261 $2,233,988 $2,207,904 
Operating income (loss):
Healthcare$115,412 $105,227 $302,565 $298,777 
Applied Sterilization Technologies81,626 65,468 222,416 198,889 
Life Sciences41,541 37,731 136,435 103,085 
Corporate(47,941)(45,260)(158,463)(151,613)
Total operating income before adjustments$190,638 $163,166 $502,953 $449,138 
Less: Adjustments
Amortization of acquired intangible assets (1)
$23,194 $17,508 $62,649 $53,407 
Acquisition and integration related charges (2)
11,563 1,721 13,984 5,585 
Redomiciliation and tax restructuring costs (3)
296 487 850 3,274 
(Gain) on fair value adjustment of acquisition related contingent consideration(500)— (500)— 
Net loss on divestiture of businesses (1)
 76 5 2,553 
Amortization of inventory and property "step up" to fair value (1)
1,784 602 3,101 1,783 
COVID-19 incremental costs (4)
7,251 — 20,460 — 
Restructuring charges (5)
20 385 110 3,328 
Total operating income$147,030 $142,387 $402,294 $379,208 
Revenue from External Customers by Products and Services [Table Text Block]
 Three Months Ended December 31, Nine Months Ended December 31,
 2020201920202019
Healthcare:
Capital equipment$147,855 $155,408 $407,610 428,894
Consumables148,839 130,255 355,390 362,370
Service224,968 223,559 629,247 648,973 
Total Healthcare Revenues $521,662 $509,222 $1,392,247 $1,440,237 
Applied Sterilization Technologies Service Revenues$176,462 $156,266 $498,371 $463,459 
Life Sciences:
Capital equipment
$28,993 $31,762 $88,664 $84,993 
Consumables49,627 46,370 164,262 132,939 
Service32,180 30,641 90,444 86,276 
Total Life Sciences Revenues$110,800 $108,773 $343,370 $304,208 
Total Revenues$808,924 $774,261 $2,233,988 $2,207,904 
Revenue from External Customers by Geographic Areas [Table Text Block]
Three Months Ended December 31, Nine Months Ended December 31,
2020201920202019
Revenues:
Ireland$20,316 $16,126 $51,779 $46,405 
United States572,397 562,502 1,613,554 1,611,755 
Other locations216,211 195,633 568,655 549,744 
Total Revenues
$808,924 $774,261 $2,233,988 $2,207,904 
Reconciliation of Assets from Segment to Consolidated
Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments.
Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.
December 31, 2020March 31, 2020
Assets:
Healthcare and Life Sciences$3,595,753 $2,705,377 
Applied Sterilization Technologies2,985,027 2,720,205 
Total assets
$6,580,780 $5,425,582 
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.20.4
Shares and Preferred Shares Shares and Preferred Shares (Tables)
9 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares [Table Text Block]
 Three Months Ended December 31, Nine Months Ended December 31,
Denominator (shares in thousands):2020201920202019
Weighted average shares outstanding—basic85,330 84,788 85,153 84,740 
Dilutive effect of share equivalents702 840 698 890 
Weighted average shares outstanding and share equivalents—diluted86,032 85,628 85,851 85,630 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:
 Three Months Ended December 31, Nine Months Ended December 31,
(shares in thousands)2020201920202019
Number of share options278 347 370 270 
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation Share-Based Compensation (Tables)
9 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Assumptions Used
The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2021 and 2020:
 Fiscal 2021Fiscal 2020
Risk-free interest rate0.46 %2.26 %
Expected life of options6.0 years6.2 years
Expected dividend yield of stock0.96 %1.22 %
Expected volatility of stock23.04 %20.27 %
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding
A summary of share option activity is as follows:
 Number of
Options
Weighted
Average
Exercise
Price Per Share
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at March 31, 20201,796,126 $91.29 
Granted288,936 181.33 
Exercised(385,090)68.75 
Forfeited(47,955)121.18 
Outstanding at December 31, 20201,652,017 $111.43 6.9 years$129,044 
Exercisable at December 31, 2020897,953 $83.41 5.6 years$95,303 
Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest
A summary of the non-vested restricted share and share unit activity is presented below:
 Number of
Restricted
Shares
Number of Restricted Share UnitsWeighted-Average
Grant Date
Fair Value
Non-vested at March 31, 2020575,830 30,894 $98.07 
Granted139,229 14,208 164.58 
Vested(158,250)(16,238)84.61 
Forfeited(23,997)(228)103.36 
Non-vested at December 31, 2020532,812 28,636 $120.26 
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.20.4
Financial and Other Guarantees Financial and Other Gurantees (Tables)
9 Months Ended
Dec. 31, 2020
Product Warranties Disclosures [Abstract]  
Schedule of Product Warranty Liability
Changes in our warranty liability during the first nine months of fiscal 2021 were as follows:
Warranties
Balance, March 31, 2020$7,381 
Warranties issued during the period7,411 
Settlements made during the period(7,996)
Balance, December 31, 2020$6,796 
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Derivatives and Hedging Derivatives and Hedging (Tables)
9 Months Ended
Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value
 Asset DerivativesLiability Derivatives
Fair Value atFair Value atFair Value atFair Value at
Balance sheet locationDecember 31, 2020March 31, 2020December 31, 2020March 31, 2020
Prepaid & Other$1,377 $124 $ $ 
Accrued expenses and other$— $— $659 $912 
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance
The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:
 Location of gain (loss)
recognized in income
Amount of gain (loss) recognized in income
Three Months Ended December 31, Nine Months Ended December 31,
2020201920202019
Foreign currency forward contractsSelling, general and administrative$741 $79 $661 $784 
Commodity swap contractsCost of revenues$153 $(398)$904 $271 
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements Fair Value Measurements (Tables)
9 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2020 are summarized as follows:
Contingent Consideration
Balance at March 31, 2020$15,988 
Additions334 
Assumed in acquisition of Key Surgical2,940 
Payments(917)
Reversal (500)
Currency translation adjustments86 
Balance at December 31, 2020$17,931 
Fair Value Option, Disclosures
The following table shows the fair value of our financial assets and liabilities at December 31, 2020 and March 31, 2020:
  Fair Value Measurements
 Carrying ValueQuoted Prices
in Active Markets
for Identical Assets
Significant Other
Observable Inputs
Significant
Unobservable
Inputs
Level 1Level 2Level 3
December 31,March 31,December 31,March 31,December 31,March 31,December 31,March 31,
Assets:
Cash and cash equivalents$252,502 $319,581 $252,502 $319,581 $ $— $ $— 
Forward and swap contracts (1)
1,377 124  — 1,377 124  — 
Equity investments(2)
10,484 9,624 10,484 9,624  —  — 
Other investments 2,785 2,507 2,785 2,507  —  — 
Liabilities:
Forward and swap contracts (1)
$659 $912 $ $— $659 $912 $ $— 
Deferred compensation plans (2)
1,822 1,475 1,822 1,475  —  — 
Long term debt (3)
1,713,199 1,150,521  — 1,781,304 1,143,978  — 
Contingent consideration obligations (4)
17,931 15,988  —  — 17,931 15,988 
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.20.4
Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)
9 Months Ended
Dec. 31, 2020
Reclassifications out of AOCI [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended December 31, 2020 and 2019 were as follows:
Defined Benefit Plans (1)
Currency Translation (2)
Total Accumulated Other Comprehensive Income (Loss)
Three MonthsNine MonthsThree MonthsNine MonthsThree MonthsNine Months
Beginning Balance$(7,833)$(6,813)$(122,780)$(228,650)$(130,613)$(235,463)
Other Comprehensive Income before reclassifications323 972 128,737 234,607 129,060 235,579 
Amounts reclassified from Accumulated Other Comprehensive (Loss) (833)(2,502)  (833)(2,502)
Net current-period Other Comprehensive (Loss) Income(510)(1,530)128,737 234,607 128,227 233,077 
Balance at December 31, 2020$(8,343)$(8,343)$5,957 $5,957 $(2,386)$(2,386)
(1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.
(2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
Defined Benefit Plans (1)
Currency Translation (2)
Total Accumulated Other Comprehensive Income (Loss)
Three MonthsNine MonthsThree MonthsNine MonthsThree MonthsNine Months
Beginning Balance$(5,215)$(4,204)$(220,502)$(155,574)$(225,717)$(159,778)
Other Comprehensive Income (Loss) before reclassifications195 576 77,299 12,371 77,494 12,947 
Amounts reclassified from Accumulated Other Comprehensive (Loss)(699)(2,091)— — (699)(2,091)
Net current-period Other Comprehensive (Loss)(504)(1,515)77,299 12,371 76,795 10,856 
Balance at December 31, 2019$(5,719)$(5,719)$(143,203)$(143,203)$(148,922)$(148,922)
(1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.
(2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Restructuring (Tables)
9 Months Ended
Dec. 31, 2020
Restructuring [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] Restructuring
Fiscal 2019 Restructuring Plan. During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions were eliminated. The Company relocated the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions were designed to enhance profitability and improve efficiency.
Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $43,961 related to these restructuring actions, of which $31,660 was recorded as restructuring expenses and $12,301 was recorded in cost of revenues, with a total of $34,062, $7,568 and $668 related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1,663. Additional restructuring expenses related to this plan are not expected to be material to our results of operations.
Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The remaining liability balances at December 31, 2020 and March 31, 2020 are not material.
For more information relating to our restructuring efforts, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Revenue, Remaining Performance Obligation, Amount   $ 1,014,800  
Deferred Revenues, Amount recognized in period from certain capital contracts $ 14,609    
Deferred Cost of Revenues, Amount recognized in period from certain capital contracts $ 7,560    
Deferred Revenue, Revenue Recognized   $ 38,181 $ 46,744
Expected recognition within the next year [Member]      
Revenue, Remaining Performance Obligation, Percentage   50.00%  
Expected recognition beyond the next year [Member] [Member]      
Revenue, Remaining Performance Obligation, Percentage   42.00%  
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.20.4
Business Acquisitions and Divestitures Fiscal 2018 Acquisitions (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Mar. 31, 2020
Business Acquisition [Line Items]          
Contingent consideration $ 17,931   $ 17,931   $ 15,988
Deferred consideration 1,194 $ 894 1,194 $ 894  
Proceeds from Sales of Business, Affiliate and Productive Assets       439  
Gain (Loss) on Disposition of Business [1] $ 0 $ (76) (5) (2,553)  
Approximate annual revenues of divested entity       5,000  
Business Combination, Acquisition Related Costs     $ 10,842    
Business Acquisition, Date of Acquisition [Abstract]          
Business Acquisition, Effective Date of Acquisition     Nov. 18, 2020    
Payments to Acquire Businesses, Net of Cash Acquired     $ 869,431 107,166  
Series of Individually Immaterial Business Acquisitions          
Business Acquisition, Date of Acquisition [Abstract]          
Payments to Acquire Businesses, Net of Cash Acquired     20,908 $ 117,259  
Key Surgical [Domain]          
Business Acquisition, Date of Acquisition [Abstract]          
Payments to Acquire Businesses, Net of Cash Acquired     $ 849,717    
[1] For more information regarding our recent acquisitions and divestitures refer to Note 2 titled" Business Acquisitions and Divestitures" and our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Mar. 31, 2020
Business Acquisition [Line Items]          
Revenues $ 808,924 $ 774,261 $ 2,233,988 $ 2,207,904  
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Cash [1] 12,615   12,615    
Accounts receivable [1] 13,967   13,967    
Inventory [1] 22,167   22,167    
Property, plant, and equipment [1] 6,032   6,032    
Other assets [1] 6,680   6,680    
Goodwill 2,926,551   2,926,551   $ 2,356,085
Total Assets [1] 975,709   975,709    
Current liabilities [1] 17,683   17,683    
Non-current liabilities [1] 95,694   95,694    
Total Liabilities [1] 113,377   113,377    
Net Assets [1] $ 862,332   $ 862,332    
[1] Purchase price allocation is still preliminary as of December 31, 2020, as valuation has not been finalized.
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.20.4
Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Revenues $ 808,924 $ 774,261 $ 2,233,988 $ 2,207,904
Pre-tax gain or loss on sale of business [1] 0 76 5 2,553
Deferred consideration $ 1,194 $ 894 $ 1,194 $ 894
[1] For more information regarding our recent acquisitions and divestitures refer to Note 2 titled" Business Acquisitions and Divestitures" and our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Business Acquisitions and Divestitures Revenues by Type (Details)
$ in Thousands
9 Months Ended
Dec. 31, 2019
USD ($)
Business Combinations [Abstract]  
Loss on sale of HSS China Operations $ 2,330
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.20.4
Business Acquisitions and Divestitures (Details) 2020
$ in Thousands
Dec. 31, 2020
USD ($)
[1]
Business Acquisitions and Divestitures [Abstract]  
Cash $ 12,615
Accounts receivable 13,967
Inventory 22,167
Property, plant, and equipment 6,032
Other assets 6,680
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 491,009 [2]
Business Acquisition, Goodwill, Expected Tax Deductible Amount 423,239
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets 975,709
Current liabilities (17,683)
Non-current liabilities (95,694)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities (113,377)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $ 862,332
[1] Purchase price allocation is still preliminary as of December 31, 2020, as valuation has not been finalized.
[2] Intangible assets resulting from the Key Surgical acquisition may consists of patents, trade names, Customer Relationships, non-compete agreements, and technologies, pending the outcome of the final valuation
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Inventories, Net Inventories, Net (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Mar. 31, 2020
Raw materials $ 102,212 $ 94,321
Work in process 42,109 35,643
Finished goods 185,762 151,381
LIFO reserve (18,753) (16,937)
Reserve for excess and obsolete inventory (17,198) (16,149)
Inventories, net $ 294,132 $ 248,259
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
9 Months Ended
Dec. 31, 2020
Mar. 31, 2020
Property, Plant and Equipment [Abstract]    
Property, Plant and Equipment
Information related to the major categories of our depreciable assets is as follows:
 December 31,
2020
March 31,
2020
Land and land improvements (1)
$69,591 $65,994 
Buildings and leasehold improvements567,113 531,267 
Machinery and equipment753,851 682,488 
Information systems186,421 181,112 
Radioisotope567,353 508,593 
Construction in progress (1)
211,183 159,731 
Total property, plant, and equipment2,355,512 2,129,185 
Less: accumulated depreciation and depletion(1,128,617)(1,017,330)
Property, plant, and equipment, net$1,226,895 $1,111,855 
(1)Land is not depreciated. Construction in progress is not depreciated until placed in service.
 
Property, Plant and Equipment [Line Items]    
Land and land improvements [1] $ 69,591 $ 65,994
Buildings and leasehold improvements 567,113 531,267
Machinery and equipment 753,851 682,488
Radioisotope 567,353 508,593
Construction in progress [1] 211,183 159,731
Total property, plant, and equipment 2,355,512 2,129,185
Less: accumulated depreciation and depletion (1,128,617) (1,017,330)
Property, plant, and equipment, net 1,226,895 1,111,855
Capitalized Computer Hardware/Software, Gross $ 186,421 $ 181,112
[1] Land is not depreciated. Construction in progress is not depreciated until placed in service.
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Debt Debt (Details) - USD ($)
$ in Thousands
9 Months Ended
Dec. 31, 2020
Mar. 31, 2020
Debt Disclosure [Abstract]    
Schedule of Debt
Indebtedness was as follows:
 December 31,
2020
March 31,
2020
Credit Agreement$304,618 $275,449 
Term Loan550,000 — 
Private Placement 864,425 878,409 
Deferred financing costs(5,844)(3,337)
Total long term debt$1,713,199 $1,150,521 
 
Debt Instrument [Line Items]    
Private Placement $ 864,425 $ 878,409
Deferred financing costs 5,844 3,337
Credit Agreement 304,618 275,449
Loans Payable to Bank 550,000 0
Total long term debt $ 1,713,199 $ 1,150,521
Principal repayment rate year 1 1.25%  
Term loan quarterly principal repayment rate year 2023 1.875%  
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.20.4
Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Mar. 31, 2020
Accrued payroll and other related liabilities:    
Compensation and related items $ 67,883 $ 42,205
Accrued vacation/paid time off 14,663 9,917
Accrued bonuses 51,100 53,041
Accrued employee commissions 14,591 19,298
Other postretirement benefit obligations-current portion 1,488 1,488
Other employee benefit plans obligations-current portion 2,606 2,312
Accrued expenses and other:    
Deferred revenues 44,308 53,299
Service liabilities 38,948 47,505
Self-insured risk reserves-current portion 9,711 7,342
Accrued dealer commissions 25,174 15,827
Accrued warranty 6,796 7,381
Asset retirement obligation-current portion 1,202 2,671
Other 58,494 58,158
Total accrued expenses and other 184,633 192,183
Other liabilities:    
Self-insured risk reserves-long-term portion 17,452 17,452
Other postretirement benefit obligations-long-term portion 8,587 9,880
Defined benefit pension plans obligations-long-term portion 10,152 10,987
Other employee benefit plans obligations-long-term portion 2,341 2,333
Accrued long-term income taxes 10,841 11,959
Asset retirement obligation-long-term portion 12,379 9,843
Long-term liabilities, other 27,512 27,892
Other Liabilities, Noncurrent 89,264 90,346
Employee-related Liabilities, Current $ 152,331 $ 128,261
XML 69 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Income Tax Expense Income Tax Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Percent [Abstract]        
Effective Income Tax Rate, Continuing Operations 17.80% 21.90% 18.80% 18.80%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent     21.00%  
Uncertain Tax Liability Resulting From IRS Notice $ 40,000   $ 40,000  
XML 70 R53.htm IDEA: XBRL DOCUMENT v3.20.4
Business Segment Information Business Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Mar. 31, 2020
Segment Reporting Information [Line Items]          
Revenues $ 808,924 $ 774,261 $ 2,233,988 $ 2,207,904  
Segment operating income 147,030 142,387 402,294 379,208  
Restructuring Charges [1] 20 385 110 3,328  
Amortization of acquired intangible assets [2] 23,194 17,508 62,649 53,407  
Business Combination, Acquisition Related Costs [3] 11,563 1,721 13,984 5,585  
loss (gain) on fair value contingent consideration adjustments (500) 0 (500) 0  
Impact of TCJA [4] 296 487 850 3,274  
Net loss on divestiture of businesses [2] 0 76 5 2,553  
Amortization of inventory and property step-up to fair value [2] 1,784 602 3,101 1,783  
COVID-19 incremental costs [5] 7,251 0 20,460 0  
Assets 6,580,780   6,580,780   $ 5,425,582
Life Sciences          
Segment Reporting Information [Line Items]          
Revenues 110,800 108,773 343,370 304,208  
Segment operating income 41,541 37,731 136,435 103,085  
Applied Sterilization Technologies          
Segment Reporting Information [Line Items]          
Revenues 176,462 156,266 498,371 463,459  
Segment operating income 81,626 65,468 222,416 198,889  
Assets 2,985,027   2,985,027   2,720,205
Segment operating income          
Segment Reporting Information [Line Items]          
Revenues 808,924 774,261 2,233,988 2,207,904  
Segment operating income 190,638 163,166 502,953 449,138  
Healthcare [Member] [Member]          
Segment Reporting Information [Line Items]          
Revenues 521,662 509,222 1,392,247 1,440,237  
Segment operating income 115,412 105,227 302,565 298,777  
Healthcare and Life Sciences [Member]          
Segment Reporting Information [Line Items]          
Assets 3,595,753   3,595,753   $ 2,705,377
Corporate Segment [Member]          
Segment Reporting Information [Line Items]          
Segment operating income (47,941) (45,260) (158,463) (151,613)  
Other foreign locations [Member]          
Segment Reporting Information [Line Items]          
Revenues 216,211 195,633 568,655 549,744  
UNITED STATES          
Segment Reporting Information [Line Items]          
Revenues 572,397 562,502 1,613,554 1,611,755  
UNITED KINGDOM          
Segment Reporting Information [Line Items]          
Revenues 20,316 16,126 51,779 46,405  
Consumable revenues [Member] | Life Sciences          
Segment Reporting Information [Line Items]          
Revenues 49,627 46,370 164,262 132,939  
Consumable revenues [Member] | Healthcare [Member] [Member]          
Segment Reporting Information [Line Items]          
Revenues 148,839 130,255 355,390 362,370  
Sales Revenue, Services, Net [Member] | Life Sciences          
Segment Reporting Information [Line Items]          
Revenues 32,180 30,641 90,444 86,276  
Sales Revenue, Services, Net [Member] | Healthcare [Member] [Member]          
Segment Reporting Information [Line Items]          
Revenues 224,968 223,559 629,247 648,973  
Capital equipment revenues [Member] | Life Sciences          
Segment Reporting Information [Line Items]          
Revenues 28,993 31,762 88,664 84,993  
Capital equipment revenues [Member] | Healthcare [Member] [Member]          
Segment Reporting Information [Line Items]          
Revenues $ 147,855 $ 155,408 $ 407,610 $ 428,894  
[1] For more information regarding our restructuring efforts refer to Note 17 titled, "Restructuring"
[2] For more information regarding our recent acquisitions and divestitures refer to Note 2 titled" Business Acquisitions and Divestitures" and our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
[3] Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.
[4] Costs incurred in connection with the Redomiciliation and tax restructuring.
[5] COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.
XML 71 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Shares and Preferred Shares Ordinary Shares (Details)
3 Months Ended 9 Months Ended
Dec. 31, 2020
$ / shares
shares
Dec. 31, 2019
shares
Dec. 31, 2020
$ / shares
shares
Dec. 31, 2019
shares
Dec. 31, 2020
EUR (€)
shares
Mar. 31, 2020
$ / shares
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]            
Weighted average shares outstanding - basic 85,330,000 84,788,000 85,153,000 84,740,000    
Dilutive effect of share equivalents 702,000 840,000 698,000 890,000    
Weighted average shares outstanding and share equivalents - diluted 86,032,000 85,628,000 85,851,000 85,630,000    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Preferred Stock, Shares Authorized         50,000,000  
Common Stock, Par or Stated Value Per Share | $ / shares $ 0.001   $ 0.001     $ 0.001
Preferred Stock, Par or Stated Value Per Share | $ / shares $ 0.001   $ 0.001      
Deferred Ordinary Shares         25,000  
Employee share option            
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Number of share options that are antidilutive 278,000 347,000 370,000 270,000    
Euro Member Countries, Euro            
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Par Value (Euros) of Deferred Ordinary Shares | €         € 1.00  
XML 72 R55.htm IDEA: XBRL DOCUMENT v3.20.4
Shares and Preferred Shares Preferred Shares (Details)
Dec. 31, 2020
$ / shares
Class of Stock [Line Items]  
Preferred shares, par value $ 0.001
XML 73 R56.htm IDEA: XBRL DOCUMENT v3.20.4
Repurchases of Shares (Details) - USD ($)
$ in Thousands
9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Jul. 30, 2019
May 07, 2019
Equity, Class of Treasury Stock [Line Items]        
Share repurchase program, number of shares authorized $ 333,932   $ 300,000 $ 78,979
Shares repurchased during period, number 35,000 205,059    
Aggregate value of shares repurchased pursuant to authorization $ 5,047 $ 30,000    
Shares obtained in connection with share based compensation award programs 85,574 100,124    
Payments for shares obtained in connection with share based compensation programs $ 9,512 $ 10,318    
XML 74 R57.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation Share-Based Compensation (Details) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]    
Remaining shares available for grant 3,592,261  
Weighted-average assumptions used for options granted:    
Risk-free interest rate 0.46% 2.26%
Expected life of options 6 years 6 years 2 months 12 days
Exptected dividend yield of stock 0.96% 1.22%
Expected volatility of stock 23.04% 20.27%
Estimated forfeiture rate 2.78% 2.77%
Summary of share option activity:    
Outstanding at March 31, 2017 1,796,126  
Granted 288,936  
Exercised (385,090)  
Forfeited (47,955)  
Outstanding at June 30, 2017 1,652,017  
Exercisable at June 30, 2017 897,953  
Weighted average exercise price:    
Outstanding at March 31, 2017 $ 91.29  
Granted 181.33  
Exercised 68.75  
Forfeited 121.18  
Outstanding at June 30, 2017 111.43  
Exercisable at June 30, 2017 $ 83.41  
Average Remaining Contractual Term, Outstanding at June 30, 2017 6 years 10 months 24 days  
Aggregate Intrinsic Value, Outstanding at June 30, 2017 $ 129,044  
Average Remaining Contractual Term, Exercisable at June 30, 2017 5 years 7 months 6 days  
Aggregate Intrinsic Value, Exercisable at June 30, 2017 $ 95,303  
Non-vested stock options outstanding expected to vest 736,801  
Ordinary shares, closing price $ 189.54  
Total intrinsic value of stock options exercised $ 36,850 $ 36,939
Net cash proceeds from the exercise of stock options $ 26,018 $ 22,958
Weighted average grant date fair value of stock option grants, per share $ 27.66 $ 23.52
Summary of non-vested restricted share activity:    
Unrecognized compensation cost related to nonvested share-based compensation granted $ 51,583  
Weighted Average Period For Total Compensation Expense Not Yet Recognized 2 years 1 month 6 days  
Stock Appreciation Rights (SARs) [Member]    
Weighted average exercise price:    
FairValueOfOutstandingStockAppreciationRights $ 491 $ 629
Restricted Stock    
Summary of non-vested restricted share activity:    
Number of Restricted Shares, Non-vested at Beginning of Period 575,830  
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period $ 98.07  
Number of Restricted Shares, Granted 139,229  
Weighted-Average Grant Date Fair Value, Granted $ 164.58  
Number of Restricted Shares, Vested (158,250)  
Weighted-Average Grant Date Fair Value, Vested $ 84.61  
Number of Restricted Shares, Canceled (23,997)  
Weighted-Average Grant Date Fair Value, Canceled $ 103.36  
Number of Restricted Shares, Non-vested at End of Period 532,812  
Weighted-Average Grant Date Fair Value, Non-vested at End of Period $ 120.26  
Fair Value, Share-based Payment Awards, Other than Options $ 14,764  
Restricted Stock Units (RSUs)    
Summary of non-vested restricted share activity:    
Number of Restricted Shares, Non-vested at Beginning of Period 30,894  
Number of Restricted Shares, Granted 14,208  
Number of Restricted Shares, Vested (16,238)  
Number of Restricted Shares, Canceled (228)  
Number of Restricted Shares, Non-vested at End of Period 28,636  
XML 75 R58.htm IDEA: XBRL DOCUMENT v3.20.4
Financial and Other Guarantees Financial and Other Guarantees (Details)
$ in Thousands
9 Months Ended
Dec. 31, 2020
USD ($)
Product Warranty Liability [Line Items]  
Balance, March 31, 2017 $ 7,381
Warranties issued during the period 7,411
Settlement made during the period (7,996)
Balance, June 30, 2017 $ 6,796
XML 76 R59.htm IDEA: XBRL DOCUMENT v3.20.4
Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details)
€ in Thousands, £ in Thousands, $ in Thousands, $ in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
lb
Dec. 31, 2019
USD ($)
Dec. 31, 2020
GBP (£)
Dec. 31, 2020
MXN ($)
Dec. 31, 2020
CAD ($)
Dec. 31, 2020
EUR (€)
Dec. 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Derivative [Line Items]                    
Non-derivative Net Investment Hedge                 $ 51,323  
Prepaid & Other                    
Derivative [Line Items]                    
Asset derivatives                 1,377 $ 124
Liability derivatives                 0 0
Accrued expenses and other                    
Derivative [Line Items]                    
Asset derivatives                 0 0
Liability derivatives                 $ 659 $ 912
Foreign currency forward contracts | Selling, general, and administrative expense                    
Derivative [Line Items]                    
Gain (Loss) on Derivative Instruments, Net, Pretax $ 741 $ 79 $ 661 $ 784            
Commodity swap contracts                    
Derivative [Line Items]                    
Derivative, notional amount, weight | lb     946,800              
Commodity swap contracts | Cost of Sales [Member]                    
Derivative [Line Items]                    
Gain (Loss) on Derivative Instruments, Net, Pretax $ (153) $ 398 $ (904) $ (271)            
Mexican peso | Foreign currency forward contracts                    
Derivative [Line Items]                    
Liability derivatives           $ 35,000        
Canadian dollar | Foreign currency forward contracts                    
Derivative [Line Items]                    
Liability derivatives             $ 2,200      
euro | Foreign currency forward contracts                    
Derivative [Line Items]                    
Derivative Asset, Notional Amount | €               € 4,000    
British pounds sterling | Foreign currency forward contracts                    
Derivative [Line Items]                    
Liability derivatives | £         £ 30,500          
XML 77 R60.htm IDEA: XBRL DOCUMENT v3.20.4
Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Foreign currency forward contracts | Selling, general, and administrative expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain (loss) recognized in income $ (741) $ (79) $ (661) $ (784)
Commodity swap contracts | Cost of revenues        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain (loss) recognized in income $ 153 $ (398) $ 904 $ 271
XML 78 R61.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements Fair Value Hierarchy (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Mar. 31, 2020
Reported Value Measurement [Member]          
Assets:          
Cash and cash equivalents $ 252,502   $ 252,502   $ 319,581
Forward and swap contracts [1] 1,377   1,377   124
Equity Securities, FV-NI [2] 10,484   10,484   9,624
Investments 2,785   2,785   2,507
Liabilities:          
Forward and swap contracts [1] 659   659   912
Deferred compensation plans [2] 1,822   1,822   1,475
Contingent consideration obligations 17,931   17,931   15,988
Debt Instrument, Fair Value Disclosure [3] 1,713,199   1,713,199   1,150,521
Debt and Equity Securities, Gain (Loss) (210) $ (636) (138) $ 1,843  
Investment Owned, at Cost 4,955   4,955    
Contingent consideration obligations 17,931   17,931   15,988
Level 1          
Assets:          
Cash and cash equivalents 252,502   252,502   319,581
Forward and swap contracts 0   0   0
Equity Securities, FV-NI [2] 10,484   10,484   9,624
Investments 2,785   2,785   2,507
Liabilities:          
Forward and swap contracts 0   0   0
Deferred compensation plans [2] 1,822   1,822   1,475
Contingent consideration obligations 0   0   0
Debt Instrument, Fair Value Disclosure 0   0   0
Level 2          
Assets:          
Cash and cash equivalents 0   0   0
Forward and swap contracts [1] 1,377   1,377   124
Equity Securities, FV-NI 0   0   0
Investments 0   0   0
Liabilities:          
Forward and swap contracts [1] 659   659   912
Deferred compensation plans 0   0   0
Contingent consideration obligations 0   0   0
Debt Instrument, Fair Value Disclosure [3] 1,781,304   1,781,304   1,143,978
Level 3          
Assets:          
Cash and cash equivalents 0   0   0
Forward and swap contracts 0   0   0
Equity Securities, FV-NI 0   0   0
Investments 0   0   0
Liabilities:          
Forward and swap contracts 0   0   0
Deferred compensation plans 0   0   0
Contingent consideration obligations [4] 17,931   17,931   15,988
Debt Instrument, Fair Value Disclosure $ 0   $ 0   $ 0
[1] The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[2] We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the third quarter and first nine months of fiscal 2021, we recorded gains of $210 and $138, respectively, related to these investments
[3] We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
[4] Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates
XML 79 R62.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements Contingent Consideration Rollforward (Details) - USD ($)
$ in Thousands
9 Months Ended
Dec. 31, 2020
Mar. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Contingent consideration $ 17,931 $ 15,988
Additions    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Change in contingent consideration 334  
Contingent consideration gain loss [Member]    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Change in contingent consideration 2,940  
Payments    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Change in contingent consideration (917)  
Foreign currency translation adjustment    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Change in contingent consideration 86  
Reversal of Liability Balance    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Change in contingent consideration (500)  
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Contingent consideration [1] 17,931 15,988
Fair value $ 0 $ 0
[1] Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates
XML 80 R63.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements Available-for-sale securities (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]        
Equity Securities, FV-NI, Gain (Loss) $ 210 $ 636 $ 138 $ (1,843)
XML 81 R64.htm IDEA: XBRL DOCUMENT v3.20.4
Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Mar. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                
Accumulated Other Comprehensive Income (Loss), Net of Tax $ (2,386) $ (148,922) $ (2,386) $ (148,922) $ (130,613) $ (235,463) $ (225,717) $ (159,778)
Other Comprehensive Income (Loss), Net of Tax 129,060 77,494 235,579 12,947        
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax (833) (699) [1] (2,502) (2,091)        
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent (128,227) (76,795) (233,077) (10,856)        
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]                
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax (8,343) (5,719) (8,343) (5,719) (7,833) (6,813) (5,215) (4,204)
Other Comprehensive Income (Loss), Net of Tax 323 195 972 576        
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax [2] (833) (699) (2,502) (2,091)        
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent 510 504 1,530 1,515        
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]                
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax 5,957 (143,203) 5,957 (143,203) $ (122,780) $ (228,650) $ (220,502) $ (155,574)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax 128,737 77,299 234,607 12,371        
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 0 [1] 0 0 [1] 0 [1]        
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent $ (128,737) $ (77,299) $ (234,607) $ (12,371)        
[1] The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
[2] The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.
XML 82 R65.htm IDEA: XBRL DOCUMENT v3.20.4
Loans Receivable (Details)
€ in Thousands, $ in Thousands
3 Months Ended
Jun. 30, 2017
Dec. 31, 2020
USD ($)
Dec. 31, 2020
EUR (€)
Mar. 31, 2020
USD ($)
Mar. 31, 2020
EUR (€)
Oct. 31, 2019
EUR (€)
Mar. 31, 2017
EUR (€)
Accounts, Notes, Loans and Financing Receivable [Line Items]              
Investments   $ 4,955          
Line of Credit Provide   11,606          
Loan Agreement Max Borrowing Amount Dutch Linen Sale | €             € 15,000
Balance under credit facility expected to be forgiven in acquisition   10,536          
Financing Receivable [Member]              
Accounts, Notes, Loans and Financing Receivable [Line Items]              
Loans Receivable, Net   10,326   $ 7,084      
Loans Receivable [Member]              
Accounts, Notes, Loans and Financing Receivable [Line Items]              
Interest Rate Period 15 years            
Other Receivables   $ 8,966 € 7,300 $ 8,072 € 7,300 € 7,300  
Years 1-4, 4% Int Rate [Member]              
Accounts, Notes, Loans and Financing Receivable [Line Items]              
Interest rate on loan receivable           4.00% 4.00%
Years 5-6,8% Int Rate [Member] [Member]              
Accounts, Notes, Loans and Financing Receivable [Line Items]              
Interest rate on loan receivable           8.00%  
Loan Rate 4% [Member] [Domain]              
Accounts, Notes, Loans and Financing Receivable [Line Items]              
Interest rate on loan receivable   4.00% 4.00%        
Years 5-15, 12% Int Rate [Member]              
Accounts, Notes, Loans and Financing Receivable [Line Items]              
Interest rate on loan receivable             12.00%
XML 83 R66.htm IDEA: XBRL DOCUMENT v3.20.4
Restructuring (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
plan
Dec. 31, 2019
USD ($)
Restructuring and Related Cost, Expected Number of Positions Eliminated | plan     200  
Restructuring Charges [1] $ 20 $ 385 $ 110 $ 3,328
Restructuring Costs 20 (448) 110 667
Restructuring Costs LTD Since Plan Inception     43,961  
Restructuring Costs 20 (448) 110 667
Restructuring Charges [1] $ 20 $ 385 $ 110 $ 3,328
Restructuring and Related Activities Disclosure [Text Block]     Restructuring
Fiscal 2019 Restructuring Plan. During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions were eliminated. The Company relocated the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions were designed to enhance profitability and improve efficiency.
Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $43,961 related to these restructuring actions, of which $31,660 was recorded as restructuring expenses and $12,301 was recorded in cost of revenues, with a total of $34,062, $7,568 and $668 related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1,663. Additional restructuring expenses related to this plan are not expected to be material to our results of operations.
Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The remaining liability balances at December 31, 2020 and March 31, 2020 are not material.
For more information relating to our restructuring efforts, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.
 
Operating Income (Loss) [Member]        
Restructuring Costs     $ 31,660  
Restructuring Costs     31,660  
Cost of Sales [Member]        
Restructuring Costs     12,301  
Restructuring Costs     12,301  
Applied Sterilization Technologies [Member]        
Restructuring Costs     7,568  
Restructuring Costs     7,568  
Life Science Member [Member]        
Restructuring Costs     668  
Restructuring Costs     668  
Healthcare        
Restructuring Costs     34,062  
Restructuring Costs     34,062  
Corporate Segment [Member]        
Restructuring Costs     1,663  
Restructuring Costs     $ 1,663  
[1] For more information regarding our restructuring efforts refer to Note 17 titled, "Restructuring"
XML 84 R67.htm IDEA: XBRL DOCUMENT v3.20.4
Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Mar. 31, 2021
Mar. 31, 2020
Subsequent Events [Abstract]        
Subsequent Events Subsequent Events
On January 12, 2021, we announced the signing of a definitive agreement to acquire Cantel Medical Corp. (NYSE: CMD "Cantel"), through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and dental Customers. Under the terms of the agreement, we will acquire Cantel in a cash and stock transaction valued at $84.66 per Cantel common share, based on STERIS’s closing share price of $200.46 on January 11, 2021. This represents a total equity value of approximately $3.6 billion and a total enterprise value of approximately $4.6 billion. The agreement has been unanimously approved by the Boards of Directors of both companies. The acquisition is subject to certain closing conditions, including Cantel shareholder vote and regulatory approvals.
We expect to fund the cash portion of the transaction consideration and repay or otherwise satisfy a significant amount of Cantel’s existing debt obligations with approximately $2.0 billion of new debt. We have fully committed bridge financing and are working with our lenders and advisors on a long-term plan.
On January 4, 2021, we purchased the remaining outstanding shares of an equity investment that we made in fiscal 2019, for approximately $44,255, subject to any working capital adjustments. In addition to the purchase price, the acquisition agreement included the capitalization of the outstanding principal and accumulated interest under a credit facility in the amount of $10,536. For more information refer to Note 18 titled, "Loans Receivable". We plan to integrate the business into our Applied Sterilization Technologies business segment and to fund the transaction through a combination of cash on hand and credit facility borrowings.
     
Business Acquisition, Date of Acquisition [Abstract]        
Payments to Acquire Businesses, Net of Cash Acquired $ 869,431 $ 107,166    
Common Stock, Par or Stated Value Per Share $ 0.001     $ 0.001
Proceeds from Issuance of Private Placement $ 550,000 $ 0    
Subsequent Event [Member]        
Subsequent Event [Line Items]        
Subsequent Event - Business Acquisition Equity Value of Acquiree     $ 3,600,000  
Subsequent Event - Business Acquisition Enterprise Value of Acquiree     4,600,000  
Subsequent event- Forgiveness of Loan Receivable     10,536  
Business Acquisition, Date of Acquisition [Abstract]        
Payments to Acquire Businesses, Net of Cash Acquired     44,255  
Proceeds from Issuance of Private Placement     $ 2,000,000  
Subsequent Event [Member] | Equity Investment [Domain]        
Subsequent Events [Abstract]        
Subsequent Event, Date     Jan. 04, 2021  
Subsequent Event [Line Items]        
Subsequent Event, Date     Jan. 04, 2021  
Subsequent Event [Member] | Cantel [Domain]        
Subsequent Events [Abstract]        
Subsequent Event, Date     Jan. 12, 2021  
Subsequent Event [Line Items]        
Subsequent Event, Date     Jan. 12, 2021  
Business Acquisition, Date of Acquisition [Abstract]        
Common Stock, Par or Stated Value Per Share     $ 84.66  
Business Acquisition, Share Price     $ 200.46  
EXCEL 85 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

/ MYY >[QE_$AM")'I.DTQ<#S92;J\,0T0;DF)QR;8D@SD4KED;$G M-7@?7P],%1%)2"25"0P_.S(G2:(L01Q?*J.#VJ=2;#X?K-\4R4,RCUB0.4L^ MT5ANK@?# 8K)"N>)O&?[=Z1*R%/V(I:(XAOM*UES@*)<2)96RA!!2K/R%S]7 M0#04G"X%NU*P3Q3L+@6G4G#>ZL&M%-RW>O J!>]4(>A0\"L%_U3![5 (*H5B M]8T2W6)I%ECBR9BS/>)*&JRIAV)]"VU8$9HI*CY(#F\IZ,G)PP9S(A#.8K0$ M$A#.28RJR3]Y3#/@YV%\MB 2TT2M(W"(2][5(*HU[A7'52W:3H>'Z!2)>C8C7B\B")KEJ.HBL5M"%U)H4F"#R M):<[G)!,ZK@T\UKQ!$";%A!ML:';QFO1%O-';;1"C;51-P1^#8'_W:10=;B% M"U E5O!I"^?,;P?KFXX&(XV@Y]L:LN@$@2YMG+06G6ZD@AJIH'2 MI*)O5P_KL(:]"]AHD))%3Q>'JC+-Y89Q^K=V?6Z&+9 \L_SH01K5T8QZHX'T M4\B\"F6)H)WTL^QB# MW1M#F&X3]I54=0BQK=I)/=O$.O9AJ[\1_\?[USJV9:N_+Q\/!,VW&%6K]=M<0Z]B6K?Z^'.:28Y+-0%4M-]B!][GN7_KZAP;#%6T%]/H'R41>-,)2O.E>.N;0GEI#KV:C=H MZ4G5BGIU3BN$T;BBI82OB]NW0)&"O#SAUK/U#7]:W&M/YF?6U=S2S"^LJ["\ MOQ_-EW\GP(%[38'D"5F!*_,R $;P\H9>#B3;%A?$1R;ANED\;@B."5<"\'[% MF#P,E(/Z?Y+)OU!+ P04 " )0$E2ONA0E^8! #? P &0 'AL+W=O M(!I*E.DY5-4QJ)MD), M JE:-?: >'"32V/5CH-];<:WQW;2$ 3E)?&=[_^[._N<==H<;8U(\*ID8Y=1 M3=0^,&:+&A6W,]UBXW8J;10G9YH#LZU!7@:1DBR)X_=,<=%$>19\6Y-G^D12 M-+@U8$]*71Q/XE"3=[ \:_D!=TC/[=8XBXV44BALK- -&*R6 MT8?YPRKU\2'@J\#.3M;@.]EK??3&8[F,8E\02BS($[C[G7&-4GJ0*^/'P(S& ME%XX75_H'T/OKI<]M[C6\D645"^C^PA*K/A)TI/N/N'0S\+S"BUM^$+7QRX6 M$10G2UH-8E>!$DW_YZ_#.4P$R>T503((DE!WGRA4N>'$\\SH#HR/=C2_"*T& MM2M.-/Y2=F3(( MWSZ[?7@D5/;[?^CI2$\#_?8*_?<9] 7?0,L-G+D\X;\.H8?=!9A_#^<\GL7Q M/&/G:0ULX%H?(#; MK[2FB^&G8GS3^2]02P,$% @ "4!)4JB3WYQ1 P @0D !D !X;"]W M;W)K&ULG5;;CMHP$/T5*^I#*VTW=P(K0-H%JK;J M2JNEEX>J#R8QB;6)G=K.4OKU'3LA#23057D 7^:,Q,Y[NN'B2&2$*_2IR M)F=6IE1Y8]LRSDB!Y34O"8.=+1<%5C 5J2U+07!B0$5N>XXSL@M,F36?FK4' M,9_R2N64D0>!9%446.SO2,YW,\NU#@N/-,V47K#GTQ*G9$W4E_)!P,QN61): M$"8I9TB0[-&"(H*"L_L6_FG/H (!G&. U .\4$)P!^ W ?RD@ M: #!*< _ P@;@)%NU]K-P2VQPO.IX#LDM#6PZ8$Y?8.&\Z),WY.U$K!+ :?F MCZ2L1)S!44O$MVB=80&CUTNB,,WE&_06?5DOT>M7;] K1!GZG/%*8I;(J:W MN^:PX\;37>W).^-I@NXY4YE$*Y:0Y!AO0]1MZ-XA]#OO(N&2Q-?(=Z^0YWC. M0#R+%\/=R0!\>1G^L.=$0^N@L_#:-OJ'SS]"M?E94[:_0 M(L?2)/(S% U9B3U:*QX_H>^? ( ^*%+('Q?X=C,R;G1)>Y[[OC_QO:G]W$W%@)FC M/\=FJ[Y9-)Y$D];J2&O8:@W_K55VQ"8HJ01E*2J)H#PY:!Z25S.'W;C#7MB+ MOI7GA$YX)NY1&_?H8MRW:2I(BA5!SSBO2"I@KK$CXD9]0[ MW] )HA,U?2/_*%5'8J)63/22)/ -E"4&84,IBCEC3;?94975XDS32&"O@$8J M<=V+=E@DAQLZ6+BB7@+&81@%)\+Z5J[CN%XPK&S<*AM?5/: ]]!VE430\P\) M^B^9EP2.>SF9A.[)GVS1-W(=WQV?R+,[O:8@(C5-7D(H%5-U[6Y7VW?$K6F? M)^MW[LVB?@[\I:D?)_=8I)1)E),M4#K7$9RYJ!M^/5&\-!UMPQ7T1S/,X(U$ MA#: _2WGZC#1#MI7U_P/4$L#!!0 ( E 25*]9+8N2P@ %@F 9 M>&PO=V]R:W-H965TGDY62JW?SV9EM!(9+YUB+7+]RZ*0&5?ZJUS.RK44 M/*Z%LG1&7->?93S))V792;%2:Y.)&HG*395P^78BT>#R=X,GNPFVR M7*GJPNSL9,V7XDZH^_6-U-]FG98XR41>)D6.I%B<3L[Q^TL65@+U'=\2\5CV M/J/*E8>B^%%]^12?3MS*(I&*2%4JN/YO*RY%FE::M!U_M$HGW9J58/_S3OO' MVGGMS ,OQ661?D]BM3J=!!,4BP7?I.JV>/RG:!UBE;ZH2,OZ7_38WNM.4+0I M59&UPMJ"+,F;__G/-A ] >);!$@K0)X+,(L ;05H[6AC6>W6%5?\[$06CTA6 M=VMMU8)*6;]$4W=]=H3>_O$6_H!DJ*X$2)3FZSQ-5OM,7]>>OJV)3\CPN3V9*FULM M.HM:TRX:TXC%M!!]+G*U*M&'/!;QOOQ,N]GY2G:^7A!0X96('$3Q.T1EKKHV#H'X81/I>2YTNABT6AAR?4O^^&/]67SQ^YC-%O_]8J MT2[S.'J^VQ[/8O$CH0"DFNQ)CKL"+7\?Q_C.49+$8<\EQL MSX]YY\<!=T'D7'/).->[%R3:)11ZCIT2D<>6H1LWHQYB;L$K7"0&=@;80ZKC?JS0$YUR%SR!WL&FIQ88=*E6BB;2IU(1*U MD<):2@=T$6<>C'IS6 [VID>4&(;KIM&IMZ3"Q[:G,1^-&!O"+YZ&/B3\.O]C0$Z:@*;\VD#JZ*!TL2H(@ MI+8U#05AF(,^_!0R2DK+JD.FF=* N:%K6=90#6;@LA^;_+0LRX;+>O.0,8(=:HDT,I!'\^FIK9?NK^H$SMV0],0A'8(0#:ZV5W7.58 <' MEE4-F!$8S%Y::ZVZ/4,P=CQ;S W"D:,0[NA2:]7U1E$J%O/-V(5_C1K.3O96'H>IXEZ 9G"8RSQP3]Q0D"+\G:H,]W,?#]03&^B]%/MWJ(YRFE+J1[@Z,12\GQ*[S M5@6J;AXU,!Q0WISZ@0WXJ0%^"@/_M=0V5(UE<^I^AZ*T*"NK:L8;,Z55&.SQ M0>@P2WI2PP<4YH.OA=)IF'1[N:WVLCN#=*$3$&VT2_0W4H>)F1:M:=M';PMI M:''!L N%V>6+4"CBY4I'KXB$B$NTD$6&U*K72CQW:-0-,K"/^&Z/AUHW1FXC M(;/0%>V-AF"Z&O1!]7Q#5ZZNM05/Y/C6-'?I%%H+V:33J&MTD#YD[OC^<]=& M;J,.(Q;7# %2[]AS5&Z*LQJSZ'ROZ[0^71USK**&[2A,/?>Y%%&QS)/_Z@6B M_K M*JKYCDAY6__:IAU>].9N>R)+>ZO6FM'/!X998($Q:LB-PN36Y<..06Z$ M3(H8Z68*-56[-T&L1@FYSO0OA4+_T15QVSD_:O2!>=2.MAL&.4P@U/ AA\_5:[T[2F%X_2"C1F[OSV_(M^NVSR!Z$A,:;U- 5_=L.%]00#H4)YZ.N MSIH#KQ>]MJ-VM.]GX^;H;H2#%/)"_+PXAS?YQ *>GJ$B#Z:B6U.$=\.IT[Y2 M0RK>T7.3/UOOGJ$![P -;*JTJ=;L^]02;*\GT*W)A5@F>=V+Z;N;LAJ=<@_G M+&RN*]LR>_ ,U'O'0?UT5]KU21!=55!?)=.NHWJ=U4,0#P/']G\6!WF,# M^$0#QAHXUGK#<0ZF(;&FL0%[#P;[8R,*V<:&+9;O.39B]PR0>S"8@L'Z5F_O MJ#W#T<]4\PIAMO0S$.S!$'QLL #;YL,3JN?8'O]X!JX]^'0!ANJ2YY%(+08% MPV 1&H:6,9EGL-V#L?W86('=)V*6.;73*#'@S&+Q? 'D?\AB&C7:I/;"C M),"6YH\9,F#P">-U8'?87CP,:O4@PQ94PR/LP+"J9Y/U.:R.[[4^8$A]RN Y MNK8?*MCPM("]N6\YMS%#(0RFD.>\W3R!1V]N[^[+MP"?,H/Q[/_6M+/> V 8 MQ_]Z$F?#43YU@]"V 0;5V9] =8!FV,A$WR.NA668 74&@_HK688-Q_I3[!-J ML\= .?N;H)R-03FQV6. G!V8"OV56#D<#)' '^#YK/>.3B;DLGYUJ=0'RTVN MFE=8NJO=ZU'G]4M!SZY?X/>7S4M.1DWSSM5G+G45E"@5"ZW2=>;:)MF\QM1\ M4<6Z?A/HH5"JR.J/*\%C(:L;].^+HE"[+]4"W&PO=V]R:W-H965T"R'-*,BM+<_#T*0Y%LR!_S@N#(;8W!.YDH] MN\EU-@HB)P@%IM8A,/J\X"4*X8!(QN\&,V@I7>+F>(U^Y;V3ESDS>*G$$\]L M/@I. \APP2IA[]7J*S9^^@XO5<+X7U@UL5$ :66L*IID4E!P67_9:W,.&PEQ M9T="W"3$7G=-Y%5.F67CH58KT"Z:T-S 6_79)(Y+5Y0'JVF74YX=7W')9,J9 M "8S^&9SU/"E8II)BVC@/]N'4[2,"W,$!\ E?,]592C0#$-+VAQ#F#8Z)K6. M>(>.,[A3TN8&/LL,LW_S0_+4&HO7QB;Q7L IIB?0[1Q#',71X\,4#@^.]L!V MV_/J>MCN#MB95EF56GABVAW"&]QR-N>"T^CG+<7"M<7"_-K#U&N9>IZIMX-I MP@0=/1[#'=-IWECI)-N.M@8:>"#W"E_&2?>T,PQ?MM#W6_K^7OK&(*9X>402MEL%<*=08KD#J!I9N?X<>$#-X) M^92Z2).]*,DC>L8<;[[9 O?3=R4"J*FGK)]RN MM@WPHG[W?\/K[DF79,FE 8$+2HU.$G*NZXY43ZPJ?1>8*TL]Q0]S:N*H70#M M+Y2RZXDC:/\6QG\ 4$L#!!0 ( E 25(&8%(8;@4 "D8 9 >&PO M=V]R:W-H965T)Y M03NA/&V-AMG8C1P-Q5+'/&4W$JEEDE#Y>\QBL3IJX=;3P#<^FVLST!X-%W3& M;IG^OKB1<-L%1QD2+)[H]:Q_CPJ^\;@VS&#\Y6:NT:F5#NA/AE;BZB MHY9G/&(Q"[6!H/#SP"8LC@T2^/%O =HJWVD,UZ^?T$^SX"&8.ZK81,1_\4C/ MCUK]%HK8/5W&^IM8G;,BH*[!"T6LLK]H58#GKG(ZC2SA\KBJ5E2 MMUK"4PYV>C1EDC]04]8*T31"YRR:\72&3BF7Z >-EPR)>[0V:Q^-:4S3D*'; M;,E?BI!FBV-ORC3EL?J(/KSK^T'G,^(I^G,NE@IPP>S#.QSXFX/O7W4_;&L( MV3C>#HOPQGEXI"8\'UV)5,\5.DDC%E783]WV X=]&Z@N^29/?(^)$W#*P@/D MXWU$/.)]OYVBO?%=?$*E)/OWTQ8V?*HPOK22/%\=:-<4?D"RK/*]DLE M\3-8_T4E03\OX1FZT"Q1_SB0.R5R)T/NU"!?B_139-&O074N4I B#9]VG2D6 MJ^(R!PTR4--9/(RZV"?^L/U0X4NW]*7K].5&L@7E$?I D\5G](>>,^F(,"A1 M@X:YZY7(/:>_QTH!79:]*@W]DD-TUYC"?J]7$I4756^+3DPZU63V2^?Z3N_7W*PO^6@M^&=:\8SWP:E;P,W<6$HERQ"[!&Z5U5\'<4+^<:>_>QZ M#6<>X;L;Z19E)>X*S76] =;'JX/6F 28V/5LBP[_01 M>G7HQ%-HP*1D:?@;PLDG5I(VT3BOF!,$&T$D54+]&D+ 58APXF9B( M)!&1J4^UH@N;<1?-5HMQK^D46BG%;BVUV/LH%:8CIS&BB5BFD+-5MK.$JJUL M[Z9X6ST'G:#OU:UVJZ'8+:)U;((G$Z&TV5K<52^Z8=%%!K+:2IK65 M6&TE;FUM9J44+UFOW4^XZV\LE8I9_J"_L5:JH 9>9V.Q5,TB/5R=7V+5G+C5 M_(H]\I"F:,&4@)R^+)RN'%A])DUWFL2J+''WFKM^G\[(=GOI=[VZ)4.L%!.W M%$]H2B,.G$8BCJE\,ZM6^4C3/2BQPD?<7>BNK)Z3[2Z3D%I2K3@2MSBRI7Q[ M?5K5(X.&F?2MMOG>CC*/LC8/I.9)[(\SL8#E=6;\6S.)ZI..@I MC-?5P>MN\=Q>.[A+F)QE9\L*J(%$YOOC"/UT8UY0_G=@]#]02P,$% @ "4!)4CTY*Z,H P 7PD !D M !X;"]W;W)K&ULO59;3]LP%/XK1Q$/( %I+KVA MMA*T;$,""=&Q/4Q[,,EI:I'8G>VV,.W'[]@)62FA0YNVE]9VSO>=V^?+8"W5 MO9XC&G@HUWAB#S>1.RGL[N4B'7LL&A#DF MQC(P^EOA&//<$E$8WRI.KW9I@9OC)_9W+G?*Y8YI',O\,T_-?.CU/$AQQI:Y MN9'K#UCET[9\B)H!804(MP'Q M*X"H D1O]1!7@/BM'MH5P*7NE[F[PDV88:.!DFM0UIK8[,!5WZ&I7EQ8G4R- MHJ^<<&8T0<57S#9+ Q,I?, TXR*#]R0QV+^46A\ ]7/#[! N1"(+A*EA!DDR M!BYEPES;]R=H&,\)N28KJRO !SK[-.Z(*:YCBEU,T6\U35(E_J45 M*>EV4]-?+@D$%R1@_76'RW;MLKVS#*>%7-)&D#/(G)/<.5&8R$SP[YC:/<#= MMFG: "5WQW';@WTU.NK&P#>[7+WC]L<.]%R8-V MM-7?ES9'4;^WU>"71OU6O-7?ES9A-]AJK[]Q8Q2H,G=5:^H;)5EN_GJU?@V< MNDMP:_TL.!D'#>L3>CV4E_TO^O+I<<44W3 :>B#$2T("D6?;8D&3R9,Y[B M'"[YZT L.<&Q$DJ3@3L<7@U23+/>[8VZ]X7?WK!5GM",?.%(K-(4\^T=2=CF M8\_I[6Y\I:^+7-X8W-XL\2MY(?E?RR\V^8.4#@527\02H?ZB38D= M]E"T$CE+2V&P(*59\1__*@/11< M!=PC 1C8+."5 MZQ@-\@X)<"?M<1@E(@ MZ#K"52EPU55@5 J,U&05T553G M%.3RVT=,.?J&DQ5!SP2+%2>09[E !_?_H(1C'BVVZ.R>Y)@FXAQ=HK]>[M'9 MAW/T =$,_;E@*X&S6-P,4V"U=XK% D$>HTA^(#]7=(T3N1Y,>5VHNE*J9,5?W[J!&PS=F\'Z<+Z[ MP<(ZS',FP=C9PRH.7>T=NK(Z!.5Z@WFL?!(;O$01+!8.]=_DT9U=UW?G'U,8 M"J'@P'#'&XV.@M %%!I KF_V?[3W?V2U^0&F,-^B%Q*M.,TI$1?H\=OE?YY, MWMLU?7>-WH_J-@_]L7_D?B=46$=-KIH",-X'8&PU^RE;$Y&G33D\K@WICL;! MD?5=0*$!% Q'9N,G>^,GUH7]F>(93=2\V5:W,]1D-WS'Y="BK&$]E%*'D;@* M)D=0DR.60D,KL&H)EPG.S$&P:VM8%J54 M)>/'[G%I[(0*32A_%#3$P=5Q<.VU'J:>9J^2BR +!(VARU&A8+.$OJJ/YG;& MK9LSFGC.L6^=8*$)%DS&XP;O-/$Z=N:])[,P5T'**R6^1V!H0GH!,/ ;:!$1[<+CM\>&UD"#.P0PNX-G7UF M0IP;W?1K1EVZSK!J^GV).B3SRROOZC@2!EV.-ZZB'@VZG+'O-<1 -SJ.O=/1 MO(#^N\E(?(%PCJ9,Y$:O@YJE_B0XIHDV5-52W<$X]K;CS>O4T$Z8UFDG6&B" M6=:I[D\<>UOQF:Q)@AP;NVFJ=\:_V0<[FGF=R?MUPJ6N*OD;6N&.N-" LS7# MKN9_]QWY?^K6^?=HI3^T0T(KI.J'YG#7SKJGM+4MJAH(W#60KJ&Q[08+#;#F MUM;5%.[:*;REN77KW&KH;CNA0A.JL;]U-4V[WGMTN*[F-M?.;2=F>)V":AG> M"@FMD*H?FI]<.S^=V*6V:&M*\CIC&;K43JC0A&KL4EW-?N[_A_W<.E_59K85 M$EHA58\TX[EVQGMS9SIUZQODFD^MD- *J?JDF=>U[[(+%G=M*U@SKVO?]+:S MN*?YSK/SW4DL[K7373LDM$*J;FBZ\^P<==JVO459P[;=,S!9_3U6)U1H0C6Q MG:?9SK.SW0FD/_7J=%6;RU9(:(54O3AX(VS?/[9PME??]=4,;X6$5DC5<,VL MGOTMJ]C3%>792.C&K6QBN(:OKK%1_&=4%%!I C2^C/$UOGIW>3J/YJ=?. M:NV0T JI.J)9S;.SVEMYVFOGM'9(:(54/=*UOD%H4-[Q!\NIOD)W1 MV/&&QWN.KL#0!'1\;S)JV+5[FJ,]^^ZXX'O/]MV5YFA_^)M\[VNB].W<=A+? M^W66.DZ]=DAHA53=T$SGVYGNM$V,W\YU[9#0"JGZH;G.MW/=*8SMMQ-?.R2T M0JI>''R[:M]2MC"VW[Z';(>$5DC5<$VP?O >C.UKMO+?\=O4J=].5NV0T JI M^J')RF_;@IW$NGX[1[5#0BNDZHCF*-].)6]DW;L6M=]](T/Y)N*IOU'N!@M- ML.8WRK[F)M_.36_?7Y>*KVSSW H)K9#JJ0S)D=4[FNF"M^SB[EJD_EP0-)?A M6,MP",3F:-ZXIA'F1!USBY%<'813%E\2@.U$(-= AQ3D9"[/UJ$<]"O54K.\ MP"E;9?(^SM&&H U;)3%:XBUB'(0B0M=$JE-8/3#-UBQ90V*K^P*G!&5,)C-. M2HW%L"G.);%L42PMZ=L.P&CN#>S<:WY5=MMV/H$0).2P(NZ24^KHHX==B"'"#&8Q)@<6R"4 2FF>%![M/T/V*[PI,OJ!0 MS6"!HJ"80Q1GCX*#4 M5+"(+$F"IC3!L+ZWRX*;- C#8UAK:'=7NUZ4,55A$[T;DO6US.GS"Z5B"75MR:E/ MT$W6GT!#"$],,M#1P!/3Z% QX(EG?.+#$_5;@(%VL/C1QC/FK[(,)F0.S@[[ M(VCL>?$[B.(B9TMU#'_&F_W[&3)@':P)T.J2]M;,^,OYG/^6)[LI;J22< ACRG7.CS3F),=N9Y.DH@ MI?I$9B!P9"%52@TVU=+3F0(:.Z>4>T&O-_12RD1G.G%]MVHZD;GA3,"M(CI/ M4ZHV%\#E^KSC=[8==VR9&-OA32<97<(]F(?L5F'+JZ+$+ 6AF11$P>*\\\T_ MNPP&UL%9_&"PUHUG8E.92_ED&U?Q>:=G$0&'R-@0%/]6, /.;23$\:L,VJGF MM([-YVWT[RYY3&9.-L2]M> MAT2Y-C(MG1%!RD3Q3Y_+0GS$(2@=@E<../%NA[!T"%\[]/ [D!JG,%2*K1 M9":%86*)S_91LQ@4=43=26Z7VYJJF!Q=@J&,ZV/RE3S<7Y*C+\?D"V&"_)7( M7%,1ZXEG$*2=RHM*0+,"4+ 'T)CA)QK4"LZYT"N1)8;:R-%A-X%+8_7. ^Y,I#JGRTH^Q7*OD/9 MWX.R07_4I'\7GT6DH8MD968U]4_'H3_Q5LTJ[[ :C$>CRNH%S$$%<] *\UL< M,PM+MZ0\K&(-#YB8TPKE:3LQ"45:[#L6_0N*BIB#1O'#L+^[]*,*R.@_K1"R MQ(\-X5)K\G@#Z1Q46]KC:K;Q 9/C]VHU[7T"/670)C_!N-_;39#?D':_%2Z$_.&2":IGUAY]!T/ -0:/A'GIJ+?7;Q?0.5J T MY40NJI)ML#2^*4$MD(%_P.P$M?8&P?^U&[MX)]2C_W,7DZ77X)U-W"ZS_;NX MH!;MH%VT'1$K2\1.<.&;O6/O-; VDY>@K'B_[*DE-FC?;NXNWL4[7GMW2G+. MV=(]:D(5TT 62J9DGFN,@/LG&OW*F2XVN"=XIL+QJD[6 ]R)UZW2F.E(YL)@ M*Z(Z(0L\SQ,J*-]H-,6CM#MGXR(V&"7#S1FSJY=&"X7/44D%MOXVW'7')1_AB M=;&9IJ BAG:8\%/7A;)VAJ509&8]4RE@,Q!8^".=2&6^&E#IL<,D,8@BO"$*1UR*96'1=2&R M3,E,X3O?X.%U,;)B"T8LCIW[,*]Q=,?*+-T5B":.S.)06?56URP7[G+A=7_0 M/YL%_1TCN#YQQ%U\>/44Q;T.GFZ7#(O(88'3]4Y.<2FKXJJD:!B9N&PO=V]R:W-H965T4[$VQ 97P\Z%W;L.2TAP+27D! N<#Y]J[&H9D MJH2^I1JGHAM"!3P15B+<(9&E0#T$2L+UBE!&9@P[>A8[DC $B4DIJ*(HX3A& MI>_E"73@<1K#\=$)' $MX$?&2TF*5/9=I;,S&FY29S*L,O'W9!+ '2]4)F%< MI)BVX./#^,L#>%=WI6F-OVG-T#](&&-R!H%W"G[7[[;D,_HTW+ML*^?_U,?_ MK+[3C*"9D\#R!7OY9@JFS02.M\GI_!5^Q\YN_4%S% OKC!(27A:J>@?-:6.^U]9SWIT/O:N1UW(> M:[.NO/4O?>7T=T0L:"&!X5Q+=<^^:/\0E7M6&\67UAYF7&FSL&PO M=V]R:W-H965TX 9()8/3!]4&(E\=6V7NVA=BR[_]WM6NT/$+3[^* M&6,2O<91(DY:,RGGO79;C&9VOWZ>DQ7\@H3-A]BL0BCFGZ[9Q%_.6DA5O+A4_A=";50OOT>$ZG M[(')S_/[%-[:)9<@C%DB0IZ@E$U.6F>X=T>((L@0?X3L1:P](V7*B/.OZF40 MG+0LI1&+V%@J%A1^GEF?19'B!'K\73!ME3(5X?KSDOM59CP8,Z*"]7GT9QC( MV4FKVT(!F]!%)#_QEP^L,,A1_,8\$ME?]%)@K18:+X3D<4$,&L1ADO_2U\(1 M30A(04 T A!L)K + ELGL&L(.@5!1R?HU! X!8'35();$+A-;? * J^IA&Y! MT&UJ@U\0^$TE8&L9.:NI#%P&6X]V/*U),N0XRSF[3Q] ML]R_H)*>'J?\!:4*#_S40U9 &3VD?)BH6G^0*7P-@4Z>?F+CB H13L(Q5<4G M$&P(B$_0V7B\B!<1E2Q O\L92U&?Q["=S%2=/S,T2,8\9DBG?R/YW@63-(S$ M/CI$GQ\NT-YO^^@W%";H<<87@B:!.&Y+,%,IVQX7)O5SDTB-238:\D3.!+I, M A88Z*^WT_M;Z-O@WM+'9.GC/MG*\(*-CY"-#Q"QB&70Y[(Q.?9-YKQ/^N!] MTF^VDS^P.9!;M=)OMY,/:;I5^6%CZ4;E[QI+U\DW$L$NB\W.^-D-BPV=!7]! MD4/KE&^LFZ=;8(T&DL7BRQ;%.J5BG4RQ3HUB3:OUE@NQ?X#N6*;K(WTU56-N T:FX M&FYHPA''P]XF[LXDU_$]KUOB-N+FE'%SML;MW;'*V3MK>F'B6ZZE!:L*\[R. MW]%"546!SQS/UV)EE-GQS)YP2T^X6SU1*:U)RN.&U72 ^HLT545XS]*0![N< MYE8,..S:6F9<&D"NK[GB:KM-3_B+:;LW<":.I67ZP(2R?&SVLE=ZV7MSON6) M5KIRY;H#=,_3?)N3,@U'"TE'$4.2HWNJO&URK5?5&I,N(5H]71IPGNOYCI:1 M!ABQ;O M6A,,MG.M;J^;<1LTXW9C@GF5'>76!'.[>NL:&H42K)7&G0G6(5;'G/)X[3R! M_]N65/!?5\PFE3A50;A2_0:0[^G[I 'D>#6%C\G*"^17:4?G.U1Y(J8NTB^H M=G0Q$ZK2QJY-*$-+,L)J>Q)>3=78_KE=J9"_D2-8GY%,($L?D0P@[-B6[B@3 M:JV"-_VT&O)Q\RG_BJ=6!S?$>?>PPH..C8Q++U1&O";M"4W4T!W#S P%C6M?0F90 2 MTG4=2V]31J!5V37NC*(=.%?4M:K5,(O?/LTV"BXM_D^=!#\:[.K "6.N9U?" M7<5Y'JGNOU48L3NN50FW2:SMU6W JSD7;Q]T_\_#5Z'*N@U::EWLT-9\K+K< MS?AZ-^3##\D>[&;\\:V,-T.Y.B-@_R?W4M^TDYARWP T)K\!9\Y^H^3:]"?J M]+*YLAJ"R?8AV!SF\QU4CS.&V&3"LNLO-"]<"ZZ>TA!^4Q1!'! L)1"!@(W4 M'P&[4U9A5*"$)X71> MW(6&:BC)':6BF5NB;!TD<%0%2Y<>4_Z,0S%F$9QD&5\(Q%X5$X:4%DH$7ZA0 M)()'89!Y[4'"3QY%^#RH=T][[7(H9NDTNU@5:,P7B2S.Z.5R>7M[GMUA:>M] MW+O"AO5KW/MH6N^3WH6)SR7I79G6KTGO@VE]0'H?3>MGQ.H-B67X I4&7TPZ M093A2\:MO?)&?K$]I"E4B$ 1FX!GK",/]N,TORO.7R2?9S=I(RXEC[/'&:-0 M<@H WR>V)_^ U!+ P04 " )0$E2A]TN+YT$ #S$P &0 M 'AL+W=O!DE444?%Z!2'?7/1P;_O@DI?X_):X&I#.^)/!)JG<(QW*E/-O>G 7 M7/1,[1&$X$M-0=5E#6,(0\VD_/B>D_8*FQI8O=^RWZ3!JV"F-($Q#_]B@5Q< M]/H]%,",KD+YR#>WD ?D:#Z?ATGZBS;97'?00_XJD3S*P?9)"_&5$YH*L//#5YE!LD>@Q:Z MY[%<).@Z#B#8Q1O*^2("LHW@BC02?E[%9\@R3Q$QL5?CS[@9/@%?P;&&$_/Y M:8).WGVH89DL$JNME*R:T]Y)>^SU>Q5&WZ.Y>@+EE[JTY%-RRFL<_B>;79__FB M"-"=A"CYM\&\79BW4_/V'O-W\1H2J91=UBV,<09V4[#>4]8C>^ X0V-=8](I M3#J-)M, ^ R-!01,H@?!URR .NL9CU.QCK%KNO7FW<*\VVQ>Y1==S@6 CAK= MTQ=TQ84BT8F^C'0QT&0E_072CL;HB:JL_[>5EKKNR>QAL^JG8YIFO9]>X:?7 MZ.<5#57U :V4Z CD9\F:49^%3+XB>%FJK10")#F: E)O!'.UH<9:Z:C_?<42 MIO?9NJ1Z/R;5=*P]2>T7SO8;G:UOU7N(IB":VG10\ ^.L4JP6>XY9FO75#<= MY0C(NO3F/+OYM4B9WTQ/\VG5E>69?;N^"KBR->*#W.Q2 TQ*=G*4*I1:B:T6 MM9(@E%ZA1RH!/8!@/*C=SYMIL(->@8JDR:=20'&S@GZ5"[4^RZAK=13_**3] M@?NF*2;YK!TE\:R*D.2]4T-F>F1WUDTWLD^MTW;34HH\;E;YOW6"$?YHGR+[ M/5*%RVK6I1]+)\M+93VF6F^K]ME M#L?M!E5*.6[6\JQRSD?WM%]3N$X5+&4='T772:GKI%G7?Z:"+93]EDJ04LU) MNYIGV5=+J"S A.LO_,;X2TDG1Y%T4DHZZ2CIW0LP;J'11>KL JM[;]03U_XRK N4#;: XYQO]#U!+ P04 M" )0$E2F2(:2C\' #-&@ &0 'AL+W=O-2ZO79CC^KV6B9&\ @>%=') M>LW4ZST(N;EI>:WMP&>^"HT=Z-Y>QVP%"S"_QX\*[[JYEH"O(=)<1D3!\J9U MYUT]T$LKX&;\P6&C=ZZ)=>5)RF_VYGUPT^I91"# -U8%PY]GF((05A/B^#M3 MVLIM6L'=ZZWV!^<\.O/$-$RE^),')KQI35HD@"5+A/DL-^\@? M;-*YX\L6\1-MY#H31@1K'J6_["4C8D=@TJL1H)D /1"@7HU /Q/H'RLPR 0& MQT(:9@+#8RV,,H&1XSXERS$]8X;=7BNY(60C:V$4/N4H M9VX_@S8J\4VB>+0B;V9@&!?Z+;D@/")?0IEH%@7ZNFO0EI7H^IG>::J7UNCM MDX\R,J$F\RB H$)^WBQ_V2#?11]S1^G6T2EM5#@#OT/Z7IO0'NW]OIB1-Q=O M*V#-CM;B7=9KF9^.)18LJM#T\'_Q[)'5SZ.B[]0.CHH*C #R&00S$)"IU*9- MYB\Q9@:\_92LGT 1N22/4G.;*W#%!,= =;/_(35NS5/[0V??9K_G6\R%U]WG M"M"#'/3@!-#3D*D55$7N?;.:K]Y?5>&>"HWV .=XT] I3^E/AOMSYN4YGG>@ MYZ%"3Y].JLD9YN0,3R$'5[%R4P\KEN7 R_*47P:#R8&;Y4EE-\MS1J-QM9>C MW,O1J5Z2#U]F9,$C'\@CQB)YCU>Q#=2JJ!R5( WZER.O&M0X!S4^!_7C'U-? MGE)!?7E2F?KRG%KJ)[F7D_/LOF8U-;MO\N/=5YY2WGWE.65N*O34[K[+G)S+ M_YA/[VQEA8D3-)EQ[0NI$P7DZQ=X,>1>2/];%1WS1FNV&+W2,?/AIH75I@;U M#*T#" ]HBPEW:I#])W:3=,@LO3$AX!]7 ?D[8,6%H[--9 2VB+E7[#L7#ETV,H]6J#YH$Z81OQ#V5Z)JY>I<>X2E M!K<,*&9'F>#?W86U[(/"0BDBL9(!@M8=\@ ;5&!"= Y/,A+GQR$. X'\3.Q@ M5068!=8QBUZ1&EQC%PC64*;MP ;'J>ZPW1HC1F9XX85K8V'NLX!]1XI9DR#C M9NY0QN YJO(@I($(G3)=]B6W+ G2^^K8Q-Q*?F,OBV7W.<0 M^:^=+-'R;8YUBX2.-2^T#:*0/3NY1"GG*?QBV OZAQV4!NNQ0?YQ_L6@W\:, M;(E+:9/60)T[;0L@C:$+K))&HQ[9X&(K\*6R\>2N=^5R@];!"X^V^SUO7P07 MQ,<4;A4K>(8HL:&VX2:T$6]1VB<7_4&[-Z)M35-L(+_9ADW? A E] MIJ!-[N)8<'RTP&W&\UC[ GX822%7/ /U@2^!+!S?.*)AA6V>00CHAZW)L$T3 MN Y3J6*),0"YQ7T__30_I\M]89GI=\A=$/ TTNM8V8//=;J7$3V)I'&S_.SI M$V!(6D=0EXW61%F5V.UI2T\1GQWT)XTIOJ^^O)Q9EK36=M?/14QDB-C1@[Q9 M=IGOI]LL/7- M@M/SD2D,YF(HXWY+=HKV@*>XWGU6_I B$V+)?D&LB;#U)C5_CUHX/T M5Y.1G<[3.T-=-,^T[!W('N[DZA/9HX5Y>A;SM%0K-9DO.BRON<6:9DEDP02N M]S'$%GV0=U(C5.O9H%PI4LQW-9X5G89WCE9C[E7T" WFBQ; :^X!CLBCQ[!= M5/?>.NN<=X--1X6U3=WDEE=ZWUR2G6B[+6:ZYK=P\CDI)Z#+FT2$2T M.1$=Z5ZF9;^AJ?&.%@F*GB5!95J.,UZD)]JD)O-%2J+-*:DHAQ9IP714E!8IAY[\VJ'2N_+K!3Q) M^C7.%0F(GB4!95I&QUFW"6A_I$@*M#DI5+?P]S^0>I"*K*6R34#ZO23]=+%B MRO5A606Y6Y0N<9ZQ1>/2-EZ2?)*XOMZ8$,.- &SO6GO,M*J6NKOSYGP-6!+; M;QQ85&(3:]*7:_EH_AWEWGT].!B?>EK#Z6W'LT@0L$5ZO,\984NFWD_3&R-B]ZW^2QLBUNPR!!:#L!'R^ ME$A2=F,-Y%^P;O\%4$L#!!0 ( E 25)_.E* ] < *,: 9 >&PO M=V]R:W-H965T$S M#RGI;*WT9Q,#6/:0)M*<=V)KL]-^WX0QI-ST5 82[RR43KG%4[WLFTP#CYQ1 MFO0#SQOW4RYDY^+,7;O7%V.842ISI3[3 MR6UTWO$($2006G+!\6<%UY DY EQ?"F==JJ89-@\WGK_CTL>DYES ]JQ+C_;%V,/1YV6)@;J]+2&!&D0A:__*$L M1,-@XKU@$)0&P1,#_Z4(@])@\-1@_(+!L#08[AMA5!JXU/M%[JYP4V[YQ9E6 M:Z9I-'JC U=]9XWU$I*(,K,:[PJTLQ>S?&[@2P[2LIL5_C?LU10L%XEYS=ZP M#[,I>W7TFAVQ/C,QUV"8D.R#%-9T\2(>OX]5;KB,S%G?(AQRV@_+T%=%Z."% MT"?L3DD;&W8C(XAVV$_;[?V@Q4$?ZU 5(]@6XRIH]3B%L,<&?I<%7N#M '2] MM[E_LBN?=O,[KJOH_@[SF_W-O99B#"IF#)R_P=[,^'0Y-U9C:__6XGY8N1\Z M]\-]W>\B4*L+TM!3D_$0SCLHD@;T"CH[8/\LV8]=]&W5ODR1JK,>"O+XY1RB+$ILRT0)D7R89 @HR4"56V M<6,B-"2(3DI FQZV+P6@G"WHU% H.JD2=<59BR1YFBZV.VY%A-;MG19-@;CUF&<4K;4*4I#G$BTG72'C$\G[V_>7<[^]<_)X%_ M_&_#PD09F@0WC+(*@> =X;+7&X[)H)K)LD]ZJ$!80 V. 33='&M &2,)A-T4 MH-RL9EB[!ZP3PMFPHT%OS.:8I%NM,)W*#.%JC&S@1=-A;4KAFQR)N6%S ,ER MR:5(41O1P)FO,.'YQE7Z2G$=N;I/L;JA5=J=S)6-J4X96H(I/=,,&.'*BVDB M>WY' YKE$#3*M*Q*%BH9N7&HS$*&21[1U;+ZKIZQ2FCB5\J"RUC#,D\X1M\B MY E&_048/&1ED$4NB^YPLYXI[8"4A&E./48WQ%MNM_7$&>$;II#).%:OJ9X& M[YH%1BN:;8&]@R7C6"7\0:<%V(H,\"",I20BF./]>2*6SKU!2:([CSZ/2\BX-S?8DY1P2(:3UBWR(MF[!9*T2!E3?V"=+#EBW,O M_L>;C&FFB_ZP[!E!H+*&89X2&]%>4 =BVMA#Q%>4'(TZ:]F"AR(IJE+ J(AS MY'O=T6#<8[AW9*G25*!B#UUN9TGO%'M+S/I["&.I$K7$'JZ- M#"Q=D2C79E\U>ZA>*9"D3O^<91BW*^+!>3+11 H7H+9>.CNI3W=VT$KXHH8Q>%'GU6%Y/Q MR7" NZ15:A58INS4F1ZES M,WZOD?$X^?<);I]HBG8AGSPKYVCDX=^3JC\?YNV&?5+!/CEH:\@^W4$Z!]W& M2-^K'WB\@_:U[--/.(+=6DA-:X3&(Y5_&/XW;%?_L9M"Y#]NMQEE!^QBT;0, MV:SR8.P]FHW':(,:;?#WH*TW1OLA+L*.&HB'K8CK!Q-_L"]BMR]^0[J_Q,VZ MPXRP2-<;LKX3W> 9.M_#->0%;/53C3_\GD+KUP+OC[Z'U$[+,(^F;8@[B1<* M4Z\$_E>6@K^D15/_N;8'7AN;:G7WV^7]1;5A_]]VZ&V]#?LT5;1Y:YVS6I[] MR;=XQ/9K(?4/4]*"B3OKV^[H1]K=#KO_^.&'YR\G'K]JJ74X^#8Z'-0Z'!RF MPR]G_Q5'^V=?JVYPH.HV6%<^M.U!M:#6S.";O,T):N$+#GN?TU+L=D>NV'ZP M3[5K<0S:M[]_FFNUO 7M\G9 ^NV.#DB_EKC@^'LN2D$M<$'[!O2O;9VGI?=) M<]]/+Y9V2WY0RV+0KF:[Z^%@T&H4[@9S\@Q,\5KJ"9I^XV5\"GKIOH(8?*;# MA]7B571UM?K2>;.X[;'7QR36"!+KW>,;)?%U]$ MBA.K,O?*?ZZL5:D[C('CTS0-P/L+A8_"Y0D%J+Y+7?P!4$L#!!0 ( E M25(MX''&90( 'H, - >&POXJ!PQ8\H$9DY%>[E5VNZ?8H^Q)9F,") U5U(LM MO8F_@_W[_CX03%"J-<5W.<8*U(SR,H2Y4L4[QRGC'#-4GHD" =M.WDPF[OWIU6[\I$F<0F]8S9ZWE,,*%;&K;"O9WV7;? M26P\(Y!0V@GTH0U$08&4PI+?:*?IW 0?I4!K+]:%5IA)M/;\&>P'-(TNLA0R MP;(KX\%-* HH3HT<2;+F0?Q:[K% MKM/!CKIF/WEG:D&M:3'6,?PAS;*'6/]97%"0E5 ?*CT=WOCFI.!;B5-2-WZ= M=@+&Z-XX'14%7;^G).,,V\D?7# *T&8)AY+M$ MQ0+7:G.'K^OR0W_RJ[@O=J;-^N MQRYR]A)$SH]?Y/3R^#6V=YQC%WEQE"*=]OT]N"1L71&Z*#!7L1!^,5<^VA<% MRXI017CKY21),']T4]!XA9;Z0V"+K_LG.$4558LN&<+>_HP34K'+KM>M68BV M5V]_,M/SYDW!_FLC^@M02P,$% @ "4!)4I>*NQS $P( L !? M3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2 M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'I':)"K9OJX<AMKMV?]ODDV(N?F+[45!>Q9*YUS"S_U<]]LM>"IV0AA\ZSO#091 M/^>RZ%V<[\ZUT'WWA[(BL5(5T%@U/$GQ:G[MKWZR%VGD2F;2OH]Z]=^9Z+%< M%C*7/T4ZZ@UZS&S4ZZW2\J22KTS=8OGJ MD0/(J!<-X(1KJ8VMCZC/SX'Q1<#!S:_2JFN96:$GW(H;KFQ@N=BU-L=PGB1LFEA M(4CLKFA.!<=6=PJ7ODN;N[: Z\10GTG8H>_2&IP.\FH^B^?W=Y/QQJRN+;Z709LY/2A?002.^(D/]X#J2/0/H'A(R7L'F8S@!P?LWFB^FC QD@ MD,'1(*_F#PL',D0@0UK(N+INW7/4FEVI'/+61A0&>CGTGT0YD!$"&1TODN/X MUH$\12!/CP%9,<:WX\>I _D5@?Q*"SGCMM2B>M;SK=#-_CIGQF6><^U ?D,@ MO]%"7I9&%L(8-DY^E'#Q7Y03>"^-F\P'6#8?T&+>%2]P -A6F"]L!A&1*+)=YP+9K\M]!B M+;2&-_&C$2+J8F)F&1*KI4HM]MVEP10R)'9('9\_+[F!6%5E#72.W7.MWD&W MUL8L5T>19)Q8R0< M_E&!J;*NO\<)_&_I8F)V\8CM,1N^;LH30G=6NG**EK\*.'X[)W-X1%K+5U,S"T>M5O*E6G8V+2J9EN) M$;.)=\R!2FL:PL,TXQ%K!GJL*NL2ARV@2FRJG&756UJOHH\YQB=V##J<:L_H M8([QB1WS:3C5;G Q,[FRA S M3T@^[/DTA^\VN9B8><)#F:=K/-'J-B%FGI#8/-AX8JY3%Q,S3WC$80\TN)CH MMP'D,VS;4B<;&/:8JC3:K3ET]73,/"&Q>=#16?O=Q,P3$IL''9VU,3'SA,3F MV3JI=.O#S87YZE80YF5SN#T!MH3GB4+S:I-\YU.$%:KZNLR MRZZ@;5[ (TQW']SN/A:^^!=02P,$% @ "4!)4LA!-T#(HPS=1Y +Z1 ITA@\%3$D>/E7'X@AGWZ50SONNU/= M[?NZ^#@>3G75[,:Q_Y%27>_*L:UW75].YRN;;CBVXWDY;%/?KM_;;4FZ7.8T MW,YHGI]N9RY>/_OR/Q.[S6:_+C^[]>]C.8W_&)S^=,-[W94R-HO7=MB6<=6D MC\/U=$V7@]R=)S>+E[=5,[R\29/F#E((TOF##()L_B"'()\_*" HY@_*$)3G M#[J'H/OY@QX@Z&'^H$<(>IP_2)8HXY(@:8(U@=:"7 N!UX)@"X'8@F0+@=F" M: N!VH)L"X';@G +@=R"= N!W8)X"X'>BGHK@=Z*>BN!WCIYV2;06U%O)=!; M46\ET%M1;R706U%O)=!;46\ET%M1;R706U%O)=#;4&\CT-M0;R/0VU!O(]#; M)ILE!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H[ZNT$>COJ[01Z M.^KM!'H[ZNT$>OMDLYM ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0.] O8- M[T"]@T#O0+V#0.] O8- [T"]@T#OF'RL)- [4.\@T#M0[R#0.U#O(- [4.\@ MT#NCWIE [XQZ9P*],^J="?3.J'2KWV?*WQ^=])]7B^MUP??UE^G9RP<\$YW5;4Y[]02P,$% @ "4!) M4N(A,D+Q 0 &2< !, !;0V]N=&5N=%]4>7!E&ULS=K+3L,P$ 70 M7ZFR18WK)P_1;H ML. '3#*E49/8LETH?X^3 A((*E"1N)M&K>VY$X]T5CV_ M>_84)]NN[>.\6*7DSQB+U8HZ&TOGJ<\K2QTM)LV3:ZV^>?8N'Y>!&IC,;G8;1RRYH7UOFTJF_(Z>^SK3RG3 MUX0RGQSWQ%7CXU'>4+ O$X:5[P->S]T\4@A-39-;&]*U[?(NMFU93,\MQ7)_ MB2]Z=,ME4U'MJDV7CY31![)U7!&EKBUW18_V)Z=\P[3[Y ?GCV7V!>:=M\'Y MF"<6Z/=Q;R,93D]]+D0A-?M?\3TQES[X_6B8=DWU#[/S]3ZYL![G$=GX./R. M/\[XO?XO^Q @?4B0/A1('QJD#P/2QS%('R<@?9R"],%G*(V@B,I12.4HIG(4 M5#F*JAR%58[B*D>!E:/(*E!D%2BR"A19!8JL D56@2*K0)%5H,@J4&05*+)* M%%DEBJP215:)(JM$D56BR"I19)4HLDH4626*K I%5H4BJT*15:'(JE!D52BR M*A19%8JL"D56A2*K1I%5H\BJ4635*+)J%%DUBJP:15:-(JM&D56CR&I09#4H MLAH460V*K 9%5H,BJT&1U?RGK/?.K?\X?GR6G6WZMWPV_B-N\0)02P$"% ,4 M " )0$E2!T%-8H$ "Q $ @ $ 9&]C4')O M<',O87!P+GAM;%!+ 0(4 Q0 ( E 25(73G]"[@ "L" 1 M " :\ !D;V-0&UL4$L! A0#% @ "4!)4EE/8LL^!0 @A4 !@ ("! M#0@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M"4!)4B+'!+8Y!P A1\ !@ ("!B1@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "4!)4E14DV:#!@ BA !D ("! MWE4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ "4!)4OD#!\U.!@ /@\ !D ("! F0 'AL+W=O&PO=V]R:W-H965TAN !X M;"]W;W)K&UL4$L! A0#% @ "4!)4GC9 GL> M" JQ( !D ("!-78 'AL+W=OVD+ #H'0 &0 M@(&*?@ >&PO=V]R:W-H965T&UL4$L! A0#% @ "4!)4GYX+U3C P 6 D !D M ("!OHX 'AL+W=O&PO=V]R M:W-H965T(DM"P0 -H( M 9 " @>6= !X;"]W;W)K&UL M4$L! A0#% @ "4!)4FMBQ3%1!@ A0\ !D ("!)Z( M 'AL+W=O&PO=V]R:W-H965T13W-YP0 /@- 9 M " @92Q !X;"]W;W)K&UL4$L! A0#% @ M"4!)4E.W$R36! X@H !D ("!LK8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "4!)4D!^):Y@ P 1 < !D M ("!J., 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ "4!)4E7*M$\(" #10 !D ("!X^X 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "4!) M4K<3426A @ K 4 !D ("!H_\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "4!)4L,U6PV_! .PT M !D ("!VPH! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "4!)4L4A]QO^! ^A$ !D M ("!&1@! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ "4!)4K 3BU(U @ CP0 !D ("!228! 'AL+W=O M[SMW84$ @ M#@ &0 @(&U* $ >&PO=V]R:W-H965T&UL4$L! A0#% @ "4!)4L^T M+W+;! "Q !D ("!2# ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "4!)4J)-#2S? @ M0@ !D M ("!JCX! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ "4!)4K[H4)?F 0 WP, !D ("! MY%$! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ "4!)4D=F6:2$ @ (@8 !D ("!"V ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "4!)4IUH8RR^ M"@ F3( !D ("!RFL! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "4!)4N,GW]^H!@ O1\ !D M ("!C'X! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ "4!)4G\Z4H#T!P HQH !D ("!M9$! M 'AL+W=O!Q MQF4" !Z# #0 @ '@F0$ >&PO&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " )0$E2XB$R0O$! 9)P $P M@ %,I0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 2P!+ (04 !NIP$ " ! end XML 86 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 87 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 210 402 1 true 58 0 false 10 false false R1.htm 0001001 - Document - Document and Entity Information Document Sheet http://www.steris.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED BALANCE SHEETS (unaudited) Sheet http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited CONSOLIDATED BALANCE SHEETS (unaudited) Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) Sheet http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Sheet http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) Sheet http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) Statements 5 false false R6.htm 1005006 - Statement - Statement of Comprehensive Income (Parenthetical) Sheet http://www.steris.com/role/StatementofComprehensiveIncomeParenthetical Statement of Comprehensive Income (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Statements 7 false false R8.htm 1007008 - Statement - CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement Sheet http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement Statements 8 false false R9.htm 2101101 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies(Notes) Notes http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNotes Nature of Operations and Summary of Significant Accounting Policies(Notes) Notes 9 false false R10.htm 2105102 - Disclosure - Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes) Notes http://www.steris.com/role/BusinessAcquisitionsandDivestituresBusinessAcquisitionsandDivestituresNotes Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes) Notes 10 false false R11.htm 2112103 - Disclosure - Inventories, Net (Notes) Notes http://www.steris.com/role/InventoriesNetNotes Inventories, Net (Notes) Notes 11 false false R12.htm 2115104 - Disclosure - Property, Plant and Equipment (Notes) Notes http://www.steris.com/role/PropertyPlantandEquipmentNotes Property, Plant and Equipment (Notes) Notes 12 false false R13.htm 2118105 - Disclosure - Debt (Notes) Notes http://www.steris.com/role/DebtNotes Debt (Notes) Notes 13 false false R14.htm 2122106 - Disclosure - Additional Consolidated Balance Sheets Information (Notes) Notes http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationNotes Additional Consolidated Balance Sheets Information (Notes) Notes 14 false false R15.htm 2125107 - Disclosure - Income Tax Expense (Notes) Notes http://www.steris.com/role/IncomeTaxExpenseNotes Income Tax Expense (Notes) Notes 15 false false R16.htm 2127108 - Disclosure - Contingencies (Notes) Notes http://www.steris.com/role/ContingenciesNotes Contingencies (Notes) Notes 16 false false R17.htm 2128109 - Disclosure - Business Segment Information (Notes) Notes http://www.steris.com/role/BusinessSegmentInformationNotes Business Segment Information (Notes) Notes 17 false false R18.htm 2131110 - Disclosure - Shares and Preferred Shares (Notes) Notes http://www.steris.com/role/SharesandPreferredSharesNotes Shares and Preferred Shares (Notes) Notes 18 false false R19.htm 2135111 - Disclosure - Equity Sheet http://www.steris.com/role/Equity Equity Notes 19 false false R20.htm 2137112 - Disclosure - Share-Based Compensation (Notes) Notes http://www.steris.com/role/ShareBasedCompensationNotes Share-Based Compensation (Notes) Notes 20 false false R21.htm 2140113 - Disclosure - Financial and Other Guarantees(Notes) Notes http://www.steris.com/role/FinancialandOtherGuaranteesNotes Financial and Other Guarantees(Notes) Notes 21 false false R22.htm 2144114 - Disclosure - Derivatives and Hedging (Notes) Notes http://www.steris.com/role/DerivativesandHedgingNotes Derivatives and Hedging (Notes) Notes 22 false false R23.htm 2148115 - Disclosure - Fair Value Measurements (Notes) Notes http://www.steris.com/role/FairValueMeasurementsNotes Fair Value Measurements (Notes) Notes 23 false false R24.htm 2153116 - Disclosure - Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes) Notes http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeNotes Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes) Notes 24 false false R25.htm 2156117 - Disclosure - Loans Receivable (Notes) Notes http://www.steris.com/role/LoansReceivableNotes Loans Receivable (Notes) Notes 25 false false R26.htm 2159118 - Disclosure - Restructuring (Notes) Notes http://www.steris.com/role/RestructuringNotes Restructuring (Notes) Notes 26 false false R27.htm 2162119 - Disclosure - Unusual or Infrequently Occurring Items Sheet http://www.steris.com/role/UnusualorInfrequentlyOccurringItems Unusual or Infrequently Occurring Items Notes 27 false false R28.htm 2165120 - Disclosure - Subsequent Events Sheet http://www.steris.com/role/SubsequentEvents Subsequent Events Notes 28 false false R29.htm 2202201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies) Sheet http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAccountingPoliciesPolicies Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies) Policies http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNotes 29 false false R30.htm 2304301 - Disclosure - Accounting Policies (Tables) Sheet http://www.steris.com/role/AccountingPoliciesTables Accounting Policies (Tables) Tables 30 false false R31.htm 2306302 - Disclosure - Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables) Sheet http://www.steris.com/role/BusinessAcquisitionsandDivestituresBusinessAcquisitionsandDivestituresTables Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables) Tables http://www.steris.com/role/BusinessAcquisitionsandDivestituresBusinessAcquisitionsandDivestituresNotes 31 false false R32.htm 2313303 - Disclosure - Inventories, Net Inventories, Net (Tables) Sheet http://www.steris.com/role/InventoriesNetInventoriesNetTables Inventories, Net Inventories, Net (Tables) Tables 32 false false R33.htm 2323306 - Disclosure - Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables) Sheet http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationTables Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables) Tables 33 false false R34.htm 2329307 - Disclosure - Business Segment Information Business Segment Information (Tables) Sheet http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationTables Business Segment Information Business Segment Information (Tables) Tables 34 false false R35.htm 2332308 - Disclosure - Shares and Preferred Shares Shares and Preferred Shares (Tables) Sheet http://www.steris.com/role/SharesandPreferredSharesSharesandPreferredSharesTables Shares and Preferred Shares Shares and Preferred Shares (Tables) Tables 35 false false R36.htm 2338309 - Disclosure - Share-Based Compensation Share-Based Compensation (Tables) Sheet http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationTables Share-Based Compensation Share-Based Compensation (Tables) Tables 36 false false R37.htm 2341310 - Disclosure - Financial and Other Guarantees Financial and Other Gurantees (Tables) Sheet http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuranteesTables Financial and Other Guarantees Financial and Other Gurantees (Tables) Tables 37 false false R38.htm 2345311 - Disclosure - Derivatives and Hedging Derivatives and Hedging (Tables) Sheet http://www.steris.com/role/DerivativesandHedgingDerivativesandHedgingTables Derivatives and Hedging Derivatives and Hedging (Tables) Tables 38 false false R39.htm 2349312 - Disclosure - Fair Value Measurements Fair Value Measurements (Tables) Sheet http://www.steris.com/role/FairValueMeasurementsFairValueMeasurementsTables Fair Value Measurements Fair Value Measurements (Tables) Tables 39 false false R40.htm 2354313 - Disclosure - Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) Sheet http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeTables Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) Tables http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeNotes 40 false false R41.htm 2360315 - Disclosure - Restructuring (Tables) Sheet http://www.steris.com/role/RestructuringTables Restructuring (Tables) Tables http://www.steris.com/role/RestructuringNotes 41 false false R42.htm 2403401 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details) Sheet http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details) Details http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAccountingPoliciesPolicies 42 false false R43.htm 2407402 - Disclosure - Business Acquisitions and Divestitures Fiscal 2018 Acquisitions (Details) Sheet http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails Business Acquisitions and Divestitures Fiscal 2018 Acquisitions (Details) Details 43 false false R44.htm 2408403 - Disclosure - Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details) Sheet http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details) Details 44 false false R45.htm 2409404 - Disclosure - Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details) Sheet http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details) Details 45 false false R46.htm 2410405 - Disclosure - Business Acquisitions and Divestitures Revenues by Type (Details) Sheet http://www.steris.com/role/BusinessAcquisitionsandDivestituresRevenuesbyTypeDetails Business Acquisitions and Divestitures Revenues by Type (Details) Details 46 false false R47.htm 2411406 - Disclosure - Business Acquisitions and Divestitures (Details) 2020 Sheet http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020 Business Acquisitions and Divestitures (Details) 2020 Details http://www.steris.com/role/BusinessAcquisitionsandDivestituresBusinessAcquisitionsandDivestituresTables 47 false false R48.htm 2414407 - Disclosure - Inventories, Net Inventories, Net (Details) Sheet http://www.steris.com/role/InventoriesNetInventoriesNetDetails Inventories, Net Inventories, Net (Details) Details http://www.steris.com/role/InventoriesNetInventoriesNetTables 48 false false R49.htm 2417408 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details) Sheet http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails Property, Plant and Equipment Property, Plant and Equipment (Details) Details 49 false false R50.htm 2421409 - Disclosure - Debt Debt (Details) Sheet http://www.steris.com/role/DebtDebtDetails Debt Debt (Details) Details 50 false false R51.htm 2424410 - Disclosure - Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) Sheet http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) Details http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationTables 51 false false R52.htm 2426411 - Disclosure - Income Tax Expense Income Tax Expense (Details) Sheet http://www.steris.com/role/IncomeTaxExpenseIncomeTaxExpenseDetails Income Tax Expense Income Tax Expense (Details) Details 52 false false R53.htm 2430412 - Disclosure - Business Segment Information Business Segment Information (Details) Sheet http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails Business Segment Information Business Segment Information (Details) Details http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationTables 53 false false R54.htm 2433413 - Disclosure - Shares and Preferred Shares Ordinary Shares (Details) Sheet http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails Shares and Preferred Shares Ordinary Shares (Details) Details 54 false false R55.htm 2434414 - Disclosure - Shares and Preferred Shares Preferred Shares (Details) Sheet http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails Shares and Preferred Shares Preferred Shares (Details) Details 55 false false R56.htm 2436415 - Disclosure - Repurchases of Shares (Details) Sheet http://www.steris.com/role/RepurchasesofSharesDetails Repurchases of Shares (Details) Details 56 false false R57.htm 2439416 - Disclosure - Share-Based Compensation Share-Based Compensation (Details) Sheet http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails Share-Based Compensation Share-Based Compensation (Details) Details http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationTables 57 false false R58.htm 2442417 - Disclosure - Financial and Other Guarantees Financial and Other Guarantees (Details) Sheet http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuaranteesDetails Financial and Other Guarantees Financial and Other Guarantees (Details) Details http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuranteesTables 58 false false R59.htm 2446419 - Disclosure - Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) Sheet http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) Details 59 false false R60.htm 2447420 - Disclosure - Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) Sheet http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) Details http://www.steris.com/role/DerivativesandHedgingDerivativesandHedgingTables 60 false false R61.htm 2450421 - Disclosure - Fair Value Measurements Fair Value Hierarchy (Details) Sheet http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails Fair Value Measurements Fair Value Hierarchy (Details) Details 61 false false R62.htm 2451422 - Disclosure - Fair Value Measurements Contingent Consideration Rollforward (Details) Sheet http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails Fair Value Measurements Contingent Consideration Rollforward (Details) Details 62 false false R63.htm 2452423 - Disclosure - Fair Value Measurements Available-for-sale securities (Details) Sheet http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails Fair Value Measurements Available-for-sale securities (Details) Details 63 false false R64.htm 2455424 - Disclosure - Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) Sheet http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) Details http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeTables 64 false false R65.htm 2458425 - Disclosure - Loans Receivable (Details) Sheet http://www.steris.com/role/LoansReceivableDetails Loans Receivable (Details) Details http://www.steris.com/role/LoansReceivableNotes 65 false false R66.htm 2461426 - Disclosure - Restructuring (Details) Sheet http://www.steris.com/role/RestructuringDetails Restructuring (Details) Details http://www.steris.com/role/RestructuringTables 66 false false R67.htm 2467428 - Disclosure - Subsequent Events (Details) Sheet http://www.steris.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.steris.com/role/SubsequentEvents 67 false false All Reports Book All Reports ste-20201231.htm ste-20201231.xsd ste-20201231_cal.xml ste-20201231_def.xml ste-20201231_lab.xml ste-20201231_pre.xml ste12312020ex151.htm ste12312020ex311.htm ste12312020ex312.htm ste12312020ex321.htm ste12312020exhibit102.htm ste12312020exhibit103.htm ste12312020exhibit104.htm ste12312020exhibit105.htm ste12312020exhibit106.htm http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/currency/2020-01-31 true true JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ste-20201231.htm": { "axisCustom": 1, "axisStandard": 17, "contextCount": 210, "dts": { "calculationLink": { "local": [ "ste-20201231_cal.xml" ] }, "definitionLink": { "local": [ "ste-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "ste-20201231.htm" ] }, "labelLink": { "local": [ "ste-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ste-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ste-20201231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 690, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 18, "http://xbrl.sec.gov/dei/2020-01-31": 18, "total": 36 }, "keyCustom": 35, "keyStandard": 367, "memberCustom": 23, "memberStandard": 35, "nsprefix": "ste", "nsuri": "http://www.steris.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityCurrentReportingStatus", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information Document", "role": "http://www.steris.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityCurrentReportingStatus", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105102 - Disclosure - Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)", "role": "http://www.steris.com/role/BusinessAcquisitionsandDivestituresBusinessAcquisitionsandDivestituresNotes", "shortName": "Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112103 - Disclosure - Inventories, Net (Notes)", "role": "http://www.steris.com/role/InventoriesNetNotes", "shortName": "Inventories, Net (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115104 - Disclosure - Property, Plant and Equipment (Notes)", "role": "http://www.steris.com/role/PropertyPlantandEquipmentNotes", "shortName": "Property, Plant and Equipment (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118105 - Disclosure - Debt (Notes)", "role": "http://www.steris.com/role/DebtNotes", "shortName": "Debt (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122106 - Disclosure - Additional Consolidated Balance Sheets Information (Notes)", "role": "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationNotes", "shortName": "Additional Consolidated Balance Sheets Information (Notes)", "subGroupType": "", "uniqueAnchor": null }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - Income Tax Expense (Notes)", "role": "http://www.steris.com/role/IncomeTaxExpenseNotes", "shortName": "Income Tax Expense (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Contingencies (Notes)", "role": "http://www.steris.com/role/ContingenciesNotes", "shortName": "Contingencies (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128109 - Disclosure - Business Segment Information (Notes)", "role": "http://www.steris.com/role/BusinessSegmentInformationNotes", "shortName": "Business Segment Information (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131110 - Disclosure - Shares and Preferred Shares (Notes)", "role": "http://www.steris.com/role/SharesandPreferredSharesNotes", "shortName": "Shares and Preferred Shares (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135111 - Disclosure - Equity", "role": "http://www.steris.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS (unaudited)", "role": "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "shortName": "CONSOLIDATED BALANCE SHEETS (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137112 - Disclosure - Share-Based Compensation (Notes)", "role": "http://www.steris.com/role/ShareBasedCompensationNotes", "shortName": "Share-Based Compensation (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140113 - Disclosure - Financial and Other Guarantees(Notes)", "role": "http://www.steris.com/role/FinancialandOtherGuaranteesNotes", "shortName": "Financial and Other Guarantees(Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144114 - Disclosure - Derivatives and Hedging (Notes)", "role": "http://www.steris.com/role/DerivativesandHedgingNotes", "shortName": "Derivatives and Hedging (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148115 - Disclosure - Fair Value Measurements (Notes)", "role": "http://www.steris.com/role/FairValueMeasurementsNotes", "shortName": "Fair Value Measurements (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153116 - Disclosure - Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes)", "role": "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeNotes", "shortName": "Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156117 - Disclosure - Loans Receivable (Notes)", "role": "http://www.steris.com/role/LoansReceivableNotes", "shortName": "Loans Receivable (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159118 - Disclosure - Restructuring (Notes)", "role": "http://www.steris.com/role/RestructuringNotes", "shortName": "Restructuring (Notes)", "subGroupType": "", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "ste:COVID19PandemicTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2162119 - Disclosure - Unusual or Infrequently Occurring Items", "role": "http://www.steris.com/role/UnusualorInfrequentlyOccurringItems", "shortName": "Unusual or Infrequently Occurring Items", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "ste:COVID19PandemicTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2165120 - Disclosure - Subsequent Events", "role": "http://www.steris.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)", "role": "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAccountingPoliciesPolicies", "shortName": "Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CapitalLeaseObligationsNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical)", "role": "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i9aed6c9cc0864c06a3536ee56d8719a8_I20200331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementEarlyAdoptionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Accounting Policies (Tables)", "role": "http://www.steris.com/role/AccountingPoliciesTables", "shortName": "Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementEarlyAdoptionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306302 - Disclosure - Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables)", "role": "http://www.steris.com/role/BusinessAcquisitionsandDivestituresBusinessAcquisitionsandDivestituresTables", "shortName": "Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Inventories, Net Inventories, Net (Tables)", "role": "http://www.steris.com/role/InventoriesNetInventoriesNetTables", "shortName": "Inventories, Net Inventories, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323306 - Disclosure - Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables)", "role": "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationTables", "shortName": "Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329307 - Disclosure - Business Segment Information Business Segment Information (Tables)", "role": "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationTables", "shortName": "Business Segment Information Business Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332308 - Disclosure - Shares and Preferred Shares Shares and Preferred Shares (Tables)", "role": "http://www.steris.com/role/SharesandPreferredSharesSharesandPreferredSharesTables", "shortName": "Shares and Preferred Shares Shares and Preferred Shares (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338309 - Disclosure - Share-Based Compensation Share-Based Compensation (Tables)", "role": "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationTables", "shortName": "Share-Based Compensation Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341310 - Disclosure - Financial and Other Guarantees Financial and Other Gurantees (Tables)", "role": "http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuranteesTables", "shortName": "Financial and Other Guarantees Financial and Other Gurantees (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345311 - Disclosure - Derivatives and Hedging Derivatives and Hedging (Tables)", "role": "http://www.steris.com/role/DerivativesandHedgingDerivativesandHedgingTables", "shortName": "Derivatives and Hedging Derivatives and Hedging (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2349312 - Disclosure - Fair Value Measurements Fair Value Measurements (Tables)", "role": "http://www.steris.com/role/FairValueMeasurementsFairValueMeasurementsTables", "shortName": "Fair Value Measurements Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)", "role": "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2354313 - Disclosure - Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)", "role": "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeTables", "shortName": "Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2360315 - Disclosure - Restructuring (Tables)", "role": "http://www.steris.com/role/RestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details)", "role": "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Business Acquisitions and Divestitures Fiscal 2018 Acquisitions (Details)", "role": "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails", "shortName": "Business Acquisitions and Divestitures Fiscal 2018 Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "id5cda59770d14d1589ca89edd082afa8_D20190401-20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details)", "role": "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails", "shortName": "Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details)", "role": "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "shortName": "Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "id5cda59770d14d1589ca89edd082afa8_D20190401-20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ste:LossOnSaleOfHSSChinaOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Business Acquisitions and Divestitures Revenues by Type (Details)", "role": "http://www.steris.com/role/BusinessAcquisitionsandDivestituresRevenuesbyTypeDetails", "shortName": "Business Acquisitions and Divestitures Revenues by Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "id5cda59770d14d1589ca89edd082afa8_D20190401-20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ste:LossOnSaleOfHSSChinaOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Business Acquisitions and Divestitures (Details) 2020", "role": "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "shortName": "Business Acquisitions and Divestitures (Details) 2020", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Inventories, Net Inventories, Net (Details)", "role": "http://www.steris.com/role/InventoriesNetInventoriesNetDetails", "shortName": "Inventories, Net Inventories, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)", "role": "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails", "shortName": "Property, Plant and Equipment Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited)", "role": "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421409 - Disclosure - Debt Debt (Details)", "role": "http://www.steris.com/role/DebtDebtDetails", "shortName": "Debt Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424410 - Disclosure - Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details)", "role": "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails", "shortName": "Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426411 - Disclosure - Income Tax Expense Income Tax Expense (Details)", "role": "http://www.steris.com/role/IncomeTaxExpenseIncomeTaxExpenseDetails", "shortName": "Income Tax Expense Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430412 - Disclosure - Business Segment Information Business Segment Information (Details)", "role": "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "shortName": "Business Segment Information Business Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "lang": "en-US", "name": "ste:Amortizationandimpairmentofacquiredintangibleassets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433413 - Disclosure - Shares and Preferred Shares Ordinary Shares (Details)", "role": "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails", "shortName": "Shares and Preferred Shares Ordinary Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434414 - Disclosure - Shares and Preferred Shares Preferred Shares (Details)", "role": "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails", "shortName": "Shares and Preferred Shares Preferred Shares (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436415 - Disclosure - Repurchases of Shares (Details)", "role": "http://www.steris.com/role/RepurchasesofSharesDetails", "shortName": "Repurchases of Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439416 - Disclosure - Share-Based Compensation Share-Based Compensation (Details)", "role": "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails", "shortName": "Share-Based Compensation Share-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i9aed6c9cc0864c06a3536ee56d8719a8_I20200331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442417 - Disclosure - Financial and Other Guarantees Financial and Other Guarantees (Details)", "role": "http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuaranteesDetails", "shortName": "Financial and Other Guarantees Financial and Other Guarantees (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ProductWarrantyAccrualWarrantiesIssued", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ste:NonderivativeNetInvestmentHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446419 - Disclosure - Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details)", "role": "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "shortName": "Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ste:NonderivativeNetInvestmentHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Statement of Comprehensive Income (Parenthetical)", "role": "http://www.steris.com/role/StatementofComprehensiveIncomeParenthetical", "shortName": "Statement of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ideb286220b054c25aca5aaaf56eddc42_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447420 - Disclosure - Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details)", "role": "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails", "shortName": "Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i7ee506f95f9b4a99a445486fdaf40c00_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450421 - Disclosure - Fair Value Measurements Fair Value Hierarchy (Details)", "role": "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails", "shortName": "Fair Value Measurements Fair Value Hierarchy (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ic0c9411ed9e54945ad527815d474928d_I20200331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451422 - Disclosure - Fair Value Measurements Contingent Consideration Rollforward (Details)", "role": "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails", "shortName": "Fair Value Measurements Contingent Consideration Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibf05ba37902d4de99f11a40d00c6fc94_D20200401-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "link:footnote", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "icfa5a313155e48eaa2e2ac57f62cc04a_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452423 - Disclosure - Fair Value Measurements Available-for-sale securities (Details)", "role": "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails", "shortName": "Fair Value Measurements Available-for-sale securities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455424 - Disclosure - Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details)", "role": "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails", "shortName": "Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i979def0dfe3d4da3b64a039d1bdb7edf_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458425 - Disclosure - Loans Receivable (Details)", "role": "http://www.steris.com/role/LoansReceivableDetails", "shortName": "Loans Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "ibeedf32a01aa455ea0cf476425a10897_I20201231", "decimals": "-3", "lang": "en-US", "name": "ste:LineofCreditProvidedtoInvestee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461426 - Disclosure - Restructuring (Details)", "role": "http://www.steris.com/role/RestructuringDetails", "shortName": "Restructuring (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467428 - Disclosure - Subsequent Events (Details)", "role": "http://www.steris.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3d07fec9c4a94244a59c461628ad8004_I20210331", "decimals": "-3", "lang": "en-US", "name": "ste:SubsequentEventBusinessAcquisitionEquityValueOfAcquiree", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)", "role": "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i17b85b21de244d3499b8177316fd2844_I20190331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement", "role": "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "shortName": "CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i17b85b21de244d3499b8177316fd2844_I20190331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies(Notes)", "role": "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNotes", "shortName": "Nature of Operations and Summary of Significant Accounting Policies(Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ste-20201231.htm", "contextRef": "i3dcaf71eda0c440ab82f395dbadd10c5_D20200401-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 58, "tag": { "country_IE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "UNITED KINGDOM" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails", "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "currency_BRL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Brazil, Brazil Real", "terseLabel": "Brazilian reals" } } }, "localname": "BRL", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian dollar" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro Member Countries, Euro", "verboseLabel": "euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "United Kingdom, Pounds", "verboseLabel": "British pounds sterling" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "currency_MXN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mexico, Pesos", "terseLabel": "Mexican peso" } } }, "localname": "MXN", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States of America, Dollars", "terseLabel": "United States of America, Dollars" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r627" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.steris.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r194", "r207", "r208", "r209", "r210", "r212", "r214", "r218" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r194", "r207", "r208", "r209", "r210", "r212", "r214", "r218" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r72", "r136" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails", "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r358", "r361", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r587", "r590" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r220", "r337", "r338", "r532", "r586", "r588" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited", "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r220", "r337", "r338", "r532", "r586", "r588" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited", "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r345", "r358", "r361", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r587", "r590" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r345", "r358", "r361", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r587", "r590" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r141", "r142", "r143", "r144", "r145", "r146", "r150", "r151", "r152", "r154", "r155", "r156", "r157", "r158", "r172", "r248", "r249", "r395", "r408", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r141", "r142", "r143", "r144", "r145", "r146", "r150", "r151", "r152", "r154", "r155", "r156", "r157", "r158", "r172", "r248", "r249", "r395", "r408", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited", "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r221", "r222", "r337", "r339", "r589", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r221", "r222", "r337", "r339", "r589", "r612", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r297", "r359", "r520" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "verboseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited", "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "ste_AccelerateddepreciationandamortizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated depreciation and amortization [Member]", "label": "Accelerated depreciation and amortization [Member]", "terseLabel": "Accelerated depreciation and amortization [Member]" } } }, "localname": "AccelerateddepreciationandamortizationMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "ste_AccruedPayrollAndOtherLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Payroll and Other Liabilities", "label": "Accrued Payroll and Other Liabilities", "terseLabel": "Accrued Payroll and Other Liabilities" } } }, "localname": "AccruedPayrollAndOtherLiabilities", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "ste_AcquisitionAndIntegrationCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "acquisition and integration costs", "label": "acquisition and integration costs", "terseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "AcquisitionAndIntegrationCosts", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "ste_AdditionalConsolidatedBalanceSheetInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Consolidated Balance Sheet Information [Table]", "label": "Additional Consolidated Balance Sheet Information [Table]", "terseLabel": "Additional Consolidated Balance Sheet Information [Table]" } } }, "localname": "AdditionalConsolidatedBalanceSheetInformationTable", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "stringItemType" }, "ste_AdditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additions [Member]", "label": "Additions [Member]", "terseLabel": "Additions" } } }, "localname": "AdditionsMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "ste_Amortizationandimpairmentofacquiredintangibleassets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "amortization and impairment of acquired intangible assets", "label": "amortization and impairment of acquired intangible assets", "terseLabel": "Amortization of acquired intangible assets" } } }, "localname": "Amortizationandimpairmentofacquiredintangibleassets", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "ste_Amortizationofinventoryandpropertystepuptofairvalue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "amortization of inventory and property step up to fair value", "label": "amortization of inventory and property step up to fair value", "terseLabel": "Amortization of inventory and property step-up to fair value" } } }, "localname": "Amortizationofinventoryandpropertystepuptofairvalue", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "ste_AppliedInfectionControlMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Applied Infection Control [Member]", "label": "Applied Infection Control [Member]", "terseLabel": "Applied Infection Control" } } }, "localname": "AppliedInfectionControlMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "domainItemType" }, "ste_AppliedSterilizationTechnologiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Applied Sterilization Technologies [Member]", "label": "Applied Sterilization Technologies [Member]", "terseLabel": "Applied Sterilization Technologies [Member]", "verboseLabel": "Applied Sterilization Technologies" } } }, "localname": "AppliedSterilizationTechnologiesMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "ste_ApproximateAggregatePurchasePriceOfAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Approximate aggregate purchase price of acquisitions", "label": "Approximate aggregate purchase price of acquisitions", "terseLabel": "Approximate purchase price of entity" } } }, "localname": "ApproximateAggregatePurchasePriceOfAcquisitions", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ste_ApproximateAnnualRevenuesOfDivestedEntity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Approximate annual revenues of divested entity", "label": "Approximate annual revenues of divested entity", "terseLabel": "Approximate annual revenues of divested entity" } } }, "localname": "ApproximateAnnualRevenuesOfDivestedEntity", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ste_AssetimpairmentchargesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset impairment charges [Member]", "label": "Asset impairment charges [Member]", "terseLabel": "Asset impairment charges [Member]" } } }, "localname": "AssetimpairmentchargesMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "ste_BalanceUnderCreditFacilityExpectedToBeForgivenInAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Balance under credit facility expected to be forgiven in acquisition", "label": "Balance under credit facility expected to be forgiven in acquisition", "terseLabel": "Balance under credit facility expected to be forgiven in acquisition" } } }, "localname": "BalanceUnderCreditFacilityExpectedToBeForgivenInAcquisition", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "monetaryItemType" }, "ste_BusinessAcquisitionsandDivestituresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisitions and Divestitures [Abstract]", "label": "Business Acquisitions and Divestitures [Abstract]", "terseLabel": "Business Acquisitions and Divestitures [Abstract]" } } }, "localname": "BusinessAcquisitionsandDivestituresAbstract", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020" ], "xbrltype": "stringItemType" }, "ste_COVID19PandemicTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19 Pandemic", "label": "COVID-19 Pandemic [Text Block]", "terseLabel": "COVID-19 Pandemic" } } }, "localname": "COVID19PandemicTextBlock", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/UnusualorInfrequentlyOccurringItems" ], "xbrltype": "textBlockItemType" }, "ste_COVID19incrementalcosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "COVID-19 incremental costs", "label": "COVID-19 incremental costs", "terseLabel": "COVID-19 incremental costs" } } }, "localname": "COVID19incrementalcosts", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "ste_CantelDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cantel", "label": "Cantel [Domain]", "terseLabel": "Cantel [Domain]" } } }, "localname": "CantelDomain", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ste_CapitalequipmentrevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital equipment revenues [Member]", "label": "Capital equipment revenues [Member]", "terseLabel": "Capital equipment revenues [Member]" } } }, "localname": "CapitalequipmentrevenuesMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ste_CapitalizedComputerHardwareSoftwareGross": { "auth_ref": [], "calculation": { "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails": { "order": 6.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Capitalized Computer Hardware/Software, Gross", "label": "Capitalized Computer Hardware/Software, Gross", "terseLabel": "Capitalized Computer Hardware/Software, Gross" } } }, "localname": "CapitalizedComputerHardwareSoftwareGross", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ste_CommonStockFairMarketValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Fair Market Value Per Share", "label": "Common Stock, Fair Market Value Per Share", "terseLabel": "Ordinary shares, closing price" } } }, "localname": "CommonStockFairMarketValuePerShare", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "ste_CompassMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Compass Medical [Member]", "label": "Compass Medical [Member]", "terseLabel": "Compass Medical Inc." } } }, "localname": "CompassMedicalMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ste_ConsolidatedStatementsOfComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated Statements of Comprehensive Income [Abstract]", "label": "Consolidated Statements of Comprehensive Income [Abstract]", "terseLabel": "Consolidated Statements of Comprehensive Income [Abstract]" } } }, "localname": "ConsolidatedStatementsOfComprehensiveIncomeAbstract", "nsuri": "http://www.steris.com/20201231", "xbrltype": "stringItemType" }, "ste_ConsumablerevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consumable revenues [Member]", "label": "Consumable revenues [Member]", "terseLabel": "Consumable revenues [Member]" } } }, "localname": "ConsumablerevenuesMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ste_ContingentConsiderationAssumedInAcquisitionOfKeyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent consideration assumed in acquisition of Key", "label": "Contingent consideration assumed in acquisition of Key [Member]", "terseLabel": "Contingent consideration gain loss [Member]" } } }, "localname": "ContingentConsiderationAssumedInAcquisitionOfKeyMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "ste_ContingentConsiderationRollforwardAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration Rollforward [Abstract]", "label": "Contingent Consideration Rollforward [Abstract]", "terseLabel": "Contingent Consideration Rollforward [Abstract]" } } }, "localname": "ContingentConsiderationRollforwardAbstract", "nsuri": "http://www.steris.com/20201231", "xbrltype": "stringItemType" }, "ste_CreditFacilityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit facility term", "label": "Credit facility term", "terseLabel": "Credit facility term" } } }, "localname": "CreditFacilityTerm", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "dateItemType" }, "ste_DeferredConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred consideration", "label": "Deferred consideration", "terseLabel": "Deferred consideration" } } }, "localname": "DeferredConsideration", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ste_DeferredCostofRevenuesAmountrecognizedinperiodfromcertaincapitalcontracts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Cost of Revenues, Amount recognized in period from certain capital contracts", "label": "Deferred Cost of Revenues, Amount recognized in period from certain capital contracts", "terseLabel": "Deferred Cost of Revenues, Amount recognized in period from certain capital contracts" } } }, "localname": "DeferredCostofRevenuesAmountrecognizedinperiodfromcertaincapitalcontracts", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "monetaryItemType" }, "ste_DeferredOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Ordinary Shares", "label": "Deferred Ordinary Shares", "terseLabel": "Deferred Ordinary Shares" } } }, "localname": "DeferredOrdinaryShares", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "sharesItemType" }, "ste_DeferredRevenuesAmountrecognizedinperiodfromcertaincapitalcontracts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Revenues, Amount recognized in period from certain capital contracts", "label": "Deferred Revenues, Amount recognized in period from certain capital contracts", "terseLabel": "Deferred Revenues, Amount recognized in period from certain capital contracts" } } }, "localname": "DeferredRevenuesAmountrecognizedinperiodfromcertaincapitalcontracts", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "monetaryItemType" }, "ste_DeferredServiceRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Service Revenue", "label": "Deferred Service Revenue", "terseLabel": "Deferred Service Revenue" } } }, "localname": "DeferredServiceRevenue", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/FinancialandOtherGuaranteesDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ste_DutchLinenLoanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dutch Linen Loan [Domain]", "label": "Dutch Linen Loan [Domain]", "terseLabel": "Dutch Linen Loan [Domain]" } } }, "localname": "DutchLinenLoanDomain", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "ste_EntityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity [Abstract]", "label": "Entity [Abstract]", "terseLabel": "Entity [Abstract]" } } }, "localname": "EntityAbstract", "nsuri": "http://www.steris.com/20201231", "xbrltype": "stringItemType" }, "ste_EquityInvesteeLoanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Investee Loan [Domain]", "label": "Equity Investee Loan [Domain]", "terseLabel": "Equity Investee Loan [Domain]" } } }, "localname": "EquityInvesteeLoanDomain", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "ste_EquityInvestmentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Investment", "label": "Equity Investment [Domain]", "terseLabel": "Equity Investment [Domain]" } } }, "localname": "EquityInvestmentDomain", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ste_ExpectedrecognitionbeyondthenextyearMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected recognition beyond the next year [Member] [Member]", "label": "Expected recognition beyond the next year [Member] [Member]", "terseLabel": "Expected recognition beyond the next year [Member] [Member]" } } }, "localname": "ExpectedrecognitionbeyondthenextyearMemberMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "ste_ExpectedrecognitionwithinthenextyearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected recognition within the next year [Member]", "label": "Expected recognition within the next year [Member]", "terseLabel": "Expected recognition within the next year [Member]" } } }, "localname": "ExpectedrecognitionwithinthenextyearMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "ste_Fairvalueofoutstandingstockappreciationrights": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "FairValueOfOutstandingStockAppreciationRights", "label": "FairValueOfOutstandingStockAppreciationRights", "terseLabel": "FairValueOfOutstandingStockAppreciationRights" } } }, "localname": "Fairvalueofoutstandingstockappreciationrights", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ste_Fiscal2017DivestituresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal 2017 Divestitures [Abstract]", "label": "Fiscal 2017 Divestitures [Abstract]", "terseLabel": "Fiscal 2017 Divestitures [Abstract]" } } }, "localname": "Fiscal2017DivestituresAbstract", "nsuri": "http://www.steris.com/20201231", "xbrltype": "stringItemType" }, "ste_HCSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HCS [Member]", "label": "HCS [Member]", "terseLabel": "HCS [Member]" } } }, "localname": "HCSMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "domainItemType" }, "ste_HealthcareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healthcare", "label": "Healthcare [Member]", "terseLabel": "Healthcare" } } }, "localname": "HealthcareMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "ste_HealthcareMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healthcare [Member]", "label": "Healthcare [Member] [Member]", "terseLabel": "Healthcare [Member] [Member]" } } }, "localname": "HealthcareMemberMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ste_HealthcareProductsMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healthcare Products [Member] [Member]", "label": "Healthcare Products [Member] [Member]", "verboseLabel": "Healthcare Products" } } }, "localname": "HealthcareProductsMemberMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ste_HealthcareandLifeSciencesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healthcare and Life Sciences [Member]", "label": "Healthcare and Life Sciences [Member]", "terseLabel": "Healthcare and Life Sciences [Member]" } } }, "localname": "HealthcareandLifeSciencesMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ste_IncludingImpactofAdoptionofASU201601Domain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Including Impact of Adoption of ASU 2016-01 [Domain]", "label": "Including Impact of Adoption of ASU 2016-01 [Domain]", "terseLabel": "Including Impact of Adoption of ASU 2016-01 [Domain]" } } }, "localname": "IncludingImpactofAdoptionofASU201601Domain", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "ste_InterestrateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate [Axis]", "label": "Interest rate [Axis]", "terseLabel": "Interest rate [Axis]", "verboseLabel": "Interest rate" } } }, "localname": "InterestrateAxis", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "ste_InterestrateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Interest rate [Axis]", "label": "Interest rate [Domain]", "terseLabel": "Interest rate [Domain]" } } }, "localname": "InterestrateDomain", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "ste_Interestrateonloanreceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate on loan receivable", "label": "Interest rate on loan receivable", "terseLabel": "Interest rate on loan receivable" } } }, "localname": "Interestrateonloanreceivable", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "percentItemType" }, "ste_KeySurgicalDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Key Surgical", "label": "Key Surgical [Domain]", "terseLabel": "Key Surgical [Domain]" } } }, "localname": "KeySurgicalDomain", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ste_LifeScienceMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Science Member [Member]", "label": "Life Science Member [Member]", "terseLabel": "Life Science Member [Member]", "verboseLabel": "Life Sciences" } } }, "localname": "LifeScienceMemberMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "ste_LineofCreditProvidedtoInvestee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Line of Credit Provided to Investee", "label": "Line of Credit Provided to Investee", "terseLabel": "Line of Credit Provide" } } }, "localname": "LineofCreditProvidedtoInvestee", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "monetaryItemType" }, "ste_LoanAgreementMaxBorrowingAmountDutchLinenSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loan Agreement Max Borrowing Amount Dutch Linen Sale", "label": "Loan Agreement Max Borrowing Amount Dutch Linen Sale", "terseLabel": "Loan Agreement Max Borrowing Amount Dutch Linen Sale" } } }, "localname": "LoanAgreementMaxBorrowingAmountDutchLinenSale", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "monetaryItemType" }, "ste_LoanRate4MemberDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Rate 4% [Member] [Domain]", "label": "Loan Rate 4% [Member] [Domain]", "terseLabel": "Loan Rate 4% [Member] [Domain]" } } }, "localname": "LoanRate4MemberDomain", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "ste_Longtermliabilitiesother": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term liabilities, other", "label": "Long-term liabilities, other", "terseLabel": "Long-term liabilities, other" } } }, "localname": "Longtermliabilitiesother", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "ste_LossOnSaleOfHSSChinaOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss on sale of HSS China Operations", "label": "Loss on sale of HSS China Operations", "terseLabel": "Loss on sale of HSS China Operations" } } }, "localname": "LossOnSaleOfHSSChinaOperations", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresRevenuesbyTypeDetails" ], "xbrltype": "monetaryItemType" }, "ste_Lossgainonfairvaluecontingentconsiderationadjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "loss (gain) on fair value contingent consideration adjustments", "label": "loss (gain) on fair value contingent consideration adjustments", "terseLabel": "loss (gain) on fair value contingent consideration adjustments" } } }, "localname": "Lossgainonfairvaluecontingentconsiderationadjustments", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "ste_MedisafeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medisafe [Member]", "label": "Medisafe [Member]", "terseLabel": "Medisafe" } } }, "localname": "MedisafeMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ste_MutualFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mutual Funds [Member]", "label": "Mutual Funds [Member]", "terseLabel": "Mutual funds" } } }, "localname": "MutualFundsMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails" ], "xbrltype": "domainItemType" }, "ste_NetherlandsLinenManagementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Netherlands Linen Management [Domain]", "label": "Netherlands Linen Management [Domain]", "terseLabel": "Netherlands Linen Management Services" } } }, "localname": "NetherlandsLinenManagementDomain", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "domainItemType" }, "ste_NonControllingInterestPeriodIncreaseDecreaseFromTranslationAndOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non controlling interest period increase (decrease) from translation and other", "label": "Non controlling interest period increase (decrease) from translation and other", "terseLabel": "Non controlling interest period increase (decrease) from translation and other" } } }, "localname": "NonControllingInterestPeriodIncreaseDecreaseFromTranslationAndOther", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "monetaryItemType" }, "ste_NonderivativeNetInvestmentHedge": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-derivative Net Investment Hedge", "label": "Non-derivative Net Investment Hedge", "terseLabel": "Non-derivative Net Investment Hedge" } } }, "localname": "NonderivativeNetInvestmentHedge", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails" ], "xbrltype": "monetaryItemType" }, "ste_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes to Financial Statements [Abstract]", "label": "Notes To Financial Statements [Abstract]", "terseLabel": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.steris.com/20201231", "xbrltype": "stringItemType" }, "ste_OperatingsegmentallMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OperatingSegmentAll [Member]", "label": "OperatingSegmentAll [Member]", "terseLabel": "Segment operating income" } } }, "localname": "OperatingsegmentallMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ste_OtherInvestmentsLevel3table": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Investments Level 3 table", "label": "Other Investments Level 3 table", "terseLabel": "Other Investments Level 3 table" } } }, "localname": "OtherInvestmentsLevel3table", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "ste_OtherReceivabletypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Receivable type [Axis]", "label": "Other Receivable type [Axis]", "terseLabel": "Other Receivable type [Axis]" } } }, "localname": "OtherReceivabletypeAxis", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "ste_OtherforeignlocationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other foreign locations [Member]", "label": "Other foreign locations [Member]", "terseLabel": "Other foreign locations [Member]" } } }, "localname": "OtherforeignlocationsMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ste_ParValueEurosofDeferredOrdinaryShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Par Value (Euros) of Deferred Ordinary Shares", "label": "Par Value (Euros) of Deferred Ordinary Shares", "terseLabel": "Par Value (Euros) of Deferred Ordinary Shares" } } }, "localname": "ParValueEurosofDeferredOrdinaryShares", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "monetaryItemType" }, "ste_PaymentsForAcquisitionOfSubsidiaryInterestsInNoncontrollingInterest": { "auth_ref": [], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for acquisition of subsidiary interests in noncontrolling interest", "label": "Payments for acquisition of subsidiary interests in noncontrolling interest", "negatedTerseLabel": "Payments for Repurchase of Other Equity" } } }, "localname": "PaymentsForAcquisitionOfSubsidiaryInterestsInNoncontrollingInterest", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "ste_PhoenixandEndoTekMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phoenix and Endo-Tek [Member]", "label": "Phoenix and Endo-Tek [Member]", "terseLabel": "Phoenix Surgical Holdings, Ltd. and Endo-Tel LLP" } } }, "localname": "PhoenixandEndoTekMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ste_Principaloutstandingonloanreceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Principal outstanding on loan receivable - amount outstanding on loans receivable", "label": "Principal outstanding on loan receivable", "terseLabel": "Principal outstanding on loan receivable" } } }, "localname": "Principaloutstandingonloanreceivable", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "monetaryItemType" }, "ste_ProductRationalizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Rationalization [Member]", "label": "Product Rationalization [Member]", "terseLabel": "Product Rationalization [Member]" } } }, "localname": "ProductRationalizationMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "ste_Purchasepriceofacquiredentity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase price of acquired entity", "label": "Purchase price of acquired entity", "terseLabel": "Purchase price of acquired entity" } } }, "localname": "Purchasepriceofacquiredentity", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ste_ReclassificationsoutofAOCIAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reclassifications out of AOCI [Abstract]", "label": "Reclassifications out of AOCI [Abstract]", "terseLabel": "Reclassifications out of AOCI [Abstract]" } } }, "localname": "ReclassificationsoutofAOCIAbstract", "nsuri": "http://www.steris.com/20201231", "xbrltype": "stringItemType" }, "ste_RedomiciliatonAndTaxRestructuringCostsAxRestructuring": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "redomiciliaton and tax restructuring costs ax restructuring", "label": "redomiciliaton and tax restructuring costs ax restructuring", "terseLabel": "Impact of TCJA" } } }, "localname": "RedomiciliatonAndTaxRestructuringCostsAxRestructuring", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "ste_ReductionsandPayoutMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reductions and Payout [Member]", "label": "Reductions and Payout [Member]", "terseLabel": "Payments" } } }, "localname": "ReductionsandPayoutMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "ste_RestructuringAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring [Abstract]", "label": "Restructuring [Abstract]", "terseLabel": "Restructuring [Abstract]" } } }, "localname": "RestructuringAbstract", "nsuri": "http://www.steris.com/20201231", "xbrltype": "stringItemType" }, "ste_RestructuringCostsLTDSincePlanInception": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restructuring Costs LTD Since Plan Inception", "label": "Restructuring Costs LTD Since Plan Inception", "terseLabel": "Restructuring Costs LTD Since Plan Inception" } } }, "localname": "RestructuringCostsLTDSincePlanInception", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "ste_RestructuringexpenseincurredsincePlaninception": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restructuring expense incurred since Plan inception", "label": "Restructuring expense incurred since Plan inception", "terseLabel": "Restructuring expense incurred since Plan inception" } } }, "localname": "RestructuringexpenseincurredsincePlaninception", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "ste_ReversalOfLiabilityBalanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reversal of Liability Balance", "label": "Reversal of Liability Balance [Member]", "terseLabel": "Reversal of Liability Balance" } } }, "localname": "ReversalOfLiabilityBalanceMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "ste_Serviceliabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Service liabilities", "label": "Service liabilities", "terseLabel": "Service liabilities" } } }, "localname": "Serviceliabilities", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "ste_ServicerevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service revenues [Member]", "label": "Service revenues [Member]", "terseLabel": "Sales Revenue, Services, Net [Member]" } } }, "localname": "ServicerevenuesMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ste_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated forfeiture rate is based upon historical activity and represents an estimate of the granted options not exptected to vest.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "terseLabel": "Estimated forfeiture rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "ste_SubsequentEventAcquisitionAcquireeClosingSharePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Subsequent Event - Acquisition Acquiree Closing Share Price", "label": "Subsequent Event - Acquisition Acquiree Closing Share Price", "terseLabel": "Subsequent Event - Acquisition Acquiree Closing Share Price" } } }, "localname": "SubsequentEventAcquisitionAcquireeClosingSharePrice", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ste_SubsequentEventAcquisitionAcquirerStockPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Subsequent Event - Acquisition Acquirer Stock Price", "label": "Subsequent Event - Acquisition Acquirer Stock Price", "terseLabel": "Subsequent Event - Acquisition Acquirer Stock Price" } } }, "localname": "SubsequentEventAcquisitionAcquirerStockPrice", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ste_SubsequentEventBusinessAcquisitionAmountOfNewBorrowingArrangements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Subsequent Event - Business Acquisition Amount of New Borrowing Arrangements", "label": "Subsequent Event - Business Acquisition Amount of New Borrowing Arrangements", "terseLabel": "Subsequent Event - Acquisition Amount of New Borrowing Arrangements" } } }, "localname": "SubsequentEventBusinessAcquisitionAmountOfNewBorrowingArrangements", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ste_SubsequentEventBusinessAcquisitionEnterpriseValueOfAcquiree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Subsequent Event - Business Acquisition Enterprise Value of Acquiree", "label": "Subsequent Event - Business Acquisition Enterprise Value of Acquiree", "terseLabel": "Subsequent Event - Business Acquisition Enterprise Value of Acquiree" } } }, "localname": "SubsequentEventBusinessAcquisitionEnterpriseValueOfAcquiree", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ste_SubsequentEventBusinessAcquisitionEquityValueOfAcquiree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Subsequent Event - Business Acquisition Equity Value of Acquiree", "label": "Subsequent Event - Business Acquisition Equity Value of Acquiree", "terseLabel": "Subsequent Event - Business Acquisition Equity Value of Acquiree" } } }, "localname": "SubsequentEventBusinessAcquisitionEquityValueOfAcquiree", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ste_SubsequentEventBusinessAcquisitionPurchasePriceOfEntity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Subsequent Event - Business Acquisition Purchase Price of Entity", "label": "Subsequent Event - Business Acquisition Purchase Price of Entity", "terseLabel": "Subsequent Event - Business Acquisition Purchase Price of Entity" } } }, "localname": "SubsequentEventBusinessAcquisitionPurchasePriceOfEntity", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ste_SubsequentEventForgivenessOfLoanReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Subsequent event- Forgiveness of Loan Receivable", "label": "Subsequent event- Forgiveness of Loan Receivable", "terseLabel": "Subsequent event- Forgiveness of Loan Receivable" } } }, "localname": "SubsequentEventForgivenessOfLoanReceivable", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ste_SubsequentEventPurchasePriceOfEntityNetOfTaxBenefits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Subsequent Event - Purchase Price of Entity Net of Tax Benefits", "label": "Subsequent Event - Purchase Price of Entity Net of Tax Benefits", "terseLabel": "Subsequent Event - Purchase Price of Entity Net of Tax Benefits" } } }, "localname": "SubsequentEventPurchasePriceOfEntityNetOfTaxBenefits", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ste_SubsequentEventUnsecuredTermLoanCreditFacility": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Subsequent Event - Unsecured Term Loan Credit Facility", "label": "Subsequent Event - Unsecured Term Loan Credit Facility", "terseLabel": "Subsequent Event - Unsecured Term Loan Credit Facility" } } }, "localname": "SubsequentEventUnsecuredTermLoanCreditFacility", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ste_SynergyHealthLabsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Synergy Health Labs [Member]", "label": "Synergy Health Labs [Member]", "terseLabel": "Synergy Health Labs" } } }, "localname": "SynergyHealthLabsMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "domainItemType" }, "ste_TermLoanQuarterlyPrincipalRepaymentRateYear2022": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan quarterly principal repayment rate year 2022", "label": "Term loan quarterly principal repayment rate year 2022", "terseLabel": "Principal repayment rate year 1" } } }, "localname": "TermLoanQuarterlyPrincipalRepaymentRateYear2022", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "percentItemType" }, "ste_TermLoanQuarterlyPrincipalRepaymentRateYear2023": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan quarterly principal repayment rate year 2023", "label": "Term loan quarterly principal repayment rate year 2023", "terseLabel": "Term loan quarterly principal repayment rate year 2023" } } }, "localname": "TermLoanQuarterlyPrincipalRepaymentRateYear2023", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "percentItemType" }, "ste_TermOfInterestRateFirstForYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of interest rate first for years", "label": "Term of interest rate first for years", "terseLabel": "Term of interest rate first for years" } } }, "localname": "TermOfInterestRateFirstForYears", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "dateItemType" }, "ste_TermOfLoanAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of Loan Agreement", "label": "Term of Loan Agreement", "terseLabel": "Interest Rate Period" } } }, "localname": "TermOfLoanAgreement", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "durationStringItemType" }, "ste_TotalOtherLongTermLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total Other Long Term Liabilities", "label": "Total Other Long Term Liabilities", "terseLabel": "Total other liabilities" } } }, "localname": "TotalOtherLongTermLiabilities", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "ste_TypeofotherreceivableAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "type of other receivable [Axis]", "label": "Type of other receivable [Axis]", "terseLabel": "Type of other receivable [Axis]" } } }, "localname": "TypeofotherreceivableAxis", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "ste_UKLinenManagementServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UK Linen Management Services [Member]", "label": "UK Linen Management Services [Member]", "terseLabel": "UK Linen Management Services" } } }, "localname": "UKLinenManagementServicesMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "domainItemType" }, "ste_USLinenManagementServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US Linen Management Services [Member]", "label": "US Linen Management Services [Member]", "terseLabel": "US Linen Management Services" } } }, "localname": "USLinenManagementServicesMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "domainItemType" }, "ste_UncertainTaxLiabilityResultingFromIRSNotice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Uncertain Tax Liability Resulting From IRS Notice", "label": "Uncertain Tax Liability Resulting From IRS Notice", "terseLabel": "Uncertain Tax Liability Resulting From IRS Notice" } } }, "localname": "UncertainTaxLiabilityResultingFromIRSNotice", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/IncomeTaxExpenseIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ste_ValueEUROSOrdinarySharesDeferred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value (EUROS) Ordinary Shares Deferred", "label": "Value (EUROS) Ordinary Shares Deferred", "terseLabel": "Value (EUROS) Ordinary Shares Deferred" } } }, "localname": "ValueEUROSOrdinarySharesDeferred", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "monetaryItemType" }, "ste_Years144IntRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Years 1-4, 4% Int Rate [Member] - Interest rate for first four years", "label": "Years 1-4, 4% Int Rate [Member]", "terseLabel": "Years 1-4, 4% Int Rate [Member]", "verboseLabel": "Years 1-4, 4% Int Rate" } } }, "localname": "Years144IntRateMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "ste_Years51512IntRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Years 5-15, 12% Int Rate [Member] - Interest rate for years 5-15 of the agreement", "label": "Years 5-15, 12% Int Rate [Member]", "terseLabel": "Years 5-15, 12% Int Rate [Member]", "verboseLabel": "Years 5-15, 12% Int Rate" } } }, "localname": "Years51512IntRateMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "ste_Years568IntRateMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Years 5-6,8% Int Rate [Member] [Member]", "label": "Years 5-6,8% Int Rate [Member] [Member]", "terseLabel": "Years 5-6,8% Int Rate [Member] [Member]" } } }, "localname": "Years568IntRateMemberMember", "nsuri": "http://www.steris.com/20201231", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingGuidanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Previous accounting guidance and the new accounting guidance.", "label": "Accounting Guidance [Domain]", "terseLabel": "Accounting Guidance [Domain]" } } }, "localname": "AccountingGuidanceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails", "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]", "terseLabel": "Accounting Standards Update 2016-01 [Member]" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails", "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Information by billing status of receivables.", "label": "Billing Status, Type [Axis]", "terseLabel": "Billing Status, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Information by industry of counterparty. A counterparty is the other party that participates in a financial transaction.", "label": "Industry of Counterparty, Type [Axis]", "terseLabel": "Industry of Counterparty, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.", "label": "Legal Entity of Counterparty, Type [Axis]", "terseLabel": "Legal Entity of Counterparty, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r15", "r36", "r227", "r228" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable (net of allowances of $11,605 and $12,051 respectively)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrentAndNoncurrent": { "auth_ref": [ "r545", "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.", "label": "Accrued Bonuses", "terseLabel": "Accrued bonuses" } } }, "localname": "AccruedBonusesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r30", "r539", "r567" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Accrued income taxes" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r32", "r539", "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Accrued long-term income taxes" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued expenses and other" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued expenses and other:" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r545", "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued Liabilities", "terseLabel": "Total accrued expenses and other" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes": { "auth_ref": [ "r578" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.", "label": "Accrued Liabilities for Commissions, Expense and Taxes", "terseLabel": "Accrued employee commissions" } } }, "localname": "AccruedLiabilitiesForCommissionsExpenseAndTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued expenses and other", "verboseLabel": "Accrued Liabilities [Member]" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedSalesCommissionCurrentAndNoncurrent": { "auth_ref": [ "r30", "r32", "r540", "r566" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions.", "label": "Accrued Sales Commission", "terseLabel": "Accrued dealer commissions" } } }, "localname": "AccruedSalesCommissionCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r22", "r53", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Vacation, Current", "terseLabel": "Accrued vacation/paid time off" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r81", "r87", "r88", "r451" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r49", "r275" ], "calculation": { "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and depletion" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r77", "r78", "r79", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r82", "r87", "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "terseLabel": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r74", "r84", "r86", "r87", "r485" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r38", "r84", "r86", "r87", "r570", "r598", "r602" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r83", "r87", "r88", "r141", "r142", "r144", "r451", "r593", "r594" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r75", "r87", "r88", "r451", "r502", "r503", "r504", "r505", "r507" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis": { "auth_ref": [ "r145", "r146", "r147", "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by type of change in accounting principle. Excludes change from amendment to accounting standards.", "label": "Change in Accounting Principle, Type [Axis]", "terseLabel": "Adjustments for Change in Accounting Principle [Axis]" } } }, "localname": "AdjustmentsForChangeInAccountingPrincipleAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r145", "r146", "r147", "r148", "r244", "r245", "r246", "r247", "r248", "r249", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r405", "r406", "r407", "r408", "r533", "r534", "r535", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r42", "r230", "r250" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for Doubtful Accounts Receivable, Current" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Number of share options that are antidilutive" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetRetirementObligationCurrent": { "auth_ref": [ "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.", "label": "Asset Retirement Obligation, Current", "terseLabel": "Asset retirement obligation-current portion" } } }, "localname": "AssetRetirementObligationCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetRetirementObligationsNoncurrent": { "auth_ref": [ "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.", "label": "Asset Retirement Obligations, Noncurrent", "terseLabel": "Asset retirement obligation-long-term portion" } } }, "localname": "AssetRetirementObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r134", "r202", "r209", "r216", "r243", "r444", "r453", "r491", "r538", "r565" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r17", "r19", "r69", "r134", "r243", "r444", "r453", "r491" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Member]", "terseLabel": "Assets [Member]" } } }, "localname": "AssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in equity securities classified as available-for-sale.", "label": "Available-for-sale Equity Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized gains" } } }, "localname": "AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in equity securities classified as available-for-sale.", "label": "Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Unrealized losses" } } }, "localname": "AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale [Abstract]", "terseLabel": "Debt Securities, Available-for-sale [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r364", "r386" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuaranteesDetails", "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r462", "r465" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuaranteesDetails", "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r21", "r274" ], "calculation": { "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and leasehold improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r357", "r360" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails", "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r357", "r360", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails", "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Acquisition, Date of Acquisition [Abstract]", "terseLabel": "Business Acquisition, Date of Acquisition [Abstract]" } } }, "localname": "BusinessAcquisitionDateOfAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails", "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "auth_ref": [ "r421", "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.", "label": "Business Acquisition, Effective Date of Acquisition", "terseLabel": "Business Acquisition, Effective Date of Acquisition" } } }, "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percent of shares acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r435" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Business Acquisition, Goodwill, Expected Tax Deductible Amount" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Business Acquisition, Share Price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r420" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r430", "r431", "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business Combination, Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r126", "r436" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r429", "r432", "r434" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration obligations", "verboseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails", "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails", "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination Disclosure" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresBusinessAcquisitionsandDivestituresNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "negatedTerseLabel": "Current liabilities", "terseLabel": "Current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r427", "r428" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r427", "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r427", "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities": { "auth_ref": [ "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities", "negatedTerseLabel": "Non-current liabilities", "terseLabel": "Non-current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r428" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "terseLabel": "Long-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r427", "r428" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant, and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresDetails2020", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalLeaseObligationsCurrent": { "auth_ref": [ "r28", "r514", "r515" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.", "label": "Capital Lease Obligations, Current", "terseLabel": "Capital Lease Obligations, Current" } } }, "localname": "CapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsNoncurrent": { "auth_ref": [ "r56", "r514", "r515" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.", "label": "Capital Lease Obligations, Noncurrent", "terseLabel": "Capital Lease Obligations, Noncurrent" } } }, "localname": "CapitalLeaseObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r625" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Information systems" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r487", "r488" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Reported Value Measurement [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r13", "r47", "r129" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Increase (decrease) in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r123", "r499" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingPrincipleMember": { "auth_ref": [ "r145", "r146", "r147", "r148" ], "lang": { "en-us": { "role": { "documentation": "Change in accounting principle. Excludes change from amendment to accounting standards.", "label": "Change in Accounting Principle, Type [Domain]", "terseLabel": "Adjustments for Change in Accounting Principle [Domain]" } } }, "localname": "ChangeInAccountingPrincipleMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by type of borrower determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk.", "label": "Type of Borrower [Axis]", "terseLabel": "Class of Financing Receivable, Type of Borrower [Axis]" } } }, "localname": "ClassOfFinancingReceivableTypeOfBorrowerAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of entity or individual who borrows funds.", "label": "Class of Financing Receivable, Type of Borrower [Domain]", "terseLabel": "Class of Financing Receivable, Type of Borrower [Domain]" } } }, "localname": "ClassOfFinancingReceivableTypeOfBorrowerDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r133", "r134", "r161", "r162", "r163", "r165", "r167", "r176", "r177", "r178", "r243", "r491" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r322", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Share repurchases" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralAxis": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Information by category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Axis]", "terseLabel": "Collateral [Axis]" } } }, "localname": "CollateralAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Domain]", "terseLabel": "Collateral [Domain]" } } }, "localname": "CollateralDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r58", "r296", "r548", "r575" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommodityContractMember": { "auth_ref": [ "r346", "r468" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to commodity prices.", "label": "Commodity Contract [Member]", "terseLabel": "Commodity swap contracts" } } }, "localname": "CommodityContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Common Stock, Dividends, Per Share, Cash Paid" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared per common share outstanding" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r141", "r142" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails", "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r35", "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r35" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common shares, with $0.001 par value; 500,000 authorized; 85,337 shares issued; and 84,924 shares outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r91", "r93", "r94", "r101", "r553", "r582" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r100", "r109", "r552", "r581" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "verboseLabel": "Comprehensive Income (Loss) Note [Text Block]" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r184", "r185", "r225", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r184", "r185", "r225", "r489", "r490", "r603" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r184", "r185", "r225", "r489", "r490", "r603" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r184", "r185", "r225", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r130", "r446" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r274" ], "calculation": { "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractTerminationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Contract Termination [Member]", "terseLabel": "Contract Termination [Member]" } } }, "localname": "ContractTerminationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateMember": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.", "label": "Corporate Segment [Member]", "terseLabel": "Corporate Segment [Member]" } } }, "localname": "CorporateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r104", "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.", "label": "Cost of Goods and Service Benchmark [Member]", "terseLabel": "Cost of Goods, Total [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r105", "r134", "r243", "r491" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "totalLabel": "Total cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenues:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales [Member]", "verboseLabel": "Cost of revenues" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt Instrument, Fair Value Disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r56", "r137", "r314", "r318", "r319", "r320", "r510", "r511", "r513", "r561" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred Compensation Liability, Current and Noncurrent", "terseLabel": "Deferred compensation plans" } } }, "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r50", "r512" ], "calculation": { "http://www.steris.com/role/DebtDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Deferred financing costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r135", "r404", "r411", "r412", "r413" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.", "label": "Deferred Income Taxes and Other Tax Liabilities, Noncurrent", "terseLabel": "Deferred Income Taxes and Other Tax Liabilities, Noncurrent" } } }, "localname": "DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred revenues" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Revenue [Abstract]", "terseLabel": "Deferred Revenue [Abstract]" } } }, "localname": "DeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]", "terseLabel": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Deferred Revenue, Revenue Recognized" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": { "auth_ref": [ "r32", "r342", "r343", "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.", "label": "Liability, Defined Benefit Pension Plan, Noncurrent", "terseLabel": "Defined benefit pension plans obligations-long-term portion" } } }, "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r127", "r197" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation, depletion, and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotionalAmount": { "auth_ref": [ "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative asset.", "label": "Derivative Asset, Notional Amount", "terseLabel": "Derivative Asset, Notional Amount" } } }, "localname": "DerivativeAssetNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r70", "r71", "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Asset derivatives", "verboseLabel": "Forward and swap contracts" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative, Gain (Loss) on Derivative, Net [Abstract]", "terseLabel": "Derivative, Gain (Loss) on Derivative, Net [Abstract]" } } }, "localname": "DerivativeGainLossOnDerivativeNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r463", "r464", "r467", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r461", "r463", "r467", "r470", "r471", "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r70", "r71", "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Liability derivatives", "verboseLabel": "Forward and swap contracts" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNonmonetaryNotionalAmountMass": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nominal mass used to calculate payments on a derivative instrument.", "label": "Derivative, Nonmonetary Notional Amount, Mass", "terseLabel": "Derivative, notional amount, weight" } } }, "localname": "DerivativeNonmonetaryNotionalAmountMass", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails" ], "xbrltype": "massItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r357", "r360" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends, Common Stock, Cash", "terseLabel": "Dividends, Common Stock, Cash" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per common share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r102", "r150", "r151", "r152", "r153", "r154", "r159", "r161", "r165", "r166", "r167", "r172", "r173", "r554", "r583" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r102", "r150", "r151", "r152", "r153", "r154", "r161", "r165", "r166", "r167", "r172", "r173", "r554", "r583" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r168", "r170", "r171", "r174" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r499" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective Income Tax Rate, Continuing Operations" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/IncomeTaxExpenseIncomeTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r400", "r414" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/IncomeTaxExpenseIncomeTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee-related Liabilities, Current", "verboseLabel": "Accrued payroll and other related liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current [Abstract]", "terseLabel": "Accrued payroll and other related liabilities:" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r545", "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Employee-related Liabilities", "terseLabel": "Compensation and related items" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to nonvested share-based compensation granted" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted Average Period For Total Compensation Expense Not Yet Recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee share option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r141", "r142", "r144", "r146", "r155", "r158", "r175", "r247", "r313", "r321", "r392", "r393", "r394", "r407", "r408", "r501", "r502", "r503", "r504", "r505", "r507", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited", "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMember": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Trading in a derivative instrument whose primary underlying risk is tied to share prices.", "label": "Equity [Member]", "terseLabel": "Equity [Member]" } } }, "localname": "EquityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesByIndustryAxis": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Axis]", "terseLabel": "Industry Sector [Axis]" } } }, "localname": "EquitySecuritiesByIndustryAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity Securities, FV-NI" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedTerseLabel": "Debt and Equity Securities, Gain (Loss)", "terseLabel": "Equity Securities, FV-NI, Gain (Loss)" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails", "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesIndustryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Domain]", "terseLabel": "Industry Sector [Domain]" } } }, "localname": "EquitySecuritiesIndustryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r25", "r29", "r241", "r564", "r609", "r610", "r611" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Marketable equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtraordinaryAndUnusualItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unusual or Infrequent Items, or Both [Abstract]" } } }, "localname": "ExtraordinaryAndUnusualItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r476", "r487", "r488" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r356", "r477", "r522", "r523", "r524" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "netLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails", "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r476", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r346", "r347", "r352", "r356", "r477", "r522" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "verboseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r346", "r347", "r352", "r356", "r477", "r523" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r356", "r477", "r524" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]", "verboseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails", "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r478", "r480" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r478", "r480" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "verboseLabel": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r356", "r522", "r523", "r524" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "verboseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails", "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock": { "auth_ref": [ "r492", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about asset and liability measured at fair value under fair value option.", "label": "Fair Value Option, Disclosures [Table Text Block]", "terseLabel": "Fair Value Option, Disclosures" } } }, "localname": "FairValueOptionQuantitativeDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r462", "r466", "r473" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Financing Receivable [Member]", "terseLabel": "Financing Receivable [Member]" } } }, "localname": "FinanceReceivablesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]", "terseLabel": "Assets:" } } }, "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablePortfolioSegmentAxis": { "auth_ref": [ "r251", "r252", "r257" ], "lang": { "en-us": { "role": { "documentation": "Information by the level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses.", "label": "Financing Receivable Portfolio Segment [Axis]", "terseLabel": "Financing Receivable Portfolio Segment [Axis]" } } }, "localname": "FinancingReceivablePortfolioSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablePortfolioSegmentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses.", "label": "Financing Receivable Portfolio Segment [Domain]", "terseLabel": "Financing Receivable Portfolio Segment [Domain]" } } }, "localname": "FinancingReceivablePortfolioSegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": { "auth_ref": [ "r229", "r231", "r232", "r253", "r254", "r256", "r258", "r260", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk.", "label": "Class of Financing Receivable [Axis]", "terseLabel": "Class of Financing Receivable, Type [Axis]" } } }, "localname": "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk.", "label": "Class of Financing Receivable [Domain]", "terseLabel": "Class of Financing Receivable, Type [Domain]" } } }, "localname": "FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forward contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r463" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedTerseLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Amount of gain (loss) recognized in income" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r127", "r452" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedLabel": "Loss on sale of businesses, net", "negatedNetLabel": "Net loss on divestiture of businesses", "negatedTerseLabel": "Pre-tax gain or loss on sale of business", "terseLabel": "Gain (Loss) on Disposition of Business" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails", "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r127" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "(Gain) loss on the disposal of property, plant, and equipment, and intangibles, net" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r263", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]", "terseLabel": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Domain]", "terseLabel": "Geographic Distribution [Domain]" } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r269", "r270", "r537" ], "calculation": { "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 }, "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r103", "r134", "r202", "r208", "r212", "r215", "r218", "r243", "r491" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r98", "r202", "r208", "r212", "r215", "r218", "r536", "r550", "r557", "r584" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income tax expense" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r357", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r9", "r10", "r11", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r401", "r402", "r403", "r409", "r415", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Tax Expense" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/IncomeTaxExpenseNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r157", "r158", "r200", "r399", "r410", "r416", "r585" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r126" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r126" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r126" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accruals and other, net" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r126" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, net of effects of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r126" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInRestructuringReserve": { "auth_ref": [ "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.", "label": "Increase (Decrease) in Restructuring Reserve", "negatedTerseLabel": "Increase (Decrease) in Restructuring Reserve" } } }, "localname": "IncreaseDecreaseInRestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndustryOfCounterpartyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The industry of the party or parties having primary responsibility to meet the obligations of the arrangement with the entity.", "label": "Industry of Counterparty [Domain]", "terseLabel": "Industry of Counterparty [Domain]" } } }, "localname": "IndustryOfCounterpartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r272", "r273" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible Assets, Net (Excluding Goodwill)" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r96", "r196", "r509", "r512", "r555" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventories [Member]", "terseLabel": "Inventories [Member]" } } }, "localname": "InventoriesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/InventoriesNetInventoriesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventories, Net" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/InventoriesNetNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r63" ], "calculation": { "http://www.steris.com/role/InventoriesNetInventoriesNetDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/InventoriesNetInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r67" ], "calculation": { "http://www.steris.com/role/InventoriesNetInventoriesNetDetails": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedTerseLabel": "LIFO reserve" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/InventoriesNetInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r14", "r66" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.steris.com/role/InventoriesNetInventoriesNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventories, net", "verboseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/InventoriesNetInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r65" ], "calculation": { "http://www.steris.com/role/InventoriesNetInventoriesNetDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/InventoriesNetInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r66", "r139", "r266" ], "calculation": { "http://www.steris.com/role/InventoriesNetInventoriesNetDetails": { "order": 5.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedTerseLabel": "Reserve for excess and obsolete inventory" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/InventoriesNetInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r64" ], "calculation": { "http://www.steris.com/role/InventoriesNetInventoriesNetDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/InventoriesNetInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtCost": { "auth_ref": [ "r604" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of the investment.", "label": "Investment Owned, at Cost", "terseLabel": "Investments", "verboseLabel": "Investment Owned, at Cost" } } }, "localname": "InvestmentOwnedAtCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails", "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentSecondaryCategorizationAxis": { "auth_ref": [ "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "documentation": "Information by second categorization of investments, which may include, but is not limited to industry.", "label": "Investment Secondary Categorization [Axis]", "terseLabel": "Investment Secondary Categorization [Axis]" } } }, "localname": "InvestmentSecondaryCategorizationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Investments": { "auth_ref": [ "r576" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsBySecondaryCategorizationDomain": { "auth_ref": [ "r605", "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "documentation": "Investments in the \"Investment Holdings [Table]\" and the \"Summary of Investment Holdings [Table]\" are often categorized at two levels. The first categorization is the investment type. The second categorization can vary. The usual secondary categorizations are industry, country or geography.", "label": "Investments by Secondary Categorization [Domain]", "terseLabel": "Investments by Secondary Categorization [Domain]" } } }, "localname": "InvestmentsBySecondaryCategorizationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments", "verboseLabel": "Fair value" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails", "http://www.steris.com/role/FairValueMeasurementsContingentConsiderationRollforwardDetails", "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r20", "r48" ], "calculation": { "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land and land improvements" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of the other party participating in a financial transaction.", "label": "Legal Entity Type of Counterparty [Domain]", "terseLabel": "Legal Entity Type of Counterparty [Domain]" } } }, "localname": "LegalEntityTypeOfCounterpartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r52", "r134", "r210", "r243", "r445", "r453", "r454", "r491" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r41", "r134", "r243", "r491", "r544", "r573" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "terseLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r54", "r134", "r243", "r445", "r453", "r454", "r491" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of total liabilities, when it serves as a benchmark in a concentration of risk calculation. Sum of all reported liabilities as of the balance sheet date.", "label": "Liabilities, Total [Member]", "terseLabel": "Liability [Member]" } } }, "localname": "LiabilitiesTotalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r31", "r542", "r563" ], "calculation": { "http://www.steris.com/role/DebtDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Credit Agreement" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansAndLeasesReceivableGrossCarryingAmount": { "auth_ref": [ "r227" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allowance of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes deferred interest and fees, undisbursed portion of loan balance, unamortized costs and premiums and discounts from face amounts. Excludes loans and leases covered under loss sharing agreements.", "label": "Loans and Leases Receivable, Gross", "terseLabel": "Loan agreement principal amount, maximum" } } }, "localname": "LoansAndLeasesReceivableGrossCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions": { "auth_ref": [ "r517", "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the amount of new advances made to related parties in the form of loan and lease receivables.", "label": "Loans and Leases Receivable, Related Parties, Additions", "terseLabel": "Loans and Leases Receivable, Related Parties, Additions" } } }, "localname": "LoansAndLeasesReceivableRelatedPartiesAdditions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LoansPayableToBank": { "auth_ref": [ "r31", "r542", "r562" ], "calculation": { "http://www.steris.com/role/DebtDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the normal operating cycle if longer.", "label": "Loans Payable to Bank", "terseLabel": "Loans Payable to Bank" } } }, "localname": "LoansPayableToBank", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An amount of money or property, or a portion thereof, leant to a borrower (debtor) in exchange for a promise to repay the amount borrowed plus interest at a date certain in the future.", "label": "Loans Receivable [Member]", "terseLabel": "Loans Receivable [Member]" } } }, "localname": "LoansReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r31", "r307", "r542", "r569" ], "calculation": { "http://www.steris.com/role/DebtDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Total long term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Long term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term indebtedness" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r56", "r306" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDisclosures": { "auth_ref": [ "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.", "label": "Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "LossContingencyDisclosures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ContingenciesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r21", "r274" ], "calculation": { "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialsSuppliesAndOther": { "auth_ref": [], "calculation": { "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of capitalized costs of materials, supplies, and other assets, which are not included in inventory but used in production.", "label": "Materials, Supplies, and Other", "terseLabel": "Radioisotope" } } }, "localname": "MaterialsSuppliesAndOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r12", "r437" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Business acquisitions and divestitures" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresBusinessAcquisitionsandDivestituresNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r62", "r134", "r243", "r491", "r543", "r572" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest", "verboseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r321", "r442", "r443" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedTerseLabel": "Payments for Repurchase of Other Equity" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r179", "r189" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r123" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r123" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r123", "r125", "r128" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r11", "r89", "r92", "r99", "r128", "r134", "r145", "r150", "r151", "r152", "r153", "r157", "r158", "r164", "r202", "r208", "r212", "r215", "r218", "r243", "r491", "r551", "r580" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Net income (loss) attributable to shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r89", "r92", "r157", "r158", "r448", "r456" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net Income (Loss) Attributable to Noncontrolling Interest", "verboseLabel": "Less: Net Income Attributable to Noncontrolling Interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementEarlyAdoptionTableTextBlock": { "auth_ref": [ "r149", "r152" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial statement line items and the effect of the guidance on the financial statement line items if the entity elects early adoption of accounting guidance.", "label": "New Accounting Pronouncement, Early Adoption [Table Text Block]", "terseLabel": "New Accounting Pronouncement, Early Adoption" } } }, "localname": "NewAccountingPronouncementEarlyAdoptionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards Impacting the Company" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r141", "r142", "r144", "r321", "r438" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r107" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total non-operating expenses, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Non-operating expenses, net:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r36", "r227", "r255" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Loans Receivable, Net" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]", "terseLabel": "Operating Expense [Member]" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r202", "r208", "r212", "r215", "r218" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Segment operating income", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing operating income (loss).", "label": "Operating Income (Loss) [Member]", "terseLabel": "Operating Income (Loss) [Member]" } } }, "localname": "OperatingIncomeLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r516" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r545", "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r462", "r473" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets [Member]" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r80", "r84", "r353" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax", "terseLabel": "Amortization of pension and postretirement benefits plans costs, (net of taxes of $173 ,$171, $520 and $512, respectively)" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r76", "r84", "r497", "r498", "r500" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Change in cumulative foreign current translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax", "terseLabel": "Amortization of pension and postretirement benefits plans costs, tax" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/StatementofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r77", "r78", "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "negatedTerseLabel": "Other Comprehensive (Loss) Income, Available-for-sale Securities Adjustment, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r90", "r93", "r95", "r100", "r313", "r501", "r506", "r507", "r552", "r581" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r90", "r93", "r440", "r441", "r450" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "negatedTotalLabel": "Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited", "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "auth_ref": [ "r82", "r84", "r353", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r546" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "terseLabel": "Other" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r57" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other Liabilities, Noncurrent" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent [Abstract]", "terseLabel": "Other liabilities:" } } }, "localname": "OtherLiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLongTermDebt": { "auth_ref": [ "r31", "r542", "r569" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other.", "label": "Other Long-term Debt", "terseLabel": "Other Long-term Debt" } } }, "localname": "OtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r128" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r108" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Interest income and miscellaneous expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitsPayableCurrentAndNoncurrent": { "auth_ref": [ "r541", "r568" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for retirement benefits, classified as other.", "label": "Liability, Other Retirement Benefits", "terseLabel": "Other postretirement benefit obligations-current portion" } } }, "localname": "OtherPostretirementBenefitsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitsPayableNoncurrent": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, classified as noncurrent, for retirement benefits, classified as other.", "label": "Liability, Other Retirement Benefits, Noncurrent", "terseLabel": "Other postretirement benefit obligations-long-term portion" } } }, "localname": "OtherPostretirementBenefitsPayableNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r16", "r18", "r268" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Other Receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r112", "r115", "r138" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Payments for (Proceeds from) Other Investing Activities" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r119" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of ordinary shares", "negatedTerseLabel": "Payments for Repurchase of Common Stock", "terseLabel": "Payments for Repurchase of Common Stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r119" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Cash dividends paid to ordinary shareholders" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "auth_ref": [ "r119" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.", "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "negatedTerseLabel": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders" } } }, "localname": "PaymentsOfDividendsMinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r121" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Deferred financing fees and debt issuance costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": { "auth_ref": [ "r121" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for financing costs associated with business combinations.", "label": "Payments of Merger Related Costs, Financing Activities", "negatedTerseLabel": "Acquisition related deferred or contingent consideration" } } }, "localname": "PaymentsOfMergerRelatedCostsFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "terseLabel": "Payments for shares obtained in connection with share based compensation programs" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r113" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of businesses, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited", "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r115" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchase of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r114" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant, equipment, and intangibles, net" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r342", "r344", "r541", "r568" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits.", "label": "Liability, Retirement and Postemployment Benefits", "terseLabel": "Other employee benefit plans obligations-current portion" } } }, "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r32", "r342", "r343", "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.", "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent", "terseLabel": "Other employee benefit plans obligations-long-term portion" } } }, "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionContributions": { "auth_ref": [ "r124" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.", "label": "Payment for Pension Benefits", "negatedTerseLabel": "Payment for Pension Benefits" } } }, "localname": "PensionContributions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionExpense": { "auth_ref": [], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.", "label": "Pension Cost (Reversal of Cost)", "terseLabel": "Pension Cost (Reversal of Cost)" } } }, "localname": "PensionExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred shares, annual dividend rate" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]" } } }, "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred shares, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails", "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r312", "r314", "r316" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Preferred Stock, Redemption Price Per Share", "terseLabel": "Preferred shares, redemption price per share" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred shares, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred Stock, Value, issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid & Other", "verboseLabel": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "negatedLabel": "Proceeds from sale of business" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "auth_ref": [ "r110" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.", "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "terseLabel": "Proceeds from Divestiture of Businesses, Net of Cash Divested" } } }, "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r117" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from Issuance of Private Placement" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited", "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r118" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Proceeds from Noncontrolling Interests", "terseLabel": "Proceeds from issuance of equity to minority shareholders" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r118", "r121", "r138" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Proceeds from (Payments for) Other Financing Activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r138" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Proceeds (Payments) under credit facilities, net" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r111" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from the sale of property, plant, equipment, and intangibles" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "auth_ref": [ "r112" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.", "label": "Proceeds from Sales of Business, Affiliate and Productive Assets", "terseLabel": "Proceeds from Sales of Business, Affiliate and Productive Assets" } } }, "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r116", "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Net cash proceeds from the exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ProductWarrantiesDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product Warranties Disclosures [Abstract]", "terseLabel": "Product Warranties Disclosures [Abstract]" } } }, "localname": "ProductWarrantiesDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r302", "r303", "r545" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "periodEndLabel": "Balance, June 30, 2017", "periodStartLabel": "Balance, March 31, 2017", "verboseLabel": "Accrued warranty" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails", "http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuaranteesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Warranties issued during the period" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuaranteesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Product Warranty Disclosure [Text Block]", "terseLabel": "Product Warranty Disclosure" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FinancialandOtherGuaranteesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProductWarrantyLiabilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Warranty Liability [Line Items]", "terseLabel": "Product Warranty Liability [Line Items]" } } }, "localname": "ProductWarrantyLiabilityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuaranteesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyLiabilityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about product warranty liability, including, but not limited to, reductions in the liability for payments made under the warranty, changes in the liability for accruals related to product warranties issued, and changes in the liability for accruals related to preexisting warranties.", "label": "Product Warranty Liability [Table]", "terseLabel": "Product Warranty Liability [Table]" } } }, "localname": "ProductWarrantyLiabilityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuaranteesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r11", "r89", "r92", "r122", "r134", "r145", "r157", "r158", "r202", "r208", "r212", "r215", "r218", "r243", "r440", "r447", "r449", "r456", "r457", "r491", "r557" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net Income", "verboseLabel": "Net Income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r49", "r276" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment by Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r281", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r48", "r274" ], "calculation": { "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property, plant, and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r26", "r27", "r276", "r574" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant, and equipment, net", "verboseLabel": "Property, plant, and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r26", "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r26", "r274" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to prospectively adopted accounting guidance.", "label": "Prospective Adoption of New Accounting Pronouncements [Axis]", "terseLabel": "Prospective Adoption of New Accounting Pronouncements [Axis]", "verboseLabel": "Scenario [Axis]" } } }, "localname": "ProspectiveAdoptionOfNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails", "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/InventoriesNetInventoriesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/InventoriesNetInventoriesNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]", "terseLabel": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReceivablesBillingStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.", "label": "Receivables Billing Status [Domain]", "terseLabel": "Receivables Billing Status [Domain]" } } }, "localname": "ReceivablesBillingStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r87", "r88", "r95", "r501", "r505", "r507" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reclassification from AOCI, Current Period, Tax [Abstract]", "terseLabel": "Reclassification from AOCI, Current Period, Tax [Abstract]" } } }, "localname": "ReclassificationFromAociCurrentPeriodTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r209", "r212" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r120" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term obligations" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r398", "r625" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails", "http://www.steris.com/role/RestructuringNotes", "http://www.steris.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expected cost remaining for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost Remaining", "terseLabel": "Restructuring and Related Cost, Expected Cost Remaining" } } }, "localname": "RestructuringAndRelatedCostExpectedCostRemaining1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The expected number of positions to be eliminated as a result of restructuring activities.", "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated", "terseLabel": "Restructuring and Related Cost, Expected Number of Positions Eliminated" } } }, "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r127", "r283", "r288", "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r127" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Restructuring Costs" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "terseLabel": "Restructuring, Impairment, and Other Activities Disclosure" } } }, "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r284", "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r283", "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Restructuring Reserve, Accrual Adjustment" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r37", "r321", "r395", "r571", "r597", "r602" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r141", "r142", "r144", "r146", "r155", "r158", "r247", "r392", "r393", "r394", "r407", "r408", "r593", "r595" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r131", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r131", "r132" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r327" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Percentage", "terseLabel": "Revenue, Remaining Performance Obligation, Percentage" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r97", "r134", "r193", "r194", "r207", "r213", "r214", "r220", "r221", "r225", "r243", "r491", "r557" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r87", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesSharesandPreferredSharesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r235", "r236", "r237", "r238", "r239", "r240", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsAvailableforsalesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017AcquisitionsDetails", "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresBusinessAcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r463", "r467", "r471" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingDerivativesandHedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DerivativesandHedgingDerivativesandHedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Revenue from External Customers by Products and Services [Table Text Block]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r24", "r44", "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/InventoriesNetInventoriesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuranteesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r49", "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r286", "r287", "r291" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs [Table Text Block]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r284", "r292" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r202", "r205", "r211", "r271" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r202", "r205", "r211", "r271" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r364", "r386" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based CompensationArrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r59", "r133", "r176", "r177", "r309", "r310", "r311", "r314", "r315", "r317", "r318", "r319", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesPreferredSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Weighted Average Number of Shares [Table Text Block]" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesSharesandPreferredSharesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r190", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r207", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r218", "r225", "r586" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]", "verboseLabel": "Business Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/LoansReceivableDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r190", "r191", "r192", "r202", "r206", "r212", "r216", "r217", "r218", "r219", "r220", "r224", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Business Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SelfInsuranceReserveCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Current", "terseLabel": "Self-insured risk reserves-current portion" } } }, "localname": "SelfInsuranceReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReserveNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Noncurrent", "terseLabel": "Self-insured risk reserves-long-term portion" } } }, "localname": "SelfInsuranceReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r106" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general, and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general, and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2017DivestituresDetails", "http://www.steris.com/role/DerivativesandHedgingFairValueofDerivativesBalanceSheetLocationDetails", "http://www.steris.com/role/DerivativesandHedgingGainLossonDerivativesIncomeStatementLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotes": { "auth_ref": [ "r547", "r579" ], "calculation": { "http://www.steris.com/role/DebtDebtDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Senior Notes", "terseLabel": "Private Placement" } } }, "localname": "SeniorNotes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/DebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Business Acquisitions" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessAcquisitionsandDivestituresFiscal2018AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r126" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Number of Restricted Shares, Canceled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Canceled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of Restricted Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Restricted Shares, Non-vested at End of Period", "periodStartLabel": "Number of Restricted Shares, Non-vested at Beginning of Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Summary of non-vested restricted share activity:" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Non-vested at End of Period", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Number of Restricted Shares, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair Value, Share-based Payment Awards, Other than Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Weighted-average assumptions used for options granted:" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Exptected dividend yield of stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Expected volatility of stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Item]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Remaining shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at June 30, 2017" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at June 30, 2017" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Canceled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of stock option grants, per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding at June 30, 2017" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r367", "r386" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at June 30, 2017", "periodStartLabel": "Outstanding at March 31, 2017" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Summary of share option activity:" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at June 30, 2017", "periodStartLabel": "Outstanding at March 31, 2017" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price:" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Non-vested stock options outstanding expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r362", "r365" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Canceled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r380", "r396" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable at June 30, 2017" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Average Remaining Contractual Term, Exercisable at June 30, 2017" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Average Remaining Contractual Term, Outstanding at June 30, 2017" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Shares, Issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares obtained in connection with share based compensation award programs" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandardProductWarrantyAccrualPayments": { "auth_ref": [ "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedLabel": "Settlement made during the period" } } }, "localname": "StandardProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FinancialandOtherGuaranteesFinancialandOtherGuaranteesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r190", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r207", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r218", "r225", "r271", "r278", "r285", "r294", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Business Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/BusinessSegmentInformationBusinessSegmentInformationDetails", "http://www.steris.com/role/LoansReceivableDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r33", "r34", "r35", "r133", "r134", "r161", "r162", "r163", "r165", "r167", "r176", "r177", "r178", "r243", "r313", "r491" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r60", "r141", "r142", "r144", "r146", "r155", "r158", "r175", "r247", "r313", "r321", "r392", "r393", "r394", "r407", "r408", "r501", "r502", "r503", "r504", "r505", "r507", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited", "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationDetails", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSunaudited", "http://www.steris.com/role/InventoriesNetInventoriesNetDetails", "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r141", "r142", "r144", "r175", "r532" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunauditedConsolidatedBalanceSheetParenthetical", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEunaudited", "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRevenueTableDetails", "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs) [Member]" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r34", "r35", "r313", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r34", "r35", "r313", "r321", "r370" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r34", "r35", "r321", "r363", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase program, number of shares authorized" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r34", "r35", "r313", "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "terseLabel": "Aggregate value of shares repurchased pursuant to authorization" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r34", "r35", "r313", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Shares repurchased during period, number" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RepurchasesofSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r35", "r39", "r40", "r134", "r233", "r243", "r491" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "terseLabel": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r134", "r141", "r142", "r144", "r146", "r155", "r243", "r247", "r321", "r392", "r393", "r394", "r407", "r408", "r438", "r439", "r455", "r491", "r501", "r502", "r507", "r594", "r595" ], "calculation": { "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDBALANCESHEETSunaudited", "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/LoansReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r508", "r519" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r508", "r519" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r508", "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails", "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r508", "r519" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/ShareBasedCompensationShareBasedCompensationDetails", "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsDate": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Date the event occurred after the balance sheet date but before financial statements are issues or available to be issued, in CCYY-MM-DD format.", "label": "Subsequent Event, Date", "terseLabel": "Subsequent Event, Date" } } }, "localname": "SubsequentEventsDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r518", "r521" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SubsequentEvents", "http://www.steris.com/role/SubsequentEventsDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Additional Consolidated Balance Sheets Information" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationAdditionalConsolidatedBalanceSheetsInformationTables", "http://www.steris.com/role/AdditionalConsolidatedBalanceSheetsInformationNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r35", "r313", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury Stock, Shares, Acquired" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Treasury Stock [Text Block]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r145", "r146", "r147", "r148", "r244", "r245", "r246", "r247", "r248", "r249", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r405", "r406", "r407", "r408", "r533", "r534", "r535", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Including Impact of Adoption of ASU 2016-01 [Domain]", "verboseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/CONSOLIDATEDSTATEMENTOFSHAREHOLDERSEQUITYStatement", "http://www.steris.com/role/ReclassificationsoutofAccumulatedOtherComprehensiveIncomeReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Unrealized Gain (Loss) on Investments [Table Text Block]" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/FairValueMeasurementsFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r180", "r181", "r182", "r183", "r186", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Dilutive effect of share equivalents" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r160", "r167" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding and share equivalents - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r159", "r167" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.steris.com/role/SharesandPreferredSharesOrdinarySharesDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r12": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5066-111524" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5111-111524" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953401-111524" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921830-210448" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921833-210448" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82922352-210448" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82922355-210448" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/subtopic&trid=2127163" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "450", "URI": "http://asc.fasb.org/subtopic&trid=2127197" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21564-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208821" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r397": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r419": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e845-128460" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e848-128460" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r437": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624186-113959" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r475": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r482": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14172-108612" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14210-108612" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14217-108612" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL75039408-165497" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121569800&loc=d3e45023-112735" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121616839&loc=d3e45280-112737" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r521": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.7(e))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.2(ii))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r626": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r627": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r628": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r629": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r631": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 92 0001757898-21-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001757898-21-000007-xbrl.zip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�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�-F)X1PVP_1+DA\E\;AWMO9JLE)=67B MYMN6&E;.]TPP?Y/MN6M/)-" 4I?(6,0Q0<,=^#,2C@B!,P5-O60-B816H]91 MM&_'%U_ 0P+#F5';!6O>)N VF M]I2?]I1/__/%(3'WG,"S8>=!,'('3ED2SQ:N")GK4"&38)'E]/,:TT5)0J67 M)G&*V/O422-7.G%*8^F*)/ 97T.ZJ#WZ^NB_']]\\7W!90+V,I6)9Q,\I.>LG.\_R6F+/%"1FPO0D^=Q9$=18EC MPXHH]Q",$(&W[V#PJ:S@[J4E=!2]4,:Z\LMJJ[BH0) LEB!VP$11NTD/[FDX M0U84$MM %H*3EG&$0M6R=V?P3K-BLD)\F0+Q)4N-PUTJ-8X?K=08G:!WIW\> M';CQ>U! LI_QK:DDOBVY_X)\[I_ Y]S]W/^(S_G[V/L//3XX'IQ< MGGSG-Y_^.J+3W']Z<-G_!&LX^?YG__/Y1WKR^W^^?S[X^P;6#=(")(AWZ)]\ M__7RT]<>%A+=@!$''!%*W_?M.(@Q%"L3FP4.LP,0L4!(,O52.5U)3$$Q".&% MJ1LGA#'!6)R(U(DB-Q!1X#K3E<1JQVTWMLH]O[N4^-GT/=R_3U,5VCA W>&A M&[DA$6$8@]GELB2):)SR '%<%1)+N9M79C>U897("WAO1$I5Z"M*^B3C I9: M%!8VPZ"TFD95J>ZAS+&R:>9JG/3@HTN=_3!B %H7*S 9:I%W!MVRL MOX!G][-1=H'/4B"M\"43"J;1++G3P"42F"//=4=X7PH$)L:<+)=BG)M.G!%< M/](1-?PGB,T>2$8X;ONJQT".*A3Q D%?BPP.E>5P(X;= 45'HYL,8$]TUZ'% M%/AM"?*$ #>-CK'R&/#O,]=8!$-B/V_#/8*KB!7O9)Z57I%T^NI?P5VTQ76>7 %;0YWPUX8O1A- G# M<)AX*]1D)1J/67F%Q:.VLDJ5UP>B7G/NKQ 3:E1MFEJ,KA_EN51E/OJI0%%# MU3>C$O!BJ)19(GN9O);Z%J-YY N;4<#_$' +07RR%$@!:WS,G@YF]EV!7NDM M!)\3]A=W8VK7].^ENG81P):F9%#%:EV-G0.. :++-$'.V8Y2MX\+D$I @:C) M58_K$+')39:A?+U.C;73O^JI (<4JAP7B;\D6+T_-[+:+Q5R!H*_LL:%*5<8 M*>J 6QO&5&MBJ=35WK@B"4\8WDH\5Z 47"]"I?]WG(D2 JD$1YHDU;0GOV6Z ML4U7M$S=#&O.>T"\V"I7?HJ+NAGF?V-]UU#5EBL@9J#Z(M/%I&+VM5G=Y6E6 M7FV @HZ GV9J?;KM KN.N3K>7%Z,>ZR2,VHU" !=8#E);_KTU;HR33GU>7V:C-(055@/TL5TYO[4N,TU!N93?)5)F!:)6 M8F]E4JTB[*>RO1M(!O"UDC M;B%I-L1D0_KUAH,+6Y5/E'V2\/0+.9"FW5M#@J#$5GQ7H8$ISANKHI^:*H>@ MA2Y,JZZU&+Y](?3UR\&]CA?C7K<0UBV$=0MAW4)8MQ#63P)A'6V[3WJ_C_G7 M90:2:<+"K@ ]FVX*ULN#IC0WG[+ U+5L,&7%E_ZH+K%)QV!'F!_:BZ-A M/C-!9,9KV3SNP$-A!T"7WQ$,W&SH#\,2CXPR4!?@Z_K[+8G_?3L^V+_^//CW MY>?O0__XJX!G??C[]/?#FT]_?7(^G1_3TX-][_/!A][QUT.XQR?WY/M_Z._/X?\NG\UTN%^//];W)\\/GOD]\_WAZ? MPWJ_?O1/#GK]__E^^/WTX.A+['EQ'-/(]B+BVR3T$IM%7F@+(J. !I*2,)X) M5 6>C%/)N1<3(H'0TH0$G%,_P=-PV'0 <*;IX2%8 O<^FFXY+=M=3_?,33.# MCK=4./0JE(J!,=VBPO1D?(#K]Z#(?CB\0G?-C]ZQK%7"VF.Y4FZ]^>N\<-E5#AHYQV9CA\&_:!O]9?IJK M>87B3UQ:_>#M0+#?,%OM^\??C[[( &Q5[G);^&E@$]\/[=B/J V*W_%"0E(W M]/?>1J0[K\;H"F?,:>+@:M]UUVG'2E34&OZM_5GEU(5O"C69H6I.1;KE\MZF MS\>EEU^-Q=QHWE1/>X]K:RG%4,K)P?$7L'NI)WAJ4XIE#"0([ BGQD0^=4/) M"0]EJ$8?=,D<4AG6G!;D#D+1>??:<,/LIPJRC =LD/6'XP(SSU=J4HFPDEME_?PZ9+E0MM !'(F. M4, _P%VYM#1RILIO;67=^32, X:-QLG7,M5MTENEZ@7*UT&:B=RTT>)*+U\. M>V@A7F-KO:Y:4*G!85YN&Y#_LD5HJSMZ&T=X^TLV"@72\: $P0"[MS'65]G/ M#>,7MK5 T[V.>&$OTRUFXA3>Z0W*J@*^+=+;J41\#7ZA3Z&REJKLG9H7W,C6 M5=G;AL#;4+.!VK*54&EHX@8T( X1X$-3)XE3AX0L$@'!^7-TK@=]%T#Y>ZQI MD:+X+1_VCXIBC.GMT_0 MJP5K%JPDN.O1U^H Z9\$'#;16N?@,]L,QF$=L@D M"2B(7$$2,-^ZF?8R)ZZQ0FF"@$"[*U/N5&K[W<'CAY83BW"#=O4&W MJ2!=%+N!8$'J).#+P07,C2*XR@N8'[DQ8]LF?#'\MD%!=E?HCT0TI9*%CO I MD0Z-$NJG(9P#L$Z<.$D;^GN4T-_W_2\IMBJXA-L)8\Q&1]..?9_9KI>ZCDB9 MDW V%?HC\R-_6RG"'@#I-1.7!'M(:E/;2[2/OV:TJ M23T?&@>I]*5D<2)'I^D[L,3,-V);6DLVKN%/#O[S1;J"@?LJ[#2)$7Q.,INI M0251$L2> T++0]!*TO'FXMXV? :<0UEJQK(UQG,7I_"%WNX5&!I2"GIF1]"2,'=*X!BS[, M-HZ_>"(_/_[B."E-8R+M%-2P36*/V(D?@-B)@<0Y#Q/'BWX,3VNH+B9>-Z1M@?'C%1BK@N(=73S;Y<7?6]B] M="WM/0)L6TIPRW+'% QO(56'"U@*'^1%5F@0UO>ZH1"1V,8#%3+^+X'>9W! M315!H&W9A_,NRW=5Q4M?,\;J)=E/;2N6$=MFU?&%'?Y3QZ2JDLH" M*[2M7ZG"8GVGG[%2'<]XNA"_8P(NVJ6<>%A1[:0NR$(,@8Y*!P(!R4&!!6(& M64"WS]:$97(X992FK$T>88N K7X]P*VP5#P0ZVBRH2A,U?+B7@'M'%S*!PRA^V%.BB5TX:U8Y3KHNX6:%^;@;_32PP,S1:EYC7 M.VO& /[>HJIG$"$V9-L9N1.0[08R3*)TK(6L=*9 MD"G_IY0FD_WNDXT/(^P15MR]B(65J.*74HS!C'J%C&7JK^ 7B+27#7Y^8^8X M&%94QD?5-V&5+1,:!OX;7EUH3.CQ !$[@1WQGT@]UO J&Z@8A>H=*J9V=1[W MJ>"B[DA7E^J-;(9K"HE CSE0839GN.D=QS;_G#+809;E0/!J$8;>>[U:Q)CI MRJI@P@S-K..>=SPOS8=] V*0->I0X"SAB,66B87Y-@<(Y4Q3F#$YC!&R76N? MS_CGJJEZKH1'1:(Y0V$*F-;\*;[^/X7I--?C4O[2FHB5Z!T-69^"L8UE,J4Y M7HE()4^J9',N==:BTBNU+:^N,'16M409\;) _"H=E$JA8 X*R<>Y!EWHL9NB M8OUFA_^X9[B_V>MO7OGL\%UUC5JT>E^L%1JKOK1:)R^O#?1M]LOKE*R[0^NJ M"IIB5-0!_]ZMJ>OKW>JO=CN;AF/39WQHO _,B![#)BB# M22>4APCL/M)8$R-30H6OA+ %L(Z>CNM:6%FO>O:QQL?(N'J75MH: X.MDBXH M\N$[(RNT)64DJXGPPM-*60K'QPS>]N4"^AZQOQ&W RMJ;T![R 9(=^^VB1YB M'@)ORR\;SYB>G7P?@\_Q$#%;E*6W*WN6D]<]M8_X2_&+3B ?YH-BI/_ZOUG_ MZHWU">CDPOKCC_BQ8YU>9L.M7^]O,LGKM+ZV M/-Q[YOD\@ G8Q2XMA\DW.7)(;[O62O%VDW0]V6$V]WUA-N#M83;VUA[&VMO M8^U+0 I>8>G(X,+NR73TVF]^DJOE^Q7N8%/&3.0@[=![^*RVNY:#]UWXI*<. M^Q^='QX;E(*N,45F_CS>/]G_7<&HF)#CF75P=/;NX]G9T>F)PI"!'_SQZ>SH MS#K]K8&^\N[TY.#HO/S-A\.SCW^#D6Z/;=0J M[RS@Y5%S\E[5$7"0%7RL?0+T7O;1(T(''3BT3@"\*SL\U&\:68/3&O'C52-6 M>WR@+-S],A1;QG5ZS,173*"SX6KPB4<83WH.L @Z7"9"7_6:O%YX-K."88(3 M-W@::FN"-YL;Z# II5S251;Y#4:[2T 5 Z;9A(%YTV[U6K=:H3:R?* &:Z@H M[! #%C=2%93!5[S,L-0QU<=Y$[KD7J**:(E@?41P:\+8BZA 9,"%.4;T5/#W M"F@A+Y-N[4&L\2!PLR?8D;.^5)O>;O/:MOER>*,AOK1N*71>1@'KSK4&VJU_ M!'W3@*'5L-.F(+_"ET7!HS)V[>ZO5[ZH'*M"PE$U'DJBEZ79!DQ7=>;6'0JJ MYU>%X#O613Z\44V%(VP,5K496'C>!-JNH8F5X6P:?#KZP7!^WL%];M<&PI.'OT)DJ7I(.)4P2 3Z3"ZD['"HJZ*MAOIH5- MNOK>!'.)*V\LM!GO90(,O5&YTQR!J@$3<>(@%M?HVIIB*S$5D:L/E FNC>4*SJD8]Y4$KG]P=X'V M8AJO*;:>\]*@^PLVOM"!B,8\#MVF:,QV^$-[ BT]/P4]SU6AUBN3ZC@X.RVS M'%M&Y+"R2FYC@.4"30E=:H^XK]KP5B .NF*M:,Q0+$O6P-/@IC4>8?FQXG7V MQ].L,LH9$"[:-$C%QL&IV*.<*-.Q^B"N,]W.#%?Z 57FRES&07AZ'*RDF0,? MHLJ"=8'EO"75J/=HQ,%.:[1[]?J[[]S^)9M6;>4!WF7>:@\5[=L25ZRR;@TE MXUPE-%7G7&THW!BU6-FI2C]K=*3:0%YH3R8X=:Z0S8%9RN2&'V"X%=U6UD@^ M3@UFD[ERR[$(,BO*D5B*;E21.,K?DC,Q+&(0ZAK3 \JMX@@URTO'*@&CT<-"U,_ MS$VIZ/S-4L7&F-+ 8YR\>]?:GS_08:("=>YMF]B".-]P@!W\]?NI3!F2L#6? MAE55/KL&R:3D0QEH0,B,RJRL0B456L-)R1.SGG1W;]>B 1_*65ZEKCA0BF)Q MD'=7Q.'^)+-]J(K1K3/[?U0#(N:!P/0M!<96&+:GNE]$DYC& M>B]MCH%NH--&>BY'X]Q,(%(S)U&UMZ[_4]#+>R,UMXIN:H=H1JBS8IX64-+* M.'RILO7&_D=,72!2VM03JI?6$."-(-O M-5-R^O*R;L@HY.(UZDDS3/X"[EAJ38GJMH>5D[*OZH@P)*Z31Q:_Q-&FE1)G MVB+EV.:-Q1&W!1;/=# I*_7=?[E!$(KZFV*<7Z@;]/#E39\_VKM%:6H81%)A MG7YHC=RGX(?:Y=A61JA7N!('E*4SYEJ]7 6M8)RH:8Z !^)$Q!+P1E]7-"+! M?]KO/YQVK+-/9^>'QY:ND',/FS_N("N-%P"N *E6RH%Y:P''ZF0H,C$S)6IJ .E_&>3F-,/EGCAQG^JJWI8@X8PN*8 M:\M9:PQH\7&NDA=;REAYM<"'!BGFS?.L;C!'?"_;T1[?,8!ZVQ(=OYONPA+N M!D&Z%& ,[LGA-]ACE:P[4]'S.:AB\U^/3KX>O=J:_$<#L5#-?@599'#N[QG^ MJL:HEPD/!7^CNP!F)\+J'.3QD6X"AH>=GUK_.OSCO77Z\8/U[N/9^>GQX8_3C_\<8#!?[TNC:\S&%[KU.FE M9+W1)5> 2!@?R%(P6'@F&U)X@J8KX6LQ!:2M^TI[PT27EZE8@L[/E)-J86?& M [":I-7/OND]J9X^AX,Z!L(&E1!HA@M3@S^M3%[M_7ZT]_,BG=+0&NH-&BIC M8O-G=[R1[WS=L#@G(C\:J:@1(P)3,!\FNAK.]"WCB_;-7&$A[X_L-)?8"-+H M][UH+&\X "(U ]U@M_4_F7 M]S 5]B@ZAR ;R_J4YER2(:T9IRGE1%E#96!6)>NARJIROZ)PHGIMH9 M%%JH^:4B]NEA >"#_*MBQ,XRT3=\]!_(K&>:66LEL]X]<9?3J9M4Z%@M@"DG M;;#6!*F[.360Z/A*G9*"XP(AG#ZI]FIA]"F1V5LW2L M,[. HYKD?J!&8EMTZ[D:P]'[NXRR3Z0@#>ZB27!?SBBQJTL&.\'E>&0\ &Z M*%?Y[F,46\8E,GU=NB:ED(W?H3X7^(Q!65S'+DR-DZJ*'EZ5^7T3,\<&%OSF M9ICWA(K1,V1\GDNF @*#L4+G5V-6<]0DT+2TP4X6:XFP$^\C]:05^IA MV"!4A@=0/9:8@^,K5$KB&I61T5;-6PC9@U?)L:A!U3LI#\M,VQLU9 IH66P. M&FAM 73(LU()E, 16 T[.N!:F;XJ*YHF+_EMS569@;%5M94W814I8GC3N*^0 M?55*C*-KC&E0XQ\V"ZU*6_$:;3%0';HQNE2YIF=%\XV]38=\;*"OKX'54#ZKNR:9XC"NLW?,++0"*3W]\^C =F,+ MQ*S J.*"X4;#P?R?@P."2Z[KE*8J[!+9&][4BJ.Z_KVY?F^EL,C&U(6ZXVLU M8HPOX8PVYG7K0SC(L+50MU]OTEJ9:Z=M?/3T1@VX4[2#KC6 O1LU,*DK 6L$ MT_1$.1SZID_7 &IC[_7_D[?6F>'OCO7''^_ 5VQ^MO=S=^(WVGE'%U;+@\IW MU^Z1M)JNU92[HQY=N:#SXD%*.L'/2Z4QY6F9B5C*-IE>5"*UZ*T2 =4XLMI7 MJ++PNJY0MK(K 6L2=5"?L-B*XQ_]M6X+L-[A6U$M'-VT9KE#W< ML&JC0)3>JN;FXC-!H2A'N591$]$,%:Y0RM54)B_:679Q@=; :'H\XKSZD6)B MUENA=GMJ8J?G=.,EMKZV"$0YH&%R/#E.0G2[7GFKI27YZJ/3GE 6F/FOENMU M:LN #08@'KF9*Z*FKFN#G%4%M->R,9L26QGU5IIA[-:Q,;G>#?.KKO7JY-/9 MX6OKW?$!J$3U@STU+J"0C0U3X]-&0_STQA! , M:^02L)Y!%G2# .NDRVMQXC:F6BZ5C9R4$SUTR+-"L>.]85'-LZW%#9"WTR4! M7E"=I88R<)&;=#.U+B/%S=12RTAPM2B#%M[D&+\;E./+C85K+D/_"9X,3+?H M4E)?"MMYWMR[VC\9@[.=]J&U'?=R3@VIR%Q/76:'8"F46N+,7NLTZPBUYDD:K?%JENP5K:(M6= M6/PC *=O;=1L)C@XWZI]2N-U)MZI,= 24#MZ=+M*+$QFV! Z 5785) M5BUF7@X$*&JHD/F:8Y@F,!;FA^O1Y;QD8LJ!*?=T,+/OJN%';Z'R5-5N3.U: MF=+!:^M4F$J%5 %&3C>RN7A-+Y:A*.DEXPO!6XKFJ M<$)^+1O@/CHV>ZFSG1.DFO; *]0H/SK7,G4S%9L$XH6%5Y_BHM"%P7#H4%FK M"I,-8<\=88[(:1+%R-&80VD+WITU?K M,CB3S8"R K\;%U<:4Q)CZ(C44!\WF..8TM0;I;.S3!6[@\;$W&VF*2B7\KM$ MRJS2;X;5"\4">K1>O?$U!=3/QI7I %2-E(IG?)&;NOO:CB^? 9[?H ETUD#/ M?6-=PN$ 1=6/FO""-(JD G)'?Z@PD3@-L@OL9.ZM2S3F\VV!49,R3H ;5XO) MAO2K'=4&:%19+3J!8J#XKHI%-'!@:ZILQ":6CN-&V^/D_G6)N9()257E_)OB M'L-_0#[C:O9FDY+5M6PP)0U+O:X'[6'$H?R!R8?,GUFA85MG]!/'4+("E$%Q M#LR9P*%B:K"OT2C,&C5B'DH'-A\[I72T\ZSXN\*Y*6V*&EX&? MRIM+[&_-'$](\P)'5HI+IA@5CY!MZD@FS$205(+EL;D6X4VR ?])1< MKJNQ4%'-%LLI;F;7PWS&&E2Z= S:8\"5VON]6=E M7:6F%!OY4Q:?<56RVPB^33]E^,UM^L97O,ZGD^ZS@QS-*.LJS$;W-$)Y_#O;K*;G,-MPQS<9W!& M+E:EXIFZX]4YM'0EU9P5Q&/(S(3@% >"(VP;@H-K#/+%6?D7QW_GRFN[9U_F MO]V<4KK%B_S1,KHE*MQ,^$4OJK3PE:^ CP4*J#VYVVP0K6K/ MYU6]72TVG\%%-W50/1'*KO:'*=Y)7Q8.ZS4##V=3&+[L.8S@A6G*K"4MFWNC&K M:UGW;?*](SN0NXG?=5;?V_LRM/A/N+/_D][H];]^!SM,I!2FU"F1 YEFVKF= M.2J=#9UWKKO/:*=3'37+<9@J;71)6-N#G4G;S@66(U.6W9WR%Y/"0_3*V*P+$4_&V3%*-<]565[ MX-GODY-*ZT7,%'O./V=MLYM8876Q6F0CZIBCMCLWYB@N[],*X+19>6=EOKU/P(_4^8GR4ISB7!^YM6EB/#\F&K$>'.BNYW M5?K/")7:8%1[\P_JN-VH(D;EDV!DK$H;:G+V_;"N4)^T@^_@A";5\\4+06O= MC]U&4&W.,E0QJQ]UW0G&N==$>%5(.;<-IS:F%R-<[^GI (N#SF6,>1*.NZJ4 MFO^Z6(K',)G(/ ;_8D5V^28N4G+9-)=K3U2>J%''K.UIRTSFR@S(VV9 MV1:LI2TSVXG%[W29V=UV[3A?,/I)[9C2];[3#7_"@,C\$+W2#!X%KQM_,SD= M<_4N8PP!LK*6^(IEE9.!E>R3$UMU@Y4;JMZ8(0;3,-*E.B%VW\.^=RC(XFDP M"]TTMLQ U:S$DJO#FXLL)>,P?J@S_'7TL6O#L%K62>G)\9F/#K9 M/WEWM/^'=7RX?_;QP^'9FDC1[VX25F?9D:&/-5.I^?S)P4Z+:TPT&(PR:(T7 M.-'C@(9\7T_):@PZ'=@UX!S^PDP_G<2>,?5!YK$=5=^5"[T>TW?8'.)D!@05 M^-1$CFZP_F943?TM&L-/G@&MZ(%1=YQR8T]'V@E7]&&@(9M3I3I-(FK,J]$^ M3VZ@7*:&32F0^&&!TPJQ'U W0.&EJ,07+.GE['L](:1"U%?',#*0HP:$[@++ MG9&>D6'08Q]P53^'6$V],G@^'U*K'&>C2P\K/+6J5W.R55-KF*RIRJJ19RKJ M7K*S@FK34ZEM/:6ZG$U6,K%*(((BZPUQ!<6PKO/%VF]XF4LS^D]5"M3/$VS$ M*J": MIC*T#>""QL!6/2N\U.2-(6U-7;]XEOJS%"Y_R=DJ;O."5:!E=!\C=,JQ;?7( M.BP6K;L?%S)0(['<".X8H0-.ALZ&*PY:^.Q2/S0(4U<8ZQQQV5\X.\%/F="F ME-&T)"C8,]494%J$56V6&GC%RWEUPV2D[4 , .O&L,RF].X4(!WRNT$38XOCE=4PP0K@3T:=E0QONJI MP*9\;7E./&O.[*R=-_]K_-NI8)Z9.:K;M34IZ1VH9 C36<9,UWO,S&F_8S:; M"@W_IL**/:2ALAJ\,,H!'H%):2S1'G6:F.VZ[Q,(YR)38-17O7&AZTZD*.I2 M%03G7?%6G89%J>R^2066#8P GGKQ5=YU,KKW8UD.SM).SSR6EVIE3) MS.PK#!1!-:>S&GLZR02K5A'J$(7CQJ\?)8<8+PD-CDM:\@ 5MF?C!/'?<&)F MO\KP,_HMLH%:A+GIS#1R'UH:)/L--3: VCKL1 M]3%6.\KA?Z*\O0GC=E48]Y>1F/TN=+IA%"W\VNFZ#_R.^MZ#KKQKL:[7]3Q_ MEQ9+E[KM+^K4],D!!2!U_=\]?V]J",5K[^J;Y99B0), (L1/DX4FOW7+AGL9 MQ)G#(.;%[W@GQ])<,?/3>)G7U_F7S6S 3!1);< )BK-C+9I7 @5:Z20.Q_ 04?R\#OJH?VIDJ!*Q5PJ+/!-6^ M^)ENW'RQ@W;!*KPU6V##P7H#30NA9;V+98CMA[9JF@K7 MMO^.M5&Y>'].01W$/Z8W>'WOWWSO'!^Y52].';<31G1#Y7YWF"+K% #6B@?1 ME2Q_5*.:#Y'O'*IWPE(O)$C>JC-OSOR MY@'1^&GA\R,6_P\1]9S-WCJBGB]WB!ONGAV[ 5/UV9/' B,L"C=W1,_(QIK/ M?+]-9(T>PVJZ[SIC)]?(_I88CC&%4[[\SGI3/QJS6/\&;0NGS]\9WP\[H;-+ M08VUG] 3F<_K67#+Z>N*FSQ?3E^03_"CCA.07>4V917\HFH&'E*U3W>H:G]N MX\+.5]@2[#'1YIHON1 S#E% MI!5*Y.1(ZDET5U022]>,FK+^!]W*-, V"DX?4.\Y6S:S=16@H!6#,-REHLJ= MJ0#UNWY,=F6Q\"5]V&TW1 ;!LZFMC98*/[WXVMIS);47%M=:ZRTK?<*?[@*- MMI7 VU@)?$\,ZD66""_:T:D2X757=/Q8UFW[-NR=@C-^HBW;J9UYKU%MK3D[ M9"3Y5.#)U=W63U'ZV3Z@?<"+?\":JB)4[B74,>.M+9 X5XA?981C$P42VYSX M7%.)PU:F+N>_6^1$G=@CNU>DL$55NKM,\6M*]6\EQ<]_MS D'2]P6ZIKJ>XI MRSY))PC\G2>Z9]Z00+IT(T>TB7?]Z=$\T758\>T]7M@]7I(35LU/Q*%-MU?R M];9$&MM[[, ]UM2XIC5RO!U\,E]%G>DAB#\6KG@I[48+NM%\OQ.XS@[Y]VU' MVE,;O:[3(<$#80':8WJJ8_+\CDM6[3%H3^F)3XEV-\-(6^-!KL6 WVZS!#%F MQWU5E?F8B91G$VN9;YFX<81J9XT\M5*.P MXX9.>TS;?4RO7*?C>][R.'/M"3WU"=$N?>KCV1K#Y,>R[KN0LVKOL9WW6*=E MO$M9]PN)\^FO+F\?EGK?A8**]A[;7:2RW8[D$8+=J(%D2[N/*U@N6VV@+&H( M[/CN]D:KMSN.MM7GO<"S"SKN/5CY[9ZONQ*AX\9W^]+MEJ\[=A]T'W7'M\;' M>@'!WX^#K)IZ6K2!WQ\81Q1Z'3]N8=Q;$EEIX[3%M]S'%G2A>M7Z@ M/:2G-K6[45LS]\SC":>C2YDCH")\.&C+YGX@#@&.J>>Z.V2;M)4^3RU/8]H) M_+;9>,N/R7,Z-%Q5\[6G]-3,Y+SLGO#9N1!F35N$:'TG='25]LL&/)>LD,(B M7?I3!]&>_Q$Y43>VX*F];#B8PGM> C&Z8[$*A5JH&X8AZ?HS-U3C#_3( PUH M"?^"?^36K61YUYJGS!>2U5/MV_EE5N\96&QI3_)18<&:;D:7^!:LU[.2<0$7 M%D4U54$/BPUSU1Z2],1^-]9@-O(:/\UP.>":+KO5[=2?R;F!S89N K.#M+#8:Y5DRUFC8!JD[@YWGHW)$1"X5SA[C_QUG>O["S%/V MKZYZF8J1P:;TLN]J9=:YY)<#V-8+6->"IXNQ>NCUL#?NR^F[_I&ETCJ#MQKP MJ1N8RVK2$[*O=LB,I;C*AV+,S;85NMW5#&Q47U^RO,^L=^,">$SFB$C.QW@; M6/0UXQSW7EV:9&KYO*B):6<9=KKKM[%[M!O\M 8NO9XI_D*"F4NR^"X+"XB!=.MC0/GYU.\#S^\I@E_MC<[G"I?_ M4Y3W0S[=2@$\*WU@V\871@N[$%[P[2*>-ZR^9OY^2VS:Y0T4/6QWN#4"XN M-0T]!ZDT71#1X'#,H?VDM+_GS%'^/V!-N$'77R M^^+Q2+MR8O/388US<[N1,0-I"!)ZG0=' Z]+UWER^K1F%4W'NKG,^*7F1@:> M!.BH6^"]M) C% NLXE>TOA:?]NXS:&7G:^MI(M[8&W)FIJ$UCM^IW /&,U; M*^/&8*JLZ@88HQ('H<&W[]B "59-:3LI1F'0[Y0]O=2-*+L69R49NV#-H$;#\SU MNR\0%M/XBYSX%DQN1SOQ;?OGCK43WS:U^!^=^-9.^YK\KIWVU2ZVG?;53OM: MVY25$[1?%P[[:F=]/>$!M;.^'I/0VUE?[:RO#6]8.^NKG?75/J!]P X^X"7! MS+>SOE;?L^VX'1M]U-PNV\ MKQ_'K.YX;M1Q F^'?/P6<.&IS=X.#E\)GG[^+SH:[?B:*P/:;M/J97;M@)7+\= M^;6])^1W23ORZT&)]UU(6[7WV,Y[M"._VI%?[3TV4J>RW8YD._)KQM+OA&&\ MM;[@=H?1MOJ\%T3+@@YQ[@;[;?=\W=YTQP_O3G"W6[[N=/5]^>KGXF.]@.!O M._)K;75S@>MW*&U#ORV1W%$W%[A@$])VHM36'U08KYKY; _IB0_)Z;IMV=PS MCRFT8[_6%8L(HDY Z0Y9)VVQSU.[TB3NA.19]ASOX&FX42=V[U9PV[WGSXDU M_.YFV&)+3(WG.,/+[7HE>'_'\TG7F4';'R BZ(/0^Q5HR)RY8+LYQDO.F>(U MS"_8(.-3,X*6F(ZU>-+.TI._JI$5,I?+S2.8'=_S N=ZX4'>NR_SWZZ<&[34 M(G-9C'MJ"(E:+CY'7:]V=)C"35*9ZS,NQB L0.SAG>#^XQQ7#?]G[H&_GCMA MR-)IQJ<;9M38J(GQ17.(;ZFQ#'(RKWYATL:8S_@@\435^!R-C(\ M )]EPW&!!Z8V5XJ.NG..0LN<=9KEQ M%OP:_MK7Y)_+"Y:;K4@X6P;A\QC&DPN,)RNN M!A&;C7KPT=X)&\$!X\]/002R>A_.QGT@-]Q#ZPRT'XX<8?"B^YS#R2A">@\W M1L[?^WGWAXC<,9W.;4ZG>[#V^9$A;_/%X+3,KD3V?<.#EA##]\Z^(]UXPYLR M5XJO-#=IX_@&/'!:WN+EW[<#2VSBEIH\1_=+3'CY2GA_AQU> MF^!N1?%6C.1SE2Q6D]C<;K1&UX $&W%ZW8.5&PP+QHZ9IQF$'7#-;(N)?&<^_W0-,7CP_VG'Y3X M(L<,ANV8P2U82SMF<"<6_Z-C!C>J3=0=7Z->S_C=*6TE&4! %X7U/A^FV:B[ MH<2VG@N+(<)TV.L-;Y0)H6PYHX *%0*\4$N]4DN=&@^,2F19S59-2%_B2DM? MY,:OES0D-CUA,G3"!TV8=+NA2Q]EM.##!A;>-UJ0/,X-5VQW M]O[%+D>S"]I]R1WMOE,YY^V=Z==.G7Q[KB3YPK&3UCJV!GX*KLQ=)3%;OTWW M#XR[XPV?\\:8>7'_3/)?YFW2 NGA/0?IT4X$?>J)H.W@SX<-_EPKC,)#=V^[ M@!5^;SA$/X2GL(4C ML'M _X\0>LL\?#HUN#LS+?#WBO*\G:$9,O?<2D&WH= MXOMMF\H+I?B7-^C/Q<:LV&FIKJ6ZIVQHZ80M^O:V=QUY+WVZY%H 6+;>^#45 MX2WHR@.L1;]#O%T:1]Z"1#RY>>5U@F!55=<>TU,?D],)@Q869\M/*6@'E?U8 M-&X;C) %B>@AEE,WZY0V$8Q;.KFQ;1[DFB)UR[__MC#/_!?W">U$@;M#AMFJ M![#ET9:=9:0UA6)VCY$6Q&E\M^/3!T9J6F)NB7F;7MPE';KRS.@=H^550I(_ M1M?;=[[DH2A)CWFX.^@[S'>:MM=W:!;S8$,=%FJQ"[GQ.2D-LO*!<,1PC(T+ MZRSK:%>Y\ZMLZVS:7-P2,H[0[O9.PRLK3[N M94RE=1_WKM^CS8.W>9EEE)/3=79(.>U"4FB=RNFE$.>"$&;\8K.&&_" MOH> M+S"+VHB';-KK,LZQ@7N8XQ_O;CQR@5KTNKM4&[;V8]HZF;E9C^\E,L8"1Q(8 MHR7.UC]=CW^ZY'2(3>,+1=1_$+Z0UPW"\%& 91Z&K7,?L(SW."@X[6)W;+%! MBR_4X@N=(#[<0GBA%EVH11=JT85:=*%'):(67:A%%]I@05*++M0^H'U 6_74 MH@NUZ$(D3F"+"MQWF>)?'LX+">(.]3<#(])2W4NE.M?M +WM/-&M MDD/';0#MG]>M@65:A%%7KHB\>!VR%!L$/VV*H'L.51EIUE MI!:(99*1*,)SM:A"+3$_ V*FGZ@Z]"""K5 M..TJGVB5;7E-FX%;)L$0=E_>J*M-;'0+*G07J-#=N/M;?=QMT^;J]VBSWVU* M9@F9Z<==ND/*:1=R0BVHT-JTUNIA@5T@D!94:/5[O, D:@LJM$&?S=\IK+VU M']/6R]<5]VX!<9AVWH6&P@K'[VS1JF M5L%ZL!CXRQ!N=*5#K(7Z0:%=V@)^7E@WLM?#_^+M^+# GQ3%D&<,'W.3C2[5 M-W.OAV_8R&*Y1(827:LBREW=\@4I(RL=YFH71I=9+JS_CED^DCEN;9H5(!$L MS_%<*Y=]!G<45MK#71E9")+V$^QI_PJV2%BCH;K' C-LF6LI4=\^M'?PGZN>?- G^^!%/$]V\(R8SU":_@1^'($2XYD0.)+R.7NHL M60?SGK" 3W:2EM0=7V>PVQF_VZ#5^@2.G8UP:PZ_7*Z4RD*41&L) M;_TEH &V,(DM3&(+D_A81-3")+8PB4^<(SF=\=!:L,3V >T#7G0U]YGL]50N MXD(.0#ST=#B9B7XVR(H1RHOK1RDZ^.'R[MWOT][*IKOY[^9&7LDOQ M+Q;3+O0ZL1>V5-=2W1.^6]PAY(']KUM$U@Y1.]IX-F-SNI6B#%J5?_ M( O)(7I\K9\?W7S,>@0?Y=F<[: <$]M;@&%1*M:6^TI/?$I MO2)Q"ZJXO:?C=/T65/%91^O )AGE8SX:Y\TP_J9['[::5Q9ED7;(&FD]O"?7 MT[G)/CEP5_=&TS?/EU06QKRCJQ,$# M\4U:?FGYY87Q2]R)@E4S<,^-6U8)9;XX: K:774"YC:0QY:$4A=EU>)QQ2ZDG>22_6VS%!;[FO5NV&VQ]\MD$VHV*&].< .GWWWA&Z;IH[WA M7?T<_V1;LQ;K,I?I_]W[7UF<>B1(4\D\&I,T)9%P2.($D1^$PO6Y_R4$A_R? MO["=73S[_^U]:7/;2)+V7T%XW>_($1!-@+<]VQ%JV>[6M*^QU#V[GS:*0%%$ M&P0X."1K?OV;F54%%$B (BE2!"5L[/;*)%&H(^_*?/*8)X^2,IP8Y_ Z8-J8 MEE+"/C4MS![V.EL59MNM_F"PEXI<>R\5N?9^RH>;R1[99/M-8793F%VKTK[/ MB/%169?=E&4W9=E-6793EKU7(FK*LINR[$>^JFO*LIL7-"]HRK*;LNRF+'O# MM?6LMFGWFE36YTKQSZ] MF'U/J+-)[5-3 MCWV$)G%3C[V[ID9#:G-&J.J.9'9+7:S[1Q MY;.*US6%V;LJ7+*:<%9#'I7G\Q1B/T_\B$YZO:<1*6DJLYO*[!U7KQU?<=IN M"Z^/J/:LXL:M-S*MP1&&3HZEL.W),M)NJSR/B)$J+O(&?;/?>U@99T/,]3K3 M9TO,=#\XW!Q\[UCH>),8W5,K)C[IM-JU.MC:1/864NG[*S+I'\4)>\@8VH&5 ME'TWLVQFN;N(=AT\YJH(@7%J? X38\99 #.>I'YKKS'L9HRG-<9J!(GC[<:> MI6/_JJ=CGQ72L6O2J/T21(@W 7$2)-2@/0RP%A_K\A.*A\5K9);G+=Q/_M]_ M#6V[_?;RU__'9O.W9_1/Z^TK@T6B_SO\C$K.:)0Q##GQ\+UQ$IO&A,LF\/,H MG/ XAI_1!*(;S^'P/;SMAOOT)-4S)J_>3J KD\']>Y!K_3ED$YX#$ M,O%BT$B&W;8M(P0%1;^*V8S#87IPI'>++*7R. M6XGO<_--S ].[$HLMJU\RY"UX#5P7G'J)R0F8)#S+W]>O#NU1@9LHLMGGB/? MSN(4?FC<LE4QP\YMGC+>,+B=F*28):3#S2BJA" Y :0C:# ML)DRW"\C@/V$P=S42?0GS>Q#;P9_W7#\4"I@7)[^$E@8CI)P9QK \5VC$V/, M?9:@B(,I!.$-DZ+_GH<4).7K46MP<1%C$'.ADR)!AH%I MC-,$1!(<1@"NBP][GM#/3+ JIB!H26"R.1LKDP*F'0/)>C[M)AZ*D*FSL1<( MX9NO".T4^I&;HM$A]T8<%G/PV3"B'\D)HV5#?\?I?!Y&B?XC@V8,J[QF8+*$ M'M@\,2P*AN6!&\9..+_+WJ69D552M%1F=EJ]&MG-']1Q@RHIIDA]]5GP.&*@ M?&8MXY!"Z-)#_8__F1.]2;6[>KLRM0O/I5$$I#2/$-CJ1RZ1R,3'W[_L=EMM M V;NX_ $T2=81PB1J# XL*FP9=$P-C R_!&$FQ,NB;PS.A (_!,[F6 MPDZH*:$J6L9Y&,T168-G;RSN@#-%^S<6,NBEMG,M%R"YQ,U]!\PXQ,RA'Z/>>K.F[V=91>?/*D6X MP0NE_: ]#MJ#;= >>W:K:XWV O.W'7C@2I@_T*7=HYFLW;*[^P%0W,O.]D;5 M7Y< *!X]QEA5XMF*-3TU?,(K$HN5 (7&+K;FJ5#&4R'[!EJO@=8[^,9M#ZVW M,??5;_G56)[/%#!PA7/2( 9 MG<&P.:#:'M!@=#@4KMW&66L9U'BX<_9T>P=O",_P]%H$EV_ P.RW:XPC5=,N MQ,^6BS8L9W]Z7%2^ 4.SV[D'H:&AY(:2CX"23X:=7J4!?7 :WJ1J\M!Y4[V^ MM57>5+TW>U//*FWJ4OJY/@BZ>"M$W M65--UM3!-Z[)FFJRIIJLJ>8%3=94DS759$UIFG%@MGO]VD;'FS29YY0FTVF; M@[;=$$1#$!G>JMGO]IO,J29SJD9Y'Q694UUS,*@DU28QY_"RQ#:M_N:PW,T! M/>(!]:W#'%"3./6L+\J;Q*ERW] V[6&3.=7DFS3Y)@_9 'MH]CKW9 4WI-R0 M\A&0\DG?M'O5Y2$'I^)=0L[O&QYM)>C88G1= ^)]V6Z-BC"('0T7T17@<@^# MY%T;%O>* "35W"3H(?P0]A7V9!O08\[M@=W=X\X>%)108J+[(6Q4C@6':)(Q M0L%-_%!8[H0OB=AQ EHVT$"7V0PVCX S'38G<+W_$)YFD5Y:1D9!)R+8\ZHZ MVH.8E<&U "T&ZK**U&7GU&4^*GF9.24I,/F9A"#&S4+X.@3,2^X*N,$G$9_@ MN *G$0$6#:NG_NGH"(N3#&$Q+D%8_,"\R/B3^?#B3P+JG'[P@G#Q9J% >U;H MCJ^J$1CE^7=M$1N/L#%,/DVJ'RE+_3P$ MF7=&Q>W0_SN-X@;N+CVRA5. M)GM;X:J,IK^SVLS%F (O_/>+__)&$[O;GTPX ^7=G4RZ0[?=';?[PTY_X%H= MI_-_@Q<_7_W]-3O:R;-CGCQ:2" HS^%U*&%H*27L4UM#AD9<'^?U0MP]7+$? M"N3UL/"N]V*DRLL2#5M;=*F!8R55IO] J/('0J<6< 0?BJ.ZK^S_?JO=L[?) M_N^"_=K>"Q!I?[LG[TFH;_?6RU&OP62[K>%PVPD]^F3;K8YU-#MKM^Q1?Y-2 MA07SS^JN:(AY-)G<3?G"8\&^1N'MXE7?46U32<;Q^BM\RAOSE4@^?2$'I#Z$=/ MZ"==L]O=/*NT;C3^:(6+![;CUX;![+7L5S\]K*199AX0VST3PUQ;FZ<6:U-462/@4#*%[M? M CGV,1X*![>_ZU]K--SR^K<_V@M$66^[2^5[[OT&]E[NJO\> M)CL"*EBO9^;AYVIU6P-KO0DUM[]/^O;W4<#KCOV*L[G[;>Y^F[O?YNZW=AO7 MW/TV=[]UB]8W=[_%7AW8?ZI[1(&YFEX7-$S67(E5+KS?-]O#U>TI&T)O"/WX M";UGVI;U-.B\N?\MV@FM47/YVUS^;GOY.VPN?YO+WX/O63EQ('$^00)I+G]W M??E;*/(>'@RJYE_&7T0QOEG#U:C?<^_3O_<"XW;JP1+H]>KGMY[O&V-N7/, M\22Y:]+WWFP.,\=W$&@*C>J'B/"2SPX1)VD&8\]'>!988QJ+><.VN%XB)A-P M&"<#J_3#.#8<%D5WL(.W+$+\%P*_N6&>3QD,^/S]\7 IE: M9V=RB(6M-F:H-H;^*FY,ZZ"@4010D:,H:7NA-B'; R>-(H1'4L(H1PV[G?) MP5JXR)'YB.T2H"4-<@KEPX3=A!$QX8)H.Q+.HQ'7ARCY)8WA,Y!'E_R:X*:^ M\3CU$Q*M7X3$ L%Y6-@2T"E"> H9'/%Y&"7B"A4EA/@W'=E8K286JXG?&+]Q MD)]3D+:@1,[F<]\#FKA$%>U[_Z'%&5?.#P?2W= MJC^"&R(L,Q\U'JKH7'TY80STD4Q98L3IG,Z"U&F0>"!=SI'Q@CO:2&(<(PCQ ML$ 'DPHCG9V-E0 /@_2"TP$["C4\@I5%X4P=H/93(0U;QOF7/R_>G8(P(Z[% M'P%OBSDQ/PZ-*8.7C#G(@'5'%-!^8@AA9W!CSNZBT,\&CN/0\6@?;CV0NGPV M]\,[#GL]9YX+9)?0*F_#Z#MI;'@"I2HP$BYW)D#58,_8=X[2AB1NB$8CR!_< MNVQ-L'4NGWE.+H9K+FY64M!7 KJ#-9Z!U/4-J8Y,4$.*H5V-HY'(P)3*L>HT MU#F2S/CMNLQN?(U"-W40YD[[\!+T'(P,AMHECVX\!\VW K<+0^Q^.2%4=+[Z;B4:@_GXGT!&M..+Q,:8(A0VLY$N!Y@1O ; ME'@2.A*<$H>#!X@(BPA<2-X&[L8T'PM^<^.Y. S("=^]A;]UOP8/,)T19<\S MVD74QSG-8,;0L\1=%UK0"\ K\7U!FG%&S?B51,O,'Q;4JM9"4E).A@05IF>1 MFY/1JAJO>@GYO*=A+%X7%[@E&T)--DK%V^&?L0-DB$3.O"C>F:@[+-&L85N< MO#B[O'KQ*CN([ S@Z),(?!=R?8I^-ZB=:&>FZV$WN""GLSV$[?.N R!\;<6"YF+N^_$&7&66T7\I.VD^ M!.BV53L/ AW]22&,D>DW.8J:[/V_A"?DAP@&J&P9$A?R")2;B@:A%Z^CB.Y5 M0BBNF.,@_"^%?$)P9CQ)_)H%D&E2E$T9O"[#T7"VF:NH0^%*^_18W+F51W/F MN@27NV K1?R:122;T6+*-LG+K%L4R.N!!"\]<29";=^$#P8O^P"O-:SVZ>_9 M=A.PL8A'?&*1,RT&(TQ#O.T3NQ-?V"/Q18,KK!]MMUWL$%.28I^0%6T0QB5(=HS2U\]$,MW-7ROO/4[Q5032F.O MV."?J6;D^,RD#Z5A"]Q2NC.3-U6Z,@87,D85XV9.=?&!(YCIJ=>W= MT\"^YCH^*DP1%/)N2OB:2HYM]ZX[2LY MG_[>-$2U&Z)Z+C6_Y9G;WZ33_&:K!-V'%&4/<7[*C:B#+T;7%;4@=1 M4"X9M9O_?63K/[B$XXBK]\N66)>"C?*U]6S+[/>/"9U]-\4Q#<7OIL*XSA1? M443<'IFV;3\5JJLS<6TF3FM)0Q4%IV9G9)MV=U!;N;D_0CUB>MQ,V-62'BMJ M3,UNMVW:G<'>:6);+_HH+>7[TQT?XDT_J!ZZ9%MK5P]=A=3>-[M'97&N(.%# MHX0<.XE4B+->W[3[_>:8ZG),Y9S<'0W-SL!J.+DAD:KSZ?8[9K>W:?.#'1[3 MLXKL%:H'&JB6S4T3JVT.V^TC$FCU"TL\&1*I,$W:0W,PV!1L\2B.J=:G4S5L5HVB&76P",H9Y(J2X%7&_#ZB%5M? MQM;Z6F3?,-[UO# I7_405-[(?DH@WK4"-GYFG+5O2.-Z$P!O'3FHT0^-?BCAK?; '+6[=:3O1T)H/ZAP M^[)8/7R"L*:OMDNBWB&Z\/Y2:)_,"XYBDC5\P;-*\,A3H0\1&JFS&MZ1B5M+ M95MU^=,SNU:3E_)<*7Y'AF93= M/@^C>=CTH]]*F)UT!^:H:RTAI39.3EUDR4FW9]K]]A,[H5H?1 6K6+VAV>UW MJDZBJ:#:DL"MGF7VK;WNZR-53QV4/J_*NXB,^22,N"%:QL]$.Y;'3R ZS@S? M)GM>#[:US7ZGR9UO=%PHQWR5??:MCGJ M=1KMT&B'1COL%I>J.S*MSJ;I"DU=U8X$VT<>QV^,LP=Z3TVE3UT+JAZS&\U> MQGE48)BJ!J)V]T!]MT4>Y2R$N=MYD<B[EH;&:<:,%YT3NWRGZMR8J_OJ3R5E(8J@ :SUZ]O M,+S)5-FV=]' 7IV>W>SLMCG5YFA87\^V.=8M+0NS=T\6]!$E=]79L/C&W7#F M.9[OL[ EZN[C!V^.HZ#LY%?F M!:\,L*,FS(N,&^:G>@)]=L4L(SE9Y 8&AK7B+^#/V'.Y".VLD3'R5-R BLJ9 M7KNR?JEQK;85RT/;LM\V;FM#KS7;T\/2:Q,,^/DS3PP$?T<%!C/D<>(E:<11 M;8W3&'X>Q[S)A'JJ5F*Y2)/LUS@2#8E4MGAJNIC7YH0JBFP:]FV(H[H#3Z^W M:;/?^B'.'+/=M9B&[@4W/$C"Z(ZN8XQYA+7YR9WQ(D[XW$CG+XPDU",,QV>2 M/RZX+A57WN:@QC?>1PHKC8$\O@9 M8\--C;+ZX1.OG9E=3[OL_,N?%^].K1$B(D4<;W"8+W)ACL_B,DZZ31!L6W$] M,.W>,8GKQH>NX25%3'AD:II^7UK9A^?+R53;TF MSK6]L#XB0=TXR(^=O;@Q2GYS1(\=J+8:#F[(8T7^<<<^8#.]YXOL?4 8;[$; M;SIP9FZ8(KR6VH2U\,OJ"/NP6S#776Q07=B^0BMT!V:['2\VFC&1C,> MME_KR+2WQ:<\/+>1Z_PZ8?!2%=>F_^QT*WLM^[Z]M*OC\G9KN&;^Z4XG/5QC MRB]^-HP/863,L+N6%TS":*: W*Y9A(=CA&D$_W*P(%BK%XXI'5@KS(KA1Q,> M83;PYS#AAFW YSYW7QB_R'(MXVSQ\7?:XR_H$WS961"DS#>^\7D8)5C^!1.< M&5;[]'<#YF&/1*?M8JW M'L=&'?9!J6,3L#\O71@)M'NO^ RZ.CPX% M.6XM;*:6<=RLUGVUGVO=]4ZB.L-/<59,1X'$CXO+OF5)$GGCE'0@RM]LH#@% MT10F(5JIIC'G44R#X6=X[#?0I?$<^#NPDQ-(^ "D2*X M,ZY#.*& WAZGX]AS/104-\SS<8''3F.]@S+[6KI>3W< (P^T\*)RMP:&5.^F M\:*0'_&B2MO^_/=Q]/KG2I$NI]FU!:K*\N;>>FXRE2:K_J T/=OY(VP,5F:: M5#^B&9AHUO#H\2UO.HVNM9"/H?UW&N7*[IJ?CB/.OI^R"4SV#?-OV5W\XG5A M33,O4(-W<0,7UUZYPLED;RL4:MGE3BC4_AOP'W@D^.#OK#9S,:9 W/_]XK^\ MT<3N]B<3SNS>J#N9=(=NNSMN]X>=_L"U.D[G_P8O?K[Z^VMVM)-GQSQY5&Z@ M(<[A=:*#%?NYC'UTG@"S%-A"2H@^S%5^@H*ZOV V6KT#Y9B1*/B-,S^9.@PD M?>T=@##CA;,[0TJ,!VZ.6G0T(MA^.%[,9!VO @^')T0(+P0O=5JEM M5'DM_E@[=QX>*$9);P_B=(9629P?VW4$0UO=5NCFA5^!Q^EWD"L':7@__6,BYY=.,YFI@!5X/1 M;B&B#A !\V%2$["Z#+3##9">4RD!XL,>^ PG[ ;4$:H42>-"CB*-2^)&72/)'42GU3+*1#10FA31 M'>!WDJB6V1G9FDQ50AKX7,9MY([A(P2ISZE+A%]X4'0\PHIP44721 5\.$UNG^Y MH$5?V&!R#/QU*7O2"Q]+$CQI7IYX49P4F&Z!GVM)L@<]D[.DTFS$'=7D7\RO M47I0?)E%TV6-0]);E08,R!7CF!BP(C*.,6CP5\_I^6 M9!^^4HT+OWEI@Z4ZR@0A2Q;%IU7:[.K@)]I:%O/9LFYAR8+*83U7&A!!6+ M,V7!-5^,!"E9ALH#+_.@]2$K_\* Z-L>/&J)/IWA-[>V7SN>[ GEW 4GJ_ =JZX M,PU@!MO]59&K#*W'C8,@:MGEA%=S1L M=3>PE^Y;1+??*=F5JD485\0<.2^H&<;*@#+"Z)H%H)Q!D-SB'15:"IG.F51J MLNK[JR,BU8_>A!N7L)S T9U%.B;$]+!EPI>V;:97,]I5G)FZU ME'6KF74%2W>@;%QA\NHVKFG<3CUG*@4N"%'A)X632,^[9B9I-U M<&X/[.YC6[('W]U[3-PB5ZYEY0[M5KMHY![2A,\-[*!@85M=4+;WFM@#J]5? M:6&#MGP2]M?5:G=FL49)$\LCE/%"V_5*I/*#M%UODT#/M@NP5)RJT[:UTWZX M6K%'NK9>8_YRTG_3IRLH1OKUMMVRA)JPV[CM^297A^GDSW&"RUKE_C=:^)[E M-]X73%CUUIAK&BSSQ?)'96BU(D"5*X!UPB%Z](A2K%R16V?*!!)<[K2LG1HM'0IK(95VNH]CM'1&RFCI=&K+Z[D=,_-^E'"EY_[W MB_NS@"QK^&(+7G[\$CH9.@/3#.2:0$Y7Z0K?> SFFY/WKCEVT30)?;#<2$O* MNT\,Y\,@P.-:.!_Y+@SP2@#I$"U8A\538P+/QAMSLJ1=:_2F22C5$TKM)J&T M!G-I$DJ/8O(/32BUK*)HMD0%KI2"2IA0^2-LC,_F,7^C_GCK>O'<9W=OO("6 M1P^5M F1;(<^R:"/G"=!@N3PDBE;Q)0+-9OBN_Z@-1Q6?XW6X7;?]3K#K9Y< M-5FKT^H/MIW002;;66O8S=K+'J:.>O2 FOP5:ZK$$1NMLWRA30^S >6X")_1 M0ODD+)3W2VE\A8UY*J>^2NN>N"C0(NDDA"F\Q(V7NHYN0Q\:3U)AXT M7=M!@'G;;DF]6GMC;U3RGN91>..Y(GLL#P]@Z?4- MN"Z:C[D]+LE>8$>.#U5DM_A!1P0:4M'$L8U-88ZPE6--T7\:+ML#=L\1<5D% M-,_(,COVEAUM'P=Y9V?V;0VTZ0FEB7G!*VIZ&6^N2^_AUSISWF;ZK98\5+Z$ M$\ML=WKFJ-U9BA?PHG=&YFCX6B?U/!(<-XU$)FZ M Y*+SXD7L,#9G2NRK1U49P;;D4-12\ZK@!3MVF:OTSD^G^&( 'SK3/$[,NYK M2?$5NL;J=A=Q)GMTAVI7=N2 MBM;-[=:@MO+T@41\B/W\Z1E15$6DO==:W;"]UJ=:OJ:?=G)U<#0"\P.F=&;) M58W=_=SM[DYG8 [:1QBK;^SNQN[>3HEUAF:[WSUPX]PE4/KM$GRIJ^O^-I)& M?(,VM>>LD=2,D9]SU"U?M4;:2#0F=5/A'W/3[! M<[V.V"P^&FR8;5GN#XRO7@3PO^IVZFPIO'H(;C-*V4U&@TOOT@QRYN'[EW0[ MHQ7<;<9L=K^=E]]OP&S%N@47ODKC&(?0BA>H%$@O8"#X(\IT0^F1+ZNDCF&M MV6LSJBYCN)=R"[T0.HNT?&H-#U8<@E1A]]\>CC*+>X,8"&IWRI,9OZ81''(L ML&! JH"(2^Y,8^XS1$K40!-E.PN@!P^Q7PF]OA8,F&&B:B65HDCKI=7OEM3_ MK<=F5J^CE0ZO61-;AN%2KBM@MK!X'!HV_2_"EY$U9^N7"Z_8_KUCG3Q$\33L MNS/V+;07 C(>R[Y#DD$%G%XL>\R F5$+CGVW/F2E5K!YRX5Z?3GLC[2"6,&L M[4$.)%*L[J,PR@2ABF[CKC@FFK. M3*A:VP]A4_*?+[*G-=R /U]\A,%BXQMWN'>#(8P7^_6L'N,0'QSE^.7..)'^ MUROC@[=G3MAPNBK;IL[NH!Y]*Q'Y# W< MC7W0W?B1^9P:/_*)Z,JO*G0%A."'\!QX+S,C'/O>M0R9U2$VJNNL&-815,&3 MD,**^)QY&-[L:0$70)MA"@KMQ MWG7"B^,4NR\B_]5/OI2YMJO0CZ1X06,3B'"N5HMJN=?3P[O".D9VN\+UHI5: MP:=%X[>WA6^*268DP8]J7%4"U:?'70K>@_ M9)1<-M?"'8C=649.7=_4!3+'92_ZYD M&^X_(/>_4Y?"N:.$W8;EA3$88IDVI);#M=!\FX>#A&VM81&BV;C>BLLZ=B\H MR?6GT]:F8RVT"5AS.JHKO#2-OTJ7X&OF$N!#-T^;* &AD\)Q(OJ"#GMF;]!=\?Y%[4/?G(YI\D6 ^%L6N5F^ULJICW)# ME:9^2+F[F>[,S@W[W;3A['JC; XF3WZY% MI2GF@K''C/TIF25."?I;]/0IL$X3LJJ#O*:K,]A[#[8.'& R)U&Y%XAO&OKP M0#T,]JWL=5606%@KR:Y1CHQNHK4%IK0UP.0HX,$$]("@>=J%+8WSZG=K31[4 MN]O#BGUHP)/K#^';@"+4*388U5L2B_F*#-!LDD^S"(Y&M\DDT!2_O>/AI]%4$6 M1-EHIZPEUD87N7#:P^6&5/?);>,DYES$&$$_R%@.&X= Z2KP_SD,3G\]._MJ M?,CN!]0^OB!.0$F SV%=IG;W(?JTB0N=")/$\#J9*86D9RPN%(5B[\K"%KT2 MV9)Z->ED>0^7:H/V7C1Z).RRDAJ_R.NI"I@DVMD.=31E50V017%)KV57_L8: M';2A:+D4_+G)G1-8$]>M"%9*C" M?6R]'/0U&[J2TDW51Y[RP"EW!LR=K%4V&.(%&5[Q?I)W):MIH<4Q96C0M[N: M)T'Q]SS^EM5XQ+D25]1WILHXL%TA/%>^C/Q%HV)&KL^3!(WO_(#U%Z]Z6]6. M[:S\HPS*HH;5'V1K?.-4)2BK;VK)YO_BY"@%Q-LIDB_P"__A:67IQ,OXQT&[ MTL-.WC ?:6S,?$;M/[.)">N<4A<63 @4'_$4I(K(;\4G\FQ7IZS2F7P2O.4B MO\3/^B\&:&5+<:(4HW:\P/_421;X!]9ZEU]28?I<$D:%KK34>[N6Y(!W<,#T M,>QT;,!,;I.I2=,]3\&= 2$6RV:K!G,O!W=*=(4M.%W,H>2#<63B3>C7P?8XQ?#A.IM<%8< M1:K9.B88W7$=+SR;,"LQ*O%@]*W6AZ5.60,B%-E0>)A M>032MZYYB3=!@P5A D;[9.)A6]R$K.94$O$D1:+6*I7(@YPQ0<[XTXAYP/2: MY8[/QEE.@?:%IFZD3D8JP9E(YQV\!CA#? N9Z1':Y8$QQ@EB6_3%);" M"R ZI4U ^AYH$1MH:S%%S!R#$XIT7P]<*-Q(XK%;I"^\_8\G=QA]U*K8\LM^ M,6[6QSDC#_23%2)8P M15&JC"//O>8Z(Z+8 096GG.6$.JC"2ZCLLR]\>(P(F9BFEI%K)/MVS/;UA&U M9SY'>8%Y=MR$-]PV[D2)Z'N%6:&B[6)L),4)*[T[+8^^$,1>$@[P@-' MA^.K-QKA??X."#9QFF0P^-YW3L(0%RKBA6..QOI-Z-\(,@0'/Z7NG.097S-? M1=W1&#+U"*$$])+:2KS%\9DW0\-KZH&U"KIVC-'#&_U.@46>B&8*6SF-XLRH M5L J\!KOA@N6P/6:!FAPL%WO3 K^^J RL7B)2>4=4)WL\B#*1C=S@QYC&=LPDS.EO#G$7**"5C#^$CEG>FN!W:;FAKEQL-FWP# MV\#!CLQV&182TIN)]7S\4.YKYDJ9I)K"-(%S!&5&WYN8J13+,/1?*:SJA+>N M6Z81^]Y<7*G 8##*.(UPL!L.J_+12G8P"2J)7V7[!*.R,=6%H3TC]PD%GAQ1 M9#B*ZQWZ?>9ZXN]IK208?+"J'#&W"?-\/!J,2[.H^,&,<8IHDP_U@\1B.*T3/";@!N _, M <(!8:Z(UXNA"=(,A.J,72^-+#^5@7>?,S(?--BSB8?<)[>'RR(B3V+'/GNDWN7 WFTN3.'<7D]Y [=T_8XA$M M-+PECEQT*C/U2X'<%)2 4[!(94F C)W=HO4D_ <1%8+O/##;'">-(H[1)W P M8 ,H;6),41\*+)*1#_\B#UD%-$0<5T8(T?B9"64F4B488MW%LC0NC^P2,%X4 M3CA!^("^^2MU"5N2XF0_$-L2YP$V =V14" /WL.NY?6)C-L)^P?]D9C[N=\^ M8["PS"7!JQVY?C)BO6D84L5(&N11+3"-$#DYSBQ#$72A%]-^SD/<.E2-J$@Q M=G<12&AK+R %1S47OGBI&D\&A$3.B#+X= ,/-AI](SUVB8C.C"P]Y2EA"(&C ML@&;6_&XK#28 MXZV7DV3T(^\\U:S@V'P7 Y&:0^AZL,*(PI9T0X'Q3W6.=+Z2Y$4<3B9*W'"R M?L5U&T,84X?>Z04JF*K,H1@L<>&\&"+SY H8TK#-\]5>L8[NXR ?_YL7?%;,]!*ZQ/D*,49'1 M^"\95P6+4VP&$< ?@9<0)BTQ\H1C -4WQ;;+6RH'/\ _@S X_:-UV0)9 GXB M4AZ2);A=F*P29IB7^#J>4*I.G@&CXOC"L40_,4L$!8&5B( JR#:RKV';L X$ M:1D38?37J9"_ T*";K HDQ1FFXH+H]S[:AGG^;6+1K0XHL]NL[BP ;P9D-4, M_J\?A\J'P2 \WDOP&_2)YRQ.=$[!])^+;Y<&K IH3SKN\M9)+$C2M=Q2"1Q/ M;X]X@@[? VZB#Q2$^3*9G/XB+CV-RRGZB&?:1'+Y MAU0EE8UVBUCZ?82$G%*P4%XP5BJH[#;9++][#K.[Y>,CT@]AA+6=IQ_#D,RD MRTR#K+F2SL87:8_7P0+4O@H[_U,$1SR17$!+]N62-:4IQ2J*S!EG@129E(@I M!5-^6XIB,<9?[NX-+.+-FFT8=0EQ%"3EB!-N%55[X_GX"$#66-P M,;,24Q!,PFV0[B7#DXG+%!2H9D? .RD1O MPPG>F?2G]59]A&'6Q<^$G1,O?BQ#HTN?YV;DTE=XV[3T81ZV7_RU2@Y8^#P! MPN/+'\.2.9B4RU_ 6>$V+'XLQ,G22Y6)O?@%4-($M]OA)0-ABNK2:^>8#P&+ MXD7KHF6G;P%@Q#O9R= M!LSUC>-%3CJ+*$2F-Z7F1$H7M8Q/J%F!L/"( M@R3S;(6[(CTPZ:-)YXODIRR1,89, ]5ED28A99_)W)X#YS82I8ER3(?UT'$]'5KF4X M&2\%<-8R!=.DW"EX%QJYXM>*2 UZ#[\6%Y7BL5B<.%DD!C%MK%D[2\?: D?$ MQZ$HX.!G%PG@D8D- LN,"T^>O-"$?1>),G/2)>)=E$ 4W*WB39R0X4URF_\[ MNA)X;4N6'#XM)3.YOC0WLJ)%)$WJ42P -(^RU;O[E_E:9 MREW)FM)/UOW.:($HJIZ/S2R',948'ZL@@Q'B,RH*I-J9EBTCE J(I)2NX M7&.*5\/?^9W,[0TDK\TPQH._$80 0G;JS669D)-G.,YNX-< M."&-,9DSI1*&@D.2)4+GH7&!$WG3]*WX$WGE]*J1VSL[;\EP%&V+]1H12@VDT\ON'C0+Z>2>:@R,K7L. M)N!QF4-*MJ9Z4$U2JS M&OX1CK%]?)(9&E?G_SA3UD59A%]>6>>)[9KA@X8I85JHD#(.EB%3T%6[T%(R M$Z6)S^Z0:+3,&9EM+'('4+'.T9>4]X=YJ#9#$EQ*A:HX,]8I(+1VWSQGAKAHS/"M6'SZ%L2*I>58D#M*-9%[01GET7( TDN%".@<33%:^3:4< NL( MVL]6A^F /!8ECN)"0_%).IYY5.,H6$6-J0'BX:\0,1)L,U'E0VD5IM@?P2KB MZA0Y-,-/R%@0U;;X4!;AY1=O\^QS&=FEQ-G7=!V/\D!F@V8H4CK#*P8OIG?* MP>\-2=X3AFRBD'M7TG"N9,^)*W7X( T0Y%_#@W##VP +O? PQ"V$@,L3-[0" M6!#LJ4(!;\)@NB)Y^W5&S4F$E1%C%D4>A:"8^U<:)QEQZQY )"""(G:K%1N) M.UWXX0WS?.G!9' 1XBXXD=Q"F%DJZE;&HIKPHE\U!+8__4%ELZC$76E8F.*P ME"Q2EX>1!,L4,)G4DD+^'.V.^V5)&5QFXBR=S*X4K+W,'"M0@LT +D.N;Z13U$1@W(2FL-^+"-0$]$* MS%;/"#0+MD>.:&LNUM"HG-ZB=!;5 X6$/;H6$P)#I/GA_;8L% 4=$$8"K@L$ MO_A,Y!!AJ0-W4E5/JJ2^6K^7'% #^XO40_HQ"RX%_I& !ZM#L>G^3 M_,)_N<;'%"E= H3"OU.WULO3?]V8@G5A\KQB6X;7"*4NB1>10)8">"!X?XD0 M)D_%=,7?$TD= I"%,%=$P5\6PGW_AZ"BZI@T4EPH,"ZHF%',L9'O>S[ZQ3)I MKY!WIZ' 2]?8Y]=>[+."F%4.K3("#G -E+\% +#?E^YW?&91I=>XY2\9-%28,.;I0JA'SP:5%1 MJM_*-[H>188(1R+_2G^."N5+ZR>I0$I>4:GI6JH4P@: M,&Q6 P?$8D%"N4=SOZF5)=$(1S/+A$1Y)GLP8 #-<<3E)%6U$R2%9SUWLB WLV\$8(HER1,@+L\ ML3WOA_ 6QV@J8A\O&4\XF>3?;>]NT3C@_ ;GP)\_[^X@&&0BL;GHI4BBH\I M@N$8JKQ5 ,AA@L0M'X,DXLNP_$5B,HU_IBP"J0)JI>3[?V)>I\!,6?QVB ]3 ME2:(,E?"#X82:%(1)NC .,3+M5A'_9J3#A50?WZ]O:V%>/6Q:=>U +% M=FQ9>W'U_I/1:1F& MZ(>Q_-]__G'V^>KBZNSJXL_WQMGG=P9\\%']^]W%Y?G'+Y=_?'M_:9S]\N6/ M*^/3V;??WU\9H A_K]R-:EE[SS;61TA?"/D18GHCHVM U1LB;^EPNP0UFG4^ M1V(VUW(MFA5]?E,%B!UD)$T(*L,_U?U$EAJWB(A7DV"?16' M/#@S%6X8J C$O! X23@^?."K?[_S8K1A13\^ N?Z)!)]$"4V QM[I 8Q^0(Q M^U3,0VS+J@XP<#H@.C9J ?,$Z/6#C^$&ECNSDO3$!7D1:DR4R2KL3+J6H9B% M^$0V'Z',EL6FCH*,B[F6V9NX4M?7A-$HL'0%L+76>5T4__U;V"D+W;1%0S3B M(5<(?XG\E+\DQUU&(J1[0\0;Y=A%B^E-TU3?0:I(R8!\W=#W&5XL8L9"0,27 MX70N/A+%XH!E'85TTYBU[.TF_*66HPEZ:5FT M:[#W&+:>B697KA#OFB3/.R>(^W6J"JP4Y>427 7Z=6&-@.EIA(V2/O$?B.!A MS'D<9K$8;)<42/DLT/U=SR5#@6//A5 MBN)2!N32H(A7+6 ?8Q#&+/)"F,L95A^()67CY&TIC)L0E0(%1&0+IQ/OE0YV M @XP[+;HQ829=_("0;Q<:-PPD@K7P&OU-*8>!-=!%L(D1&&BU#L[%Y5DN&A3TC 5<"QP!8AT1O@C,XR_/ISO1@EQ]+&KR_( M*BKQ0E<;B^NZJ(-M^F^^K;?K*4SP;JO*^SS_\OGJVY>/E^1Y?OWVY?S].W0V MGT*<[P_J'D(IZ.D<$\]4%IJHF%!X1UD_/\UPS=V]Q0N'KR!I\=>^\5XD+@'S M?,$J;WB5*J/[^OY+5D6'[\J?^9#=HBX]\R%[1ECAF$(C/-+LU@S;(!(JK. X MER.0DG!1\^9[8@%NYD<*.1KZ@F<)E]<55Z4,1?M$(11_2['QN=5AIU;OA(N) M6SU7_@N>FZ7^-4THS?:U+%9X)H26->ITZ15RLM0A7D*@P'&&Z,?GHK"7)2 M(,C)U@0I>K +T#)7V4WXI'*(1:SD'73&L]J@0IMXV_GGV[ M,BXN*'/ ?OOEZK?WWXR+SQ^^?/MT=G7QY7.%A[&S68[63-! ];.U0]/I/%F' MQJIT:#Z^__7LH_!DWK^[^/SKKER9PZ7I%*^I%.)'WBQ3[T.YR M!R+V"-AE#T33$#T.!UJ+0U,^K"Z^/F6F^-]BNNA*14H!CG8&-M!=[)$!GCM) MY\4TKF]Y;[$O>=5;(?WDL;'\[.K[Y\NZR^ MFCD\9UD]T;G-8'G6H9O3I()OQ)9,P5V>7Z;UZC2-NS UXJGLKH(]$@1&^HV' MB?(*CCEOHYNSI6P'VE*<02U /X@?9@VEUB9J&?:MI&VZ*(MD.'C,,:30_ONYC^^>^B.6[F8N$-Z:F# ?%YS-^H/]X"J_L46O0'51^W6Y9E=^M M&K8_;+5[G;6&?4U3%M.&]>.&_?>+SHMLBYCS_3H*P4(]E6SO@#8#XUCNG4@- MA?,G164HH2"_1:FY_*64H6_L^0_#*AJ=.%S)1A]( !$/ 0=HG= RDI+[NL66 M2>52N6FKMS02\WNB.Y[;'86-+B72_HZ(]&GOZ%F9/#4^8:-P,N&B>>O^K=:( MNW)'J_?K>#;K0]ZCJ[K802^\UUI7B\0?U6$R+]H5VLUSLJQ:"?NNE#*-J[IZX;'G+7"*7<.+7>-TH.KTX M+-N*EG&QSB"J;VAIB[1;GKTD#40?UA5LJO9F\715M:OJ?X-S^Y!&6&*"4&FF MO+N3C;9*BI@H+U];QF+"'\Q-*\PLMM&>P^5*O:HF!^QV>5?,+A!=ZL5Z_ MN:+D2O6P1(3/F2B:RYI\P>J*EO##1+P2!6T4!"_V(8:.1MA<+)^)%PO"$61+ M^;>2.BF]1Y9)X^U368H+HZ0++DI^)/2#*MA7R90KVGF:&A95UN98/JY8328) MEVHCO 9='@"F*RM *==5PSW7T-"!_ESRN#/EA;?VP8JN%AG+Y5PMLZ'FPLG$ M'F(RG4;QAX:.FN.CY4YS/"?^#&1FJT18*ZA3TL1I%*2.3*\GHK__E0MXK6@@V]MB M[]S;*=90E;"@Q!DT95=LF=J]L/6%IMH/LZH>XDDFLVANY@9@+2_FEG%,#!<6#D6*O>/+X/ HV+UILR\,22DDT]?X\LQ $ M&0*B%7OT8"ZB7T8^N<@F7J80I$PRP66B7"* "[I\5I4K>0?G8E$[B1@I55PN MJ_Q @N2H:P3-(O,E94:$P"]:%F&%EA18'F,@\2C,HQ)+AV 6/)3_J93?=*4G M 3E_5W6!EO. MAQX5O6P%T*::GA#.") N#A(U4+;\$D%-!8[4T'!]2[M4Y"XD:_1&9-VLE 0K MF'E]ZVC=0<%3D0=%:8*0SN(D*Z4^Q"U@R(PB0DXHE9)T)0>1=: 4;'X-L+$ MZ"AK<*<,9D%:62#"-+)F$OKH8V[J]-HR/B^/F%WDDP,C_9GUC>:,-43TB^/%8:0B)3Y5F7$NJM'H+,,F)17>JJ=L>* MD%O&F?17"1U?CY*+@\XDH^!J^+V/[N7U5.+)D&4%%1V-& MHPH"VE*W/B4AK,+-0Q-B7A!=N8I6:EFW'D"UI2*(Y?)QLNJ&$2-PJB<7_1;9 M5/:0*1SYQ.<_)'!KB4;:)5OMX9 .45Q?>5*Y^L 65Z=XA2NV_B0WK:61(C[/ M#$19@X8/^"%!R-)EJ\P &$>>>\U5EN2$.1*;6_V,QLI1VE^1-:7ZWJE;756J M-F=W>DM'A\53O6Q_D5\Q;.JY,EU:!'(SQ$OYB(K3RH@QS28<^WFW);W>$AT) M'=49 >!\+M##1'\D=;%"99B49(XBB]+70" M!RU.'>7VT%6ZA T60L[E/\RKF3.:RJJ*.XS2Y#PX;7[ M@8*SUZ+J?>/HK7RYR'V.48&,$15>JAYVK=H/>03E7;"<,$3/A)DN;X\7P5OI M@%26[YC?A?)N5)9,WIMAHJ5UJ*0."8HAZ"/#A"UZ9=B7DMV$D7B&D&(S2-CE M=.'JK. -U.(6B9M;F%+;O.5)F%I?4KW-)>9TCT&,T-V/9FN!RP?B N,R=.'T M[Q23)V*A) 28I2X0WZ@154W.3>HCRD9^9YBA;BC#32%IB%IUV8$D)_JW0L>K M\;21!(RQKJ4TT@U)1Z@LO]LPHGLUA\T]ZJ B_RBF"^7LI2:9W]05.MH1W$=F M>6A3FF-W.^\&] MF'5%V$:@M9ZHZRU(JV%LYF%)@J0#R*]I%"]!AI-4FZ.8L M8J"I0(.F&.89P(+84PD"&*H*]/R@37&W2BB7;NJ4;'*J>N)F$U!;N[2G1:S[ MLATV\\TQQ5YH&R2V=?7.+Q"#9NFA$L4@1"!A=&2K+I1>1 [F8B%^(85$T=U; MH<=2 ?("5C_*-RR$ 6J%@V'7(F[#(N$1"K$KNOB@-!;M)$6CT'R32SR"RGN^ MA7JHUD)%U+ UK"[$NP<"\ R?ZX?(]?RFK^W9?R[TEG/;8H_Q)@X;HQP(I9:R2B&+^$ M6"@+E/<.;$GA.\O>V@0D*-*R=7-]'H77$9O).(;$42SYG1HEN[>@XI ?JC+@ MY6#4:ANP2)_:!>#M P:EV ^N;O(4%K?LHOVJ9<#\12?#]GTKH#H42IW,/#E5 M1:'M0,D<"VY3'H-]V<$4C@VGBUB2."T)$J65*B<""8O%BYO2Z71:HXU>(Q X M9[)OC=X42<.[$ENDG6O5J,7(X MP )UF'K%.L4TM?W!VAA9OR":(E)V;JBR=&6#$/#WLLH'Y=OI,5.K/>Z=6O+* MV#B#URP>1)[![XAD8A?[N\>R5B$4P'+R,M0E'PT&P4D@M#=7=W5:%3$\'5&] MJO*YS[_\>?'N%%@#ENGRF>>8)9,@"#?MO8%Q!JZU;U1C81P?6-T'U=PR3A"F MI B GIUI8=U40Y+ODVMT>B9,4H4JLAX%BE)D@()=7R-< ;;?R.5-KT3:E/,_ MY2HS45RX1+7QDS@+#99^XD5Q8@2(!CN#YZ9Q&32]"(#! 0Q[9F_0K3H J1!* M]W_4ZF7[7W(-(7AB3*=,@8X@EHD\!$XLY66\,WEX:-Q&(%;,):!3$ F26-6' MNB0N]M^06ZO; 2BJ!%[R6LT%I-I:/K 2A?1FS>WM%;>W5P$P5K/<3ZO;&G9Z M6^5^KOZNUZE^Z;89I=:PU>_T=SY9N]4;[#[]=6^3M8?;G=?*R?9;O=%V![;Z MNU%_M)>=[=J[ 'S9\+I(%>+,;M2.$XSGF5+9SB;:X3$]^6!EEB!8AVCE$5+H@US0)NRQMYCC M,W!\C\BW;;BDQE9<(WSK'N)KA%F=UO:@0%T3BUMCARDGY- QN.:R9)O-.")_ MN#G@YH"; VX.N#X'_*!PU^-< 5:"I!0*OD>+]=ZCW1<0]5K#WCHU\LM &;A% MIYV6A8\OKIC%7* HG%A9VN+CYOR*2M!W(1<8E@K*;Z#*F_(2/ZVH294S4=FE MP42F=-[CZJ4U[+=L"\'@5/F8@'#&$O>+2^J *3$$C&[;.OG^BO)FL;IRS*?, MG\CZ9(%)AO"R(6+&BOHIO3;U=AJJ,E$70:%=@7?5^W9P*)3"=/F/J3?VDK<' MG^!#\%&>P(K8DUO1YD@J97QT%.@I_4KTE/?_\]O%+Q=7E\L%R/?TI3_$@MX+ M.HL5I!UU-[A(N*R4Z+?075 MJE7+8S/>$2K^'+]>H[%>YX#=B[8(#9O#X#YP\\N/@U=Z]9]-IE"7MM#7J#X6CX M&J9K6:..9??LMMWO=OJ=U^ZH,[+MGLM_V%9KFH 04+6(>>(1CUWR^-WT(?3S\V/GX\-XW?^9UQF8(.1OP/*GR4'>%+OO[$ G"A M",V7OOS7Y6]?<<0+ ES./R\\1)\L^]C99W-?0"S_$GE 6U\DEOLY=6<50,&7 M3I@8GSS?F<)1&2?@0B.X4FPHT0/<@"[VAS":&P-^!PU^U2HS99R-R[$;D M/&F1TVUW^I8-X[='_=[KP(&_K.&P/_AA_1_(G5,I>(J=SD2$;"+;H"D1] \6 MI @;9 D99"W(H)SQ00B$/HMH5_[()!.("5.(C?/H+D:L;MEE[3(=&Q9]I35_ M@"]=$C3G83UMLL2?UH@(J?S) M&(6W7/0ENP8S JQ3;/="@+&R(UK6'1([ZGBNQR)/R!W=%X[SIV/3N('?A*G> MVLP+XL1+4MEY*S9\%#/X4WS3/[Y^"J-KV)ASB@[\PH+OIO&Y==:B9EYG[LP+ MO#B)1'_4LVO! VR;?T$N,?+2[)#'@J:S>7#\^;+3L.71\V7G4/R98$MRVR6AC.WY\QNPYE'S9G= M1>D\ZZ;E)KJ>%9A/JTL]L M,'23'!8TY^N86);)< -.!?MP]5' MS=6]X^-J1/BUQ$]Z#4?OG*/[#4'9'?K)H$X)'F^$%W"?6L8[[SOFD0"7?P?G5_R3 M7B?^6LQ 6XY=X^W002[Y[Y$)"PFP_<,EP!Z3%.JM==772*'#60E63PJ0CSS! MZLMO_(WQ1\!2E[3Q!=*3-P.V4K=7%\$$V)%&WHQC#I@R?D0*OAL/VPF'K7-8V''9(#K/7XK!<*S4<5B<.6Z^\J>&P M W*8O:T.HZJ!-3GP4K9\'K7[:NA+%HU9P./3+S]\?D>L"=_8[;;=<.(^HD!6 MZ_+\MWTQXR&6=$$%X\:E,^4S9KP+G70FKM+K7+-Z9"1S?O;Q"9+,.?,=!8#P MT0N^(TY20T![(:!W[S\\00)ZQR=>X#7TLW_Z^7CVRQ.DGX]LS/VXH9W]TL[7 M;^^?(.U\C7@,F]UHK[U3T#IYB4=#/>?A#?ID"*1(H7QP3-&9>\<2)J[*3D0T M7Y;>2&+[GU^^?11U+_ "!I_@]9EV0V>]*B&X)53-M0"E'A,CL12FK#; B=:" M[[LE<&)OG\")]<5&//A<'@*#>%R39\<\^_/KY[.H/S;HI MG:G$5[1ZQ,$OUA+"U0\^MA34HX<8+I2 AI3PE840N9-&(/)Y7 SQP]?6J-,U MZ4??^#556\!04U!L;NK?&0Y+$7(XF7J(E#@/HT0B^\9PN/ %6%8(HBC1@B6Z M,-&9_ %ECZ4!/$3CL329AA&LSEW& #X(XO("Z/:FX(U+6-I[0G/LM5M6=RLT M1\2!;%=_O3_U!HVOM7;U,C?M>5^4.SYU_%KX_>S;^\_&Q];QB]_ M?+OZ\KELTRJSF#= GZ\SW..+GW]G$0]H$](H*0=TK/F)K[=.4FM_(D \^L>> M2WF/J-LCD$SRLNI\ZO$)* @G!,F-&8WRINK);LH'/HXH07(D\B./T56KC5=F M5WMEK\>A>P?_;YK,_)__/U!+ P04 " )0$E2KI=PE^P5 "+]@ $ M '-T92TR,#(P,3(S,2YX.7,ZE:C46)\JUV)B7?=ESK ML1Q+LTF>4A )2CA# 5J0]%CY]6F I$2))$C(\I(G=-4F8Y'H;@ ?NM'=N/"7 MO[XL/.,9R++MSC@>XX^*!C4RW=WHRL'Z>7?3.SNT3C/N= MP>G [5@G4ZLS17VK,^@-;.ML,.V>FEW)],6_\.TY7B #&D;]BQ?_T]$\")87 MQ\<_?OSX^*/_D?'9<:_;-8__\?5^+(L>Q64]0K]OE7Z9$W)_Y'FRV@?*]K]OIF4E0P(@K6A/H!HO::-664AHM\ B?@Q\%JB8^A M4 =*@5 [+<<)UG1I(8/CZ.5:1#G_;=ZAWQ&/-_WI(G\J*9(WLMF=KMD1#4=! MP,DT#/ MXXMK[*+0@XJ%](\0><0EV(&!YF$QE+8*I%X'B,]P\( 6V%\BN[RO M/_]D& )_LE@R'A@T0[BNL,^#K;I&(^:>V2B0:I#NO@S1,?8"7_SJ;%A\?/&= MH^/J%8 >FR&TU*]$FC"J2/SD=97)PK=_;20O_>JDM-,\/S\_?A'J5EB/K K) M\AWQ9\?LZ8DMTL7JLN%7)Z$[1!TVID:O#@G=*^N0;V*J5"5-^1 1BKJ_:4A"*[0&N ,6'HZZIL'MMI&GVVX@L4-/HOS_ MO?4.=G5;#R2$DO^&QB\YUFT\D/C@;^Z#O:"?P'N#.)^.DA@(4>>&!B18W8&% MX O)-WEW9 B2;T]W16ZKK%$E3DE-DKIL,/S[?O8N*XB()P1]\JTVV/U%RR^&&"C0*QJ]'#>'1_ M=SVH!1&/H2!S#E>9I MQ$R-B*OQ8<01&8A+Y FW>SS'.'A$X&$$/ TG=_#V%9I= MQE -=;_;M510;[@;HUMCP_]=V;B/B_6]ZL5@W'7V[O1W\_E.'-X:?&\:3;/=7036!O2/XMU:KQK7TV[WK!*N M:TF/\U(D$;TA;! M^X""D&/FCB"DEE7Q(1H@/4G:; ME/T5.&6?)/^^^1!1B%:-FUX7_GN+<9/[[$/RU_MXJ@3J$W[&-,03-/7P-0X0 M\=Y^(.7)5(T@J]NWWF8$Q34Q9%6,#W%EVC1TLNC(OJ@X" JI57#VNU8_"V>N M,D?@3BGTPMG^$Q">)8EU#L.,'1(QXOT(1#9_AD +5[L/ E,G6+=03 MUD::M]3B-/>JQ=KG21P&/1V5/ZA$M9DXZ;_Y@'DW,#G@W$*'(P^>U@V%[EG@?#'DPQ<&3/UT)JD,/@GSN2O#-KB77@_8! M/Q%G3%>&[(1WT'-AB7M%[/LY&-1IGFJ 34LN#NT#\!I/&9$.1E9N(4EY^-![%+HG5!VG9';O_2";TJ\%$&5&:_7P&? M+&#M"Y)4/:TUT55AI#9YEB77474Q:^'L]1AM6%T]>BC:P@G3P5*L,VK8O!(> M:O,W,+.^9\+P9T.RC#:!)DQ;: L+.[CPA8Z%W)N[VFZ>]'6!+8&]?195'QDM M.[L_>[7U/;7D;H?#(=]"NWR-ISHF>%-<;6W/S&RP)VA;:%1%L_6V 6Q1*%?O MS?->-M<:]7,;E]I%R\7_=&:E'1KE7-/K]@N&==3G[9LYDM[3F@]VB916OF=: MW7-%G[?09@\=1[)"7M%Q"S]UADG#NN_#6#D/@(7*YH0V4A3G-?RM8UCMFS7T MH- KK;6)Y.WKH3:Y_?Y!1M ^@ZY]YOPMT=::(OZ,BJBG'7D[>5H%&!DQIQ9..[N=N?M;,[]:C9E:$4\L M,[,?,0>K//A:J$A@9,0V34PU3R?DT*E5Z-3,)E^VF+10>Y+5SC&>B832?DYX M&1,U+&=F-EI:+\+&+%ON6A=W-B_I^Q!U"$5]% MO[3LKQY+M<7M6V9F/XX*P43&&M%W&[ON_YV?!\&T@*<:5,LR,YL%5*!F];2% MJ(H5\F!5#:VXK'HN')C9D#XB;%&O/N%ER.TY\K'/W#WT0D&OUH$3R\PL8J:8 MR:.Y[1WLLNF7T!&.N,P&4U\W?E@I=,;2+6 MOYQ1,,?\UQ!Q1 .L%8J7@M?)VQ8:8SUTDE=:9OEU(I0&VA+[@P\R!-:OWXWU#@Q1 M9!P?SCP4\ 5LU6"#QFV*9.?NS\_$6L@TI7&294J5^WKFM M/:G"NU5.8/L5$7K/?%_ LGX=;7I:W]EZN$&RCS3U,#FU>AF7O&B8".G&!R'_ M+X;X"$=ZG,3[O#97W+9ZJ*R5^2M&HE-%CVB%T<7TZ@G\S,PFD5/:G6;7P@D\ MMUMS'VK%R[I3^;;BZ"L!#:]DW@:A2^$,P1M^SQJ(O?O$B6^R?6*>YS+^ W'G]2A7EZ%&W;1ZE;5Y(]/8 M$FJDI+Z/@J2[AL_0#<+,0<_X"*P=MD-.Q+?77H]^.6\UZCVKE\UC%Z"^EM4! M81TAS=B(:R7<3]CVD._+2Z@%2Y^% 7.'MATN1-UPE)O*^6;*+F%5.@W/K*:Z M*;T^$?)G5KTR%35 H@CO4C+C]%ONYV%VZ37)V^=<_NDC0\='K:MR2E=W8/6S MRWUUC]OV>2C;'AT\*);ZCF![Q8"+;0_WVCHA\AC_(ZZ'/\1 M0DN\U0B<2"ZZY"[ BXJ(5&&DM% G/3.["AUS-1@WTGR--6-#OWLVFEBN"UT?)5Z'8M>ZC!3VTE+:N7B5LJX]A"^SD.IW[4(3?BBO"J MAQEVJ=26<6!F-UYL6!@1CQ9WNM91H7Q:M74[Z6>C^0P ;;1CN[VI=Z2G@%AM MH4ZM7O;(?A:+_VY;],OQBW^!EDM"72:>1+\I95'=Y2-X@KUH@Y6 "GK_7\/E MTB/8 2N.;5%.K"(#XZ]X,<7\R$!3<(>1'7PZ J\8'QD4+?"GHQ(B2CRY))D0 MO4RY1RZ6 #5S1(4_'3EAM#9]9/B D_A@C/CU*V?A\M-15)S !')D!+(X992& MBPN'+1"A8F817(Z.B]KT-0Q@.KVY%3L.ZZ0]=R]D(6*,##V8SC&?SQ M&)_B?>3$QB,W_=6==,M<4#] -$A>3:.]G9^.;(X=$E3LCNC) M@E%01KZJT!^;2@XIC+@ SZ+NOV)^H&A^"9D.S#O-=?#TS5K[R)D#P>>3E(P\ M\F_YAWH0JVGJ'L]BK0'YH%X. 8NH;DE^V;I;L'-VQ1\NQ%>3.;;9C))_0UUI M5!>7LX6-.<1O_>@FI..*)^ MY.L-X[-OA=UP$-Z-5?G2.YMWKT9CH"*QKF3 MDDEO]/O=M7E.!)SBA3#7*F^EL'Q#+5ATK8_X!)H?R"_[2&M1!&51Z=IMUW:P MF?/9S&@Z'KD/^,#SH#@_T,A3<-RF9C\2TP\>\RJD.! MHNJR::A!CA,R8Y%.2R+ ";;GE'EL!IY6I71.*77=F%]%H8\(C$2H&$)]OR#N M_$ )F M-GQ+364*YWYR/4[T\TY/S57T#=7OV$%\!-3P@M@3_!)<>LS^7N91YA"\E1(' MB8CJ&14!!'/?,J]R E-'1%117'RG4L>M[$DPU9"5;>%_X*1%\QML,,P<.^) MB\7G 8=QPXISH]4Y'+RU>NZE4#=Q[FWDWL>YGE4E MN/1V9FT)[5$[8V&@ORD]QL8ZD"'NRY9H3[4#HS=PK MV4N/G#V#[C@!B](1N-A=*B-KIJ.TDWC86?&[ 1L2K!YP,'(GZ.424^R2ZEF, MBLP:VC$KBOEL%R[4C(Z1(F[1Y-+,X?=/C+@_, =F#RRE2*>H02PL7C>D!6[(T/?# MA=@0DLIPCMS?\*ILP7<_;G7W@H3'M*SJ6&8+U]V&G)RT6%Z\%AV)H6U#=<0. M!K'ZG:QF5T&^ F5#VQS-Y"=G6]:_RN1?0%*WYLJ.WZSE^O<0M'O]0)EY5M(T M-;_&%E!8*I6X>NH>?#M6\);Q&?@:P@49N7*=LGP51(=%,T.)3< CZJM>O,TO6S>,\E3QA*WO M\EY?^UGJ<5:AK-G1%!>T ._&BDI#Q@P1S0J'F%+\$*YC+U496AT/= MBBM<[LA,KA,RQR69[!4'=PRQ>]?E&P;9%"?A;9,OUH$19)NP2)U/W5IJH$+I7 M\6RF(R!R9N%"U*OBXF]A^;H!_T;CY?<)>EFO_3UA/_3$ !6[H.^>QC#WJR)D M+1X-#1;3.V4Q+G?OBLO7C>AF1;[JRGU3QN)MXFAX3,]W97MZLR7K1C)]<& 3*(S*OU!L GO$0K45:DET2VJ=?M]92.G!:?6OV@!RQB!O$)*G\GP.5T M=0_GG0:_)<9GVZNIF@ I9=-0TU2:$,=7'O-!461*[)7)]3Q>#>T7 M/6WM'TCK^S5K_=;^WC)C7E"X[@7*\7X+E&5D=9NM!R9"KOA3/P_BV%ZR#B ^ M#%2LE*5TS0S*RD]^Y6ZC>L5)L@)^S>R>H6W#(^$E.@[>^,$P[:+4">^290DM M'G6/_W( HRA.+A#%EW)PQ;[$O?DU=,)ZPM"31'@;*)!'G"%^SQ[7&&X_4QST MV(M;0Q@H7])9P M7ZSCRFT3)W?_E5-*:,JFXHKL17W#UUGFZ[3-TU%MLS1O+@P F!M+P; %,_.HNPN9/E M.%J% =S;RGS\,JADY*+@Y!J2],% MA>M7;SH#AW&1NK.,*2_W*B9HZ'R^G>T73G+QMM:2JU*+BM=M:'[#JW'(9^+:4[7[DU.P[KK?$A]JT^N:ISIG MQ\JH:G8&Y,Y3EW%,9M1CL<]2LJ%.15(W2+O[;/1VY32E%3E[9:=XQ:B3V2NK MO>>VA$_=+:^0]1>I+9C4?'S E81BG@WU9S23R ?(&NL8'\D]W0AY2;]OS_$" M??[I/U!+ P04 " )0$E2*UV3]A,C "1?@$ % '-T92TR,#(P,3(S M,5]C86PN>&UL[7U9+,O:EH[LG9%NN:B@UP^ )F)1.;?_O/KZ>399^CF MX]GT[S^QG^E/SV :9VD\_?3WGW[_^)K8G_[S'W_YR]_^#R'_]>+#VV>O9O'\ M%*:+9R\[\ M(S[Z,%R?/_I5@_L>SW,U.G_UKUOTQ_NP)^3 MQ3-..;O]:?=7%SP%YBE1V7DBI8S$@0*2047/,C=:R?_[Z:_W?F-\HIGXT.YG-8S%^>=QWJ8L1"=#DR1KCFC$@3);%6)N), ML"J"$ ;D36%=9'BB[J8(KB'JH(O/9EV"#C>'GYY]@;*47^X3*U)]%[^#VLU5 MZO(;S^?GIZN92!!9%?<0M0E"^)-#2#4U5 /&F^EG M''O672 A(RV=50DM'I6"(5(D3;RA^$.HK(!38;5I 83K1&RB>/'D%-];S-44 M?;0X@>Y]!V=^G Z_GL%T#E>,@0C6@Q(D^HC6KL@>>5*&>!UHX,+:%)OLBG>3 MM D(Y),#02455(/$\6(6_SB935"<\[)A%?LU3LZ+,_9^UBW%O5ATXW"^*"O5 MQ]F[&;IJTP5*#Y_XZ*M#M"2G)''=DIYXQ@/Q/B2(FFH!K 5\ MZI!?7X@CQC0WZ&<2*U)"C 1!/$# U9QIR"P8Y_AN!+)/=M8CH.WV!!RHJVH3 M[[?Q=-8M!7#)E(S2K:P_P,DA/ MU=#R=NS#>#)>C&&.WL4:#!L=@Z+((G.\;!X:T1P3)]H)GG5*QNLFZ\U#A%5D M?&1U"C:CFR1Y1N,X48I[H^#$9!JRIBDKGQKSN$^+:55,W(9]7[GOFV&"YK1T M-#H"P5@BO<2UG5-#,A. ;QM#0Q/,M#!,'G,*Y2%VND3U"2V>C1=^\A;\'(["9/QI"8YYD?B5HP*0I;") M*.J 2 <*W=:0B3')\B1HCERW"2L^0-F>KLY;H>+[@&)-=50#_2O(@,,GG*:S M4_CHORY7A:5WBR^N,7^-4 ]!J&0%23JCG1TL)TXQ39#&H!)E@')J@9L>M.[I MPCL(2:U55C=,M9X>"AI 1T\T<\B_5)Q8%Q/127MI!3B0M 6$[B9IGV*5M9!2 M20$M=MBK8!G-5@JE7(G!!2*U0D:MU21XR-1PIIQNO='N89RR%@ &"KR>XF?3 M3Q^A.WT%87$-A-E1FYE1)&;<]F3QOD-6N/>9'%@HQR30Y+!J/3F; $ ]-0 , M%WS+V:^T%DYE3EA@C$C*+<&U1Q(CF#*126I!/<;LKV9M?V-4V,PU.E'9>Q1X MM!)G'55$!&.<](+3T.@$_SZR]M3.[H..#3_ MN8,;YIQT),CDB&0IDZ"I)C0Y;X%)D4)HE.*QGJ(]-9UK@*..%JJG_KSW%R5^ M]NW$F5-KG49CGB9/I-*9>!XI,1:L!8[DQ":Y'NO)V5-#NA(N*"\1 +=0#Q3+!942=M)(I M')LA*B64,U*#/R@+GFO*=:1M%H3E\$.9>-_-SJ!;7+R?^.GB8)K*0<)9R;\N M"5=2NA"STD11793% K&:!@(0A,P2 H4F 8/[B-HG.[H' FYCNIK\ZT42D1YD M?OII:<]_*&(\RK_/8N1[JBS'7RY/F7V:S]&4\F8R"5QYQB4:YB>B]13#$ M4^L(N+I,I:QUNF(IX8)I(ZP()*0DC#0QFF[3<@^>3,#$?#= MJ< 0F5>#]0=8^/$4TJ'OIK@]S@]B/#\]7T:?7T$>QS%Z6;B>JH1<(UU6E)D\VX5S:Q7!XF;9_\FLKHJ*R7FI&^*SJ6%CBB^*R#$YC.QY]A%9I^ M.YL7D^LH?_1?1S)'[Y5&I@W2)S5#@YP[1Q+^2\JH+0?;*/ZW#9W[Y!Q51E)+ MC=V"U=^>WQ;?6WS=JB+!R]ET/IN,4^'LA9^4TA3')P"+][Y8"2>P&",A-RFM M5+9@LY%W4=N@APQJEHHX_H@_?SM\]_'XZ/71^\,/!Q_?X*>U:D8\]/2Z MZ* METI5)+Y%LOZ,1:8YH]*%I!O="MN( MO'URI(=AY;MK7O754]&[G@,^IE3O>06?83);'EU>D61"8LG&3)@%M+1CU&AI ME]N0&IC)420NFJR)]U*UEZMD%:#44T9-?"RZ\[@X[Y#)E[/Y8HZK-^[02BN2 ME"P78ZTH'$82668>8LXB02-0W")EGWSBZD@8(O9JZG\WF\YN&@)7:,P ()7Q MQ">(1 9 )UPX2I2SVD,V4;$F3L"=%%4X(UU>I[UB,&432H"*.*%IJ82)_Y*@ MB74#E M&8%+K]4QI-C$=KJ?K'W:"MM@HZ):JD%EY<4L/:(0LX: ZS'CR]M&+A'GO" , M[;@LO>8\-X'%GR0,7_:NW+O7J-*7LRD*^1SE?+F?S:;S%Y!G'5Q+ZC[\BI8K MHFL\]=W%&P3%_(["!&"]H!$%PQ24"C2H?6?P!^ $7JX2+]#Q*F$'GP4*)4ABC0IHD,E +,] A,N4)Z>DT4WR M'NZ@9\O%N^W.7A5+PT3?)+J7L]=4:$VD#QE_ "7>2D.8L<+A7H&&>9-8SYW1 MO3ZNV&>8GJ-CD8UWO&REV9=K5I$#L>@:D,13EN@70M9-0M17!.S3&MA7Q]\[ M7#V$6PVIQ<,[RI7\X[.D:\?\;T\^NW]A\-?#]\=O_GGX9MW^/*PQ;GEO<.T.\#]3?UIH M^6](O_CQ=(D(W!U1^:^6D?WWN%?.TK?$-J-2YM9K0E7QO!SS*%.4KD4#AT$4 MVIHFAE]+IO9I6]@EYM<&,OS#I4Y7=V%B!]BEVOX\3X[%@5-&I_XZG M;P1Q=%*Y%X%XY701F",V*T]"C,*7K/G0)K'B'IH>VZ 0D?)DH+35BZ@C,*%D MD'NB>'9921#,-.%1&*4/55[#]]#K&-L\?7A K3;A#6.2#W!2+Q)9.B6^[V:?Q_BT%Q>_STO1M-(I M;5Y2' [0ROF\JF:J@*7(?"96!TJDE6BXH$U%(!F#;SGO5)-B+9N3.#B&Z2\* MF.4\)!+4X&$&Y\4ED!&RGDT MX-KD_&U!XS[9$+M"6",--H'8J_&2^<5YAW2^.$>7%.9S6)G)15BKSR&-.&AN MRYDC%:7I*65 G J&*.^C$LY*0YLL[7V(W:=$ZT< 71.=UD/?[05X)8KE>R.E M2GLBZ9:W!(A,WA#/M"6\M"OB+%ECVZ#L'J*V+.;T8^Z2?974#C9K@'WY"0); M6YV$3D3SDBIA8ZG\H4I'%)=T=-*%-OV1MR%RRXI1/R:L:BFQ.LQ>S[KK2^HR MI+1.&A9BTBD",2!Q \]H'@;M,BF]&W*2MO1V:(FT#>G\X34$D,,^B&!(D.B::EVPL2 M9[00UC?9';N2T7-.JG\29]63!+P3*D2AITSR0CGG)<'"SW M8'U,H)ID.&Q.XC[YUX^-L*$:K-<+)F>(:,XDI!.0 M I!H?6E @C*PX#6)$+(-0DLAF]Q/WH;(?7*H=X:R9EILO9*M,VZ8YB%PR&A" MV](C&KTW+W4F23'PR^M-HDEF2M_(_./63'[LE6RH!ELC;-U>C@1D#U&0X&0N M[AHEEKERZS_98!F+U#:Y6]K7&NMU4>^&YM],OV\0,M)2^5#ZL.JE26.X)RYD M1S0+3DFKC0A-',)-B-LG<[01LM;<\*NKLYK7/F]1]KZ#,S].5RV +^\D7K7_ MO:SZ+'6B+C @)5.!2.T\01E( IDSD)YG99K6RRGZ&@HN9@5H9(ZRK*DIDWY_GNI>@IG.NW1TU=-.UA^/D $ MM+L+IK665E!%B6.ZM+6.&$LH3[$S-&KHKK=]:]U%#V% YG:P*FCGGKU M-BYO8AQ-5UDZ5V>1(Q<,.)TYX;PLN@C;!BOG! ML%)%.L@CI=BPG]/X/)"ZL'JNO8*V:GDLPM 7R^5 MRK^0$>/29.) IY*<[*AH8N]L0MQ&2/K!8M;5E=:BE&ABD)-@C"BA'8YO#7$Q M9H(FF$\R,LI3DY5GRPH^CWRWH#8T>BJ@'@#*Y;W9],\:[Y(:D!RM)2E+S7!! M<"5;W:L/AF697!-;Y289&P'A!PL%#U!$;3"4$JS+2]2E]NI(<"-92=AEK-16 M,.C46R& Y, 2]3+?#UJNWT]:2<5:+.B%L/*KM((/*X*K?H,B.@ *%+G(R*C:IAUTW^W&7^;5[BO8!^9/;8. Q\MJL MIE9EA!%/N)S)8#6Q-"3BO(E!^:U[3)#]VEC="@&'B?'-UIGI4^( M(I\UD3JB9499)-1%%$14(=LFV9=/."T&0X>(X?32!5%UI)H56:2HY)X M#H%XG8VD -3&)KGH=6_4[#)+^(F@M!$&'N-.3A *4J! ?# <+1*&<\BC@X3O M><&4D%DT"3SUM4JW%\8'.+N\NGB4W\ZFGSY"=_H*PF+DF,RVQ'A\TH@ [A0) M,@'AQE/KDT7F&W526$_04Z@?,Q1"WW=>J*"<)J4\KMUW769:K./F%EDR2QV4SISE ,TAR]Y32B C MXB$IPWF;SI@/T_844H7;[65U5-9D6[OA"I3L5,1Z!VF\& 5K,ABTQJ)']UD& M#204^BQ$S4IC0?2J6^]M=U*W93KQ#P&GZEIKN3A=7S"3=B8X08ED'KW*["WQ M(C("+)0FE2Q3OZMU:P)/555)/5Z,U\?HX,XX:[#$>4K$*7K",@ MP"$]UA-KN2766=QP%?)NFX1R[R;I":02MUQW!NAG,%[F"[ANG2U+[,W'14Y' M^?@\S,=I7#HC7^ZL\S?3.UI_19? *L6)$5$43S*74A>L/7I]_.O!A\-?C]Z^.OQP?/C_ M?G_S\?]_:U9QDZC^+2'N'Z11:X@M.!O:9..=+U6F9_GR('$VG?MI.BZ@[2YF M^7C\:3K.XUBJGJ^N")=>5[/)."(XWLT6.(NVE_/@(8=+O2[7CZB#[]^Y^KU; MQ=Q#QZ-J:U/Y/*(*+[N#?RRW[E_!PH\G.];=.@(>56D/2F2HMKX?=7A]T5- MCS297H_GR#8*UU[_4O^%?_"0.]''%ESO4@=F]SI8.^1N=? PUY4:SUT1]7)V M&M"Y+.-]@#C#K?^_T;E-Z,R@#5"FX:J"WE7CB(/I]>*.^-GY*93>NJ/D)5,, M))$) I&Q),]X10D-C@>9./=M6AA5YF-H0*8F.9>U"[,P3*%+3ZQ)*%XK$K%< M22* 2C!1Z!2;U$FOS\H^W2AZ3/S?COP\,FBJ12-K\G&]A*Q+0".+C!BM/9$A MH6RUL0A8J:.B'%_L_0S8LE+PSNJV_JCSH"]^GL!D4,EXRE&LUA+IK"BWC2,) M65M&E4G,-$G+VLED>%PQOSSO2L?DZ](6/@7&$B?@W[-E7)(91&GI6UK%VYR)=V!)#LHI MH#9IU:1E5'/.]NG&Q(\^789#:R]GS%4=^EC*\P9!.)ABED=)@O61N.RU3RZ) M+/;>2U[GRSWROKVZ#GJC95"Y#9S1^(R^U&316J+_DTL;56Z2$BPX:'(IO"U; M/^J^W6-V--VRA^%I+Q>@2S-D]EWOCJKQWR"Y;B+ZD(9;RWL80#XP3 MQ40RQE%\>^]-VCNYVZ?[JC_P1*F#KKV<.#?VQF7!@1%$GI6,CD"(K%07-B08 M8"2 U)FB@ZM=D]LC;=G:\E+N_TZ51\'37LZ1-].%GWX:?_ORDJV/)W[ZRVR6 MOHPGDQ'-%"0:D>7(!IJK2!A57PF.X+6(R.<*9F\3]J8)F'T;6"XJRO,>P;#7CIJ>/=FJ\RR MZ^_N*)]NW9 [SJ=[D.L=Y#1>)LW/P\5''+*I[-$UCWE.%R>9"VNLS??-4[&7^#A]86S<.4MY14 M_[5LDZ>VE57+[.IOD;^2$D<3ETY10[QBZ)^);,NE8$%4HL*DI#A7HH5!=YV( MX;Z;+\QGP^ @H\6QV(,[GT7Y..N$@YT4*I MP)B/,K1%]PUR]NG$KSX(^DN^/@I>CZ?C^0FDXA/-1R%'H;U#"**HB(R2$XM. M$ $3 A=>2M&F.^MZ M2&33HF?MLJ*4>IE-D[CV.F*V/+AIFV-?'P)]Q5X? /_TD_/+N,R2' 1D$(Z% M((E.@(#4*I-@I":0>1(Q^Y1S: J#[TC:JWJA]<$P3 4-PU,WCO7\M6.]OK[F M P\<[B]L0_%0O^K.L>[\H+=?VGNHAA+=BLO=R[J_9]M_K,>0=DLO^,YC_;+T MVV MP1.9E21AF<\NO!:")Y=EDWYJ]Y.U3WYS-<2L*1992S/5;*B#&,]/SY=%WC;I M2GUWDHQ@D+WPI;9NL0!YLB0P(TEBP5-/(6C:Q.*JQ78AM!L%'47?-:KCW M32"JC&..>B*<-D0ZM&9#4(8H[TN17LLL:](]:9NE;7NFW^)..0K16=#&$9<- MBMN@;VT-=T1Q--=3DI!3DP3',OB36)NW1\#MJ;&UG"NF,8TGI27<'!EZ9 M:F#YS<>3\12ZB^\Y3Q5]D#*5!60;4+<\LFV0B;V+-WDW2/L5 &\*D MDDXJ8N3RD.;X_.QL4K*/IFF5IDFE34[91)1=]OD1"%G\K_08TQ:I$UPU@L@= M%.U3^ M^ Z.9WE1?J\HTUX%1G,D)@E7_WA'^ M6P^HP^M=%-7BMG^,_?83ZO';,AY^HZ6QMT"%1.N4LH2[2A""!,"MQ6CILE,R M\#8%,^_N,=V'(3^=O_<7!2,?9R_\](]1YM)0:G!=I+1T.!>9^,@"<5PKH;F2 MZ,NW8>LV*?L4.^FM^>\B)<,D7LV*?049N@[2JC$)+)N4E ILL6E#:;$)AWZ M7!I-:N\L89H'I4%DIIK42[N#GKV*+%<#00WA5T,"+K+PK(V*? 1[UYWU?*U?1\#-/QK%O:>",E@E8Z4*), MYD1*AD!++B/NO,-5*.6HFN3]7J-AGX(7U;3<5\8-'8R#E):W4ORDN,AH_*9R M@/7"3\K* SE;7"SDZT(V.[;_=NFM"=JUZH; M+KE]UG1_-VH75.VWKIM<4WPSQ7_"1__U\.L93.?0_VK=NN?4N!7U('VU17#[ M]9"+8YL]N;Z8-N)AJ. 0M*6M%$R'M/%;\Y *[1 ?H*S6Y=YC^%3BN!6LBH>> M6._Z[D8TMQ/0W9\,[BO58["68MV.T\>0^/#K_7U&>QR9-UD!CT]\!^42_/ON M,LZQ>J?O*G#_\X8+;@MZ6XGFKO=[S_Z> [43YC8.+G,)_EH7BXYV'#N=^4TBJSY@4.L\Q!0%=CD!5\W],JS8=-:&TCE/7O#MOW MMANDE0@WYVR7DAVX4F\YRFYEVV0NK\[HQB7\M,HZ_.7<=WZZ@/X&[8./'"ZV M[:AN**,U'UU^TGN.#QFMJ62WXW6W0K_ZJ/_\'S;>K@5_+[\-17]UM']93*^) MN.\8HZF(-^%K>%I9-_Z,1']>VN>_0OHTGG[JGQQYY\-J))MM1FD3B:Q]QEPUD>EK/^Y*&0Z8Y6N?7S]T>EL2+ 894)4&;B3_@1)HHI5?_'CZ M=C:?ES&_?;PZQ3E>^,7R/EDCO?09NI%F!DMA\'9W!8W?P,_/N]4UOM[&[]T/ MJ["!;4AI$XFL?;._E;OM$(VDMS%7;67ZZQ@ZW\63BP$6U78#M);G_1PUD>:W M$^!%2:T8)R2@\/1A-IGD6??%=ZFR=#W+<1/H'GW&@,G%PY+G'^0/Q MO%L6N*\L]8<':B3M+3D<'GB.$S^?C_-XM?G-9^>+6;Y6IF/IPY0(40(Q%:(V#^^!)^4_%J5/$"2M?TYU";18+FX-T7\RW_&@ZD)H M9(.MRBZ@G=<_5KOF(346FOLIJ\KY@#W_^Z=4YKW-7GEM@"'[V)K'5&:_">Q_ MGY[/S_UDUKV9Y@[^?8[>S^3B"#>CK@SY9@&G?<2QR5.'2V=KVG<@K-[S9_-G M[T1P+>;:!L/VGX%;/'PG FR3CW4>YJOA#DO)]5[9+[K6& /2G^YX4GTY/#@%+J\'EQ_!S^$??_D?4$L#!!0 ( E M25)CX$+)N*T *&,!P 4 5\\,-G'$_ZH^'??A1_X3_^@,,T MROWAQ[_]^/N'7YC_\7_^V[_\R__X_QC[WS^_?_/#RU&:G>-P^L.+,<(4\P]_ M]*>??OB/C)-__E#&H_,?_F,T_F?_,S#V;_/_Z,7HXNNX__'3] ?)I5C^Z?BO M(0)' 9R9$H!IK1,+:) 5- E$DO'7GW[ZXX\__O(EC@=_&8T_ M_B0Y5S\M?OO'JU__!Y?PP]K?J%^Q MQ:^Q^BTF)%/B+U\F^<=_^Y#3 ]UA^N/KG[^]?WT7:'TY_ROWS MGZY^YR<8# CQ_!.F7R_P;S].^N<7 UQ\[],8RUKTBR574*;"^=?Z:3_MC>D3 M 1FG641&W\5A5? .,:[Z]/TQ7W\6RUA@-IAVB/CN9W>*=W0._2X%?.>C.T [ M_R!VCN<1QUU"O?6Y-W N0"XCK!\YF>*X/_E+&IW_- >WV%AAF%\-I_WIU]?# M,AJ?S]_\Q<\>QDR?2K@D%_+RU?[7C3[V!F32C?ZP7W_ZAKZ\^NP*L&/P^&6* MPXSYQQ_Z^6\_]EV&S$TV()+2PGE((9>HH@O:%$#?V^@)=1F+A0Q&Z=8#!W47 M'5W3/H"(@_EW>QG[O3N?2:O'UU,\G_102>V,4TQSZ^GH$8J.'A%8]")9F4/) M2MU5G,E"$2>8_O)Q]/DG>LI/E9GZCSE%C(NK_?=?[T=P2<\^ZWJ/'_N3Z1B& MT[=PCCUC?C#@5ZR1HMXLE=CL4^'"_VMP_TN[V<7#)) M")9EY+2J)!E@<H[H',LOR86B MG] N$02PH# Q;:QA(0M2M&B5]"H9 [%#1F\]_&BHW5VD=SE6^W!\0FAR1?3+ M #[V DK+A49ZO"+WU@7%O$7#4$OP@5 ZZ.)MO?709\_I[B*\RZ7NXGW]I3]) M,/A/A/$O])U)3]+I[I--S(1,9P$0'\'2'Z!*+-YRJVT7!M2:QS][?KL0ZUVF M37=,7VXFEZ 4*!E+IN.":\ET#54%'@QA1 %2%4[;3.=#BY%!@,BW$,.\-[3;"6!:,,:P8R-$@YBQ7A FVIGO=\Y\]VYT( M]B[9K@,?Z1+9>[P8C:?]X<>S*4Q)"7TIH)+GA$M6)8R>12P$,XH84B)[H71Q M0M^'X=F3WIF [Q+O]R?^]7"*8TC3_F>4^3>1K M!^Y8=,JRF)S5(0:1>.J,[UN//A*:=Q?GBGA(%T&OT?GY:'@V':5_GGV",4Y. M9]-ZT5;O+GLQ99$$+\SJY&B]7I(:&L4X3Z4(5S!'V]VV?@^2(R&_,V&OT(6] M@F.7\,[.83#X>3:AU4XF/9!%@R,?44JGR9$@4"&XR"R/6NDL FEJ9^3?>O21 ML+V[.%?0NU?([!+/JW,"<$["G(%JWO%TQ;K2Z,Q^0CS%58G 5^,9L/IF,Z8 MC+U<=.31>.9$)JL1$RU4J\Q,00?!:9)"%_&6#: <"??=B7N%.NP5=+O$]P&^ MO,[D+_1+_S+/Z4I1P948"Y)%:7W-#!-D8()++/%BM.>89?"=*<(:$$>B EV( M> 7Y>T7@:E;;X-VGT7"Q,67TV7H4K,1 QXWRY"XB$AA=P/$B,:0N@NK+SWWV M%.\ER!6L[A5J>T&K.QDCS/<6D504SEE6M8QIP3,+KA":**))D@MR$KN(I=YX MYK-G/!U@8DL?NBD')!] ,W2&EJIX M8D&1*H(N,6.R+MKNPB8K #Q[NKL1[0K".XB07<&IY\OI^,/HCV'/EX0V%,-D MJ5&[PBT=+!J9YUJ&($W@IKN;KSN//RZR=Q3K"JH[B)8M,%VZ>;V40K#"1%90 MF[KC..:Q&A4A>J]4],9VEPQZ^]E'1O(. EW!< >!L2M [T:3*0S^3_]B;BT6 MX-*3=C'C:SJ%3)KY( 4CLQ$3(&2O.G^?;R$X+K9W%^X*SO<*FYUAFHT)F)#Q M0W\Z(# \"H14TZ.B)K] "1: ?#UC92Q>.S(CNG"5EY_[[/G=2Y K6-TK^D7V M?[T\._MZ'D>#G@+/"R;R\F))A*34+,?LF'0)M!29^U ZH/360Y\]G[N+< 69 M>T6S%IKUZDOZ!,./."\+R4XY"U8S'FTD*]^2E>^YKU6NUD%&+DT7N62KGOWL MJ=U;H"L8[B")[.P3#@:+"S)%KEK5+&9"JG"*9#& 8#'9X*/0QOKN,HAN/OG9 ML[NG,%=PNW^>6!\G'R#2H1!=R$85.@I,U2V9-1T*P&E1)B94'(PV7=&Z>&B' MC-ZHQ3X,CSL);E6)U ^7A;5_38/1!//??IR.9_CMFZ/A%+],7PVP!E3^]N,$ M/]ZH7?UI26ZTM'_N5H?[XO3MV>F;UR]//KQZ^?/)FY.W+UZ=_?KJU8>SV1!F MN3_%)2W;H\B%T?9.5G>VA45,@H'.$5%F:]**R^#%VU%@ M$N>OR-43+E]''$PGB^\LOY?KH>RZO2P^\60RP>GD)-:JT33M%1>*39 8E!AJ MP%>R( "8-D4(AUZ'M+H:?<^%W89QN'.D(XX7>T\'4NVP#OK_YKU/\. P$U.IB]@//Y*SLD_8# C1S-)\%+2B1IJ$KPWM.R< P/4 M')3V&I"W4(*-T#V64NS%Y*@U#0UTY22E&D*$!)%LIKH?%X MLKX>?"<5H_)4@ M];)!BZYJX_P26*5442'+6AFCO+8 *^+T^RO 31#'0/C.0NVP$GR!Y73Z"&TA(]B74O/RG.$<7,HK M2I+VI_P^4,_:'^A,V@U.]OD^=+G6MZ-A6I1$6D^[4.0LOXSF67._OWP;G/:7>'HJ:6>T34Q+4C@-0-L9*1V3.OL8E!0H MF[!\^?AG3>L.$FQP5+_I0^P/YI%MVE;F18^?1@/Z[$G=8J9?KY<:)(^*0V < MA66:9]*WZ +#F))%\$'G%:V;]F=Z4X#//L#7A(D&GOT-G,O&33"DND%&)@U9 M(U=)W+4%AI:Z6*,3N";'_GI(A]>*-C2NUY5].&@8]WD'7VO\X;I! B9N;*8W M05I5"RP5 Y5IJY-:.[!)D$_2,N)S&\ZC:L5>A*T)^.PA[38Z,)YAKM5XY_@! MOERON:>])*^%[!47%*TUZT282KU 54Z1$ 0/:U$JE-\&@=HJ-1BFYD MWM8E62!*G#RA )&9,L^!CX<M&A+!/!Y&7]P0S W()I)%@QS)\5:&:0N9>9D,"ZC!*L@^F!5EG/NKRPY8 MCU276K/6ZNYR-3(TI.=D )'1K&A33%:SJ(6@+5=ES97()331I_60CE1M.N*@ MK4'2XSG+I&@+#+I&?*7P#*S/+'$?35+<"-,ZQ'6D_.\JY0:62.T V)^>S].J MAOG%:%A[O.(PS:%)Y#$%PTK1L8YG"\SS""R! 1? .:Z;F*+W8#I2A>B*A0[[ M:=^$=M4B\C+;CD=;0I".00!.ZZRS_81PA,P5F4IR4C0);"T#.6)5V%G>';;8 M7N!YCU.2#>97,!Z24D[(EYZ=S^;!%;)^^JD_[=F0'1DMCAE5F\^%7.J9I1AD M.L.$*4GY)F[+P]".5$CR>0M M3D\+6=_:I?JD!=M&!8Z 961] JTJ9S8#N>1ZE-+MCKL ?[M M-GI9"CWI:2>,!ICT6C'M UE1RGK&N4H.0_)<-BHI6H9RI"JRI\R[[!6^@/1; M?S@:+QK5XV3:RQD=+Z(PC8+4TN1Y\F[RP;A MZW62]JK!K#8/>%>'59#$I]-Q/\ZF]<;XPZBZV61:DV#I$S]>+R-XB-[6_)50 M[P P1\4UGUA"A2AIB9+[499+V( M!%F;[).)9G0*2?!'R34[4K7JE(\NVZ-?AP8OL/9T'GY\@S#!]_V/G\CF^GV" M\Q3*GC/(A5&%+"U:OQ8ELQAS1<>%0E3*8Y/\@7M1/?MTQ.YDWN!BZ.^C4?ZC M/QCTA T>:T_W3,NAK:S4.$!RC!,(:T1&XYH<4PL SY[FG239X ;F=9UW_K%/ MQ]95ICM.7WVY.MNN,3IAI=16,Y0>F4ZUNC75J:<1Y3F! D!:-K4VDG:'E2TNVMXX,0S2%BQ"5 M6]%'OXO2\_M@/7O-Z%#J+2YK5J.[<7VH;)#INW+@:V7!5PSL$6P7.?M8@K2A15] M0SMLLG.0#EB-R-Y#EMVVP-I>'2;CZ3?X9PF',.Z/3K[T)SU,V8 @BR>2;\,T M<#K0H/8^#4:Z2/80J>\&&D$/N*$-]-6R)JQ%T*$R?"(IC-,L(J/OUCCU:+B! MA>2=)MNBP,!B,_JBFU"^C\.]CHW2LN=.WMDG,L8G)[/II]&X_]^8>\6D8.J,0"^A3J0RY/CE&DY2 J/(0FIH8CW? M#^O9JTB'4F_2 _8NNM>3R8R091L#"BUJHHAEV@1!]FY=OG=)\< EJ"8IG.LA M':4N["#M!K?LJY"=SJ:3*0QK]E OU0GN%H&ABI[1IE4;RH3(?$E:(%=6R";' MR0.XCE(C=I5[@RK)V_#>P?AT/!= GM=POL/Q''$O<>6X2[5U*B?+*)!7'#P= M;%FK:!(D4[!)4L9F\(Y,23IAH4%MY(T*WSNG7#0.A!6)R9+).T:P=0BQ8(9[ M&^GD ^^;E##=@^G9:T57\FY0R7@'VM4A)V(Q)I3(DG&:EIN1[)PXW\V\<9PK M[]K!.CY-V%7B+0H:;X!;>WA9#465$)BP9/IJ,+JV \D,K4\RJZ@06F\-1VL_ M="W_%A6%&]4NJ$ 0D=?8"4JRANM$-$R>Y1BMXBI9M$TNO9Y-]<@^6M(Y RWJ M"'?I3"=4C;:C9R+7P0ZTW=6(6ZAM'30ZB:3>32K,GD4_P8Z5J#4_*W1J[[CH M4D9=5 %J#3636+MM.VGK1)#$8@D1"^>T4S:JFW\B%0;[\+^'+)]NA8$S4=B8 M-%/:N,M2V5#(NQ8YFR CK4AL$MYX]A4&6['Y8(7!-E(]6';Y)J#^=!4&6S&U M49KY+F(^F YXS5$;CF0*%S*%?>U,5RPR67A(7,LB^296YE/D?NL*@^ZIWT:Z M!ZTP(#.$;%C,+!=09(9(8!XPLI+(Y@5G16@SXO2I5QCLLNMW*^W#5!AL@NC/ M76&P%61R&-C1!-;YL'=9[QSR%;+XQB$*QE&KQ@ 85D5JE" M;BJ26C9Y4;O/^+\,F%Q_[G57,!]ESJ#KM.G:'-D)79UQ6V?Z",.=SP*;1"/6 MX'D2 :IM6+\;Y=Q?S@UR^M_C9QS.\-M<6GID<76G132%:64L\T'6;&) :$H M(YJ$NI>!')[P3ABZTUEZ#_$VL#D6>'HITXDI#9V KDYMD]'1"4B>EL@@F54V":$ ML4E9D$(VV;M7HCF.%WE_0;=P)N>@ZAW9O/LFCC_W$T[.1H/<0Q5,AB"9-X"U MI;@D9&0PA.!8M:6Z*M$_)%)-(3;I3;@;O\#K2$9_+=PG=D]'$ MLYL@?> GPO>2CJO!Z**^)M?@("K-=6!2>'I+C! UAA&9C:ZV5*&3RS49,G8O MJF-1D.Y$W\!H('#3\2Q-9V-:=C5G)KWBC>96&9;)9&4:R><%S@VYL &$ J+2 M-W$/[T(Y(@W81\B'L"5Z,1>K(/+:<)O6YSAGWCK'N%-"D19:CVVFT2XC.1;2 M]Q-Q ZOA&M"W$6.]DJQ#49,:%7DK&GEF7FM/1Q-A*2A3V2B%;'?6OV$Y,IMQ M1R$WJ*5^.QJ.;J.ZTLAO"\8$2:7$3$KDV'!;^W72OVH?3R>MB*J-__ @LN/0 MB6X):%!EO9C?M+!)E)4J@1;,*@U,T]I8]"$S,DE4",$$X9N8@TLX#L]^QTS= MK6386C/5[/>U*^XI 45EY9G/J)G6M1=$3HXX Z%%"!I\F^9,]\(Z-IWH MD(0&WL%Z8&:>9,F!&1,2TZ'6_F<'3!19[[D53VT,AS^-8G0C^B;SE!:&S2\D MDLOAZ3,">67YC(:3G[&,QGBCU.;5%Y('/;\_A/'7>:[$FOF!7&#R9%,S'GED M.I&]'7-0+ J(!D&7R)OL.0W7=!PFS%,AO4$OD6O(5^_7SSC$&NVWB"+5SGC" M.U\'4F42%W*FN !RW(N U.2*= V>8]*C_83=H$?(Y07/W%G3M5MU':X<0BFT MNVK.@/PV9C@(YX04.C;I2_@-PG$PO:-(&W3]>(O3;]O71F-L"VT]=3(A4]+0 M"5LL9][XP#(4DQ2I:!%-VL)LC?0X5*4M02T:B=Q"W/,>!%E=ED5K3*U.#8PL MO\QDYDK:$I1O<\]V"\41JL)6@FW1(.05C(>D=I-%-XKK)29OP7($IG0TETN, M01=6IYIX39:]Q28;Q#I QT%^)^)NT01D&=C/,.FG7K8F".-)'4,-ZRHAF.>( MS$COBY0B<]TD1W8EFL-K0#=L/: "VTNZ0:!L&=3+_F VK3U2%6U GF"5).@4 M\JB8U^"9XR"#=S((T23):@V>(U6!7:3=))GVNEG1R_[G?L9A_@81TX#^RCVA MBG$& BO>"Z9M+1PS2K&@0I%)9-2F251L$W#'<49T3D.+;D!+E?"2 MZ>0RC]I$ESM#E3J0JYK!!:M=8H4.FV32;<3V*@#/?&_?6Z8=&O\W M\-RLZ%KL.1N ZGIK7XOF\%O[_D3=9;TC*;=YS5> 0X?D7?C" L@Z3PF$]EK6OK*U@%-8QVK/ M9);%"\C0)"?N%HK#^? =,G/W8G!'L3;H;W&UKBLP7)B(T?#JIQ927!&8 M5Q(9R(!:U]'SNDE [Q:*8^!X=[$^9CNE%Z>_O7O_ZM=7;\]>_^/5Z[?TY:L6 M?97N?4RS!DN;+VZITY+36H$*0@@RW:6446/(JJ1<"O*@Y-I.2_<^L?.62V@] M*!"<*0#.M*D]-WS4I'/D'#BE,Z8F^W/W+9=N9$Z@X5F[*%A.0.^@<^0VR1Q8 M M8IL"GL?-0&FI!%O)M,%]X[PPX,7H_&*,GZI+]AF_82.@I^4#?'E'1_^HSC08 MUTG/+_'R[^M[MNQ25EXKIKC+-?T\LEB29EEPVNZ"EMHWR6#='_JS5Z4#L]>B M0GC-"EY6,C!?)>Z^&\"P+NCW(9R/QM,ZY.WO).[Y+DIF*6V8+^=%SY=K7:R\ M5SCPD#TRGC#4Z;+ 0B$'049IDR0I8^:'U,PN%O4(=T*[-JN[?N[\,CZ\E@&27W#:6VW#.AW,!^G5(0V.A:D5]@#T]YX M%M$"DSH 3R84*]LTJ=H/]W=5;LAS [ME!?+K-XAKE6NV(!.FCHH3J)EW(C*? MD!<5-9>RU;C?=9B>O:7;E;Q;M$F[?2$- H4K*K$4HF!:(KT4/AGFE"-7#[C1 MKDUT_ZFDX>U#\QZR?.PTO#M+>/5?L_[T:U778BNUUBK.WU%MD]M_&M+CYV@!4RXD[*U$] M\M"=_=E;3O/O3/0'TXN<%:04'19W;U'L<3A\VG+O+^P<6LL0) MA(2"&R W$'12&4P.N7!>+$I%WMGZ*_N[S^G\HMX)%R6G-SFJ7&NW5:%_Q<2* MU3D5=-'Y)@T6FE[4>YY3$L$S$'5BF!.9>1,ETSF0)DEC9&P2T'YB%_7;<'O/ M1?TVTFQP47^2_^]L,JTKFWP8O4=R1U)_@+=N!S^,7L#D$T&N)6CYYZ^_3^IL M\>OFCR=IVO\\GR?^+23C'0\%"D.KD&F; H.L,BO(8VT.2?9UDR8!+1;S['7M MT1EN8+.^1#I;4W\>3J9_#_ JRGQR>>TR_WZ/WI]B8P[,D+//M,[DR85JHD$R M/ 1.%ER3*^%-P!U>JQY?#4:-.6RB9P7'XRJ%U:V<2D80.@ #3(:V;%IZ$"0. MT)JK$G),NLGY_@"N[]K5*7,-+I@6#1\P5S^!@%VJNXL>4@F:N9I]K$MPM6NV M845)[K1+:+%)#N1J.-_5J N>&MS[O+L,85PWR2S.^8B&I8R"S0L.8^"2T?[H MG?5@(V^3.7L+QG=MV8>7!E="5VAJ \OYS67M7-F+BM8Q;TH@HF8Z&G(\=%VC M$"7%4+P(;9RW%6"^:\S^'#7HH;_(SS@=GL$ 3PO)@E8__5JSF^;!T/E,EQYJ MPI-5O6BOG4V2ISTP"\]*4J;0I^K@FJ3T; ;ONVZUX+%!/_YEE#_/)N3VU@H& M\FH+TJIM+*[VR^$,HBE,"($:O38TX;;JX,N9)VS+&VA+9%#9C'2O[@PH@CA@]9-1M7= MB^I/I"^[;=&"^@GQ>QSL5(EF&>'[$GDPE."75&:;F(9-];SG2HO0W MU7A$$L6C !.:1(=V@_LG4JW.V6LS &?-!OH.OLYW3V]X3"@2\[5J5',76:@C M+9!G5Z ^>R^_,3LM+E_AZU4P[23]UZP_QEMQ=3+?OH76 MI4CH"T%3Q3FFHR7-E]XQE5(NLAB?L4GT<7.(CS!)LC'ARQ=L;=AJTX(Q(>;Y MT,$5%S:WH!(NQ B*0?2\>J*)=FYR1XT.W*!VO(0F=R-;8#Q^S6K$5X/(P4VH M+_MS<4QGXQL7.'A9[5S%=_ESS+6NFC#SNJ'7T:M9&?(\N6$"Z,1VL93<)O*T M"]@_E;(U8? 0!^6E<.;?ZV$.A=P,PUPMV->\@P^L12*:;.62C,:T1FO8Y)#M46,-O6(XCUDB<]J15*R6+&34C!P0<,4*XU.3+6QSB$>O7(W8 M:I#@M ;I+_TA#--JP1@T$F0-[J4ZAZQ@)L'0KNMET+3C!O"YU:#>+:$>:PRK M*W9:&%LW]M+7D\F,<)(O\1+CM.=S,,F!93:HS+0.E@%8VE"Y2\ QHXE-8I_K M(3V9?:@S0N]Q[O9@HT%,ZCU>7!W I^7-:/CQ X[/Y[A<228)09,,@4P[JXWFT/0291G0\:M+%TPTC!"=EM]P_!''[W% 9ER>8ULABUYQ MWB:.D:58F]HG8UA,BDQXP;D5,HEHFF0';(GS3Z1/W?/6-E1$F^5LG#[!A,RQ M&\.X>\X1/*YH^5"M,DRNUN8))L@)54&Y(E.3G+>'H?UIE*DC=AK$@+ZI^_70 M]IOHO(E>6-HU2RB1:3"!>9X4XUYJKZT/"IKDO=T/ZT^C-QVPTB"^<]-"^ZT_ M'(W[TZ_SU@.?1@-Z0KV0>*F)5%;K&$24;>+1#P [?KWI MDID&-6LK]'H!\WI\$S?":82:QIEK2ULIF;>US!>=JP4,W*1#;3G+V(Y??SKF MYZX*A9VG_4[QYG$ZOZJ;S*5_6LYF<=+/?1A?HYR\'JZ;#I8$!NDL*U"'7TLR MU6+BBH4 I?;%Y"XOU4+>Z3O9$92CU:;'H&I%.+&+L8 ;BJN7;-1&J,)RJ0%Y M5TA,/$46E4S18K'1-SGQ-H=XM-K6F*T5BK5_$^M2,$U/RZLOY! ,/^)[\C!/ MA_,,A&&N?]5Z!%"69Z>8#,+6O'=%^VT.3"DC5=%D]\4F[MLV()_] MI5@S1AJX_*M1K9X[T\LQ%R'IH"Z&7BL=G&1@G6-6DM])KU6KW*-M0#Y[[6G& M2 .'?S76$]H[Q^.OM$W^ P8S[,F8;(@Z,YX,)VD4PZ(P9 <5Y-I(Y((WN5?= M"-V1ZLL^'#3P\C<#Z7RT8*VNP^=K.P+Z(UKNF?/D3T(Q9,$UJ=?>05'V"W3< M,&CG^5RK[(KL):CB2 1*(+W:6;(@%6?)*IMC(=_:-;\XW #GLW]_6O+2H7%/4]^3?C?JH7"Y>*?/L;#YXB]/5@EFF5-PV62R.F%XK1MF3+D!>L,X$, M\\%8YD4.(8N@E&R2[7#893Y[)7["6M'"F5X:7"4%TL$AR0#R5C!M>6$^ZECS M%,$%'K.W;8=Z/?;(MWU49P]9/O;(M\EX^@W^6<(AD"+/9Q0)ZX20",:CLD]=M(]Q#CV5:.M3K]Y>S7D_>O?CU]\_+5 M^[-7_^OWUQ_^\UI M]'M/@_L_H>TF0NVQ<*6YH.1MXS @_0^&>T5CT)XC2([ MZ[4.VJ^>#W;_\SJ?$\:+-K)XQ1*O\P2"M37EJ3#A31TH$+GC3>KYNY\3-D^G MN+H;OYQS>&U"KQRDO>:B2GDAP:A0!VO7:6(3+O>A?T=I-B@L MF<>P5TSCK=CF?0H^P)>5A]KEN-Z:X)<=9F2I&%%;J406@D4FBI!:1^^2""V4 M84_-2MV#Z=FK2U?R?IR*DA1Y!H.)@3%D*;M4&QKDQ+ST2G/MI/9- MVR$]I8J2KD^B;J7?((%D#J(6?F-^.1M7'VM^%W6IQ&LF$"I!JJPE&=U1TZ&: M-9+E+8$)3 F6D-\6#2ZG1K/IMH1ZK0G7%3H,RDU5%4_4"O5>L2,G2J5H@U,E?9-<# MKST&I;,N9>.-;[(/K0/T['6C$TDW2+EYL!#*J,2YS9DT-!BF?=$L "999=(R*+PP"Y87 6"\E"U4J*L%/'M5>Q0F6]2#W+W Z'&%EDSYR#ROEQ&J M#D6I(YE!>0LE6FYB$^6Z"^79J\F>TEU!^-[1VSM%E4G;++7RS"*O+;=#81 X M,NYUD02IJ-@DC?KQ*UP;[PE;278%U7L'="_]KDOSN5X:"-39LP2)5H::-%#5 M&B++L^!@E&@32KL)XME3O+-$5]"[=^#TOC/H/68\O[B*%CRLT)>=HZNU)IJ,D!=WC9#5J=P5]X#N4>]F+/74)I\!B"28*LG%B' Q7%P&A@"@T EUZ#W,2\=[=O=0;).TM8;K2TTU ;;&K;ZT2 M*U$==I=OP-YR@Y?.1-]@JU@-#E2*RG'-R'V%FHEH6"B 9,]JF2!&&5V3GE(' MU(0##M"[( (1DSJ8D"IID?9/& MXO>!.GP(H />EC._NQ)Z@Y*0DY1FY[-Y_^EU^:570(%#3J #L[H.+*N]S:(W MB8680\$BHQ=-NH=OC/ 1VL]U1NSH$*PTV$]NY&1< 8HQ\QC)E*JF--/%9@:> MH)6$.L8@1=1-"M7N(#F\.C1B;;FIQUXB;S(39TK2P?P*QD-Z#28+5-(+C\25 M %5C99HS$#H3?PH])@E)-+$M5L,Y5FWH0/@-O)#-UVZX*B8GR[+*9&'%%!AD M41AB#(6\:"W24SI5NM@AG4071?*,1QF8QIIFK8'8!ZE+\C9BFQ9>#^R0G;WX M7J20HE',1P*AZ1QDX%QAQ4%,]+T8H=*>NW@ MO1C 9'):YA\]=^X4#^"A!(8IU%K=$EE,T3*ADE+%1I"AB;NS%M$QQ<;VDG:# MHL>;>*Y31/]KHREC;!U/(D607J<EQKJ?UM8-,@-WW$54O$FR_E8HC^[LZ9*5%E,YUL-;Z/@& M )NZ- \A? JG4J=U.A,8YK/9^3F,OX[*6?_CL%_Z"8;3 M&Z_]:-!/?9R\'4UQ+7NI%G5$;2\Z)4V!5%.FBE86LN8E0!0A6&V0 M-IE27-Y'4S:3U('4YSU^QN$,YZ[MR[JO#0ZL-ZL /*;"/"B0)4TA]SIY8Z)-+#G/Z12M4V.3*TRGX*2'@,XV M29SJOO?]E;C>8S6:+[MZE='X'(8)3^.@_W$N??IFHH?"1^R5:*.ULC"'4=9) M?YYYESTK.7@;)>IIJK M+Q$81!Z8+UG9X!1DU2CM: -T?PZ5V8J#+HL3HT>D'#MZ.H#Q;?7D,*CI,8+T)_\5H,AV5?181,$==1"'H7C#M?6+@ MDV#6\&C1ED*._Q;ZM#>@H]"JP]+2(!5MZ?6X_FNQ!-$#!:$XEYCQM5,[Y,B\ MMI()E74..4/Q3<8M/(CLV2I0&]DWR"]9NMO4W'@K5&0Y\9HKG@V+*( Y2!J% MEE$WGH/UV!U7]B%[#UD^=L>5Q1+>C4=U[MZT_QD7Z0RGY<'4"6.E](73RB)4 M27$69#+,6^!6&J%X:M,[?P>P3R2'8"O=N-N.MBU'+;)1KK']?=;/U8I?9%!M M@*ME!L$Z8(^3.-">VKN%G]WQZ4YO_L1G MK@,-Q=MQ\&X%RHA?1\-\!^4"JW4..=#ZI:@3[&MCS#IGTY:, HN7Q=G=5.'> MYQZG0G0GZ@:EY$L>^\EX7%.KYI8[?<)E/S=M>$B9LP+1UFEFA@7N+5,I96]C MINVK2=K)P]".P+OI6/X'UY!%I[X-,+;T:S8!^3@^3M<$;Z4_>[#3P&S="*L* M'A+4PI%0ZTB@WDR$(ED$HQ0X(R)O,C;C\33H :_G*2C0-J2TMUW665B2:V>2 MUZR$Q)F.=(K&C)[EC-+Q4KBTZ9D;L-VSM9LQNXVHVWLT]UM8"56, )&AFL_Y MUL"\RF2"!P/!A))S,$=AS!Y:.;H3>X/#YF<85'/^[!/B]$W][2KZNEEF+9TP MSC$7"QG@TV0=;28%T/ M[7',U&XHW$ O]I#_@7:)13,-GK*NT^2XK/N7)QJC2?1^U)W+!@&Z37_O0VO& M ^;GH15C&[&W"*U/)CA=%-Q8J4 @QWHXUDIV)"O':+)RHI#"9)&T;U)M=Q/$ MXE7S(2PRD$#K#9&4 MFAO+4Y.7?AV@XV&_"XDW:]Q^A464(#0YS4QY18!2+2#,NC"EE$8NR'S%AOW: MCXSQG27;((;YI@^Q/R YXN3#: J#16=8%V2J72V2\IGIDC*#$AW+P><@N./9 M-.E+MAK.T3#?@;0;. .T XUGF&^ 6USUI&A0H")EK)X/SYGYK 43DM,IY$ J M+(WV_)6 CD8/.I%X@R30U\//Y/:.QM\ A> +Y3M#&! MAB8J< ?)T7"_GXP;=/=Y-\8+Z.<:QAI.<+*8 ?EB-A[7P54WC5,,T6H1!$NV M$%*1)?,Q2O)LI"Z*QR#:&(&;0SP:-6G$REW]V7M6YQS7+4">/%UA@F?.D+VJ M01&@PBVS01L9A?=<-RDCN(/D:+1A/QG?)=TU:L3A4'C(-24$I61:$4Q/63!1+')LHG,Q9%!>U]J$$.7_B3!@/CT M-W]I]V8O>S_R$"JPQ:*76_^X(HP(Y)"#T0F2)S],)VFR4;QHGS:A_?ZG[WE% M=_?Q;Z[K%P/7"E !LS4Y5Z/SS-?T>E4B9A2B:-4D-_4^4/LDMYQ<7(Q'7_KG M,,63CQ_'^)'^\6XV3I]@@N_&_53[+M^0<$\$3=91;7V)TC"='+)@;&0VD6LM M(X?H_0/JO<-C'\'B[$H);J:TM!1V@TNKA0Q>C,YC?S@WNE^,YL98'2U! /OY MJN/2(N+VMD_F./VTZ?NQ!=8C4*I#,=6HM\LM M9#VA8PE2Q3J#59"V2\N"](J59!4B!HB\;+"UK/SP(^"Z&\$UN.MZ-QXEQ#SY MA61P!F1JG9;KQ9="RE:WNV&F7\NSRUK*><"EEV5.HBC#A"O5<\_ _+P 1@1/ M.QLZCDWFYNV(]PA4Z)",-;A0^SL)[ ?'M!-S@CFV%W7-#$.]QWA6\ M-IB:]- &6S( DRJ3+>U0L5",9,EI':)+7A[,,%T#\0B4IS$O#6[95HC@)8&[ MY8B=Q,F\TU@O 5JE36#>JEK/P"4+5BMFP?FLM0#;5H^0.Z!%SQ5MDHR1F>(MT]D36DZJ;ZU,@EZ$#&TLENU@'K)\A3V=LWAZ[PQT8?17 QC7(#'R5N6?)Q7.N.#+P:8=MN= \PH<7O91'&#EF(P4F&Z)VA0=T M&1.D4&>PDJ^\51[ARJQ\1\D))EGI*TO 0=VC0%:I1' MN$ACNZAI;*,"5X$+O+PF],DCK38RAY)6&VL8+$=@SH240J:OP6VPA=W[D">Q MG>U&\,V=K#M!MIO<-NDY#:(VC&6Q2,6T@AK7#)Q%KJR),@2EFS1-7 X K+W MDNEA7*%O(P-/RS]&TQO#R2?7DOL4-*!% M"\#=EK=R6?,KH&&NC6T^PZ!>%O5$LJX G0^R*,N@0/NF[E7+Q7U_69ZT.CT=HVGE&A=]*^E"97]$U6\_VE>%H*\\0MJW?CT06.IU_?#8#>]\OS\:)F*O1$]ESE9%@6 MNK8K#XF%#(+%%#P87YR23?W9IJO[_I8\;85JT'NNV?DX[YW40\ZAH)',U9PT M'>L5L...E6B+,$Y(L$TZ6K9=UO?WY(FJT&%JB/8X*ZK:UXZZ\8->02!_(@@6,#NF:R\7 MH V?Y1A\T44J'IMFJK99UO>7XHFJ4(-RM2Y7]W8T3'<6^&8T_/@!Q^\U7VP,(.J.T M=(P6.E!55@QB\BS)1&S8$)5ZGJ_0]]?FZ2K2BE?E25U*WSI0HS-&U:$3SLP[ M. I:%W 6@_,EQU*R.E1M?A?K^?Y:/#6E6?$R/*GK9I)UKR2M(2O-/"*M1P3% M/%F9+'KT/'$4-C=M=M+1.KXK_U-1DA5*O_?M\M8UU,)Y)\!GQF.)3$N>&$@" M#"9GF;UQ5C3)-'V6'0[V21AMRLQ3[W" /NEDE& IZMIFT0;F"SJ&3G$3A(G" M'JI1U+/J<+"5#FS8X6 ;+AZE5GT3@-\['.S&Y]9%Z[N0\2A:DX+FO/;RU:+. MU1:I,$@%6?&.1\R"%]-DN-3SZG#05EFVX:#C9NR_8>Y/H"S&(X-P]#\N&7?" MUO'(EM5BZ=J:B/P2#*2P2[<(*TLU;W_JDRA?V4?DHT[DU7&K #*]+V RJ8#2 M]=!;(T1)I(LL)!-JJC)96F#(K';19!F%=,M=W%;RM^JSCXG%O677\5OX[M,( MA_TO,,ROAGGT ?]Y!4E:M :#9C4"5F<8>_J75BQ:J>9-X;3=A,XU'W],C'8A MP;6Y^X_5".+F=P_4"&+5(P_;".+!12\U@@B2>X1@('.GT?BH:'NV1?' P12- MVS6"6/7T?<<_DQSP; K3N<]XSBPE]Q&"6^\./]7?FDUUFF$\OKEJ.3KXYVI+G8+AU#*Q&IGDD,T7DP(3* M+@?O-.@F ><#KK&S)@;16!6C]4SYVB(F%,F\Q\PR8'(67;*I203G\9H8/%5- M7-L381N*&O2[N#DHY<:^\"T*4:/UDDX1;0RKG:&8]CZRF&F=AOP$#@H\N0TM MM&@#;-\5;)V"=4UL \=][>0506X%!Q<)4J%W(M$[$:.N@7-KLBBJ-N)KDEG[ M9*;=/!0%C,=?23 GYW7RCV<3,>S*M%% MWYKW).&YF/.WWC;T]@BCHDBD,O7:TI,P/!>1B6 E.F.B$DV:3VT.\;M&KM/( M1C1W/&'LW;@_3/T+&(QFT\F47$62RF@XH+=I?/T.];2,DEZ.Q+*J3;2A..8M M<):"2'7:#'?I(<=\TV=]UZ>5$9^N6>JPNG#]M$Y-&"PDR8)!H+/?)%IM*;3/ MNA)$_8D,&ZC-$QES^AST9'\>&A3*M1?\P,H">IV =_^;96L :!J:T OX7SQ<7>)K!;9B?MB/MQHBHM MNW('U(,GI,8F9-H(DF,Z.U/=TEQOEC6YI5D:+I/,I4G-TY-2WP>2J(Y8>[>A MO^,S:S";(BWWM;VK8-J$.D)% MD%]KE$3AG#5I$R5XX#''KP-=RKGCC>#7%V=7(&)14MEL:02 09&1!.IY$B$+[3;+]UGS\\9/;A5P[O-NJD$XN+@;]VKAK/FQ\/BMZ M2B)<9)RBR<)B'0A=[SBD=G745:DW;YYSQ1T/F[R_]S[D^&GO3L8=WR/]_N_W MGR%<*@E. $,TM14[1+)=HV:!BUQ[(B8?-GG?'WC,\2M EW)NT&)RR1UZ4_^# M15T)>!%2IK/'EU)]&(?,2Y68UQP*^*!RFQ'&]V#Z'N+;.,2W,Y4-LGK60+MZ MM38!US+Z=B^Z)Q%CVYW+S71D#R(:A+_N!YDLF/FL R>+).=&9Q:2V$=/^9WSUY8*D M=WVZVBP#E[XP4URJGG#-9O2*_@AD=:MHHLDME&4KE(^>&K$/PW?F&K>BI^-8 MU2*_BW#A916M":YDKIDKO/K<0C&OG&0I2#20$6Q1&QB\RY_[W6*Y:['L+?^. M'>&;6!8E\AN@66V3/*@5CV%7["_Q-=3M(:Z.(X\K4"GO1,E.,4R"4-6NXT'2 M1H;(Z0C4'&,J3XB\-<=]:^ZVD5+'G/TGPG@BM"94-<_VZE0(R -YOIY)72<) MEUA[/R$M->840TC&VTVN"59^^.'.VBZD/>I25!T?H'- 1A@A;T.*(A4G(;.2 M!5D/P5CF,]#!#B6@LLZ#M9NR=_?CGS=_>XJKR[=O/.V]A^''R]TDJJ@ N&,V MY9K65^M]/&TI105NLTH@-YJ(0!]ZPT2FKY;-XUM/_6X9K;",=J:ER_#P L1" M13> L45\9G,MZ?Z5W\!2VIV!90[W$%^+-WWA!8R<]I^< M:'\*/,(F4=VGP>(ZDZES$K>16L?D_09?^N>S\X4V<<]=IIU.$W1RF;EE05BD M0T/GZ+0R,G1&WZTG'_#DW4?VHRX$M]94.FRSE46O@?CU P%JVF1E]:,.T5QE M@T4N-57Q2:!1:+4P5DOC(9E@HI+> !VP0FS25.7!]79,Y=43*BUM"+SY@$/0 MMG9!2V1EES"($G505H?L0Q'1>MJ1H[#!!-B$K#5KVX:BQ:C8/D[>XO3M:(J[ MO$BK/F5O83\(;4FB=( 9&>DL,\EK8VCWL]HB%[: !*]<[P&4NXOM]EW6T)7(=S\"-OG4 MID+?9&-'G;U'ZUR!I(TK9*4E1PZU"( :8%FS5S]@S^NEZSN1ZYHWP6M;%6V8 M"8$\="^0Q5KL[3THVMETS!M97-O?(=V!LO_%ZM6\[/?PQV]0R8/!I(<.E"HZ M,\$UF5>>!U:[_#,HQKDDE&PT"&(EFL/?A>W)^-W+TWUEW*!9U#6H_QB-__EZ M.&\Q-"%4FLX/81PCRPF8UBXR$&1=1P<>9'9H4J-RP%5PCH?ZW:7<))OB"M4O M]1[VT^4,!G**"_D]Q0@FL/:R=$&PZ&FA#D!&S+C?7YS@^#/V$GB?B\PLAE3WHEBK U Q#BE@UO1'F_-L%9CCX7U7"3?H M5W2-Z1\PF%V-/YD#F_2<4B%S51A9L89IJQP++B@FC29<+B@7^!)2DDV:I=T$<3Q<;RO1)IG; M5UBNAJ5>#1?!6,A%+0QD[?DN(3%PAC8AZ:!DJY00NBG--]$X# M]7AWPGM3OMS&M2O1-W )UF&;A\(OTQPV0=@R)_]AB(^3F-\=K1OJRYZ#E>#9*.BJP."M(U-F"%1Y^W!H^116>VC]I[V65[H5:Q)EUSM MP&8WETRW/O[DQL=_\U\R>AE]IE-!5H/3B\2" ,^,4@94#-);:'*"/@AM[P[O M),\>.=,=! Z_A-TB?:)5D]-Y8]P(93R8)Q93#3!9P;9.6E23]->!%- 67 M>X-UHQWK(1V=:G0D_0975"_@HC^%01W-7@-<%*:=)%4U"FAGD\%958O+FZC%/9B.3C&ZDG^#"[*U M*[\Z]Z36D0?+-%E 3,>BF9=8ARP8S,&16[P\C;BQAW6<"M(A"PU&79RD-#N? M#>IXGY=X,<;4OVR$@1<#G(M]F$_.1^-I_[_GWU^[F%ZT*6I?^ZVX.H/=%=H! M@S7,<5OK14$8UZ312%<+.#J]>Q1F[VJH:[:+U10$",*'9('17V21&1\8^. 8 MJB#);A_Q7&N=KKM^UV=,4XD<@PDY86 M7TQ@@5280> F)L%#@*6A="LK\C=]WM$H0#,AWU6$L'=;K/0)\ZQ.\EPKC,N< MAL!CG*_#)I1>N6]//\ MYGE^K>ULX<+6[A@):M-4C"R"(,VHHP]09^=RD[#-!M@>*\FHC4YL>EKMR$V+ M!)*UJ_^6MK )Q*;Y1P]C?*0$I*[YW51_]B3GD?0(Z'\ZNLAX0'\USCIC8") M]'7X9HQ-+AH?37\>2D5Z NJS#2>'2$FJ@W]WS3[Z]M_NG02Q!L924D-P7F29 M"CCK=!$R0/ Y::D@T_]9UUN):%MQO!L-^JF_LT2N__-.A+(:S))<"GEB2CJR MN8O228L8N,H\@D=43D#LKIIDL6W \SSLWH>R&WCC\^O@W\:C M+W_@Y%N5>P &E2C*,N<#^7G6)X+&$S-.<&LE]QZ;G$X_0/(\['Z8@AND[E2Q M/I1W1,7A;*!\%%J#8,D("AHBRCIZ %CR"LDWM=FK)H6'=T$\#SOOK=8&.3>_ MC6$T_0A7U27\8_P61O\S*"!C]N 9;3>1HL.@6<0$S @.H230KI&A'T!Y)N8^ M3,4-;&U"NM MBJ&2[O^[A E%2A=7'R?#41I^AXM/^!VNJL"U/W5M6$VVD8,898JU-BU(7@?* MRL1"+(XE%XJU@%[8;2'='H]]VC9OK><>4V%VAZH&Z&K18DWZDXXS;:QGGE/@ M$;56G)L0N8R]4T*]-$KLIN<&N2?WQ5_<3:$B%[/DVLFLMM$5Y(L$)"4$G4NV MI)>@2XO]8 V68UT5MPGB#E/MN5P%UTUMMMS4;BX0:.G*F$U@T0;R7V01M))A MS9%QDMCLG,F^E<^P"N94E[T'&WB-]W"0HAN$_*N8KH M;K8M/#A Y\=C!)0@E$#/4#I1BQ,M"]8!<\5K[WT$4$WZ01R3"5LN7H]%A%U4 MW8 ]Y>]3YCQV_=Y?BU.AN,\%YK7=NWH);.&^]H+%1F$5$=31AZ-<\KX)IE! MVZ$]E[VB9R,T.#I\'.&2RETPMMQ'NH \S:[2MX%WXL\!UCGZ@G,ST12ML1F8 ME[IV@W.9!:#E,0=:=WWR@+%)_?GI&+1E-SH' NUBE&.D =U._JI%;>.+8:[% M(W?'@TW?C\IX\FU>,+)OPM ^3SDX ^)@T59'4)BL@M;9@^":0EYO?*20%SDY M%\ZX.#A0RG9FV^VW]\[S.0*H(Y/B<,6M9MHD)Y*V*B-/NJXF'I(6O!"!%&8; M=N30H3H\%\KMGS=U#%1G3;HN^5W&II25YLY;HX.T02H4DAL$ZX3QJ2GKVHTH M<5(+HR(3LF1&&W1A8&5F/AC.N4/Q8&+NN8XH^9F(/KY">A7GI9N_#2$NFQLN M.[.^B74<:YH->$D)?7*,YWE=IO',YP#TI0677SZ M-++WSJS:VU@-PLLW*4TN,?\7I/D*OH0X". 3O3J<(=>Q-FT%%E42C!N=E7>6 M^RQ;4&@]G.=*E1Z4W^#L:HGJ[7AT.=U VH3+P?8X(FO,KG,+U[X30KH 6B+#Z.LAGTKD&7I.WF+M>%S0J-(DF7,_N,^5 M:T/%'YQ+=L=P ,>57&%TYNF59W\ MY#4+0FK&R3.-)1F7W$KKN+7ICUL?]-QHT[]V&R0]/MSX5T6OHX@!:[NG"(+B M#]KJ@7/+#*#,VL=@L,EIVU9D3_[$J5_=-[EM7M3>?<(?.+K$@=>&5_>.6UZO/./DQ3'AQ9X&B M]4=FC)&E(%)U]0/SD?8F5$EK'F)4V*6?VL-/?BYF[$%O#3^:7D[J MWO1JB00/R>?2[607WS_N"%\F0 YQY(#W$.N(I4)R<2]$^$5;=IG/. M#AB?&WU:F>>HYQ;W4&;@-3ZW3%KRMS0G+RLJD9G2B=?X7+O5:N[6AQ?/F3\- MC-)C%_%[++^#\1;9C1*2QRAL'2,;4=>R(F @Z^T[<$_?\EK;)D?RVZ$]^4.O MGK5_I,CYWEF]A!@T;:'S-D10IPM;!2PH4(0W!ZT:=71[#-;Q>=&W(3L$T'M: MH57[KT?O,.]@M:7$G$QBH!T)[T@7,17.4'$DOSW[X)J4?<+Y:6WT7K),]=IK\2'1H=P^\ \]DQ MJJ&5&ISR]7)9?4<TLX- M3A67(<3[41I_PWFNV;T4(%*4!L5D3I+T1&NUA\29XL)EBD<119,^P8^!>G:$ MZLT"QSQHO(O1ZY24+8[YK!/3=CY/I&CFC'0JY9*4:Y..W '<\V-+WQ9I=>IX M-^U]-]WA*..\^-Y[! MQ;TNPO?3KD3@$C.37BBF?1(4.CK%((AB*1PHRG;JZ??80YZ->?M59X]'>A78 M=6>@.[D7X_FL9@5)I]IIJ-3J&1T",B"7G!F;K8LE%"%X!Q-O^OPG>Q+7F](: M1"V;"3Q00H;H:5U5""0J^!I/:<&R@&(0@M:A87_U\X@ECG86NY.V&X0!6S-S M:<5)A9?"F0W&,6T F2>G@B5GI?1.Q>2:T&$KLB?/BGYUWW,[Y^TM"%;[7@SJ M^A5U**QP1S%+RIE!G<$=C2H%DY!"NP[[P.Y//E;'UA[WA<;J/74?UXS#P6_X M!2Y^'LV&LZMYYR?R@#"0(\JJ"8W.3O9V-?O?9 MQ^V==[ 1QCUJL*5%LP@V Y#FL:0:>206E5',>YV UCR;PYH.W6=HR0T][)H9 M-^6<^L_Y^!63AW@K31?LB("9$=_%*&MYL';K$R1A:-" M#'*P%>DAZEO]>O].6UT_N7<5=Q)A1>FB1,2B8@&CM*0@!3T'^AI,DA3/F =* M[R#-+F:@G74V''W!49K'4_M1>,V''*S<;@:+.W6H+PVB2;%"IA MDHZ@!X]CW$5E;R^GY+=.IY\7OET/72>W?>+!RMP)\HIFHZ!5VGMO>=;:ET1! MMB\\6ZQ7*R&KP0[H^U'SYI_LW1'R@(T0?^B-UVD;FU2???!PYYVDF,VF6_"/46HN3D N>UC8FOC8!SM#9R64P6 M>UFUI\Z'B\_]A-_'D[K4WGG ;:!O!"W/!2W+TE.@KPVRD+EG/*1(?B&Y@J%) MN4T7<(<> B[K8:N_&XI3F!A7M;Q%:<&"=HD5)S&# 7K]FF1Q7P,XP9%>W[9? M/>3;2[<-FAE^^(X36$A8_;#?QM/IH.3:IA05RZ4>.J#U#$2LO<^L+1&D0-&F M3<]#+,_0\H=JO$$V[2>LS=/3[')"L-Y]AKXC M_H2DMF$:7@SIET:+GI7WM[O*Z3?WOSEU7D6CK$ MU='/:QFSU\.?&6/:&Z!!ENBOI+9*]0^CVGSC0[D.[P<^9%U<+ S(268Z2\>B M39X%0P0'21QO4_"W"= S(DNONN\Y?_2N3S0F'?^H[M#DBMRC[Y,QQ5"S*_JM M[Y??JX^T7!8'7@4G.=(JQ^N=F@V%>:<\$]%(E8P,*H<='=*.CWY&I#B&\GO. M07WWX;_>_R3"<)06:?!PD>9NDRK"6HJ<&*9,D'(=*.9TH!5.08[9((#OP(<- M'__,;-Z'$A_:-?12<1B=]>+7^XR(H*R7@$7EB.A7Q;K6V=5EI8"5:X M2D=G30LN[('U:#F(K>G2VDZG3DV<3F;7W;T^3);M).?)/E(J!?0:L&*1A$#Z M(\;:=%\D\HN5++I3TWKZ_#M$HZ]62;8)P*G&!#6KTG+1^- @$TMUI$6C:#JZ5"^>H^DWY$ >T?*[*+?GWLLU*?OR6UW')LO+V;_-?;0!5P*2I*B7 MA+1,>_2,8AW/P!$TU"G$8KM$$1L^_WB^98^J'_>LMQZOMN_T@UX!!#%ZKZ5F M1%I=Z6H8H(^L9.ZB=,+KU5*#QUII/R\K'JZQOE]'^#ZD&!3_?CG\7CV,%60A M26^4 28C!2\:G&?1R<@$]R86KH+(7>X>'W_*4S=JCSKL\[J99+VIF?H5QU\F M\/WK,,'%?$^QCL3)/+-8)#(=K&81-+FLF%$D'BV8+DU&.FVO&U&\!*>['Q/T MS8N%9'2I1 *>9I",."" MP(&.40E@L,#)MR%?T17.62A8^E!*)5CU;[_W/S\%Z.^JN14/E MZ[UCI6)BNM@_LHQ1D5C)QUJ'6GNO@O?,&,%1!*52;C.,Z#%4S]W_[M\T#9H! M+;%<.X4=P.S@?^];\7(*_[N!M1YTVSY4U0W* NZ#$D8FERUG&'-FVGIDQ&U1 M&YPVA)3PHF/?1,*4#A.*DD;S+P>GC3SE9CL4^ZA\WT5W/I^"_#0M^3D,<);P' M*;F2A-22/!E#?WB?6,Q!,ZZBR$YF&YWN8,X-'_]4[=B'MGI^+=]\_WXQQ/RY M%N->+-/Q_L#T=32^&'\9WISC&I3$LJ@8NE"+QFH-87*2^6A%K1 H7I0.]NSV MM*=JW@:Z[+D$ZZ8R<)G* A<7UQ0T.:#UCM%J@?6@/C(0@C.9.<45SLL$75JH M;7S 4[5I/QKKN3KJ=C^X/GHQ*+PAOP"=U$P[6D""%(G)X%*(QCBANPQP7_W< MIVJT@_33N M>BXTND4$HWQG^[Y>RT6R,H0"+*4ZZ-=SPWQM@UX\+^"<*=SLYK:N?I50SNC$'; BBURTN([!!E8[)*9HE!&R2=+O"HZG:.T^ M5+JQNJ?'%G2?OQ(9I\3&CV0_G$S(6YM_9]\^5(]_WL$]<7: N]+U!G0Q-M7& M'UEK:>O)@1>8#29E'20^Z(R\#_5N^O[>W:?V?% S@^PBX(JE5$U5"]Z#MDYS ME7WV3J'2W$4R%,B-ENHN:Q\F_##)PQ%,KA9?[=]C:K?/;V:P#N*LV*EPJ2.M M@XDLI9W(9*\LC>$Q>PY)VXUV6O^H TN61K-A'EY_?/?Z6+ M2T+\"ZWP[\;?OE_.YC'HA_(S3$8UAOF(DSF*WV[;2$>T6?'"I*\+=-2%HAB0 MK&@=LE&J'BFUV//Z$N#P&??7MIJ-T_\L3/3F8?)C, MS_3S?]7"U6LU#'A.Q=3>6R;6^_PGMZ.$%G*=5 7;6Y6-YGNV OZ%TK.XUN^ M06[(_55[XTLF7,WX=XH52*4VF[(L5#TI"A^+55I'WV;Z:"=X+Y2 #6S7\U'X M',C/?W[Z\'G5S5X 'TA5?'9ZWF2F)J]&R:++BB4O/8(52CLL&@-$JXQ3MAK1>1:9]XP%TJ)_ M(S0X_;]-Q#Q07XL<3<6ACL@,+'(!M8\59Q$5,*?K&7?.UM@FH5V_8ARKF#<8CB(Y? M%[F_C<:-%'PLXUMNL^7",E-GN1.TR*)$8G6600D7(\@U,?F3,?HCQ9!M;;Z+ M7EO8FH*V@77:6YF!*3WON:<$"Y&B]Y*\%[*D)-YU!UDUE4B;0D';&?_I,Z]1\Z]EGQ8S*] M8#_CW!C3X(QY/;+?X1LNW_8N^%J6EFT#>)IJL[-A1">F'FC.H]W,W<$9I2NZ M)'(5L!9NNHJ3<\.$3%$12N=4DXS"T]!M2Y';DV7;+E9LP+*?OWV_&%\ASN]@ M/GROVKG.KC3<.)*,I5(+ ]%DDM_0;A!L,F"%#-!D--Q&1.=RUKFO\<8M-+_1 M^3M"7NO*E_VG[6UX0+.\O2X"K23N&2FU\%&0Q:(N7'F()680AK[#2S(;$_1W!YD1M;DF+&*U:%$P4SLG#"]Y;4!1G-,DS6XNF M14[=^^GT$O. )^,SCXJ@U#87%#JS.F**21&DL[QP[XYPRW\7TO&7K,,9T"4Q M;@^%-XA2.R80H/,N18CV"V&4RBI3B^)S<#7'*#&0V;!B'?T]BFQ,DPG!7< ]/U[T M8(0&[8+N8_R$&;_-G?*/DV&ZLX9)!5IQ2L[_6]-FJ*-]>S?6P/$55,80 D8%5!,WPR()/B6B*\U'VO M;:[& TS'2KSHGPU]*?KL4B(4"N"1EC@NO:X$+D1@&9D.P9> +IK06YOH\TJ) M.-"0F_(;=E'HL:ZXNV!Z2?D-.]FHRUWW/@H^6GY#]M((4$S%>6-C81C4QCS< MZN"2BBCRFHEO3\;H7?,;>K?Y+GIM8>L_/_\T$)H7:RU0_$KAC'8R,XA>L"P3 M%D&BI>SZMRT]^5SR&W:QP:I1=U5@G^VSJSWN'Y;_\.![A74 5NX+ MK$X6T+MLDM:F8$RJ")015$*-1@X>8ME%!9_P^^4D?84I3L?ET&N91S[L8%5U M!;JBONR< *$HOA-"VY1\7D:C72 M*1DL)$LO/;U6.D3-?"U2<1HXY](%X=M_:L.=0<+;IWKR!\,\J?<#:ZN&(@\IH2K6,IUK0<78?TH:Y9.KE$+%K* MTN3X?@>,SY]"?1FHQ02)1<8%#/,OX\D?\-=_#V=?OXXO,J&D;RP2P*H(-46, MXMMYCM@@^(0.32#^E]H_T#L6(T>6O1#)!6ES(U+M ?89LJNUR5K<(,'5O*_^ M)[RHE]]_C+OB=B44I3)%3E90-*QLK3.<;]79\>R5='[-<4(/ETI[ GY^=#N* MZ1I<1*W3R.)0O>B$7FEDUB"]"]DB"RH$)FGG]KI@$KQ),M1&1,>ZA&I-E7Y4 M?NH+J=M=?#D*Y#8@.M75 M54\&WS0ZZ2#%-W"\[^*Y+B/M@*AE@H'28S=8O*(+*>)PU)>0[B>3!DVV9R M H+LHOQCW-FN#ZL/FIBPX=/ZJ1KK G6U![\%)RFL!/("--HZ,CS 4LL=GW)4HW7) DAD,:<3<*V"-HJ#SN!-XD$' -^)ZOUDQZP_K/? M3"8P^K(8OGIU^RO+T\8W_X!)OCV4BL7PK(1F0KEZ@*AJH52@",+H(D1,J&*[ M??$@Z+VX"_L@^/VR'AM_6"9ZO/E!AJSOX"_CR:_T;V<#XTW@GG,*Q9!4JCSM M=EH@*U)H TX$*9M$JZT$.L'TIN/R>JTON7V"X:'_Z9CJ]7%3& M3-^,\M]P]G6"F@+1-A.O MV\OV^AZEKA=P-A%P)__^HZI7GOCY)L8 M2.X-14,4.$A1+T/JT.J?O2_+5D M=RO6!S%3Z"DBU!%-I'>K"@O6*T8!J"K%I8*FW05(2\E>7Y.FV\C!9&J0LM:K M@/^-PR]?2< W/W "7_"_QA?T:1?#V=5_$)+,B:Q=1 M!]2KE+^,)P6'L\L)SL62CD)&F05S5>>T/G@6 MI#*L7B-SM(JGU:&.:X?)-(3XROJ[TVG.A0L]3CXZ6.V+YI;3#Y>SZ0Q&-9_V MT_CB@H2K/QQD5XH"".0@UDD]6=DZ9"6Q1)HVO&0;9)L\PR;B/*&WX<0G4_VQ MXIRBB(=2+4ZB!P1:EN@+BR;0_H3>L>!%9E)K%5)1@:0] MJ7Y:9K18V&N2YJ)][<.:USNMN"E:QTD:3NOH]Z1,(I^O3AI-3(<$](X:HAZ7 MJH#QOM@VYST[0WWE:WL+G],AS(?5,.'V-?-&!#"DLNA*/5=R@05M),DE++U_ M1IAUW:=.OP"OD>65U6? D19-- \4Z>>_O@\G\W]S*Q(*H8.SM*?DE$G%VK! M>F4)!:@2"E>I7=%VO[*\TOX,.'+>QRC+T(&CC%;2IF7 4>A@*8CP+@(3(3B4 M%B3)>XZDWQ):GF)%F7L$-5%LJ=K$A0:M,E- A-%>TF(9A2"_%6*N34ME/LO# MJ0>2O*XF)^?'P[7$G9KP=W2\E_JN;4(K1+'E96[E$R;RN M>2]>1"0O.B1_[HM-1U%?7YGS9]C#=\H_D7=J4%)6]2J)Y42.MTZ%=FU=$Y(M M*)5R5$F=Y1%91_F>]-O3A*JG>;-VXMDI#I:G.YT?/BHJB"0U.F \8*P!;60^ MBL04K7M9QY!-.DT%37\ROKY6A[Y6)^+;*2XIMXEZ+4TW:8TS3M9YYBHZLHH/ MG@5E%%.88C312)-.D\#5JYBO+UCK%ZP=ZTYQ-K]-VC4'KX]OUZ@P<*X8%)^8 M!NZ9YU:Q*%1$E[Q7XC156ST+^OJ>M7[/6C+O%-5!V>]C\IK Y3H#;T, M4)O2)D6B.F^8XP:M2T+&$P5@/0OZ^J:UW]':,>^\;R >%5,F[JTUA7%EYBG9 MAD62FUGNM8E:.X?M"LF.?<)QTMN*1\T0K!4FF,B"J:G,H"4MZ;XPYW1TG(O" MU5F:H:-\K\M;XX.F%CQK=1<2MXL9=[;*)ZRTH.^_&X_FU0&7<%%K'>7 :Z%- M@4DL),1 +E.TC::='%_6)_V:]7H;_A:A5/O4G=$?D^2 M#4?385H,A=#)&240&7)4)!@%'4 68(G6"@KZK6O4YN$DF DYX MQ]:\5Z=K9?)0YOLKAACH""+[6@JLBZ]SAS(+'"@"-0F"*Z"Q-!FLTDZDU[?D M?!BSYF4X>>'A?^%T-I_%==.495R_]3!I5*,E_Y'>>A(Q,1W)H_1E?OBKP?F< MC(_J'+VOK@(^H1?EM[,HQ&W"G!YOY&IU/4GV;3R:%_'4>OF_P>1_<#9_I$\BSE25*V39!&QED)J[PQY9%XTN1W8BNS%\;%? M6STDDSWU$OMH9MW\AS_!#&\:X0QXR3*L)T $;3?SDP MX>FMILV"WO2"D7&4"73V66;;P7?=Z:$OAGUMS7%.A2B+":CO1]/9Y'*>OO)A M]A4G?WR%T?(%^GT\^C&/]NX>R'#4*@7GF(_!U&P-P7P@X6/.7-/[$B2<5YK M7F*^&+H_ 1:=TVUE=VF7IR"HM#"E).9+'2 A(3+O!2T3%AT&7[3/YW5^MJN$ M3^A-.0)5C_]6[<&S<^H+UEW0[0ZEJOV^O.]Q3>QWYY>D[W?EL5L;@0OUF84@Q:1&58<1F8UCQ2$(Z1F2R]Q&2B M,^?56FY' 5]?MY.\;@>P[)Q*PW:4<_NR4I0*1NC$T/AZ<5I($0(4N05 W^49 M4SJOT:U]:^#U?3R#][%?GI[3G>Q612S+Q^^L35%$+FDU8BD8,IB6)*HO@MXD M9Y1TBDOD3^N5?"#CZTMWDI?N,*Z=4V/%KJ+6K@S;%Q>#F4L/R'@V@GQK'1EH M,I[)(-&0E^V?Z!O72?S7E_&4+V/_#'V:=^3+>Q@?DTPV&69TU$S+VB>=&\5< MBD(7I7-6I^DMU^:^[RQ-L9V.&9WERM0^;+PP[7-FM&L ,S)F5X+R23RQ,^I] M;XK.R8#W?>IYFNRMR6PL%.LFQ90+9++B,P/4A1D#RDJ=D$SZM$SVF+A/:$\[ M]_R3WEC5HECXYV_?+\97B)]Q\F.8<+T6;M[MN<#3N0AW?_YN/)W]/I[]'YQ] MPC3^,AK^$_- >)]]34@36=8V75#+H'-DP8E@ @6ALDU7G682O;A7XCRXT:*4 MMYEDBW>BE,&UR0LYKIBO[\?Y ML*A)R6_ZBOGR C^4K7K?V(CNCUK+/%!.F^2 ]KNH L4H0; 0O2 &RR CR82E M34?#OB3HD>IP<7&V!#^-Q==E!_Y+U5^>_3_I8DR?_Q__2KX6WGYS/)KA7[.? M+^9(_N-?I_BE_F7O>HC);/!Y1A%+_9#/"4= ;^.;OX;309$YY4!2V"*1HK:( M##)Y;"@$) W*H.MRUT,/N,-9^FJ5KQL1],B[KZ2%2;HD$>B[9%#ZE$=X>!HB MC/LT2(])IW- 2QQ_CJ;?,0W+$/-/\UVK$Z@!V0XN+V:]L643FCXWY6N>L!7P MMWSIR5+C5FH^&@>X4H4K+>N )?I#!&3>@F+6ZB3 &:%=EX9[YVC[Q4>?U/2[ M:+=%KOEEG.+?+TG.GW_0'W_0/YL+2AML4J)X9GP=K>6=9Q HED4_0UR5@-?;L48Y8\7,/H=OETSOHM, M3?>@!D*=9OLZ@"N]37WHV=!G-73O$=E$U$ER%YGUAMYS6^,-1Z(Z+V4,*@:K M3Y.,=#;DW;++GCEW=[%O"\[6+AQO[G3A^#3OPO'YS:?/?YO?5] >$Z1-7E)0 M6BM-G- ,DH@,I0@@N!>.M_'5MB$[PQN:Y@18962OUGM(KX,OY#_A=#89UKZ6 M)0ER-3$^UN+YI5&/5BIPK;;QN.K__?<5 M]?Y&7\Y_,/]^5=\G+/]2___/3^]O5/V/?_SCWZ8SG RG_Y;&W_Y]KN5?AB,8 MT=))\N=YHM.OEU S_!"GOX]G.+V/93K\]OUBI=KP02NPK1_Y[[=0[XNP_-Q[ M_#@<-/XUPU'&_*__,LS_\:]#::.USGOI$M>ZY 5+WF M1\N?S*/H=%"&T5!^.3C\DEEWWVT>]HW-5' M']S0-E^FV7]#W5AF5[\-(0XOAO4OUXD9Q6G!H<95)9"?62>8@M2)B9"YCT4H MY9K4:6]%UD,OW[L/>)/2Y!(N!L4'G7E*C*=8KP$%N4DE%):53YPGH7V;NO3U M<([O>/3+B#5->0]5>H-@9CVJY9=#G+Z?3B\Q#XQ!YX5TK"3KF8X\4L@EZQEM MQCKG@ARH)M40W>"]#*H<9)0FQRRT-)/#O1[MTB^?#D+RW$EA&<7EB>D M1U:\UT5R# H;G;5T@??MA2E3@ Z!98[SFBM"561F*D?DF'71 MLDD W&4#ZL_!6%QSB>Q*E#HP>EGKA:@D6X#RK)1BO)7!^MPDP_915,?*FCWJ M\GF XD^=Z'HMT=OJ!M?\=<39;_6WJTWJT3]W(8"BU5^BT+3P0V80K&"&2_*Q MC>?&-#EUW 3H5-?//9I\W$#U#7;?=;BND^\Z(&MY1[P9VFEN>OLQ80=>'*#_ MXS+$^B@25Y;E7%LC*@3FI5 ,*31WF(&+V&3S.38SMERC'IL8NZA](R&.UYIO_(AQUL@*Y 5S0-(=B VD6M MD@[>1?+_0C"T15M9#(A!-\P'JW3M-_<^MM_Y$6W4WUFH%:/$Z"%(EXI61GM: MI)3WJ+C(DB?D .N-TE&^@TUU4Z8_+G=^OG8)WGL%Z^G!;DL\D5K7*D/[AX\VU\.9K]#:;3@;$. M*20NS'(-3!M=>SYYQ81,#E6,VMDF?80ZXCO^R=JAO%CUY%H8HL$1_BW,-],I MSJ:#!.1V)*>8DH$SG< P[RUG( 2MXU! ^BZE;0<08P'D.3%@#]4V".GNRK*>C<\'F)LTKUJ)Y3D;?5\D]GIC767.T M^N3;I0AG[^?]*NJY8MV <> L(2D."94-3!- @A8TXTX5C(%"3.FW^#@='O-T M#=NW#AO4BOQ*^OAM/)U^&-T*?:=A%0'^.*'MYZ]!] E2#(Y6'..8IHB)T?I3 M1[@:-4^EP=QDT^\*\.FRI*DI&HPK6-F;[OLE ZDU"B=J9JNO345(#1%$8EF9 M'*$DD;')Q<"CJ)X^.?I3>H.6^S=QV'1+&/;VZO87WHU'LPFD>57EVZN;\'TZ M_#*:_^[B!D7;+'1M5YH$[7GDXI++@TJR'#4'987 XEO0J9U(Q[KJ[)N!9V+D M4]^,UO83[RXG$QREJ_F1?3!!%AT\0QUM+8(JM(&3HPY1*>>Y4E%W.0#HU,_C M[H-/=>-Y+CP8]V"/'B.EM,0P>'-QL<1#WOOR_J4+ILT7H]-KVTTQ_=N7\8]_ MOW[6@C#77ZT2YC%$Q^_]L[^-QHT4?"SC1^N,0:V8% 1+<]3,!PKEHC?U^BTJ M8]T3-OHC37_:VGP7O;:P]=_^]^\#9T)M8=Y@>/?FIX%PZ$3"S)(!"L&]KN,+.#);(H53 M8&+,I7\CTI.?@Q%W56"+-_'MI]\&5@ ]BM>S45L'45A@'DCM!6UVSF4E0@,C MTI.?@Q%W56"/YXPW&'[^\]. N\)U2)H5BW5R:A*T1Y _J&BGT J=DBV,2$]^ M#D;<58$]GB;>8/CU[<=!2MD&+I'%P&VM>,TLT![/G-*TH*,K)NG^C4A/?@Y& MW%6!3<_W;D\?/PVG_[-HIQ6++B$:YDRJ9]8IDW"J,$RY^,)=3KC&F>WS>.\A MJ-=(N(W]&M1?K-?#=:>]#MA:I@\_!NXT"<3]F7(C1WJR0],[YS48N?-&UA16 MGD,F;\4!K9'TEGC:YZP1(H!:L\D\18YL224^#45V47\#:OPRGB MF#__E;[6 MWAS+873+OAC.::EK8:M)M>.CSJZN95["XE%G[K5G1;FZG4K!(!$VQ4-)0HFD8I-2T UX MGA$;^M#XD4I0YBNB!Z-0U^Y+(@6FH\@LSMUTU!@CQ;I%-.D >&YU:V?JN_9B MMP9I,H_4UG1!]EKTMJL)N]ITIE@OX4U!P)"< M44W&W3V5HK=&Q-A%[0T(\7&"WV&8?_ZK=I+#Z9MEC=;BN&BV2.M=;I9&.W+& MR4WBJM:<2[#,Z^JKI\A=$:%(TR3)I3O$XWLL?1GV08E^$ZLT\&7GS2 PWTD% MOFXE&526F!23R1L2.@CF06HF,5H$2T&=:>+"; +T;+C1B\8;K"3O1VG\#6\F MZ-Q;.Z--$H,.K!AP%' 1M!AR9MG7WDXI%6[7W)@<3H9',+VZM$VLU^"D?P.T MFWN,[>!:.K:/HCN-;]N;+;MQY !#'&\9NAF\%0(OW-<<@%JF4CCSQ246K/99 M 0KF]0"G8 E6_S)/LRCRD4JWS@JDF_K9U0'M^OZ='"J]W9FIFGR2GN M=/:A?(:+&T QIP)91L9UO<>@#9<%*)$YVI5])D?=EB:W/0^0/"=.'*;F8[2) M65OT?UTF-;Y3)C7=I*5^>R_L\^@VW1<.5L)J_X60/%"L"PF%+D5['BG"0>3> MFF"X6=]_81\4_>>F3*]A_'93YU+[A%"H7M\#)2@*E(8%+(6E;)S@+GN9FX3( MW> =K683N9$F&45+>.W3FK5@ "DS%Q5WH(N-MDDMWE.HV>R-/WN7<>YBG:;= M&]:HXB84_H07\]=W^G7X_>W5AG?[;D!]/PMA$3YS'HWDNI!H3C)2;&'1"\<$ M1=.0C'$N=1F.WN_KV*N(QR_J:\;?,^7%J>O^.N7;E"BD$058!%=((*%)[Y;^ MB"8K88P5K1MBG$]VY+GR:)=LR5WL>>P,N"[87K,E]S/E+JEP^]CAV%P!BN.S M"9PII,),5#'4 9\0FJ3&/:%LR9W,MTNVY"ZZ/V*VI.$*H@N2&>G(>^2$+904 M6>0\UR,"4[")N_XTLB4/84,?&C_R!7,.!BUFQ8B=!,U2J!H2*$:(M<@^&-/F MJ/X,+YB?B$?;ES4;E/\\?IC=!=SKA?-^MMSI+G$?0QS]PEGK$EU2@H$(=?QI M1A9TJ(LQ=_25#[$TV:6>UH5S.Y+LHO^37S@K#Y$481G7-9=/6HUPXBZ"5$CHP'\BNFGO.O."&<9]B#E87W6:H M^ME?.!_"BO?G##I\TTA'HRC6O]RI%GK6' M++2BR-,X&TTB'Q.TI+=LT WSP2I=^\W]YU/O^H@VZN\LU.KT$9V@('A).[36 MR8!"2PM>\L)F'H&O-TI'^?HSU7\.:26?I*]7!XSDV>T!C"W2SAK^#[_.( M]/:"4$3'M>*2F2PS+;PJL!C0,1^3*"KH8G*3J/Y0X(?N]#___7(XN_J,Z7(R M3_#_Y!EW@C^YW3GYOO+2J'UJEL^B9.YV=] S#6Y!03:<(ZIGU*#(!RUA?J&REL:%(T61>2V>$)V#>48V_&B UL5S3R^;E>!J7 MBP[<1!9\O111AO" K3W/DM&*,/F$+9BT"N2%$>8@.S0XWU^W?0^"MUZ[I)@+ MF;B:3&!@C68E&^L@*H^I23+N.C OC!\'VZ-!*XW; 3@?_C'"_&96CX4&%/W* MS-$R*W.=9,(-@TC(9 Q1EH*89(BJZ7)BG MY8VAI36MR*(=-LE?>AS6RZ7+H39ZR"#;-'"_T^WA$;6[QIK]R[XR"M+RBD1&:YJ/L9N4G%9"W2#L_4[D..$T1&2AZ,X*6H$$E6V23\\6U:%XBCPXW M2XM>FI=3VN2G4R)W'"ZZ+-5T:!*Z^@'D PSI.?M3=IDRD6KK]N4(#IT*-C&L8'2LR4DY9B:* M,$D6X%(W&G"Q%L\+<]S[L$J#)>M6)U?KM++(V<\B2J$ALY"+9N3TT8JJE&10 MLLC!H@MMNBUT 7>L^O331GU]6^E<:L[O"'8GN^@M3(?31>$B%R)I79CVL0X$ MEXX%J2)+14.)1H&+3;*;M^ Z>2/(WGBPF6@'VZ-%Y^'Q9*[FV_5SS:'<,@.W M"]26-3<[8#U-!4ZOMEYM1MS84"UJB1\"K OW8@[]]00T!5H)*R2SGOP[;9.I M39,C^9.@E"FHM&N['CT"[B05.BU)U+M%FJ0D3297\]K([T1YS MPF\FN/.?9 M&&0V"TM>@-4LYMK$)F?CL_7>M.E7L"/.$SKGO1G[00I2.TLUR,G<906UG!L1 M:+'KXY MRV*#9=+-8U&@$"61V67*)6"J74*:I(EW@_<2G.Z^K-/@(+QK&?5^]/UR-IUK0%Q/=TS96,MC[0M.SIZW=>6.A@DMO34Z M>EO:5HT]Q'1"CZE_:V[BS8&F:%$+M0::O/;BL@3/C6(*0VT^ZB/SGOZ@;]=F MTL9;W::CV&9,+XTE^YCB2&N)NAX0BA9M")$Y+\G7UY!8Y$#18[3 M]$-,+XTE^YABH\ONN0VU*UW?W9/"\2]F6MS'/G#Z%.M6YD0COE!Z9^C<9SB MY$<-).#$HTRZI]&KLVI&=M'ZLTN%F[@/':' M_&8RJ5U3%VO2O('J^]'B:/)#V2:E&) @W&AA&48>F';>LDA+'Y->FZR*$R$U MN44XDGROY#]+)O7H1Y.?,)B/I[U37[/PW&;SX]186V]I49@MFH) \""-(X! M2!M!."/0;'%]MCSB!7.L3^4W::7Z:,D5V3=!O4H!'Q3%"K10Q1B J2BTL:0! M[EJ73)Y'6=RYT*F!W5HF.AZNKL6-#RJDR#+D>FN8F"[.,C H&.2D+"V=)MFV M!\\]"7+T!,ISX>M)&7&&"9B/71(DA[#SU6^3C\6L74QWYYB<+S;6RA64N4QU.:%G((3'#"U>D M'(#<) _O"=_\[&3-'6Y^=C%%D[[K:P]>WE[5<3OS%R:46%R=QA4B2:]=K%=> MK@Y,\H[>&1M";E*-MQ79JS/5N_T:'))L 'AGFE,7@"U]IZT(3^,O]6S9;KPY MT"PMZA:V E6B2*BF%WQ'I6>E MC_O16(_.2(6RZ=)H.KW\AOG]Z$WZ^^5P.D?[H?POO+HM?I$<$F?*IL@T1LZB M0\>$(2Y+4;2(7>Y?]GOZ>[M0&32)&]HO9*X6KVZ805X_#G/Q>"]ZW1C MMZ#6.:IO?L#PHD;595R%P>E-X^V>6AN]_F1[SY5LMY_UD[$TYG@QP4=SH66GJ- M8=K7/CV*=$,OHX_%)FE"D\[^'?$=?X%LQZ75W;&%B1J<\*["7!U(\":ERV^7 M%S##_.N$=O<_1Q.$BXJ^[O=OZSN/?\!? X!HHI2&157'V#HMF>?D':*F!<5H M,,HV2>7L"?]+8N(Q3-S@J&]_,>;3WV_%\"FZI.E=TT&38TI*C<$@ \&M=LH% M TTVB)[POS*U7Q,?/_,S8V\/!Y5>C-& M@XZX7;2PO#.6R1B0P$J,M6"4G479"V3/OH#O4T^1\-[+W9 M:6IAK-/2BUXP;U61M'^#9=K:S+P7AEEC9!;>>[!-TM9.3:LMZ2%GQ:I=;-2 M3:N>X'4OCE145M$P!RAHD M4U#^=CF[A(M?+D?Y&DP1VN>H*%"<=P:V@3,OR7$L4:F4!<^X>KJ^]AKQP0<_ M.Z,>KKZ-[W>/-X:?,%W =#HLPS07>#J^G(W+G3.G>;%QG?@TP:]U0?V![T?T MKW'U'W;]=[^/9[C/C>.)@!Y\8WD."EZY\33&Z>*M\RHJ;9$"0.%RD*B*,AF* M&)Q>UV=-X7G@\B0XO$3Z]$B\3L4K+);22ZY#JIUAM$O):R5RU,)D'Y.4<'P6 M/]3V6=-X_^R/DT%]>D3NDH$28C"!P@NEA= 2C2\INY(1!)A0LCD^D_O)85E] M^IO\?R^7$]TO9Q^ZX+@]I93%B@35^>+&UTRKP$ '9 [16931 &^<3$:)&ATTVDGZJ5,;_%$?UE]G%QX/-FM/@W'\?3V01GPT7& MWL<+&$UOQ"M%!2E,(7EJR;-WM:HC)8JPHS91D_"IR5U18[E>WX%S($R+/*!N MXJUDI_\Q(1$N5NQR(Y+#Y,D)B4SX$ND5-XJ%4(\UG0D@'+IBFS3C:B#+*^]/ M18P&F40=1;J!BS)9+E1B62K#= F<1:!74W':NS*DDF*3U*(=<;YRM(5!&Z0F M]>9#)0]&BNA(4W6B.6C./&T?+ L;LK$!>9N13*\>]:&,/0D%&B1/[;HEP+SL MD?RAQS<( 3%QR)HY 8IIEQR++FB*$&J%JY7 8Y.9TFW$>:7Y">GQD/2F)>EO M?9R"4N?Z8F:LPP.Q]ACRGN7HN<@YY*";E&Z\>@K[$G(OTSVDEVU)KT<#RNN@ ML\:5MPJ^3>!/B3NG16:8:C%I'3'IHY L\9PRL4M\= M2OU5_?Y"%NB@U,4>,ON(D^$XW[S&M>Y6.ED8MRF3ER\2B\@]XSKQ M%ZSYLX M$7T*\7(I?C(J/*2U/X;#<#,P>#89QLMYK_T_QA^A"C-0&8W2(3'I0=?40,FB M]IP!N,2U1,5=DX+C W&_7/(>T^ /^1KZ7H:[*F^1<&]L+?Q2I"YI"VE/9N9Y MXBP7*0VGD#3K)J6@!Z$^5NG,N3#T>"8^EV*;CY/Q]#M2@/D#W^3Q]T53K=_Q M'R1TG8L)!J<[88:F:L X:(AF-&&5*3$[9] MP)ZJ%.>(5!H?V:1M+MJ6V'Z]'.:[K7XZX&I9F[,)V&DJ<=J;]N$=0G]V.29O M; +DM258M*GVCS3T D63&'J5K,*8=!OG\+A\V5)B0:UWB!/ M__R>:1F67%A^/4;;%L$3.L<"JGIKX!7SZ#4K14$1&8I3HBUG'D%W_+"A'V-N M9$A?EFB1!G7C?M;S^*TOC':F@*$7)O+$=%"*A0**16Z4M2EDA";>T$XH7YX; MU,Z(#9(O:M=$TLMRD;[>8SM@:NG[K -U&K^GH2W'C0S18!=;B\TYE92'S#A( MQ[0HP "592H4YQ)B%K9)2N7QR+'%R3DQ-W;1?\]MIVFEO+C,).?[;]\AU1*# M)33ZV^<_%QOJLI(R9Z6* ,FLHFU4FQ"9-XF@TDZJG#$RA95+KK7EH]V?>'QW MY7#KC)NKMH&O0F[4;,[O115SW4K'HQNZVR@-.%0LE6S)F>>909"19:_!I1BC MM4U:.CV*ZN7Y(OT9J5E/L!M,2UIW =72^5B+ZC3>1X_66]MYH _5-VM*L0HN MQ*0X#YY9BOZ85E8RGYQBHC9"Q*(UYB;I$D?DPQ:'X]ATV$7C;6L@?L?9;1O, MVSX.*]WX=?9.HN/=O MG+8%9BLU0?=S;Y9H$_I .G L.1$)K:\E$5$S+YPDW]TDATW*3W>#^ ],]KT98B-IVL] MMM_Y;4Q8*1S X7P>YK[-<=9^S,'-$K:#6VED$$&K$E,*M*YKY[-/5D>CP!7O MBRQIL WG :K;NRG+^L_I6WD=&II S,D5%,5Q20L90K"8027IA!80PJKV#FLW MLO)A^S<#V?!!?2NP2R,-H15R%VT44>DDLL^UM8934@BOHQ*K&NRGS<7RF&\Z M9_.;45YYR&^W"4$^X;6,4:EW<3S.2X3<8_AO22SL8+F(B#J-%J[FK?>4W(LH[,H_.L\)*"*DK9 MU?FT:T^!'W_*,[-USVIMX S/Q:UB(TSQCMR?<.Z7?83)HDIR.6!UH+F4(D:H MU"0MR)P9)&Z8S]R7)*PKJDD#@AUQ/C,>'<-:#2ZF?\(X>S^:SB:7=9E[/R)O M@4C_B:#.C\'R1YPD^@%\P4%201BO'5-:U<0A5 Q,<Z YD>.P9S]#VO:FTQYKN MBNL/G'S[4.XQAG:-A#%=B@ M4'F>0'$KXW0@. 5 M& PA<(R[6Q@49& &&7A&:R'-NDGJT">F?E[T7>/%;VW M=+SK?/XRG$QGOXPG_P=A0G*BUC%:P5! '9;H(NTJ23++N2MH9/&\RP"#+8]Y M9H;N6[$]5L56:(L3D5\@S6>T5Z #)S!)!';^&B%GG\.:+/N@_MY[]J%1'F/\9O:_NM+\,?.'H_ M>I/^?CFN>U\-B18Y>S(XIV1F(6NL;K-AOM(DD"^M7)*) M"^BP>JU^[AE,@6QGQPTAYL[Z[+TFXA;+=3IM!S3K,YFW6OD46;!B-": M4-48Y3I/T%@74K),Y'HU6E(B0 C,E^RTI;#T0;_'M69;^^''\_CZT/:X3U7U MG#8P!V2LOP=H"0M4LJX68 N)!,M'7@?6)V:2!)-E !U-5PNN?\33MF,/:NOY M3:S[?,6C%U"60BH,*(4"AM(3H*@\ Z1M7A151!;KJL":>XV'7?O:E?'%J9,\V!W)MB)0L)BLHB)J.;7.R=F%5;*D//BU2[V.@X9**_U4^_4YWX]NI= M+Q2RER:6$(IH4#)PQCW=W!)XDC7>Q? /ZOAM?U**("5S,]0&.'"=?\Y1S M#(LSM8B%,R^L=EXX$7.3X4'W8;RD3?T S08JW:+9DG/+GA:;K2K@$ZS9QYB MI(WV/D##31>")2Y>"!6 8D:%^9T9L@ &:L\"J2(77KDF)V?'L?B6W:6EP7=1 M; -#_XKC+Q/X_G68?AI.%R- JC:KF%F:F"TOS F,C"1++/!,BUFR%#N;4HIK MDAFT&=)+V@EZ,DR#N8/KD5TW9^R K>4.\1BXT^P6?1FR$S\.L,+1%I#L?)W]6"_A:=R;4(JL2HK0#>I'KU^ S9LKN<@B"[*+^%>[$Q#EHTE5W4 MR^%DK@1M@[;@+ NBCLE.PM/?G&,Y!6_ T&[9ILQY%Y O:6=J9KP&0TR[8KT^ MP>^ MFE\LQ/<$T4_S<),H M?+6.X_DP;5O4=:9$V\5D[4;K;%WHIV^OWH_R)6W]5Q_*N_I/>(]=JL0K]OL$8S?8W>(:UGN %PXLFO>M2X06VZX'3">_;[;,Q%6^Q'W1T0'D#OM;)Z9T1G?D.O9> M##D^EA5Z7C^Z@TU!6D4+)H,@ M-H"*S,P(R,UGCE7.%=0L6G0)5-5?.G8\HN MRN^9(1\GXWR99A\FGW'R8Y@6$N><$@I9F(14;V!580&LF9_X(JK@G.TR6ZL3 M&=8!>"D[S,'*[[4YURV@*NP2TO1F_NAV5'UO*1O1''\+.=Q2#\W>DY;;+ AK MP E7O/'2,L.QED^CIO7*:\8M(1,$+OO>_,XCF_Z1+>%(EM]%N;T'&:/I^&*8 MYT.UYOV]%F&5]1B#=\PZ0*8]U-YN"9DTO(0,G ?HTC*]8YBQ#L)+V09Z,$"? MS?760[H.ACN ZGL?V 3F%)'$X99ZU/ ':+GYJG =UCB/PIG Y'RX0Q)0NWD' MIKP&<)S3^M4E0_H,+?]H8' 3H 4"-D2M3&8"_W9XA3S450O89/HWSQKN'-PUY#[?0&ZH&EYQW(& MW3]Z--9R#TN M@D4>$O/<)QY$+?1LLP<P _1GAC7C+7N)6J^UXD-H*3T7+U_[=W=W%9T,4&-TX*(D/)*R5A>ULI&)X6 EB?N&LGQ#07^$E:>LSBY@Z2#%1WN M0KP+<)."[P&OY<[E<7C??7EP!9_/FONKP=RW!R6"\=H&0R*5DL@@>&F_8 C7 MZ*6AD<701%SL'&RJ5P-\-ZO/RZEHM%+):XP>1#*!KR@JA8)ME@@0 @D*08AJ0=&K-%D M?_I6KL,M/ZMLMH>N'-3AZ^?K9?CR;CS%Z5T\E@>=M"&!THPG!V8$=$"BN7(I MJ@B"R1YN['KV$W?A8',UF*S7,Q#>B8\WC>,TL]X8243"0*1$1BQ5CN3!!16$ M@)^[ZJK1]R8' ASU;;WQM0+L>Z%KS,0U.EUYS(,2_-GUQ,7FG% MG0]-DG*=:)Z!]X=;^:'K!Y_@KU>5CQBNY]F>=_4PUBUEHD6=/"-50YS00E]REN.D:>GEFTE+4U4G=9!HL#300X ;>)L^%#T MNWT\3C N%+U%&NZ6#- MT=(^.['=R3/TP7;2A>G M8K*3532@18K&DN!TWO5PFHIXN",N1"^BLI8QZ.'&4U0TG,F554Q7\4BT8+HH MX[M=2);?BG!X]%Q&2H1BDDC( _5:N7(ASV.,5+MM(91.;^YX_$M966M8M\/A M]>?@/H">W+I:Q?K[IN)C+'>25142-2PO#)%#$=L!04"HDC%"%R $YK=3=M_O MJGH21QYBL)T._(\?MVR2W_+[ZA>KGY;39?L8EC">#[;9Y M3%W#=8+;LER@V6@N@3=3ZPD+58FE97DV8ARY@-7 MD6@J59$P*.&<"CEF-(D%3(B^23+\(93A)>YW[)6CI ]8^IW'U[/%\LW?5QCR MYU^ORT'Z17H_6ZP&3RM.J M:E+B, SVZ6OP!G+H827\R;Q6L=#Z /3E\PF3BSKLK4^6$8T-W*#Z^Q[:UU]@ M_AD7(Z8,H#*4*%EN)9B(Q%K,],32G6Y: MC#BG4KL8"9Y$TE),O,"7Q>H#PSCQ]LW8?^/EZB:7L^6J%Y M]^GGCYN)Z.VWB8A[=):'1&+TI=>ER93TFA'+4%)A8I2ZSP6\GJ][LDYN9=*' M7A^L>?)MQ.NCN5!-FA9^GW+? [Q]D(KW(59O(>)Y3V*X#Y@7+>)] MD+<>57,^QM3-_:]04"=X)!02$AEHCD\@40*.>\^1H64O4L2[GML/L7#E??]/ M5U>3,<:/)9L\&?]K5=/V"<.7Z6PR^SS^=AD9% ,449 0\IY4JH"ED ((5XR% M1 %"['/,W>]M9P@"CW?'K*DM*VLSO!LG_!C&F$/1-9@;2&@T.I<)''Q>SJ1G MC#@78F9V$;L"1P/M7-C2".^HD$[&'Y[:?^U1=-L@^#?)HKV?SJ]D\KR(;40<0&,MQ@8XK MP6[J"'#P!(14*C+KM.BCC7U$;?8]'$_1O35,6C%GMFKN"M//-Q46'@ Y*"(@ MS^22*K,* PB8(")7,D759Q/=KW/NYJU/>!MTO/5JUO5M0&QD-WK J-XQ^_;] MIU.9)+ MHI%BX*.XGO!,W,+R#8ZF2I7Y1;I?DG032_0 UC(]M1/9>5)55?TX:^F$!M/' M;H#><+!8KIF[LNG6>8($"IPPQB6C7@5IXC-@QYZ$UGG(<8CM6T@+75Y-9E\1 M/^*?.(=OF_F119JD $%\$!F;*B46&/*4"29E7 #9I2THL0//Z?=DE3RV+2)4 MP=R5TUXW'=<_K#)RL$G-;02P1$@RHLV>4B6-JX%8FW>2@B.U6@ICMQO:=F90 M'GO'4W=M51LVN0V_6%ZD_Y[-XN+3; F3&U1<"@29 46A,RHO&/%,Y_"86JMH M$J"5;Y-LZ8+SU$E0T=A-$FWE1GY8?L+YJC3WEIL@)(BH-0'&/)$FQ\->EEZK MF:\A_TI22MNP8 >BYT.$&B:OF9(K9S AX 1+>C!&O)IC&*\GK&F$R]E\>7_: MLC;9X&4DR5(LUX,-\<(B@0PT( LZF#Y3_R'O?.K.;VKCRB5N/RT6N!Q?7L%X M7O;(85UDN5FR* 2*TA*;8BG"XI8X:2.QPE!,R%W2KH_O'WG'L_!U+1LV*&2[ MN"HDS&-\LRZGOD&5:% *4!(0JUOB@1(H>2S%T5I(R/HE_@Z>\+OA/'425#3V M0PH,;D7S=AIFEWA;U%?^03'N2GX &.A0XI!0TJ&^U&?8_ F5HTPP< F;A'^/ M8'H&><):%J\XU^^!MI%UZ0&N99[P473GR156\V4_C@QP1(--X^,@\WZ6TQ*S MYIV,S3M:*7+8HA(1)CKE(P0OFB2'SL"2/3G#\Y#D$/LW(,>WU6Z-\MULL8EY MN&5))&H(%2#S&AH5@;RI(8:O]K\T0FI2$+T3T>D#C(J>VQ5D##)[@WNVZZ3' M1[AMS^*E<(8;3GC0>9@@ _% 76G9H8+'TK(96_#@ 9+GY/]A9CZ%VLAOT^O% M-4QF\[?3-,<_KO/X)U\O0KG'66B[TA&X!Z>7)$2?IPY6B#@8^I9@A$S"!2ZH MEM'+@ ZXX$ Q6B'R3L*9T8&CJ&SVHW5,^C_[%"[HH7F"^;N@K0M1LR"U8%8Z M[Z1(,:^]--#0QQ'#E%!ZO.!X?90#'GX*A_314DE&.,N"D"P*:;'HR3JO-*,! M=,Q?D3X>Z1C3(2[Y>.T7ZP>_^;-<43C"\ \>,=B\CX/:,J)15NDDE.:K#'%R M3GN.Y8(LS3RW:?08OB&F.GKFV/&@ZF;K,2=0U,BH-C&_408N'5*F+%U)>X'W M#XTW; +8?MKQW_9=3ZINQ%Z:2")D[B5D7#FIM 4F8!,<28$HM(/K%A)%NG^ M4]]]NYH:0Z:^EIPP6V(I28$XIP2!/-N;[-Q$4;4(,G/8@->?H5*^!AGNIO!/8?C*!1M;D#OQ_8IYJ_ )_GZ%T^R59;8/=0B<*L)2 M43E$FDT#*N:-AQ.*>VZL[G.:=\R[GQ]+ZIN\\DVH+;R_31>E;1G&.".JV;ERU<<6 MGCM+V^KC'/'U9):7O<\?O\!\/:>-:)(Y9D9-H@J1R'+)P67V$IN "PC@,_C# M9X0^KW[B)#B%P2M7@NR%._^XG(7?USB3T0(Y&&)=*53U1>"8QM+#1?J(QB5P M?7K5'_+.E\"(8TU7-T$_1^L'^Z+%TU+M*O^->KV7P^ M^ZM(Q,[GY2+F2F!F))GTR7$@U%N6@RFFB2^2<44P,,084YY J]!G'Y(7P:*J M[GA(IJ.;%G>@_R5;=IP_Y %.6N9]2(+!O4$[>%OV73=3W@V1_6)5DS]*/#H1)2.*)5ZN M\U$"B(((J365$@.TN?MR",@GSI[F?NG(F TN9'D/7U O*9D*B97SI(5.&^ MW>7E;+K>S\'\8KXJ!8JK .Q]WN>5+?](B>0,!D9,B-D8:(NZ#P2"22MK'8O. M-&J%OA?;,Z%,;2]T,&5P0K9C;KR3$2K-=YUUI5N&B'E!]32//E+"632&,R-! M-%&6?!35,V%'/M@G91MQ%=/ MS(I]HN8G)<4A-F]/AHT^17ZI99 CG5421HL\5*98D0>V7"7/S/;93!,BG$V+ MMXZW'N? $:9N<&^K*]=?R,[S !,U>7@<6%&E< 1L=$5#6#+0 &'[>*79SO-9 M10PU[-V@+JP+ULTYX0WS^P!L&3GL17B>"***/WMP9+@S&BP>^X%:3B&J9(A- M+!%)HR%>FD0"IL@<5:Y#7!2MOIW_B8GE'W3Z" M @>QB&J4"=2"(0[+FE__1]02P,$% @ "4!)4AY&BOHP/P$ W),- !0 !S=&4M,C R,#$R M,S%?;&%B+GAM;-R]:Y/<.'(N_-V_@F>.3\1L1&.'%X $-FR?:%UF5K9&TBMI M=NV8.%&!:XO>ZJI>LDJCWE__ B2KBET7$F"!;(XC[-E6-PED/B >9 *)S'_Y MO]_NE\%7693Y>O6OWT5_#+\+Y(JO1;ZZ^]?O?OG\(\#?_=]_^Z=_^I?_!@;C;ZX3]_?ON)?Y'W%.2K7CFXM=DA_,$S^LY)T9V0^R MR-?BTX86F[>4R:66OFIM\_@@__6[,K]_6,K=[[X44IUO=ED43UHU4A(C990: M*?_WIB6F M^G;W75TM^O@2^_HLUANZG."S.'33$GEI?O%6_]1T8QKJ(-.JGX:Z6Z+*;QNY M$K)FRR=-![GXU^_T3XMM">XH?5A\^D(+^4(3K7BYOG^0J[+B[]NBH*L[:9;$ M%X^'1S[01_.KV]]H(5[_?9MO'M_H1:"HEL[R_>:++#Y_H:OW#Z:)\B?=Q*9\ MLZH_I$5,9"93E@%!N5[K(HX!RY(0I$C%*564)P@M-ONYLI K\,NGG5J5[,\C M^'<.([&YP"B%+-?;@A_6XOOEN056KZUF-<8_K.B]+!]H\X+6WI@M-2#_]FY[ MSV01K%7P46H5<:S8-*]9N@5CYH:1]4Z@<;K7_0 -!\(&60KX(:A(M?RIH_T79I M#+MU<3QL:_YLP_:$@*LA4[1D%>:-2'K\XO 'N=R4N]\ \QL01HTQ^;\GE_V' MD]EX6^R I@7O^12;)W[@:VUV/VS DZ_2N"G/.R*;]?-.Y/I+U2!]%ZP+(0OM M^)T!?$]_9;%9& K5BW'5\[>\7- P0Q&)&1"(2P 3) "+8@D2#,-$^VY1E$8V MB]29MN>VCK3$"WXU OX_NU7C'&S=Q'XE&"-S[T?Y-3?;!&9%_: _IZ)AQCY0 MK FR0_T.#M-OM?A+_^N8N\XU.PF]=.BS8X"N1]PFJ9#Y8KDC'!V,_,$J^YI>0T"(\]) M.^6M9^ E30_3K]S-OU+R/]ZMO_Z@7ZFGG_[A>.:=-#?)M+NDQ&[.7?R[VX3; M+=ZWG*^W>I%]M][(\NV:KLK;E?@Q7]$5SU=W'R67^5?*EO+%X^%GTVVU'L3: MF4LCI8"2*0>0I!1@GBC 2,J$C#(>"ZM)ZD.8N4WL@X35U^VT]GH9'#LO;"K( M1U_=G=!V]GI\P.33D[E*GDF]$Q_('7L<7MH#G9W&I7F_W9CC%'-"]6:U M*?)5F?._T.56+A)(0A73"(0))]KB$0PPA!$(PS04@G.>1722C;,^2>?&M+=W M=T6UUQKLY0PJ06^"E@X!W03_OEW)( EO@CB,LHDVSWK'?>3=,I^C.?_ML?T& M6$O?F^/O8@:;8;:C,HO=KUYA?Q_;7;:8>]O?LNYPV%)4[9:]6Z_6#[+0(IG6 M^?I>OOYF9)2+,)*(*9X!&NG_0)2$ -,T! @ACFBL>"+31?M(K9>#NCNT(I+> MLT*??*+1EKJ]39!7<@9Z#(+[O.1RJ1^3ZVT9R%ITMZ6@!W<[/O> Y32D7)\N MM"4-:E&#[QMA_^"/3^U0\4F*/3U.RFQVVA_3D^5; \U=_D6*[5*^5Q^*M=CR MS5^IX;W-X]N9FG.[DK[>=*PV"G0K!7@='6]1U4"Q-S!&A'MMRM$(Y^/5S MO4.@-0@J%3SN$ Q%SZN%YRK#M(;;0(1.[+&A[0RD0%E\S;G\69IXC(5282I0 MI$ 2,Z6]](0#RO5/E$6(0J7B..-._-9N?7;D50L7_%J+Y[A[^10X2PX:"L?8 M!&.+A#MOG-/8*RD\Z6#:&7].MY/I?/:A@7-U=Q3Y8EOF*UF6G^1=%5E0[8@3 M2+,$P10@:FR3F,8 9S(&22+B!'*(&(L67V7!UM:SMZL_E\^WW>MX7_%.RF G MYJ!3B6Z0,\E0&@H,XB2F ":9 1*!K)8Q#3,8,*I56B%=XBG(G61O<3^K5ZZ5KOVB'X]=-&VW*_K/)-^1?] M.REN5\+XN+R*L3:_.G)Z,@@Y2:((H Q&AH@B0+'(@$)*W]0,#GY& M^)PFV@]XOJ$=9V_A&?1YIGV*YQNYRWL>SRC3M4; +>?;^^W2G/Q4F]9&@4)^ MT3KD7V6]:_UV799'3(IAHF+)0D!D' .H" $,4P5P&NO_$P*&?. Z/DB>V2W% MK:W/ED+-K9 G*NT/;HQ6?W!AOU$&UG6)''VX)MRD'FVDKEBGKL)WG*5FF$C/ MM%IRT878UIE.L6@RNC7Y2J\7/]*\ MJ&-,0YK*B% ($,8"0)&%@,$4@RA4,(YEJK"8R:5\1\WFQFL[@4$C<7T1.S R M!T;H76!RK>9<[N^[?DZ6EOMU?N]Q%\/=:83I>,8*B PVR'?3MO5@_;3?E6?I7+I FED3@3<1(CP&66 M :C2&. 409#&4FEG(4HRGKGY81V]S<\;JZ0+$K?%LPO/-$G",$LY2!6G ))$ M,V^".5 B8R%):)*HU,4Z\H3F%/9*VR:II;T)&GP'1GUU 6UG-WB";^25_"KD MG-=2"TQ\KFY=W4VZWECH?;P"V+PR-+ILS?_V43[H3^B+63Y>;8M\==0G60W9(VJ,7=F_2UQ#ZCIVS1\1M"U=OKQ'%4 MMBB67>FA\+*5\NUZ7NK^KI M0Y%SNQG4#[Y7G^FW14:T8QWK50EG MPMP4Y01@ILP):!2&.$H@CT,74WE,8>>VCMW6LM=;QVL5F(TN\Z.)/FN]_0?D)W!/Y?/8N0%MC>(Z"9H- X:E0.C\TU@ MU-S%&36J'GL95.EO.M#Z>K[H/_*H>$\3,):\TR<9&!GYLRD*QNYSV!+W2C?V ME1IRNRU+N2D77*:I3&():(I" "'6"U3$",@4Y"DA7&64N"Q+QQW,;BDQ4@5B M+Z5C/,X)?FG"J(8H!$11#& F*,!$8" RQF-.L(K3V.UPXAH$ISF1^'%=F".D M:LTL?Z,/>I5=;0K*78.;3L"T6^*N 6CD9>D@6E#)YF\%N:2T3]8_Z6-2IKZD MX3&[7GQN&",>)55XE9=>K6/8:+@][L=Y8+$..,J1$ 1F&H; M(Z* \C #*$H523@+$VB5=WI WW,CHI;XP>[8(7@PPIQK0E_GA(V^]3CXCX1'O47I%WVIP>B%W'QK1KBY-M2@]4 MM;TA/;2) ?5[3/3>+@-7DA*6*@5,3#LP21X 2?3JBS+!<8PC,P#6M7L.[]IOG*IV=."JH>>AP,P>MR#9IARDW.Z#'Z6U)@9=?VB/C3O65EM>NQ MX*&"'&$&(I/ 'DJ: DS2$# BHY!*E6294Q24;<=SF\,MN:N](5E)Z^8@6H-N MYR:. >7(;'",8G,!XM>=J!Z]1%=T?/J*UGU/ZC&Z(G+L-SJ_/_%5N[?Y2K[9 MR/MR02461"47@E^-;H%1 MSC77Q/7C:\>/TX[:V':4QP'SFJ3/&\BSN-)UD.KW<1?K!$5OEZA.6QY&YS_G MJW517<>J*SB\DKS0?H#\48/P*C=YC-BV\BD_K]]IL,QIVWJYK ML5"_\N5YC M%@S'F40D!#$3PA15$D![B @0K%26Q4@2E.R*8'RVYW9?\EEQQ5'9^BEJCS^1 M.=@);4)(:CT#\S4&3S0U2=4NO!A_ZF%T7@=\8^YS M-? FVZ1K@F]$CU<&[^U?&[73NK"K_8L_2W&G.[LUT8J5SW'N/#5E,,L$B4 : MRA# #$E (8] +%,F4LIQYF;H7R/,W$S\5KQ&.\& <;L;=8*#/H,/O:\:/CLZ MGVI01J;PH>,QTBFZ#U3'"= 9(,\S!?,,1^YRX,\5;0X.$N)2BM+P_INRW-*5 M.>UY)=EFH6+%,$L3 -.( !A#INDU0B".)*$L%!R[W::_W-7K0^ M$_+3]X8;>9C2]9\DWQH#\O4W_L7L)KS3'\1"4JI$DE' LTA[Z=QXZ9G07GJ4 M1'$J<8PXLZ&,2QW,C2AV,@8[(0,CI1TG7 2QFPE\0#/V;J4;*M;SOD_UPVPO M=].]E/R/=^NO/^A7ZYFN?SB>X!>;G61:]RFUF\R]SPU-$+O1+>5LV<0B]_RY7*12<5#1#A(>*P Q!H^IC !*D%(*"IE1*1;9M/^3NO(/.$#T@&)4^TQ\IM'U:+? MB=.JVB-QFF75X5WW..(7=&F,E%]6^O&7A13YYD?*JXJ0A_H&+^2/6G/M,ZW> MK%K1:0L2ATA$) 0)0]+<6S(5!K(04!J&1"6"I]C*;;E2CKGQ5Z-*L#6Z!+Q2 M)E"--E7][%U%%28#U6ADLDZV@C/MHV*O&*W& GKV/Z M2@N4^Q<8?]B-O(9,"9O]*N /OHF(_AH8G7C<#ID.JNYI8#(VME.D3;B6;PQ, MP;BZTW:=D?5Z,.WV8T3B 07#,G3*@$-*8<2!ES;9FB M5/_&A31/NY@;9WXV?02\%BY8'N0=?+UGAZ7=1+\.H9'G>4NXFZ 1;Y1;.D>J MCW0?9]?+<]V\.=*RXX[-\9/NKF83SEUJ%[;EN[Y7)OMD+G):[&/_RC>K\S%^ M"X%H$O*0 NV6(@ QAH!2RK0%P&.F%$M91ARBKCV)934_I@^VWFEF=H):N;Y- MW$.=U.^UPZU!7R/8[^M.-2 3Q9ZT!Z&U#6=&H=QKI&VY1B6S6[=Z&B:]^]NT M V7O74\\8!.YX%,,G).K[A'F#G_>1R^3.?T>(6GO#/AL=FX%'K6X7ZMZ4_W% M^%0L8AA&"H0VQ*/6$]2*FC*N+^1=OEH9NC'AH)6PB7^)W]I._7F]IUIN7[77YB=\SL'46=DO4Y7570/S_^D M_'8 M^M=GRI9R052L%)<2)%(D ,8H 22$!&0Q8RB3BL7(Z3I9KXXCHC[V.>0?>?949B)[7%<%5AFG9>R!" M)TP[M)UAK*CI_#[?[*Y(OEROS)&87/%>CYL.![.:=XKT^%Z5:6V6V 6QG&6 MA" C&EB8$@JPS B@2(4IP1A")7+AN,?I#>6QSXBI0K]A&M$-HG.W#GKZ?:=O0#I'+VX66[P\T,CA?;ZLM@P_K M96XV#?;K)U9$,H$%H$HEVM=,B6:M. %Q0K-0$I2&$7(R."YV-3=V.D@:[$2U M68== ;8T4+S -K:Q,@PQ=\NE%PRO5LSEWJ:U:'JU/K%N^M]P#Y7_*$U)1'-: MH5<3[?ZLMYOFSFN:2"42R0!%<60*X&3:+<$QP%1;-"D5<6A7 *>SE[FQQ,X! MM ^ O@Q@-Q5X@V5D%CC(6-D;M90#;EA?QLD^_-L+7A,%=0_$S2E.NQ>/CNCK MR^].%E/=*WX[4KK_X8%NGMG5,:DAI7BU+0RY5F&'51#+^4":!4W2"&3D\#F+,#?:K#0(:A6"6H[!D\SD-[_^TF/H: G,QL>?6QHQ"YL\/V^\C+/Y(]O\AH>_G1V2Z\/8+_;OO MJNSN9A::O.MZSPNA,!$LP7JI4MQ<.Z. ,9Z:W*PXI3(BJ;#.S7K:_-P<@GV] M+2.B:P7P\P#V;Z="R-CIM/M\-W/CLYV4P4,MYJ#SHF,HGDK=D5O'QX*R?.*]C^:^W[EI]N/GYI=>\Q1QC-%@>": M#""2VAUGB(%8TC0F))*15,Z;H%T]SHT2ZCW/ML1!+7+PO1:Z_(/C&8D]\@Z; ME[[P'-M/O1K*8;N1-O!XWWSL['3ZO48;#,YN+5J]./B>FV[[BW;MJKJ )N6C MN?4E^.L$#AS M0\[N/??-FWVRV;+.@TR7RV;E12K"(N$Q8$BDFG8RDSHHBX&*($9*B10QJ^BY MSEYF9^=_NE_>&!U ;-%?H9L?UP7,K];U=XF?_Q:\^TV^+)$X@CRD$^IN! J9:5I5 M$F >AF'&,I1%5J53)Y1Y;B3]LBXVFJ\"/7>WR[K:NJKUW2?XWAQ4#*CX[VU9 MW3!WS.H_P?=@9UW.;)3'7F.J0]<.,_4F:!0/=IH'+=6K&,26\H'1?F?@-@@< M!VXU<5D:!X^U#:8;-*^U$B80>]K:"].-PTDMAPF['K;F[9.8-872/GV1)1YI2+YUJ!YK9:M5-_[@H-5CH%.Z4TF^W4"O9Z!3O%@E^-:D&E MF^/6QM5C:[ M(:1X30N3J[J\Y8U)+,4KJ7*>;Q:40 %#C 'CY@P;)0)0B# @&<(A-A1-L-OV M<7^G\]M WLD6!-P;-86^X;^$)PJEWE M > -KSG8!81M9 KI0FS "54?=/;G5!XAG.BTZCHHG8ZM+,'I.+SJ:V&R M(RQ+5=H'6;:ON%&KD/GB]6J3;QYOA=#?1?G2Q$P6CPL488Q%BD D$^T*0AD" MS)(,T%1_!Z$BC"BK#'R7.I@;B=8R!HV0-T$CIAT)7$2QFS1]8#,R4[K"8CVA M^W0_V%3ESJ@J)?_CW?KK#_K5VI[2/QR;41>;G61J]RFUF\^]SUV;W^K3AJX$ M+43YRX/0'IVFP32,FM4HC&26":SG^OMGG%]C)Z\9!72!G$"F^,&H.=.Z!1X^R;RKNTDI MW$+O8^*V>67BW#5-YH#WVTUIUA*]IM1Y5!:4"*IP%NDA(-K\3$,%J,#(I(;. M8AC&4!+6F,\@(U#<(LTC].GSZ,O27SZ>UHF"&PJ^.H MI6'YJK[<*OGZ;I7_0XHW0O>>J]S:W$O M)7E?8!%F*M(F >=<.R M:+ MS T+O0#G956=Y) &( NITA^7 $D28@"5B@"-T@00Q!2*8LIY$@ZK?.1! MNKDM5^WR2.V8^H;0CGELIV1@DJ'LU PJ/9M2/\'@_ Y^OP)+U^FYQG9LM^E9 MAO6*8DX>X1^GXI,/ 9^I+)1';"_7CO+9R;!5Y/7]PW+]*&43FG/>AWNW7GVM M\JE6[EKY>;VAR_;?7Z[+S;OUYK_DYK!*+D*H,$=) F)""8"QR9(JA00)AS05 M&>6".!W:CR;IW%:77U;%P6#F[>T;OC99-&5]/V&S#E8[;>M2ULU.SI-7[K3W M[9SN>[R/PFZ!F<503[A'=[9\PUZ_W9:<4Y:;E4^GUZ=Z<@?M;8$:' MW^=B,YZPDRX\HV-^O B-W^&P!>F#_C9DH9>]ZF2P6AP7$"8(L1"!C%3URV*] ME& : 2S#E"4215$SGVRRAXK;]^IIMI"ZY?UO.DPGK'H\/F_JNFP8_RJUSI#S1! M$J=A)@%B6.EY+U- 3)*VC,9008G"3#A5YSIJ?VZ&WTX\;>)5\CG>XCU&SVYZ M7X')R%-[#TZ7N<9>Z?[=@/1Z[A_Y]KB9/?Q!JK:OI\W MM(DKDRN\_F;\1UDNPBR4,$P2D,8L 9 B @@1'.@U0*\ F<29&)908=?#W+B^ M\I];V7=E(^? S E[(.TLO:O@&9FP#QD27O=A,CPAPK'>HR1!V'?R/(D/CG6\ MF.S@Y,&QK;YDP4.&4AAI6P\R9!(>","R5 "1R#B"0C L\3A67S([)ABR2"9C M&2B)=V/0"? Y&H,C8CV6,>B$^9R-P6)=JG[X'',+ W524=B;,NV/]OW(3MW M\.M. X_Q0O[@G"(/MX-4LTBS[8ZB;1;M 2T_SXW)U]]DP?/2A"7M[M71.&68 MIH#'U%R&CV- DD1;^CS%>IHPF""G:_'>)9P;5;<$?.;[=*>#:4?:SSI$(W.X MS_MT+3WG=Y_NXB#,Z3[=J9"_J_MT%S'V?9_N#2SG>KU?58?\'6KPOJK3? MHCKWU\M3)2WR+AQ% M2ZU!KG/IBSHXQ51EJ:G"N91C+_YV7.T9U9'9UP>@0\HYVD+DN:)C;[=3%W6T MQ>%,74?K5]TWGS]M62G_OM6<]_JKX<+FQE9U%:O,*Z:LPF+?JW?RMQ?KHEC_ MEJ_N6NQ9+J@Y?5(A XG*-%GAC ,B8@(HY5D"&20QM(Y"N%ZPIQVCL6W2T^'9W[Z=]3C9;W]/.UX3 M[8A/,FY.^^3^8.[8.O?0R62[Z?X :6^P>VQUF/W^IHKEK_,P:Q0$+1Y?ZA7Y M;EWD_ZA=BV]YN6!Q1"%&,="&/ (08E-0AR;:@D\QXB(3U&Y1=.IU;FO?0>A@ M+W7P5.S@5R.XXVU=NR&P,^*] SOR@N4!4V36O).6!S;\FXO MNUOS[W2;LLB_5M5NW\G-H;\_2W$G%YC%BL(H 3&/(@!1& .:F8L!7##*6((3 M:G43P**ON7&1%A<-74;5W?F]F:Y2!$)"90Q MP%R& (H$ IH* D24*H%DBA-&!F17OM2?U?<]?6KE_64CM9,V4%+623^$9)OJ MTF55,-5,V+V(O9VE=Q64$UW#;$2L4J?L$7S9"97['

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

% M18>*=(3/<-7YE A)$)A^\N DG MTZD_<0++Y.-RG! SO0IAJZZMBO=%;;[9\FRV.D/3S6=1:D1*I E,2%+:0R0% M&3.K)%9<(IK)4J+$9X$\+69N:]FA1&"UDD93)>WVR6^1.0.HVWIP/4PC4_?3 M(HHWUD%ON;=KP/5WMGOLCG),U;;F""Q8?50^X]'Q($MUJ^_C-5G/: MJ._*>"3;]O2II(H7#'$#'E;&2U#4]JXI(:>&%P@K6(:X>^K<:2%SXX2#GJ!3 M-""P_BRDEZ^$8@ U]AWWN!CYY,!=C]5DF6\!F'DFNPV#,9CB=N:C$R:V#2O_ M-)WMPK/^%'CB4F7+5O)-50?SUMTF]DLZD5SA!#.(L$XA9BR%M,@%)%FFF>8H M2Z23M^0I=VY$>>H^<5N?\O2U]_:H?$?C,J&.A/'('#L3>-VY>"28)Z+G>'![ M<78 : ,T[O.VR9@]P,0^V8=\_(IBF,:OWE^FK^\W[-OMCVJ[X+3 ><$X%'EF M'&&18DA)QJ H*$>]TLG1R=E(YZ M&>H,4>1;S,MRI[Y^=$;BQ+VA^V=C=%/;7R,N<&KH)<\0Y"A'$".1P)+1 N9: M$98JI*7RZIIP1L[,@U1DDA*5,88<2K6ZRMX;JS1TQWTE:^/ ?KJ!QQV>PW(Y3.M ML6 >F6UF@[#[L=982$]TKA41<:^#K1#8!DZVO%XWV=%6B)']LZV@SX>V,&^C MUNYT$\9FDQS7WXS0KVJUK;ZK]K>><0M^;YT1$^TUMSE/3U0&;2#K*.$-87C% M[6KMI\+$':V#\#GN9AWVFM"I=>B1U;1H6.""I$7),RB$K7Z9%PJ6@A$H\Y2K M7.,BU]JGZ>RQ""_?:8*^L5^LC*;(\+Y=F*HU]3PB/@:SX%I0XYI"(H6$N$ " MTC37,.,ZP[G(J7KFL?F0T)O!I=5Z*_!K/1N?QZN *H_!PB M<=GZ2,K$A'S.RF/./?MD8-5'&W*L[O0A.GY1DDQ1P@6498G,1C7+(4LEAAP1 M)=(R2?/4JTG?#*UK:#2TJ=-UR^%J^^<7\YXWZV^L M6BUR+4E."P996100T\RL_9QI6/ \-8X4HTI@O]J&9V7-;>H_415878%5%OS1 MJ.MYCCT$LAL?1()N9&((1BV@WN%%/.+6/#PO;N*ZAQ?M/JY]>/DCUW62ZC4M MM]&AE6RYZ/5LJDCO9(G-O":ZA*CW/A$"2LA5EA!3AB!N,@(*07+ M$?&JQ7-)X-R8K#EY6AZTKJ\V0LZ>+D+M1E4Q 1R9GMX_0^WM,&K^*;Z.4$1- M]KTD<]JT7T<$CA* 73\7ZC=52YO@;5_^[MO#9OV]/B_?_KY9;[>+DDF$M-EK ML4QEQE%B'-*,)9 FBB I4T1RK^X9@]+FQB=[9>L9L;0!6Q9Y4/44]W6'AL!V M]7\B03BZP]-'KZ^I[?>^'JB[$.#B.$ 2UZ<9$CBQ$^-@^['7XO*A,$*Y%>+Q MV^/27F777]-U(^J-V=_L)^+!"BDI>V(6?S'ZTASZB$6MF:W&5>JHS[ ME:3WU,!GSDQ3G+YG %A;"X!XSI(E'%ZS=J4"\:00@)1+OQ6I"%Q\UM^VDEEU 5O?SR8$?!<:@;!=6.L M6("-3$\]I Z*CG3[Z ))_/J!9^2]0,&_8;GY_87W\W M?+6IV'*[$"*1'.4%3!67AC2DL*'S)22,**Y+EFJWM@R#4N;F%1G=P+=..5^2 M.(6B*SM]9L?[S9?UG^M%BA-R@RG.^ P:'F;_MIOY6B?]Q MO_[^?YI/-[/>_/!\L@^]>9*I[F!:-]%='@U;WC_:?(OUZG;W&ZLV=9.G_0\' M7Z)-'F*8%@4C&F)$;'2WPI!I5$"6%74PPT@@CTPJ$?#U=B\"D(KI=/B(G]05"<#EN8,2\@H_ M/NNZTBQ>?7J_(%RGBH[6/?L]5FWX#F3_#)V'X] YRR=<"KZ!YOYG;WM^?S M^LE+)YFPI\SH9N+)?PMS&=Y^>UBN?RKU2=7GE[T;^[9J^D)(A8JZD#97!&(E M^'F>FO3&-&/W?'S M$BZ/0"&P+E-10E$6VG8\$)!180A1EX25,LDU(CZN6E3\)]FWM0K##NR>RC== M>?_8J+MY9%&Q''MS=Q6,WBZ8,S0Q':_+0B=UMYPQ>.YDN7\PL#-BY[*]^KG_ M\6^5VI@7??WY7GTWJ-B*AIDPW%,@! GCA4U;-1M$D3/(F9 \X1@)SA>8 MZ+LM#_$Q'7F-N 9._P:77NA$;77I)GG:II=>:!RUO_3[M'\UKH]?UVI5_3#? MA;G1,"?Z MD]KN-I4P_GF=V_"/5;7;?OK\CZ[Q$"8,TZ2$I!#&=]:%A)1G",J"I 01RDKN M%88Z*&UN%'E0%M3:@EI=\(M1>/NKGT,VC+*;'Q8-NY$Y+_#F47HHH++%2WWJE>)X@12J4<1Q@4MKEI4ARR'*&8,H1 MIB5.-1).@1?G1QB5J][EC*M-7KSEIY5+WN_)-A ML[].6VOXICN\*(HBTUQ!4O <8L(YI DOH&8E(ZGD.O/KIGXD86YSOTG1;%?^ ML'C/8Q3=IOY5V(P\\_U@\9[99TV/.;&/A4PZK\_:^'Q:GW\P;%;; G5W^E:N M'WI-(\JDS"3),$R*LJ[JG9CM8ZF@^2+D0DN)$YGXA7.=$C._"*ZZ@.):@T[/ MP!*4)S'-J,&-EX4!42FS$:U:NN170*OGRW$LM'>^EE MZZ,PL7N"K?WY\S] FJ#"S,>84+LQZK4 CDRJ;>_K 31&G]4F[JY9Q,RM- RQ2G7"F8BL^=[:0XI2@1,!)HMBT55-B M8GE42R7JR_VCG-ZO5_>&P+[UPOGK./\%UCG*,I7#M"#<%G%/(*5Y E.F6:YR M*8AV[B]X3LC<6-;J":VB_>R&FR;QP3U@YRRDPQP9"ZB1*6]DC-RCFF)@-5%8 M4Q!F7E%-E\ 8"&LZ^]')XIHN*=\/;+KXK#\%VB+0ZV5E=R-RWX1L>Z>'.NV5 M+"%8ZA2* BL;B\X@TTK ,B-))E!:,.[4U"90_MR(LV\".-AP39N^*,-TF7%' M!G]D,IXK[NXL/C+^$Q'\"./@1?]7H#BP,H2\=;)%XPJ3^^O)-:^YXN[I@S&0 M;;\V+VXK]RT$QU03:9:2G*<0DXQ!6@@.1::9*J3(N?D0V%S]7=6 MK6STS]WJ,UNJ.VW>_: VNY\?S6#N;-N/!^M1+!#%&2)I"I,LY1"GJ;;7T#G$ ME$J!"2X))]W:[C:-W00'K/$CS_!?K.*_@J51':Q7P% HD-7V8;UE2^LO/[1F MW( ':\C-OC%0;4[SU\HX]*O[BB_M*P*VQLQ^J>[ TO!5DM.^ QSWE5$,ZT=G!ZWRL9\ M?]BZ\%E\5?+1GLJ>%_K%_G9!$2J41A2:C4!NB%]FD#&205[D":**:5)Z-6YW MECPWW[]3O'8,!TG[CUI_3[?>?43<:'@4G$?FV7@0>S.I-UPQJ=)=^*19&)X$PC$P83@CX7P(?VQKUIK?W^FFOQ$9": MZ#XV"#&O^]@+6 S")OSCI(;1!L7-$&, MYI!3L]9@Q5;XN("QL)[")YP6:3??,19^(Z](!^B:\,*Z MS/\!N:'B@R%!SAU"'0%RT_$1%]^3-^M'UH^_R%_>CJ?#:W-4TU MDX6QK1 T3VW!36DVDKJ$I6W0KFBJ1=V^_](&0XB/;[3VK M5NN59M7FNVWA9-2W=<*,&//3MC+OJ46Q_?'\=L%$*I,TSZ&VVUO,$N.&"*UA M5B1%F5*>E3EUKTP2H,'5@M9:0]TY8RN4*LY_6>;GF M1:$AG]_5ZE$U1;=6=:[_?U>[KZ_-Z]??U.;C>EF)GU_4C]TK8^Z?"U9001*: MPK0TRSQ.2]OO*M$J*C#CYW)<$S8W5 M>I6+.T4#,DSJ+2V5]-4 M0*H4@BA3(B%EF9>\]+NAN5*C^5WBU,K"6EO0-\B/::X=*#="FA#\D7FK09W7 MJ+=Z@MO-QCQ2%P,#?XSB.T7"+R;=7:O2I*P8";_GY!GKM8%=R=3N$*R\0#E/ MZM8E>9&5$!OZA"7EA2'0-#$^ER@2R?P8\\G[Y\=_-O^B:DN:+>L<#K;;;2K^ MN&NRX]=-]?NOZZ6!U+,XW%-H::DS3)($%B4V_BR1.>2ERLUBI'DAS;Z^2$J? M"^Q@8*>XL;:P=I7BFM28VV>P?C2H#A1Y<0!4$XT*D6DJSTZN(0#N@4W1@F -1M%0Z&:>0U]6J$_'OFG4(B:KN\)P*F[91WRK:C M)GDG'PI.?F]K:6Q?54OSX+VMC?JX;2LVT(2EBA(SV1/+GDE20DH3!1DI!=<" MEVGNF\\^(&YNL[^G+6C5!8V^@4<#%]!V/<6,A>'HIY;A\(6D>#N@$CEK>TCB MU(G8#M:?R*UV^508LQB*VBCC.K]1S9_O5GZB,,[0O(DXX1AAK M!"F2 F(F$FB M<]"J'K6N>SAB,>G,0_JDU.:/RG.:"WB#?X23<DB;&ZTUM,7U J#@\;@L]I\ MKX3R"(^YB/4P0\5&CS[.BLIEB)ENH1,2EN_-N>0\3*#:4ES(D19,N;5P-A% MZ-S8=Z#<5E=>98QZ.!%KW682%5AWJV^&Z); M;WX>[ID.%Z^R3!.=,;/#)MM M[% RF#^TKIO3.'"-OAUMU00'/4>ZI79!).YVQ!O,RY8?;RD=/G,EO/GN]7'S=KLC;8+JDN1:,RA(HQ"3,L44H)2R*7FF$B($\\1=*3(8+QF8H;;D"'4JOD#:A+CXS #2>Q&(45GDIZ&3XX:>U9 M)CC]=& $GMI4WYGM%/YAO?JV7JD=V_S\L*Z3()9-)_"_LZU-D".<(X$@R0B# MF%$-RR37,$N01CB7&E'B0PJ.U;\"JU1:P6MT;\)>J[K]Z>ABN^+M1 MR0BHCLPM?4![.H-.:7#;@FOUCA@IYP=4U(@X1]'31K[YX7$4X>;Y#,SJ-C(&+^_GTU?A,="CMB9/7*?0@!@-'SZ<_-]EY\Z#: M_4/FX0?#W*_WZ]6]X8UOMDSUEZXM5::9S%@N8"%4"7&*"UBFAMH*1'!:E@31 MQ*F&R9"0N1&;U1%:)>N*W3?@BV^?KT%$W;RG:W$:F>-"(/)VC(8PB.D%G90S MJSG+%)<0EQY!E!8&%*A$MJ4@P MQCZQXT_>[C77)X@=_V)E -$HU\8<>28^/@'/;78'0S+RM&[TN@&M9A&S&D\9 M'#65\8F :?,73]EVE+1X\B'_BF/M&WZKMH(M_Y=BF[4S>>B(+4R"QQ *E3P_+N$7T B:J/P<[*F[15^P>*C=N&7G@]-FC:O>12[QXU-(3(OOE?; M18DP2U$J8)Y2V12:*%&>P:S@DC.""HR87ZKTL9"YT<,3'4&KI&]*] DLW9C@ M6H1&9@$_< (2GL];'S?-^82)UPQDB)8*H9LU5^$N,_Z +F4H@$Y<+\ MNU?EE%B*S8U5^G;U&U5VEG5E4/>VV2R+4VON>X=>\N,.N>,ER L,Y-CW)U.. MH?\E3&3 H][?Q-)MVJN?R(@>W1K%?G]PV=S';X]U@;@W2IN7RE=J97[8V78Z MO=;27>L\4I:2V6IN.%40)ZR$3!O',$E5(4@N$25.31K#Q,^.UP_:@U9]T.I? MMXG:]ON[GZXBY=G6,'#8'%E[M,$8FYNG&(>0MP:B;;:99(7.2DI)(7*($:BA%PE)2QXFA#) M5:XD6JS4O573C1?/B7*:=&4SZ?H"QYM[5DO;JJ1NPFY<'MYJVM;S\6P]?0[A MI-!,E5A#+5!N=AHDA8Q)"27-^X)% EU3H3+#,XFV^V=Q\O4N14%A0EB/C6V4V"KVNVMFTX"=D$@EM-T\O0!+3 M;3DK:U('Y9+%SUV1B\]?>;M_*.C0.O6,ET@7A8:"49N55":0X;2$&N597C#& MT@('W>X_ES2W1?%P< MT=RK_/XE@?.C,+W>?&NB$+8_M_::V,]?O8BPFV,:$[>1F:ZG*NAT!9VRT>N/ MN0(3T^6\*'-2W](5@>=.I//GPJBE.[0S[^;5JFV?)];W*ROPG32K2J4K>W/< M)/W>VO84&R5O5_+]H9&%^3>S $G#>N8;5NT?KFNT?OG*5K^OU_*O:KE(Y-Q M9S?H&7X##J:#ONV@L0=TUM=M97KV@Q: &]#[AG35$)JBUSL# ^APB,?R+S)\ M,9>,:0V8=/UYD;%YOIB]C!)A*^-'6U9\O6KSTQ8YPTI(FL&RS J($>*0(R8@ M9662E9KFN?3*3G_Z^KFM+:UVP/;0!;]\4M^-3+:T-ZWV-[_ZK33/D'1;"L+Q M&9FK0Z'Q9M/3",2DNV<2)N6CT]8])XPS3P46G]CW@NYWB^ZU#W_U\ZA=]*UQ MM.7=0WU$>_>XVQK.L6>XG];+Y6_KC?U'X]2F19(6!33;[ 3BA&20,8J@I&61 M:LVH5EY.[3AJSHUA/C]^^V8+TIIYTR2CKFOM 1.[ZGNU^^F9OS[2V+IQU0)PA#E"8%8*@QIR2E$0I=F6<'&^W0NN!Q!G[DM%L8D M6UFWLPE4W57$0VV5+7#0-OV4^Z:?=7K:[F!;O4U>6^L\.NU%&-K+]V$3#]C( M:\5_\EAY-$Z<=LRFZJTXS=CY-6&,A_10G\8(4J9KY1@/DB?='B.^UK\:Z)OV M*]Z4'&RD_F9^MUU02C,E,PR+DMH.D,QLM105,..9S&3*:4F=L4 M[8I=-JJ"6E?W>J#G01U>EJ)!-?)B$X225T70BRA<41+T_+LGJPEZT;Q^4=#+ M#X<=S/Q6K=A*5&SY;F5K?U@1V_WO>B>_K]C2%A/\_%6I71U49Q/$]\6GF$S2 M-"EM2:^\A%AH!$MF,*<\S41>(JZE5W&.*%K-C59Z>GN>L,09)+<#EYGFRR$L#=J[M=WC"LJ,:AZ>>"4R>M)NPCVLSV]6N MVC3'H4U]B.U']M/>K)M-7EM2?)'DN<88"YL78!RFG!I?B3(!58&*)!N%+&+N(< %C6+TT?^M(F= <@WZ MN:DW"O;7;O3S%#&5:Y:E#!*98..YL1QRI3F41'"B4JI3E+@EA85B-DTRF J# M9YAU0TT>VS4+^(8X$^.O;K'&T;L_O:<#9^\=!*6.V5&QUXG_\W_+OAO MBBUW7P7;J(^;M7P4NS;/O?7^M2R2!$L!BY24ML(T@F:V95!*1)7,:Q^O7Y-+Y@7D!NVP&A LLTRU2;M1T!:\8X>]LPU*)6^O#38-H"'T'H'-7U"'M+8.[WDFVW M=[H]ZE_=?U)"5=_M-MHV3+[3K]:;S?HOM6D+Z#!"%,]$ 0N)T6I,J?"%6'BY\: M?8VQ'RO/S@8T';ZMM4#6R,"BQUY#I$;_8T'_,CT M%QUS_V3S(.BBII[[:3!M(GH0.D=IZ6%O>9G$G=_-@[OMNU43L;*@)&.\R$O( M\D1#G.O,[,+-5CPWW)@5.-68>-U-D:!:M;%RQ@U5NYJNUQNMZD+$$>M^C#,D:;A?U3BS6ET8R?%ODB=BHL8G*LM M[NZP,"XTXBZ\-K]K^'0K[M/]FZ-F9GO*P:;ZF+?S>>B* 943"1 M)8$XR1/+%\9/R8A.6(%2Q+UN*"+I-3>&V9O5U>\WV@.K/GBJ_XW=Q8BZG5EH M+_-( ^M&6R\P7",3W2@CY1] '!?7J+''D52;-FPY+IY'$<^17^\?J//Z[I_O MWJ"R3FBN0Q&68KW=;1=ESK10*(493TNS>\0YI#:U07%>\)RP).5./> '9,R- M:VLU(2I!3U%0:^H>9'(.SF%6C 32V!<:(^+C'GT3 :>)PFX"\/**M;F Q$"0 MS;E/3A9=H:%4&M(^B4=,^F/X7@,,-%P&5L_\T+$J_4 M^0'#KTB:/_76R=+E!TSJ)\H//188!K+^]FV]^KQ;BS_;_6(ZS[O9EY@FE$DSRYE4$$N:0$Y+ M 34J&9>%V9(0[3/5W<3.;?[WF][_MMZHZGX%7K=I&S'ZW5\S0FXT$A_WD;EE M;,B]V<@/P9@4Y2AY4M[R0^,YF7E^.K"*^F;]H#:[GS8\=G>[DC;7_<&^_7VU M4N]LHYY%@3*DN*!0*^/#8"I26 I=PBQ1-*7FGYA.O"JK7Q0Y-V;K-+ZI \-W M=06]O=;@#ZLWJ!7W)"\'\-V(*RZD(Y-6!#3]:[4[ Q2U?OMEJ=/6='=&X:C. MN_LG/<]Z-[M%EY=DWOM9;;Y70FW;F!6+K8N#_R='HXL@]B0]6[J$&2XX0P"7,E-,2<<%@2I&&I6<)%RI3F M<9R0@\P9\L+Y=;--W @+'G09@"L=D3!81^:0]S:M\GWUW>R>OCQIQ#5"[* ' M,I.X(#VQ\_!!CG%P=D).?#0PAO"0(/AEO6/+]O0@1X1ELI0P5<;YP(H0R$DF M(68E%F8'1%#BU4'FM)BY\(8(82#*$2- M(3PM:=H@PD%KCZ((AY\.O<99V1BH)KCE4[7]\Y5:B:_?V.;/=ADT7DA&J!0P MSQ6WN6D"\APA*!7%!4:2)DSZW>H,"YP;*3S1%UB%P5[CT/3<2YB[W@'%0W+T M*Z%K0 RX(G)#)NZ-T069$U\@N2%P?)_D^+G C<\C7U;B'[N6QMZMOAMAZ\W/ MGMN=D SE*560E+@PKH?*8*E*"HE.2)'B,D=8>.U[+HJ<&^/L50S=W%P&V7%O M$Q6ZD2G& S7_K8PS$%%W,I>E3KN1<4;A:!_C_LF)\_%_8]7FGVSYJ.H>ODUZ MZ'^KZO[K3LG;[VK#[M4_U_8>RFX+;-SO@A>8H%)0F- 40\R5-/X0%9!P2A+" M;;J$5S;G=*K/C>=L#U5A+W*_[]6LFV_:8(:)DOO]A]^-.>@#<@ X"T&( #B#4J1TSJ \0/'*SJ!W@K_U_1EV!X%&)5G,@7(/8=POJ MQ^Z5 ?7/!19%H9-%][DQ""XLN&-'RIXZZLXJ#6?))KA> M :0N0N='0JW.3;]YX^:PU>J1+8%LU0>;(=B,U*%9ZWL#.HUK M!W&?[&N4CLE%[A#%92,'N1/SD3L2QXSD\=DK2J48LGMO.\7V*C'\OEEOMZ_9 M9O.S6MW??K-M"A:$YE1KI*',L=W@(P9I0DJ8$*)TRHM,%U[>D8?LN3&451VP M^XUJ]FX/FVHEJ@?#4*Q6]P9\8S^J;X_? JJL. Z&X]WI.!"/'HQA*[)8SZG1 M^TE5TEKUR*59_!"*7K#%4?ST95S\<#E9W,7S%6$L9MYMBYQ6NA+U[O/N<7>G M>T'S=:,CNSW=J*^V!O2AFH%19Y$AE"*M4IA26^A%4P)+EBDH59J3LD B0:D/ MKUVES=R8[KDQ8/U8UZ#LYYLT3<&>6-25&&DV/)[W--<-IQLS3C9((W/ER./C MS:=1<(W)L-6GPD=OVH2D?L;^C=/ MK,R/HO:CMK<_JNV"8I+F9A,,"ZP3B%-#S$R)U.R 4\8$(5HJY=9YZ1HU?*;X M-#V9/AN/GVVJ-?C#ZN&3#=DSB>JHP[$^&>L\<<@Y+PU&,3()[#^ M>DQ])AN,U(E3VO!W7=77Y-S_KPYC&U=1)6A2":D@RDINE*L.PI'D& MF21YF228I4\S:?:8(R\(' ^"JUJM:;#^N=VBX*S;!26D!6 M%BG$O,@@I8I"(;(,L8RJ#'E=W?3>/;?Y_W%3?;>%0S\N6<.SGF%)/=3<9GP@ M%B//\48K4*L5,=+FV-:HH3"]UT\;JW)LUU$PR8E'_+/(/ZGMSGP[[?>R#>LM M4JTSNY.D"IF%FF,&*>;2;"Q3R1A*4I)EKMGC1V^?V^3L*1B0+7X,WO ,O1J2 MT0_(OE?;=H-@:,M,UZ:[2>04\;,07)L:?OSBR5+"S]K43P4__U#8BOI&\=V[ MU7:WJ0N@OEN9&6,DV$O/SU:.[%W7F\6U2 J"89&E F*1E)!K74(L!:$90T(R MXG=2Y"Y\?N=#G;8!P1$>F"=4Y2C#"!I&M7U[$\.D!9*0)@4N,66D5%[9]^,@ M/DW/7KX#!]5OP'X FKB*1G^7\(IKQ\3-A1H'Z9'9.Q[( ?UY??&*VYO76?K$ M?7E]43GNR>O]AM!;82M$[!XW]IYY)3^I^L+C]7J[ZS(L/CS:3.$[_7'=M"': MOEU6WZJ5?6Q!1$DXRJ39OU%FUI0L@R42)10\%QSGO.3"*[_W.G7FQGY/K*EC M-5I[@#7H!NQS6!J;:N^KLPH6L80^]30'H5'/Y>G] I>;?ZI&Q?=J/6*[:MMO]8K?E6 M;>H(HG>KA\?=TT8CS?$Q+I*<*>.3*IIKB+'YB7/-(2$)(IS3#$FO\BRQ%9P; MBQ_2RFY ST30V0AL48+.2E";>0/ZAH+:TF<-A,*B?J)_&=SH_B6'>.0%X(5& MUWM=&&L(8JX4T76<=.T8"^'GJ\EH[ MZM_U[\]F "WR7 M%4&;[-E!;ZZ> M&0EE$(+E@A$,IDL5NJ^KM <5-W]*OV< M.*=L..=(R_'XY[W:;O\+L%XDHNQ967NDLC,UN-;[=0/KMD9,.D[3UXOOVW0# M]E;5 ]2WZP8\RVZ\<

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�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end